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The Relationship Between Knowledge and Beliefs About HPV, Acceptance of the HPV
Vaccine and Intentions to Practice Safer Sex Behaviors Among Female College Students
Theresa Scorcia-Wilson
ABSTRACT

Introduction. Sexually transmitted infections (STIs) continue to be highly
prevalent among young women, and STIs continue to be a challenging health issue on
college campuses. Studies have shown that the highest prevalence of human
papillomavirus (HPV) is among young adult women, ages 20 to 24, including female
college students. While the HPV vaccine has proven to be highly effective in preventing
certain high-risk types of HPV, it is not effective in preventing all types of HPV or other
STIs. Practicing other safer sex behaviors, in addition to condom use, also can help
individuals protect themselves and their partners from acquiring HPV and other STIs.
Purpose. Relationships between knowledge about HPV and the HPV vaccine, beliefs
about HPV, acceptance of the HPV vaccine, and intentions to practice safer sex behaviors
were assessed to determine if female college students who had a high acceptance of the
HPV vaccine were also more likely to practice safer sex behaviors. Methods. A
convenience sample of 2,706 undergraduate female college students, ages 18 to 24, from
three U.S. public universities, completed an online survey that measured the following
study variables: knowledge about HPV; knowledge about the HPV vaccine; acceptance
viii

of the HPV vaccine, specifically influential factors and barriers to vaccination; as well as
attitudes, normative beliefs, control beliefs and intentions for practicing safer sex
behaviors. Results. The majority of participants had a high level of knowledge of HPV
(70.4%) and the HPV vaccine (73.7%). Over one-third of the participants (37.3%)
received at least one dose of the HPV vaccine. Most participants thought they had a low
susceptibility to HPV, as 54% thought they were unlikely to contract HPV; however,
most (53.6%) thought that HPV would be a serious problem for them. The safer sex
behavior that participants thought was the easiest was refusing to have sex with a partner
that would not use a condom (51.8% “Strongly agree”) and the safer sex behavior that
participants thought to be the most difficult was asking a partner to get tested for STIs
(54.5% “Disagree”). Attitudes, normative beliefs, and control beliefs combined to
strongly predict intentions (R = .730, p < .001), and attitudes was the strongest predictor
for intentions to practice safer sex behaviors (β = .666), 95% CI [.649, .711]. There was
a significant positive correlation between vaccine acceptance and intentions to practice
safer sex behaviors (r = .087, p < .001), including likelihood of getting vaccinated against
HPV (r = .098, p < .001). Conclusions. Findings from this study demonstrate the need
for university student health centers to provide information about the HPV vaccine as
part of broader STI prevention and social marketing campaigns, targeting female college
students who are single, as well as those in monogamous relationships. Furthermore,
because young men can be carriers of HPV and the HPV vaccine is now available to
them, follow-up studies are needed to determine acceptance of the HPV vaccine among
male college students as it relates to HPV knowledge, knowledge of the vaccine, and
intentions to practice safer sex behaviors.
ix

Chapter One
Introduction
Sexually Transmitted Infections
The transition from adolescence to young adulthood presents special challenges
and opportunities for the individual. Young adults experience significant biological,
cognitive, emotional, and social changes. In addition, young adults establish patterns of
behaviors and make lifestyle choices that affect both their current and future health
(Centers for Disease Control and Prevention [CDC], 2004).
Compared to older adults, sexually active adolescents, ages 10 to 19, and young
adults, ages 20 to 24, are at high risk of acquiring sexually transmitted infections (STIs)
as they are more likely to have multiple sex partners, and they may select partners who,
themselves, are at higher risk of acquiring an STI (CDC, 2001). Significant progress has
been made in the treatment and prevention of reportable STIs, such as chlamydia and
gonorrhea, over the past few decades. However, STIs continue to be highly prevalent
among young people, and incidence of certain reportable STIs, such as syphilis, increases
each year (CDC, 2004). In a nationally representative sample, Forhan, Gottlieb,
Sternberg, Xu, Datta, McQuillan, et al. (2009) demonstrated that 1 in every 4 girls, ages
14 to 19, have had an STI. Furthermore, 19.2% of these teens developed an STI in one
year after having their first sexual experience, with only one sex partner. Approximately
19 million new STIs occur each year in the U.S., with almost half of them being among
1

persons ages 15 to 24 (Weinstock, Berman, & Cates, 2004). STIs pose serious public
health, social and economic problems for young adults (Brown, 1998). In addition to the
negative physical and psychological consequences associated with STIs, the direct
medical costs associated with diseases caused by STIs are estimated at $14.7 billion each
year (CDC, 2006).
STIs and College Students
STIs continue to be a challenging public health issue on college campuses. The
majority of college students are sexually active (Eisenberg, 2001), and engage in
activities that put themselves at high risk of acquiring STIs (Gately, 2003). In addition
to having multiple sex partners or selecting high-risk partners, many college students that
are sexually active do not take some of the necessary precautions, such as wearing a
condom, to decrease their risk of acquiring STIs (Eisenberg, 2001). Abstaining from
sexual intercourse and other high-risk sexual behaviors is the most effective way to
prevent transmission of most STIs. For persons having sexual intercourse, correct and
consistent use of latex condoms reduces risk of spreading and contracting STIs (Conant,
Hardy, Sernatinger, Spicer, & Levy, 1986; Van de Perre, Jacobs, & Sprecher-Goldberger,
1987).
However, according to a national survey by the Society for Adolescent Medicine
in 2003, more than 50% of college students living away from home reported that they
were sexually active, and 73% of those sexually active students reported having
unprotected sex, thereby increasing the risk of contracting STIs. In addition, 68% of
those students who reported having unprotected sex did not believe they were at risk of
contracting STIs (Gately, 2003).
2

Furthermore, the majority of adolescents and college students underestimate their
vulnerability to injuries and diseases including, but not limited to, STIs (Brown, 2000;
Cohn, Macfarlane, Yanez, & Imai, 1995; Finch, Donohue, & Garnham, 2002; Green,
Grant, Hill, Brizzolara, & Belmont, 2003; Johnson, McCaul, & Klein, 2002; Kershaw,
Ethier, Niccolai, Lewis, & Ickovics, 2003; Kontos, 2004; Omori & Ingersoll, 2005;
Ramirez, Ramos, Clayton, Kanowitz, & Moscicki, 1997).
Human papillomavirus
Human papillomavirus (HPV) is thought to be the most common STI in the
United States, and is most often contracted by adolescents and young adults (Winer, Lee,
Hughes, Adam, & Koutsky, 2004). Forhan, et al. (2009) also found HPV to be the most
common STI among adolescents, ages 14 to 19. The prevalence of HPV among young
people of all racial and ethnic backgrounds is of rising concern (Koutsky, 1997).
Incidence and prevalence data for HPV infection are limited as there is no mandate on
HPV reporting by health agencies or health care providers (CDC, 2003). However, it is
estimated, that at any one time, 20 million people in the U.S. have genital HPV infection
that can be sexually transmitted, approximately 6.2 million people acquire an HPV
infection each year, and an estimated 75% of persons of reproductive age have been
infected with sexually transmitted HPV (CDC, 2001). There are over 100 types of HPV,
and more than 30 of these HPV viruses are sexually transmitted by skin-to-skin contact
(National Cancer Institute [NCI], 2003). There are at least two low-risk types of sexually
transmitted HPV that have been identified to cause genital warts – HPV types 6 and 11 –
and at least 18 high-risk types that are considered to cause cervical cancer – HPV types
16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82 (Partridge & Koutsky,
3

2006). Approximately half of all cervical cancers are caused by HPV-16 (Stone, Karem,
Sternberg, McQuillan, Poon, Unger, & et al., 2003) and approximately 70% of cervical
cancers are caused by HPV types 16 or 18 (Hager, Bush, & Mcilhaney, 2004; Munoz et
al., 2003). These high-risk HPV types can lead to cancer of the cervix, vulva, vagina,
anus, or penis (Kiviat & Koutsky, 1999). Studies also suggest that a high-risk type of
HPV may be associated with a cancer in the middle part of the throat, called the
oropharynx, that includes the soft palate, the base of the throat, and the tonsils (Gillison,
et al., 2000; NCI, 2003).
Studies consistently demonstrate high levels of HPV infection among women, but
exact numbers are not known. Studies have shown that 10% to 46% of all sexually active
women are infected with HPV at any given point in time, depending on the population
evaluated (Burk et al., 1996; Koutsky, 1997; Lorincz, 1996). Dunne et al. (2007) found
that the prevalence of HPV was 26.8% among females, ages 14 to 59, and the highest
prevalence of HPV, at 44.8%, was among young women, ages 20 to 24. Several studies
preceding Dunne et al. (2007) have shown that men and women also between the ages of
20 and 24 have the highest risk of HPV infection (Becker, Stone, & Alexander, 1987;
Burk et al., 1996; Ho, Bierman, Beardsley, Chang, & Burk, 1998; Koutsky, 1997; Stone,
1989). The peak prevalence of genital warts appears to be in men and women, between
the ages of 20 and 29 years (CDC, 2006). Therefore, the college-aged population is at
high risk for exposure and acquisition of HPV, and the virus has been shown to infect
more than 40% of sexually active college students (Eisenberg, 2001). The highest levels
of HPV are among young women, including female college students. A review of studies
conducted on the prevalence and incidence of HPV among U.S. women revealed that
4

HPV prevalence ranged from 14% to more than 90%. The highest HPV prevalence was
among women attending STI clinics and college students, identifying them as priority
populations for prevention intervention (Revzina & Diclemente, 2005).
The Impact of HPV Among College Students
Research has demonstrated a low level of awareness among college students
about the risk factors and symptoms of STIs that most threaten them, including HPV
(Eisenberg, 2001; Gately, 2003; Yacobi, Tennant, Ferrante, & Roetzheim, 1999). Female
college students, across different ethnic groups, are more knowledgeable about HPV
compared to male college students (D’Urso, Thompson-Robinson, & Chandler, 2007;
Gerend & Magloire, 2008; Kenney, 1996). However, studies of U.S. female college
students show that despite the high prevalence of HPV in this population, there is low
awareness and knowledge of this viral infection (D’Urso et al., 2007; Lambert, 2001;
Ramsum, Marion, & Mathias, 1993; Vail-Smith & White, 1992; Yacobi et. al., 1999).
Gerend and Magloire (2008) revealed that since U.S. approval of the HPV vaccine
GARDASIL®, the level of knowledge and awareness about HPV, and its link to cervical
cancer, may be increasing among college students. However, misconceptions about HPV
remain, as studies have also revealed that the majority of female college students do not
understand how HPV is transmitted and are not aware of its link to genital warts (Allen,
et al., 2009; Geren & Magloire, 2008; Sanfordt & Pleasant, 2009).
Daley et al. (2008) found that women expressed confusion about HPV and could
not accurately communicate true meaning of an HPV diagnosis. Human papillomavirus
infection poses a serious public health concern for women, as specific types of HPV have
been well established as the main cause of cervical cancer (Kiviat, Koutsky, & Paavonen,
5

1999; Montero, Larkin, Houston, & Toney, 1999; Munoz & Bosch, 1996; National
Institutes of Health, 1996). Over 99% of cervical cancers contain at least one high-risk
type of HPV, and approximately 70% of cervical cancers contain HPV types 16 or 18
(Munoz et al., 2003). Studies have also demonstrated that HPV types 16 and 18 are
associated with anogenital diseases, such as vulvar, vaginal, and anal cancers. However,
not all vulvar and vaginal cancers are caused by HPV, and the exact number of these
cancer cases caused by HPV types 16 and 18 is unknown (Watson, Saraiya, Ahmed,
Cardinez, Reichman, Weir et al., 2008). Hampl, Sarajuuri, Wentzensen, Bender, and
Kueppers (2006) detected HPV types 16 or 18 in surgical samples from women. Human
papillomavirus types 16 or 18 were detected in 76% of surgical samples with vulvar
intraepithelial neoplasia or precancer, 64% of samples with vaginal intraepithelial
neoplasia, 81% of samples with anal vaginal intraepithelial neoplasia, and 42% of
samples with vulvar carcinoma.
In most cases, HPV is asymptomatic – the virus does not have any associated
symptoms – so many women may harbor it for a long time without knowing it, and if
undetected and untreated, the HPV types noted above, principally types 16 and 18, can
lead to cervical cancer. In addition, those persons who have HPV, but are unaware of it,
may continue to be sexually active and practice unsafe sexual behaviors believing they
are not infected. Therefore, they can transmit the virus to their sex partners (Schiffner &
Buki, 2006). Studies also have found that the majority of young women are not aware of
the link between HPV and cervical cancer (Lambert, 2001; Lazcano-Ponce et al., 2001;
Waller, McCaffrey, Forrest, Szarewski, Cadman, & Wardle, 2003; Waller, McCaffrey, &
Wardle, 2004). Human papillomavirus is less common among men, but prevalence rates
6

for both low-risk and high-risk types of HPV have increased over the past several
decades (Sawyer & Moss, 1993). A review of studies conducted of men revealed that the
prevalence of low-risk and high-risk types of HPV ranged from approximately 2% to
35% (Partridge & Koutsky, 2006). The highest rates of infection were found to occur
among men aged 20 to 24 (Becker et al., 1987; Burk et al., 1996; Koutsky, 1997;
Koutsky, Galloway & Holmes, 1988) and some studies have found similar HPV
prevalence rates, at approximately 28%, among men and women between 18 and 20
years of age attending the same universities (Van Doornum et al., 1994; Weaver et al.,
2004).
Studies involving different racial and ethnic groups have consistently
demonstrated that men are not as knowledgeable about HPV compared to women
(D’Urso et al., 2007; Kenney, 1996). Furthermore, the influence of cultural factors can
increase the risk of HPV for college students in certain ethnic groups. Two cultural
factors, cited in the literature, that can have an influence on sexual health are culturally
set gender roles (Suarez & Siefert, 1998) and the inability to negotiate condom usage
(Buzi, Wiemnan, & Smith, 1998; Suarez & Siefert, 1998). For example, studies have
demonstrated that cultural factors in the Latino population can increase the risk of HPV
among females. Gender roles related to social norms suggest that Latino men are
encouraged to be sexually knowledgeable and as a result, they tend to have multiple
partners while Latina women are encouraged to remain faithful and refrain from
discussions about sexual issues. Therefore, Latina women often find it difficult to
discuss and insist on the use of condoms with their partners (Buzi et al., 1998). Schiffner
and Buki (2006) conducted a study on health beliefs among Latina female college
7

students and concluded that women who do not discuss sexual health with their partners
may be less likely to utilize condoms consistently, placing them at high risk for acquiring
HPV.
Men often do not have any visible symptoms of HPV, a point of concern in terms
of transmission to sex partners. Men who are less aware of HPV and have no symptoms
will be more likely to transmit the virus to a sexual partner without knowing it.
Moreover, most of the time, men will not have any health risks associated with the highrisk types of HPV, such as cancer, so it is the women who need to be monitored for
abnormal cell changes in the cervix. In men, sexual activity is positively correlated with
HPV infection (Giuliano, 2007). Dunne, Nielson, Stome, Markowitz, & Giuliano (2006)
reported that HPV prevalence among men was typically 20% and infection rates of up to
72.9% have been documented. Furthermore, studies of HPV prevalence often among
men have reported that HPV-16 is the most prevalent high-risk type (Baldwin et al.,
2003; Bosch et al., 1996; Franceschi et al., 2002; Kataoka, Claesson, Hansson, Eriksson,
& Lindh, 1991; Lazcano-Ponce et al., 2001; Nielson et al., 2007, Weaver et al, 2004;
Wikstrom, Popescu, & Forslund, 2000). Evidence from a recent study in patients with
penile carcinoma demonstrated that HPV was present in 77.5% of cases, and HPV types
16 and 18 were present in 84.2% and 10.5% of cases, respectively (Pascual et al., 2007).
Studies of heterosexual couples have reported that concordant type-specific HPV
infections occur more often than would be expected by chance (Baken et al., 1995;
Bleeker et al., 2005). Therefore, both men and women need to be targeted for HPV
prevention because men can play a role as carriers and, unknowingly, spread the virus to
female partners.
8

Prevention of HPV
The most effective method of HPV prevention is avoidance of direct contact with
the virus, such as sexual skin-to-skin contact with a partner that has HPV, until it is
treated. However, many individuals with HPV are asymptomatic and do not have genital
warts. Consequently, they may not know that they have the virus or can transmit it to a
partner. Numerous studies have demonstrated that the use of condoms is not completely
effective in preventing HPV, as HPV infection can occur on sites that are not covered or
protected by a condom. However, the use of condoms does provide partial protection and
may reduce the risk of transmitting or acquiring HPV (National Institute of Allergy and
Infectious Diseases [NIAID], 2001). Winer et al. (2006) demonstrated that consistent use
of condoms by male partners reduced the risk of specific low-risk and high-risk types of
cervical and vulvovaginal HPV infection in women. Research has demonstrated that men
primarily use condoms as a contraceptive method (Santelli et al., 1997).
Practicing other safer sex behaviors, in addition to condom use, also can help
individuals protect themselves and their partners from contracting HPV and other STIs.
Safe sex, also referred to as “safer sex,” is defined as taking precautions prior to or during
sex that decrease the potential for transmitting or acquiring STIs (National Institutes of
Health, 2004). According to The Planned Parenthood Federation of America (2004),
safer sex behaviors are what individuals can do to lower their risk of getting STIs. Safer
sex behaviors that can significantly reduce the risk of contracting STIs include:
abstinence or not participating in any kind of sexual activity; practicing alternative types
of sexual activity other than intercourse that reduce a person’s risk of getting an STI, such
as kissing, embracing, and massage; asking a partner to get tested for STIs before
9

participating in sexual activity with them; staying in a monogamous, sexual relationship
with someone who has no history of STIs; using a condom; avoiding using drugs or
alcohol while having sex – because of their role in judgment impairment; communicating
concerns about contracting STIs with partners and how to protect each other; finding
information about HPV and other STIs and asking for information and assistance from
health care providers, including receiving regular physical examinations and testing for
the detection of HPV and other STIs.
Health care providers can perform visual physical examinations and other tests of
reproductive tissue to identify the presence of HPV among men and women. Urine
sampling and penile swabs have been used to detect HPV among men, but more research
is needed to determine the accuracy of these methods (Baldwin et al., 2003).
Transmission of HPV from a female partner can be prevented through early
detection via a gynecological exam that includes a Pap test. The Pap test is the standard
method of detecting cell and tissue abnormalities that alert practitioners to the possibility
of early to advanced stages of cervical cancer. The Pap test can reveal abnormal cell
changes known as cervical dysplasia, a precancerous condition (American Social Health
Association, 2001). Abnormal cervical cell changes can be detected more accurately
through the administration of a Pap test in combination with an HPV DNA test, versus
administering a Pap test alone. The HPV DNA tests, Cervista HPV 16/18 and Cervista
HPV HR, are now available and can detect DNA sequences of all high risk types of HPV.
The Cervista HPV 16/18 differs from Cervista HPV HR in that it can detect the specific
DNA sequences for HPV 16 and 18. Differentiating these HPV types provides health
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care providers with more information on a client’s risk of subsequently developing
cervical cancer (Food and Drug Administration [FDA], 2009).
Although there is no cure for HPV, there are various treatments for HPV,
depending on the type and severity. In addition, most forms of HPV, including the highrisk types, often disappear on their own. However, there is no guarantee that an infection
will not reappear or develop into a pre-cancerous or cancerous condition (CDC, 2002;
NCI, 2003; NIAID, 2004).
Vaccination as a Prevention Strategy
Vaccines are an effective way to prevent some STIs. A vaccine to prevent
Hepatitis B, also a sexually transmitted disease, has been available for over a decade. A
vaccine to prevent HPV and the development of genital warts and cervical cancer was
was approved by the FDA in 2006 for use in girls, adolescents and young women in the
United States. Two different variations of an HPV vaccine have been tested through
numerous clinical trials.
Both vaccines consist of L1 virus-like particles, which have the same form and
antigen properties as the L1 protein of HPV. The L1 virus-like particles self-assemble
into an empty capsid, and once they enter the body’s blood circulation, the particles
trigger an antibody response that is significantly higher than the antibody response from
natural HPV infection (Harper, et al., 2006; Villa, et al., 2005).
Clinical trials involving adolescent and young women, between the ages of 9 and
26, demonstrated GARDASIL®, developed by the pharmaceutical company, Merck &
Co., Inc., was effective in preventing incidence and persistent infection with two highrisk types of HPV – HPV-16 and HPV-18. The vaccine has been found to have the
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highest efficacy for adolescents and young women ages 16 through 26 (Gilsdorf &
Markowitz, 2006). This vaccine has been proven effective in preventing HPV types 16
and 18 from progressing into pre-cancerous cells (Reinis, 2004). The HPV-16 and HPV18 types are responsible for nearly 70% of all cervical cancers (Munoz, et al., 2003). The
vaccine also has been proven effective against HPV-6 and HPV-11, the two types that
cause the majority of cases of genital warts. Therefore, GARDASIL® protects against
four types of HPV – 6, 11, 16, and 18 (Gravitt & Shah, 2005; Koutsky et al., 2002).
Because high vaccine efficacy against infection and cell abnormalities has been
replicated in numerous studies for different female age groups, the FDA approved
GARDASIL® in 2006 for use in girls, adolescents, and young women, ages 9 to 26.
Vaccine availability in the U.S. began at the end of June 2006. The vaccine includes a
series of three shots administered over six months (Merck & Co. Inc., 2006). Since
vaccine approval in 2006, 25% of girls in the United States, aged 13 to 17 years, have
received at least 1 to 3 recommended doses of GARDASIL® (CDC, 2008).
Clinical trials have demonstrated that GARDASIL® was also highly effective in
preventing anogenital diseases, such as vulvar and vaginal precancers in women three to
five years after receiving the vaccine (Garland et al., 2007; Merck & Co., Inc., 2008;
Schiller, Castellsague, Villa, & Hildesheim, 2008). Therefore, in September 2008, the
FDA also approved the use of GARDASIL® to protect against vulvar and vaginal
cancers caused by HPV types 16 and 18 in girls and young women, ages 9 to 26 (Merck
& Co., Inc., 2008). GARDASIL® has been approved for use in 106 countries including
the United States, European Union, Australia, New Zealand, Mexico, Brazil, and Canada.
Additional applications are also under review with regulatory agencies in several
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countries throughout the world, and Merck & Co., Inc. is awaiting approval from the
FDA to expand the use of GARDASIL® in women, ages 27 to 45 (Merck & Co. Inc.,
2008a, 2008b).
Cervarix® is another HPV vaccine that has been developed by the pharmaceutical
company, GlaxoSmithKline. The main clinical study included more than 18,000 women,
ages 15 to 25, in the United States and 11 other countries. Clinical trials in this study
demonstrated that Cervarix® was approximately 93% effective in preventing HPV-16 and
HPV-18 and related pre-cancerous cell changes in women not previously infected with
either of these HPV types. In addition, the vaccine was about 53% effective in
preventing precancerous cervical lesions associated with HPV-16 and HPV-18 in women
who tested positive at the start of the study. Additional studies demonstrated that the
immune response to the vaccine was similar to that of women ages 15 to 25. Therefore,
the vaccine has been approved for use in girls and young women, ages 10 to 25
(GlaxoSmithKline, 2009; U.S. Department of Health and Human Services [USDHHS],
2009; Harper et al., 2004). This vaccine also includes a series of three shots administered
over six months. Cervarix® has been approved for use among girls and women, ages 10
to 25, in 100 countries, including the United States, European Union, Brazil, Mexico,
Australia, Singapore, South Korea, Philippines, and Taiwan. The vaccine was made
available in the United States in late 2009 (GlaxoSmithKline, 2009).
The most important factor regarding the impact of the HPV vaccine in reducing
cervical cancer is duration of protection (Jeurissen & Makar, 2009). At this point, it is
not known how long the HPV vaccines will be effective. Clinical trials of GARDASIL®
have demonstrated that the vaccine may be effective against HPV infection for up to five
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years (CDC, 2006; Garland et al., 2007; FUTURE II Study Group, 2007; FUTURE II
Study Group, 2007; Villa et al., 2006), and clinical trials of Cervarix® have demonstrated
that the vaccine may be effective for up to 6.4 years (Schwarz & Leo, 2008).
Men also have the potential to increase the incidence of genital warts and cervical
cancer among women because they can have asymptomatic HPV and transmit the virus
unknowingly. Bosch et al. (1996) measured the association between detection of highrisk type HPV-16 DNA found in men and cervical cancer diagnosis in their female
partners, and found an increased risk of cervical cancer in female partners of men who
were positive for HPV. Several studies in Colombia and Spain demonstrated that penile
HPV DNA prevalence was higher in spouses of women with cervical cancer compared to
women without cervical cancer (Castellsague et al., 1997). The findings from these
aforementioned studies may provide evidence that vaccinating boys and men against
HPV can help to prevent the occurrence of the virus in unvaccinated women, and could
potentially reduce the incidence of cervical cancer. Universal vaccination, rather than
only targeting the vaccine to girls and women, may be more effective in preventing HPV
and cervical cancer because of men’s role in HPV transmission (Koutsky, 2005).
Studies have been conducted to determine the vaccine’s effectiveness in
preventing HPV among these additional populations. A Phase III clinical trial
demonstrated the effectiveness of GARDASIL® in boys 10-to-15 years of age (Block et
al., 2006). Additional clinical trials, sponsored by Merck & Co., demonstrated the
effectiveness of GARDASIL® among men and boys, ages 10 to 26 (Merck & Co., 2009).
Based on the results of these clinical trials, in October 2009, after data was collected for
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this study, the FDA approved the vaccine for use in boys and men, ages 9 to 26, to
prevent genital warts caused by HPV-types 6 and 11 (FDA, 2009).
In addition, a study by Petaja et al. (2009) found Cervarix® to be effective and
well-tolerated in Finnish males, ages 10 to 18. An ongoing Finnish study, to be
completed in 2014, will determine if vaccinating males with Cervarix®will prevent the
transmission of HPV-types 16 and 18 in females (Petaja et al., 2009).
Target Populations for the HPV Vaccine
The HPV vaccines are considered prophylactic vaccines because they prevent
the infections that lead to genital warts and cervical cancer (Kahn, 2005). Therefore, the
optimal time to vaccinate girls at risk is in pre-adolescence and early adolescence, before
most become sexually active (Rosenthal, 2005). In addition to preventing HPV infection,
HPV vaccines also have demonstrated that they may be effective in preventing persistent
infection with HPV, thereby preventing the virus from progressing into precancerous
cervical cells. Therefore, the vaccine will benefit older adolescents and young adults
because there is no guarantee that a previous HPV infection will not reappear or develop
into a precancerous or cancerous condition (CDC, 2002; NCI, 2003; NIAID, 2004).
Cost-effectiveness studies of the HPV vaccine, in terms of increases in life
expectancy, decreased cancer incidence and mortality, and cost savings relevant to
current screening, have revealed discrepant results. There are many factors that can
influence the cost-effectiveness of the vaccine, including cost of the vaccine, duration of
protection, health insurance coverage, screening, number of sexual partners, and
background incidence of HPV-related conditions (Jeurissen & Makar, 2009). Most
studies have shown that either the Cervarix® or GARDASIL® would be cost-effective if
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high immunity from the vaccines lasts long enough. Based on these studies, researchers
recommended vaccinating adolescents by the age of 12, before most girls are sexually
active (Koutsky, 2005; Sanders & Taira, 2003), or at age 18, in conjunction with annual
or biennial Pap screening. In addition, vaccination and screening among females until
the age of 24 also has shown to be cost-effective (Kulasingam & Myers, 2003). Studies
have demonstrated that vaccinating males may not be cost-effective due to the cost of
vaccine coverage (Elbasha, Dasbach, & Insinga, 2007; Sanders & Taira, 2003; Taira,
Neukermans, & Sanders, 2004).
Although the vaccine is most efficacious when administered to youth before they
become sexually active, there are some challenges in vaccinating young girls.
Vaccination of pre-adolescents and adolescents against an STI has become a
controversial issue among certain groups, as there are concerns about whether the HPV
vaccine will increase high-risk sexual behaviors among children and youth and whether
vaccination will condone sexual activity before marriage (Stein, 2005). Furthermore,
there are concerns among health care providers about screening behaviors among
adolescents (Kahn, 2005), and whether the vaccine will be accepted among parents and
health care providers (Zimet, 2005). Parental consent is required for vaccination of
females under 18 years of age; therefore, parent acceptability is a critical issue (Zimet,
2005).
Parental and pediatrician acceptance of the HPV vaccine for young girls are
crucial for successful vaccine delivery (Zimet, Mays, & Fortenberry, 2000). Few studies
have been conducted on parental acceptance of vaccinating their children against STIs,
including HPV. Most of these studies have found high parental acceptance of
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vaccinating girls, and the most important influences for acceptability are severity of
infection, vaccine efficacy, physician recommendation, and school requirement (Davis,
Dickman, Ferris, & Dias, 2004; Lazcano-Poncen et al., 2001; Mays, Sturm & Zimet,
2004). However, a study by Zimet et al. (2005) of STI vaccine acceptance among parents
also found that parents were more likely to accept a vaccine if there were no other
behavioral interventions for prevention of the infection. A study by Noakes, Yarwood,
and Salisbury (2006) examining parental acceptance of the HPV vaccine for girls and
boys in the United Kingdom, found that most parents had concerns about offering a
vaccine to children that protected against an STI and thought that the vaccine should be
offered to children older than 10 years of age, in conjunction with a sex education
program. A study by Kahn et al. (2009) found that mothers’ intentions to vaccinate their
daughters against HPV increased with the daughters’ age. The greatest intentions among
mothers were to vaccinate their daughters if they were 16 to 18, and the lowest intentions
were for daughters ages 9 to 12.
Raley, Followwill, Zimet, and Ault (2004) found that professional society
recommendation is important for physician acceptance of an HPV vaccine. They found
the majority of members of the American College of Obstetricians and Gynecologists
(ACOG) were willing to include the vaccine in their office practice, but not willing to
vaccinate persons under the age of 17. However, most pediatricians support vaccination
for older age groups, such as over 15 years of age, compared to younger age groups, 12
years and under (Daley et al., 2006). A study by Ishibashi, Koopmans, Curlin, Alexander
and Ross (2008) found that pediatricians were much more supportive of HPV vaccination
than the general public, and that pediatricians should be aware of these differences when
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counseling and educating patients and parents about the HPV vaccine. There is a wide
range of pediatricians’ attitudes about the HPV vaccine. Factors influencing
pediatricians’ intentions to recommend HPV vaccines to patients and parents include
knowledge, personal and professional characteristics, office procedures, vaccine cost and
reimbursement, parental factors, and specific attitudes about HPV vaccination. Perceived
benefits among pediatricians about the vaccine include prevention of HPV-related disease
and the opportunity to educate adolescents, while perceived barriers include anticipated
parental beliefs, such as denial that their child would be at risk for an STI, and provider
beliefs, such as reluctance to discuss sexuality with pre-adolescents (Kahn et al., 2007).
Additionally, screening is a concern among pre-adolescents and adolescents as
they often do not routinely visit their health care provider (Kahn, 2005), and HPV
vaccination requires three visits over a six-month period (Harper et al., 2004; Koutsky et
al., 2002; Mao et al., 2006; Reinis, 2004; Villa et al., 2005). Furthermore, there is the
issue of vaccinating adolescents who may be particularly vulnerable to acquiring STIs,
such as homeless youth, street youth or incarcerated youth. These high-risk youth
populations are less likely to receive preventive health screenings, and they may be more
difficult to reach for vaccination education and programs (Kahn, 2005).
Another barrier to vaccine delivery is cost. The cost of the three-shot series is
$120 per dose for a total of $360, and Merck is providing GARDASIL® to the poor and
uninsured populations through their vaccine assistance program (Merck & Co., Inc.,
2006). Insurance plans covering approximately 60% of Americans’ health care costs are
covering part of the cost for the vaccine. However, half of 9- to 18-year-old girls are
covered under the federal government’s Vaccines for Children (VFC) program. The VFC
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program provides free vaccines to children who are uninsured, underinsured who visit
Federally Qualified and Rural Health Centers, on Medicaid, or an American Indian
(CDC, 2004). The CDC issued a recommendation to use GARDASIL® under the VFC
contract (Merck & Co., Inc., 2006), and the vaccine is now available in states through the
VFC program.
Although the vaccine is most efficacious in young girls and adolescents, there are
other female age groups that can benefit from the vaccine. In addition to vaccinating
children and adolescents, studies have also demonstrated that it also may be beneficial to
vaccinate 18-year-old women, in conjunction with a Pap test, at the first annual
gynecological exam (Kulasingham & Myers, 2003). Therefore, college-aged women
with no history of HPV infection could receive the HPV vaccine in conjunction with
regular Pap screening before or after they become sexually active. Furthermore, young
women, including college students, could receive GARDASIL® if they receive a positive
HPV DNA test for HPV types 16 or 18 to prevent other types of HPV infections.
A presentation by GlaxoSmithKline, the developer of the HPV vaccine Cervarix®,
proposed there is a medical need for this vaccine for females in three different age
groups. The first group would be targeted before most sexual activity starts, before 15
years of age. The second group involves girls, ages 15 to 25, as the first sexual encounter
and most sexual activity occurs among this age group. The second group, would,
therefore, include most college students. The third target group is women older than 25
years of age that may have already been diagnosed with HPV, may have persistent
infection with HPV, and who may have HPV, but may not know it. Research has
demonstrated that Cervarix® is well-tolerated in women over 25 years of age (Harper et
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al., 2006; GlaxoSmithKline, 2007; Monteyne, 2006). The purpose of vaccinating women
over the age of 25 would primarily be to prevent HPV infection from progressing into a
precancerous state and cervical cancer. However, early findings have demonstrated that
Cervarix® does not increase HPV viral clearance rates after six to 12 months, in women,
ages 18 to 25, who are already infected with HPV 16 and 18 (Hildesheim et al., 2007).
Based on the high prevalence of HPV among young adult women and the high
efficacy of the vaccine among this population, young adult women, in addition to girls
and adolescents, have been identified as one of the populations to benefit from the HPV
vaccine. As a result, Merck’s HPV vaccine GARDASIL® has been approved by FDA to
be used in young adult women from 18 through 26 years of age.
A study by Jain et al. (2009) revealed that, since approval of the HPV vaccine in
2006, awareness of HPV and the HPV vaccine was significantly higher (p < .05) among
young adult women, ages 18 to 26 (88.6%) compared to women, ages 27 to 49 (82.9%).
Approximately one-fourth of young adults ages 18 to 24, are college students (CDC,
1997). A study by Gerend and Magloire (2008) found that since the approval of the HPV
vaccine, awareness about HPV has increased among college students. However, the
majority of students had misconceptions about how HPV was transmitted and some were
not aware of the link between HPV and genital warts. Most college students have a low
level of knowledge about HPV because this population has been poorly educated about
HPV and there is a great desire for information about HPV infection, transmission and
prevention from this population (Lambert, 2001; Ramsum et. al, 1993; Vail-Smith &
White, 1992; Yacobi et al., 1999). The college setting presents an important opportunity
for addressing health issues, such as STIs, that have a significant impact on young adults.
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Students’ health behaviors are practiced and experienced in community, and students
influence each other’s choice and experience shared health challenges (Keeling, 2001).
Most college students are over the age of 18 and can make informed choices about their
health. Therefore, the type of controversy over vaccinating this population, as there is
currently is for youth under the age of 18, is not posing a challenge in vaccine delivery.
The majority of student health centers at U.S. public colleges and universities have
supplies of the vaccine, and vaccinations are highest among college females that have
been educated about HPV risks (Vollmer, 2006). Therefore, the collegiate venue is a
promising environment for delivering the HPV vaccine, and vaccination may offer the
opportunity to further educate students about how to protect themselves against STIs by
practicing safer sex behaviors. Staff from some of these student health centers reported
interest in developing on-campus vaccine education campaigns (S. Campbell, personal
communication, December 8, 2006; H. Rayko, personal communication, December 15,
2006; C. Robertson, personal communication, December 15, 2006).
The college student population could benefit from the HPV vaccine for the
following reasons:
•

HPV has been shown to infect more than 40% of sexually active college students
due to their high-risk sexual behaviors (Eisenberg, 2001).

•

Approximately half of all college students are sexually active while they are at
college and living away from home (Gately, 2003).

•

The HPV vaccine has been approved for use in females ages 9 through 26, an age
group that includes traditional-aged college students.

21

•

The college population often does not obtain high quality STI prevention services,
due to lack of health insurance, or inability to pay for health insurance or services
(CDC, 2003). The cost of the vaccine is covered by Merck for female college
students, ages 19 to 26, who are uninsured and meet income requirements.

•

Most college students may have HPV and may not know it; therefore, an HPV
vaccine potentially could prevent a high-risk type of HPV from progressing into a
precancerous or cancerous condition.
In addition, college students often are victims of sexual assault (i.e., forced sex or

rape) that increases their risk of acquiring STIs. According to the Violent Victimization
of College Students Report, between 1995 and 2002, approximately 15% to 20% of
college women and 5% to 15% of college men, ages 18 to 24, reported that they
experienced forced intercourse (Baum & Klaus, 2005). Also, a study by Abma, Driscoll,
and Moore (1998) found that 10% of young women, between the ages of 19 to 24, have
reported that their first pre-marital sexual intercourse experience was involuntary. The
HPV vaccine could potentially reduce the risk of college students acquiring genital warts
and cervical cancer, depending on the specific type of HPV infection, from being raped
or having forced intercourse.
A major barrier in vaccinating college students may be the high cost of the
vaccine. Merck has created a patient assistance program for vaccines that provide free
vaccines, including GARDASIL®, to adults who are uninsured and who are unable to
afford vaccines (Merck & Co., Inc., 2006). The young adult population, including
college students, is the most likely age group to be uninsured in the United States
(Agency for Healthcare Research and Quality, 2005). Eligibility requirements for the
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uninsured population to receive the free vaccine include that the person must be age 19
and older with the following income limits.
•

$43,320 for individuals

•

$58,280 for couples

•

$88,200 for a family of four (Merck & Co., Inc., 2009)

Based upon these requirements, uninsured college students have been factored
into the population to receive a free vaccine. Uninsured and low-income clients and their
licensed health care providers must obtain approval from Merck prior to administration of
the vaccine (Merck & Co., Inc., 2009).
HPV Vaccine Acceptance
Because GARDASIL® has received FDA approval, it is important to know
whether the populations prioritized to receive the vaccine are being vaccinated (World
Health Organization [WHO]-UNAIDS-CDC, 2003). There is limited research on the
number of college students that have received the vaccine since its approval, and the
numbers that have been reported vary by college campus. A study by Gerend &
Magloire (2008) revealed that 4 out of 64 female college students from two college
campuses received the vaccine, and pilot test data from an unpublished study by ScorciaWilson (2008) revealed that 43 out of 125 female college students, from three college
campuses, received the vaccine. Some studies on vaccine acceptance among college
students, indicate that persons in this population are highly receptive to the HPV vaccine
with acceptance rates as high as 88.6% among women and 77.5% among men (Gerend &
Magloire, 2008; Jones & Cook, 2008). Common factors associated with increased
vaccine acceptability among adolescents and young adults are low cost, vaccine efficacy,
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physician endorsement, and increased number of sex partners (Boehner, Howe,
Bernstein, & Rosenthal, 2003; Gerend et al., 2008; Kahn, Rosenthal, Hamann, &
Bernstein, 2003; Zimet et al., 2000). Boehner et al. (2003) found that an additional factor
associated with positive attitudes about the vaccine among college students was partner
and parental acceptance of the vaccine. This study also reported no gender differences
with respect to vaccine acceptance. Crosby, Schoenberg, Hopenhayn, Moore, and
Melhan (2007) found that additional factors significantly associated with HPV vaccine
acceptance among college-aged females were having vaginal sex in the past 12 months,
ever having an STI and ever having an abnormal pap smear. Gerend et al. (2008) found
that among a racially diverse sample of female college students, additional factors
associated with a greater acceptance of the HPV vaccine were being in a committed
relationship or dating, being sexually active, and feeling susceptible to HPV infection.
Whereas the aforementioned studies on vaccine acceptance among adolescents
and young adults have some common findings, there are conflicting results about whether
individuals are significantly more likely to get the HPV vaccine if it is targeted toward
preventing an STI versus if it is targeted toward preventing cervical cancer. Hoover,
Carfioli, and Moench (2000) found that adolescent girls and young women had higher
acceptance of a vaccine that targeted an STI rather than cervical cancer. However,
Boehner et al. (2003) and Zimet et al. (2000) did not find any significant differences in
preferences in vaccinations against HPV versus cervical cancer. Researchers believed
that the way the vaccine would be promoted (i.e., cervical cancer vaccine vs. an HPV or
STI vaccine) would be crucial for its acceptance (Horton, 2005). Merck is marketing
GARDASIL® as a cervical cancer vaccine (Merck & Co., Inc., 2006). Because the
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vaccine is being promoted as one that prevents cervical cancer, then adolescents, young
adults, and parents need to be educated about the fact that the primary cause of cervical
cancer is a STI, and the vaccine’s therapeutic effect is to prevent HPV and its progression
into cervical cancer.
Based on findings from HPV vaccine acceptance studies, most parents,
adolescents, and college students are comfortable with a vaccine that prevents the STI.
A review by of studies on acceptance of the HPV vaccine by Zimet (2005) revealed that
the majority of parents want more detailed information from pediatricians and health care
providers about HPV so they can better understand prevalence of HPV infection, how
HPV is transmitted, the consequences of HPV, and why there is a lack of clear prevention
strategies. Also, young adults, including college students, are concerned about HPV, and
want to be better informed about HPV infection, transmission, screening, and prevention.
Merck is promoting GARDASIL® as a cervical cancer vaccine through the
national advertising campaign “One Less”. Merck has not yet promoted the vaccine’s
role in preventing vulvar, vaginal or anal cancer through this campaign. The “One Less”
campaign is focused on educating the public about the HPV vaccine and the continued
importance for cervical cancer screening. However, this is a separate campaign from
Merck’s national HPV educational campaign “Tell Someone”. The “Tell Someone”
campaign was launched before GARDASIL® was available, and the purpose of the
campaign was to ensure the public’s understanding of the link between HPV and cervical
cancer (Merck & Co., Inc., 2006). Merck recently launched the campaign “3 IS KEY”,
and developed a brochure for health care providers to distribute to those patients who
receive their first shot out of the three-shot series. The purpose of the campaign and the
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brochure is to remind teens and young women, either via mail, e-mail or phone text
message, when to get their next two doses (Merck & Co., Inc., 2008). However, as with
“Tell Someone” and “One Less”, there is no information included in the “3 IS
KEY”campaign, nor materials, that reminds the target audience of how HPV is
transmitted and other methods of STI prevention.
Merck has also funded professional medical associations to assist in marketing the
vaccine, such as ACOG, the American Society for Colposcopy and Cervical Pathology,
the Society of Gynecologic Oncologists, and the American College Health Association
(ACHA). These associations developed educational programs and materials about the
HPV vaccine for health care providers to educate themselves as well as their clients.
However, Rothman & Rothman (2009) revealed that most of the material did not address
the full complexity of the issues related to the vaccine, including costs and benefits, and
recommendations for HPV and cervical cancer screening. In addition, materials
contained information that downplayed the sexually transmitted infection issues related to
HPV, primarily because of the perception that most parents might be uncomfortable
discussing a vaccine for an STI. Furthermore, the materials promoted the vaccine as an
anti-cancer vaccine rather than one that prevents an STI.
The ACHA developed an “HPV Vaccine Toolkit”, funded by Merck, for
clinicians, including talking points, sample e-mail messages to students and parents,
sample press releases, and public service announcements (AHCA, 2006). The letters to
students and parents focused on getting vaccinated to reduce worrying about getting
cervical cancer and to save one’s life, without addressing the prevention of STIs.
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Furthermore, Merck funding was not mentioned in any of the toolkit materials (Rothman
& Rothman, 2009).
Due to how the vaccine has been and is currently being promoted, it is not known
whether members of the target population and parents have a better understanding of the
cause of HPV as a result of these campaigns. In addition, it is not known whether
adolescent girls, young women and parents are being educated about the importance of
practicing safer sex behaviors to prevent additional types of HPV and other STIs at the
time of vaccination.
Statement of the Problem
Sexually active adolescents and young adults, ages 15 to 24, are at high risk of
acquiring STIs due to practicing high-risk sexual behaviors. Young adults, ages 20 to 24,
including the college-aged population, have the highest rates of HPV infection, and STIs
continue to be a challenging public health issue on college campuses. Numerous studies
have documented a low level of awareness about HPV among college students.
Consequently, they do not perceive themselves to be at high risk for HPV or other STIs,
and most college students do not practice safer sex behaviors to protect themselves
against STIs (Eisenberg, 2001; Gately, 2003; Yacobi et al., 1999). Despite the continued
practice of high-risk sexual behaviors among college students, there is a high level of
acceptance of an HPV vaccine for this population. Furthermore, research has indicated
that those who consider themselves at higher risk, such as those who have many sex
partners, have a higher acceptance of the HPV vaccine (Boehner et al., 2003). However,
the majority of college students who are at high risk are also those who report that they
do not practice safer sex behaviors to protect themselves against STIs (Eisenberg, 2001;
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Gately, 2003). These findings may be a cause for concern if college students become
vaccinated against HPV but continue to participate in risky sexual behaviors. Because
more than 50% of college students are sexually active, practice high-risk sexual
behaviors, and are, therefore, at high risk of acquiring HPV, there is a great medical need
to vaccinate this population against HPV. Because there is a high incidence of HPV
among college students, the HPV vaccine may benefit those who are already infected
with HPV by preventing infection with other types of HPV that the vaccine guards
against. Young women, including college students, have been identified as a priority
population for the HPV vaccine (Monteyne, 2005), and GARDASIL® has been approved
for use in young girls and women, ages 9 to 26 (Merck & Co., Inc., 2006). Research is
limited on the percentage of female college students, ages 18 to 26, that have received the
vaccine since its approval. However, college-aged women are obtaining the HPV
vaccine. A study by Jain et al., (2009) that incorporated data from the 2007 National
Immunization Survey among 1,102 participants, revealed that two to five months
following the release of national HPV vaccine recommendations, one in ten women 18 to
26 years old had initiated the HPV vaccine series.
Some studies have been published on the female college student population with
respect to their beliefs about the HPV vaccine and factors that influence its acceptance or
non-acceptance (Boehner et al., 2003; Crosby et al., 2007; Gerend & Magloire, 2008;
Jones & Cook, 2008). However, these studies have not examined whether a relationship
exists between knowledge about HPV, health beliefs about HPV, attitudes about or
acceptability of the HPV vaccine, likelihood of being vaccinated, and intentions to
engage in other protective sex behaviors. Because GARDASIL® does not protect against
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all types of HPV, college students’ willingness to practice safer sex behaviors, in addition
to being vaccinated against HPV, will be necessary to protect themselves from all types
of HPV, as well as other STIs. This study assesses different factors that may play a role
in college women’s acceptance of the HPV vaccine and intentions to practicing safer sex
behaviors. Understanding these factors may be helpful in determining what approach
health care providers need to take in educating this population about the vaccine. Also,
the information from this study may be helpful for university and college campuses in the
development of HPV vaccine education and promotion campaigns. Determining whether
there is a relationship between knowledge about HPV and intentions to practice safer sex
behaviors may help to reinforce the need for increased education about HPV and other
STIs by health care providers for college-aged women, and encourage providers to also
utilize the time for vaccination as a teachable moment to educate students about HPV and
safer sex behaviors.
The purpose of this study was to determine if women attending college who have
high acceptance of the HPV vaccine and are likely to become vaccinated against HPV,
also intend to practice other safer sex behaviors. Also, this study contributes to the
literature by further assessing female college students’ knowledge and beliefs about HPV
and the HPV vaccine. It examined female college students’ beliefs about their risk, and
whether their perceived susceptibility to, and perceived severity of HPV, is associated
with acceptance of the vaccine, likelihood of getting vaccinated against HPV, and
practicing other safer sex behaviors. Understanding the relationship between vaccine
acceptance and intentions to practice safer sex behaviors can assist university health
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centers in developing vaccine educational campaigns for women that also includes
promotion of other safer sex practices.
Theoretical Application
The health belief model (HBM) (Rosenstock, 1974) has been applied in several
studies to examine knowledge and beliefs about STIs, to predict behaviors against STIs,
such as condom use, and STI vaccine acceptance, including the genital herpes and HPV
vaccine (Auslander et al., 2005; Hiltabiddle, 1996; Kahn et al., 2003; Lollis, Johnson &
Antoni, 1997; McKinley & Billingham, 1998; Orr & Langefeld, 2003; Zak-Place &
Stern, 2004). The HBM will be applied in this study to measure college students’ health
beliefs related to HPV and the HPV vaccine. Health beliefs assessed among college
students include perceived susceptibility to getting HPV, perceived severity of HPV,
perceived benefits and barriers to getting vaccinated against HPV, and beliefs that certain
actions can protect themselves and others from HPV, such as practicing safer sex
behaviors and being vaccinated against HPV. Perceived susceptibility to HPV in this
study is defined as whether or not individuals believe, they and others, such as peers, are
at risk of getting HPV and their perceived level of risk, in addition to whether they
believe they are personally responsible for taking precautions against getting HPV.
Perceived severity of HPV is defined in this study as how serious individuals perceive
HPV to be in terms of emotional, social, and medical consequences. According to the
HBM, both perceived susceptibility and severity of an illness or disease are partly
dependent on knowledge about the illness or disease (Rosenstock, 1974). Therefore,
before perceived susceptibility and severity about HPV was assessed among college
students, knowledge about HPV was determined. Individuals with little or no knowledge
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about HPV most likely will neither believe they are at risk of acquiring an STI, nor
believe the STI to be an emotional, social or medical threat to themselves or others. Selfefficacy is another component of the HBM that was used to measure college students’
perceived capability to practice certain safer behaviors.
Whereas the HBM has been used to predict health-related behavior in terms of
certain belief patterns, it does not incorporate an individual’s perceptions of beliefs held
by prominent persons or figures in their life. These beliefs are also referred to as
normative beliefs. Furthermore, because the HBM is focused solely on health beliefs that
represent perceived benefits and barriers in explaining and predicting health behaviors, it
does not include the construct of an individual’s perceived behavioral control. According
to Ajzen (1988), an individual’s attitudes about performing a certain behavior, normative
beliefs of others for an individual to perform the behavior, and perceived behavioral
control effect an individual’s intention to perform that behavior. Because the HBM does
not incorporate these constructs, it cannot be used to predict intentions to perform
behaviors. The theory of planned behavior (TPB) was applied in this study as a
theoretical framework to complement the HBM. The TPB has been applied in several
studies to predict intentions of practicing safer sex behaviors among adolescents and
college students (Bensley et al., 2004; Boily, Godin, Hogben, Sherr, & Bastos, 2005;
Bryan, Fisher, & Brian, 2002; Koniak-Griffin, Lesser, Uman, & Nyamathi, 2003). The
TPB was used to measure college students’ normative beliefs regarding being vaccinated
against HPV and practicing safer sex behaviors, self-efficacy or capability in performing
safer sex behaviors, and perceived behavioral control of performing safer sexual
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behaviors. These constructs were used to measure college students’ intentions to practice
safer sex behaviors and to become vaccinated against HPV.
The constructs of the HBM and TPB were measured through an online survey
developed primarily by this researcher. Because Cervarix® was made available in the
United States in late 2009, the assessment of HPV vaccination among college students in
this study was for GARDASIL®.
Items assessing knowledge and health beliefs about HPV and the HPV vaccine,
and HPV vaccine acceptance, including influential factors and barriers to becoming
vaccinated against HPV, were adapted from an instrument developed by researchers at
the University of South Florida to assess the impact of receiving an HPV diagnosis
among women. Items assessing attitudes about practicing safer sex behaviors, and
perceptions of partners’ and friends’ attitudes about practicing safer sex behaviors were
constructed from a questionnaire development guide by Ajzen (2006). Items assessing
perceived self-efficacy and control in practicing safer sex behaviors will be adapted by a
scale developed by Morrison, Ho, Beardsley, Bierman, and Burke (1998) to assess lowrisk and high-risk sexual behaviors among female college students. The most promising
application of the health belief model is for helping to develop messages that are likely to
persuade individuals to make healthy decisions, such as through education, media, and
counseling (Glanz, Lewis, & Rimer, 1990). This study may provide valuable information
for health care providers in educating students about HPV and designing HPV vaccine
educational and promotion programs. Determining if there is a relationship between
HPV vaccine acceptance, likelihood of being vaccinated against HPV, and intention to
practice other safer sex behaviors among college students should help inform the design
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of educational campaigns or materials that are specific to the college student population.
If college students are more likely to get a vaccine than engage in other protective sex
behaviors, then vaccine educational campaigns also will need to focus on STI prevention,
in general, and include messages that promote other safe sex practices, such as
communicating with partners about STIs and asking partners to get tested before having
sex, avoiding alcohol and other drug use before and during sexual activity, and using
condoms. This more comprehensive approach may be especially necessary because the
vaccine is being promoted as a cervical cancer vaccine and not an STI vaccine.
Administering the vaccine to college students may provide a teachable moment for health
care providers, such as physicians, nurses, nurse practitioners, and physician assistants, to
relay information about additional safer sex practices.
Research Questions
•

What is the relationship between knowledge about HPV and intentions to practice
safer sex behaviors among women attending college?
o What is the relationship between knowledge about HPV and attitudes
towards practicing safer sex behaviors?
o What is the relationship between knowledge about HPV and normative
beliefs about practicing safer sex behaviors?
o What is the relationship between knowledge about HPV and perceived
control towards practicing safer sex behaviors?

•

What is the relationship between knowledge of the HPV vaccine and acceptance
of the HPV vaccine among women attending college?

•

What is the relationship between health beliefs about HPV and acceptance of the
HPV vaccine among women attending college?
o What is the relationship between perceived susceptibility to HPV and
vaccine acceptance?
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o What is the relationship between perceived severity of the HPV vaccine
and vaccine acceptance?
•

What is the relationship between acceptance of the HPV vaccine and intentions to
practice other safer sex behaviors among women attending college?
o What is the relationship between acceptance of the HPV vaccine and
attitudes towards practicing safer sex behaviors?
o What is the relationship between acceptance of the HPV vaccine and
normative beliefs about practicing safer sex behaviors?
o What is the relationship between acceptance of the HPV vaccine and
perceived control towards practicing safer sex behaviors?

Definition of Terms
Cervical cancer
A malignant neoplasm of the cervix, or the neck, of the uterus. The primary cause of
cervical cancer is infection with certain types of HPV (American Cancer Society, 2006;
Thomas, 1993).
College student
“Traditional age undergraduates, 18 to 24 years of age, who are enrolled full-time or parttime in public or private, two- or four-year institutions of higher education. Many
undergraduates are no longer of traditional age, and some students, ages 20 to 24, have
already started graduate or first professional study” (Keeling, 2001, p.2).
Genital warts
Also called “condylomata acuminate” or venereal warts. They are soft, moist, or fleshcolored bumps, caused by HPV infections, that may appear in the genital area within
weeks or months after infection (www.niaid.nih.gov/factsheets/stdhpv.htm).
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Health Belief Model
A model focused on an individual’s health beliefs and is used to explain and predict
preventive health and illness behavior in terms of certain belief patterns such as general
health values that include interest and concern about health, specific health beliefs about
vulnerability to a particular health threat and beliefs about consequences of the health
problem.
Human papillomavirus
The name of a group of viruses that includes more than 100 different types. More than
30 of these viruses are sexually transmitted and they can infect the genital area of men
and women including the skin of the penis, vulva (area outside of the vagina), or anus,
and the linings of the vagina, cervix or rectum (CDC, 2004).
Model
A diagrammatic representation of the relationship between a number of variables
(Boss, Doherty, LaRossa, Schumm, & Steinmetz, 1993).
Sexually transmitted infection
A group of infections spread through any kind of sexual contact, not just by intercourse.
These infections are caused by tiny organisms passed between individuals through
contact with the genitals, skin, mouth, rectum, or bodily fluids. Types of sexually
transmitted infections include bacterial, viral, and parasites (American College of
Obstetricians and Gynecologists, 2003).
Theoretical framework
A set of theoretical assumptions that explain the relationships among a set of phenomena
(Camp, 2001).
35

Theory
A set of interrelated concepts, definitions, and propositions that present a systematic view
of events or situations by specifying relations among variables in order to explain and
predict the events or situations (Kerlinger, 1986).
Theory of planned behavior
A theory that proposes that attitudes about performing a behavior, perceived benefits of
others regarding its performance, and perceived behavioral control over one’s ability to
perform the behavior all affect the intention to perform that behavior.
Vaccine
A suspension of infectious agents, or some part of them, given for the purpose of
establishing resistance to an infectious disease (Thomas, 1993).
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Chapter Two
Review of the Literature

To understand the purpose of studying college students’ knowledge and attitudes
about HPV and the HPV vaccine, their willingness to get vaccinated against HPV, and
their intentions to practice safer sex, relevant background literature is presented. This
literature review is presented in the areas of the history of infectious disease with a focus
on STIs in the United States; epidemiology, detection, and natural history of HPV;
cervical cancer; transmission and prevention of HPV; vaccine therapy and vaccine
acceptance; and the application of the health belief model and the theory of planned
behavior.
Infectious Disease
Infectious diseases have always been a threat to humankind, from the biblical
plagues and the Plague of Athens in ancient times, to the Black Death of the Middle
Ages, the 1918 “Spanish Flu” pandemic, and more recently, the HIV/AIDS pandemic. In
addition, historically established infectious diseases, such as West Nile Virus, human
monkey pox, dengue fever, tuberculosis, and malaria have reemerged, and some in
populations that had not previously been susceptible to getting these diseases. In
addition, common strains of bacterial infection such as Staphylococcus aureus and
Mycobacterium tuberculosis have continued to develop resistance to the antibiotics that
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were once effective against them (Fauci, 2001; Institute of Medicine, 2003; Morens,
Folkers, & Fauci, 2004). Infectious diseases remain a dominant feature of the domestic
and international public health considerations for the 21st century, as infectious diseases
continue to emerge and re-emerge in a manner that does not fit with accurate and
scientific predictions. During the past ten years, many new and reemerging microbial
threats have continued to challenge the public health and infectious disease research
communities worldwide. The infectious disease community has confronted several other
newly emerging pathogens that are threatening to humans, such as severe acute
respiratory syndrome-associated coronavirus (SARS-CoV), henipaviruses – viruses that
infect bats and can be spread to humans and livestock, the avian influenza viruses, – and,
more recently, the influenza viruses that have caused illness and death and the potential
to evolve into a pandemic (Fauci, 2001; Institute of Medicine, 2003; Morens, et al.,
2004). Each year, influenza or “flu” develops in up to 20% of all Americans, and over
200,000 Americans are hospitalized with the disease. Although influenza is a common
infectious disease, an estimated 36,000 Americans die each year from flu-related
complications (CDC, 2006). The first case of avian influenza, also referred to as
influenza A virus H5N1, was recognized in 1997 infecting 18 people in Hong Kong,
where it caused six deaths. Since 2003, over 500 humans have been infected with H5N1,
and nearly 300 of those infected have died from the virus (World Health Organization
[WHO], 2010). The current strain of H5N1 virus is highly pathogenic, as it causes
diseases in humans and animals, and the virus has killed millions of chickens and other
birds. Although the virus can cross species to infect humans, few suspected cases of
human-to-human transmission have been reported (WHO, 2006). However, the H5N1
38

virus could acquire characteristics that allow it to be readily transmitted among humans,
and that could cause a worldwide pandemic, with the potential of killing millions of
people. There is a new global pandemic of influenza A, H1N1 virus also referred to as
the “swine flu,” that is spreading from person-to-person. The first case of the H1N1 virus
originated in Mexico in March 2009, and the first case in the United States was reported
on April 15, 2009. Since the first outbreak of H1N1 was reported, an increasing number
of states and over 70 countries have reported human cases. To-date, there have been
approximately 60 million cases and over 12,000 deaths associated with H1N1 in the
United States (CDC, 2010). In 1918, a pandemic of the “Spanish Flu” killed more than
500,000 people in the U.S. and 20 million to 50 million people worldwide (NIAID,
2005). A vaccine to protect humans from H1N1 has been developed (CDC, 2009) and
vaccine development and acceptance of vaccines in preventing infectious diseases will be
discussed later.
Overall, infectious disease is the third leading cause of death each year in the U.S.
and the second leading cause of death in the world (World Health Organization [WHO],
2004). The infectious diseases that cause death worldwide are acute lower respiratory
tract infections, malaria, diarrheal disease, tuberculosis, and HIV/AIDS (Fauci, 2001).
The AIDS pandemic is an example of a truly new and emerging infectious disease
whose public health impact had not been previously experienced. Although significant
efforts have been accomplished in trying to reduce the incidence of Human
Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS), such as
through antiviral therapy, the incidence of this sexually transmitted infection continues to
increase in the U.S. and developing countries.
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Sexually transmitted infections. Sexually transmitted infections have been in
existence for thousands of years, with the earliest records dating back 5,000 years
(Handsfield, 1997) and were commonly known as venereal diseases (VD). In Latin
terms, “veneris” translates into “Venus” – the Roman goddess of love. The term sexually
transmitted disease was created approximately 90 years ago by physician Sir William
Osler who recognized the need to have a specialist who understood everything about
STIs (Royal Commission on Venereal Diseases, 1916). However, the term venereal
disease was the commonly used term until the 1990s when public health officials
introduced the new term of sexually transmitted disease to increase the public’s
understanding of how these diseases were spread and contracted (McCormack, 2000).
Venereal diseases were defined as those transmitted by sexual intercourse
(ASHA, 2005). Prior to the 1960s, syphilis and gonorrhea were the only major known
venereal diseases (Waugh, 1990). Although historical information on the exact origins of
gonorrhea and syphilis is limited, the literature contains some estimates on when and how
these diseases were recognized.
Gonorrhea is one of the oldest known venereal diseases and is referred to in the
literature as one of the first recorded diseases in history. In the Dark Ages, the term
“Clap” for gonorrhea first materialized in 1378 in La Clapier district in France, where all
the prostitutes gathered. The main medical symptoms of gonorrhea were illustrated in the
Old Testament and also by the ancient people of China, Egypt, Rome and Greece
(Edwards & Apicella, 2004). The Book of Leviticus, included in the Old Testament
contained a description of gonorrhea in a man with urethral discharge. In the fourth and
fifth centuries, the physician, Hippocrates, referred to acute gonorrhea as “strangury.”
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Hippocrates also believed that this infection stemmed from the pleasures of Venus,
demonstrating that the Greeks knew the cause of the disease (Sparling, 1999). It was not
until 130 A.D. that a famous Greek physician, Galen, introduced the term gonorrhea
when he mistakenly confused the discharge associated gonococcal urethritis with semen,
and referred to it as the “flow of seed.” In 1879, Dr. Albert Neisser, a German physician
who specialized in dermatology and venereal diseases, discovered the small bacterium
gonococcus as the second identified bacterial pathogen, and named it Neisseria
gonorrheae. He accomplished this discovery with stained smears of urethral, vaginal,
and conjunctival fluids (Haines et al., 1988; Sparling, 1999). The most notable account
of gonorrhea is in the personal diary of James Boswell, the famous biographer of Samuel
Johnson. Boswell describes his bouts with 19 different gonorrheal infections that
ultimately led to his death. He also describes his concerns over the asymptomatic
characteristic of the disease for women and how that might have resulted in several of his
wife’s miscarriages (Ober, 1970). The discovery and applications of sulfonamide
therapy, discovered by German scientist Gerhard Domagk in 1936 and penicillin
antibiotic therapy, discovered by Scottish scientist Sir Alexander Fleming in 1943, led to
a rapid decrease in gonorrhea prevalence (Hook & Handsfield, 1999; Sparling, 1999).
This trend reversed, in the early 1960s, with the onset of oral contraceptive methods, and
N. gonorrhoeae infections reached a peak incidence of over one million reported cases in
1978 in the United States. The incidence of gonococcal infection again declined in the
late 1980s, with the onset of the HIV epidemic and a coincident widespread use of barrier
contraceptives, (Handsfield, 1990; Knapp & Rice, 1995).
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Syphilis is also one of the first recorded diseases in history, but debates about its
origins have continued for nearly 500 years. There are two conflicting theories about the
origins of syphilis, also referred to as the “pox.” The Americanist theory is that the
sailors of the Christopher Columbus expedition were infected with syphilis by the natives
in the U.S. and in 1493, brought the disease with them when they returned from the New
World to Spain. The Europeanist theory is that syphilis was endemic in Europe
throughout the middle ages and became a pandemic at the end of the fifteenth century.
Another possible explanation is that syphilis was always present in Europe but was not
identified as a separate disease from leprosy before A.D. 1500. Ancient and medieval
sources have long been cited as evidence for syphilis in Europe before Columbus, but
none of the descriptions by the Greek and Roman authors are specific enough to be
certain (Rose, 1997). The earliest signs of syphilis date back to nearly 2,000 years ago
from skeletal remains found in the western region of the United States, providing more
supportive evidence for the Americanist versus the Europeanist theory (Rothschild,
2005).
The term syphilis was rarely used in its current meaning (Porter, 1999) and was
often referred to as an indeterminate range of conditions until the late nineteenth century,
and until that time was often confused with gonorrhea. Between 1500 and 1800, the
medical world was divided on the pathology of these two venereal diseases (Waugh,
1990). The first unambiguous descriptions of syphilis started at the beginning of the
fifteenth century, and these descriptions included the specific bacterium associated with
the disease, called Treponema pallidum, and that the disease was transmitted by direct
skin-to-skin contact or by sharing drinking cups (Rose, 1997). Despite conflicting ideas
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about its origin, its passage was well described as a new epidemic pox arriving in Italy in
1495, following Charles VIII’s campaign against the Spaniards for the control of Naples.
The Italians called it ‘the French sickness’; and the French called it ‘the Neapolitan
sickness’. Although each nation identified it as a disease of their enemy, syphilis was
most commonly referred to as morbus gallicus (Quetel, 1990), and believed to be due to a
new contagion that spread venereally, and called the French disease (Arrizabalaga, 1993).
The morbus gallicus spread throughout Europe as the mercenary army composed of men
from Belgium, Germany, France, Italy and Spain disbanded and returned to their
homelands. Within a decade of the first outbreak, epidemic syphilis had spread
throughout Europe. Girolamo Fracastoro, an Italian physician and poet who was also
infected with the disease, first called the disease syphilis in 1530. Syphilis was
distributed among the upper and lower rungs of society, and had reached its peak in the
sixteenth century (Rose, 1997).
Prior to the invention of modern medicines, venereal diseases were generally
incurable, and treatment was limited to treating the symptoms of the disease (Porter,
1999). In Europe, the first venereal disease clinic opened on January 31, 1747 at London
Dock Hospital. The history of sexually transmitted infections recorded in the U.S. is
fairly recent, and in 1778, a Congressional order imposed fines on any officer or enlisted
man who was admitted to a hospital with a venereal disease (Moore, 1941). This order
increased stigmatization and adversely affected the regulation of these diseases over the
next 150 years (Waugh, 1990). Data on venereal disease in the army go back to 1820,
but no special measures for venereal disease control were undertaken. In the nineteenth
century, the combination of prostitution and venereal disease was an enormous problem,
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especially in New York, and it was estimated that 1 in 20 of the U.S. population was
infected with syphilis (Waugh, 1990). In 1873, the first permanent venereal disease
clinic was opened at the Boston Dispensary. As early as 1876, the American Medical
Association considered extending public health techniques to the treatment of venereal
disease and J. Marion Sims, as president of AMA stated that, “Each new case of syphilis
or gonorrhea represents a failure of both public health and society” (Amstey, 1994, p. 17;
Vonderlehr & Hiller, 1946). In the early 1900s, Prince A. Morrow, a prominent New
York physician and also known as the “Father of Social Hygiene” brought the problem of
venereal disease into full public view, and as a result, several local groups and societies
formed in major U.S. cities to address sex hygiene. Two of these groups merged into the
American Social Hygiene Association, now known as the American Social Health
Association (ASHA). These groups shared an optimistic outlook and were committed to
fighting an undesirable social condition that they believed could be improved through
medical and educational means (ASHA, 1999). Major breakthroughs and treatments
appeared to contribute to this optimism, particularly the discovery of Arsphenamine,
referred to by the trade name Salvarsan. Salvarsan was discovered by German scientist
Paul Erhlich and Japanese scientist Sahachiro Hata in 1910 and was an effective
treatment for syphilis (Izumi & Isozumi, 2001).
Recorded data show that syphilis peaked in the U.S. in the decade following 1910,
and then again in 1947 at 76 cases per 100,000, and then fell to a low of about 4 per
100,000 in 1955-58 (Aral & Holmes, 1990). Analysis of surveillance data on cases of
syphilis and congenital syphilis reported by state and city health departments to the
Centers for Disease Control and Prevention has shown that historically, syphilis was
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distributed widely throughout the country and declined rapidly after the introduction of
penicillin therapy and broad-based public health programs, attaining its lowest levels in
the 1950s (Nakashima, Rolfs, Flock, Kilmarx, & Greenspan, 1996). The trend reversed
in 1959, and syphilis levels rose to 12 per 100,000 in 1965, and the incidence of primary
and secondary (P&S) syphilis remained static until 1980.
As stated previously, syphilis and gonorrhea were the first major STIs known
before the 1960s, and although some early trend data are included, it should be noted that
gaps exist in this data due to lack of funding for surveillance. Following the AMA’s
extension of public health control techniques, including reporting and tracking of
venereal diseases, certain states extended its contagious disease reporting to include
venereal disease. After World War I, Congress cut funding for venereal disease services
in 1920, and by 1922, Congress discontinued appropriations for state diagnosis and
treatment clinics, assuming that venereal disease was no longer a problem. With the
onset of the Great Depression, funding dropped further, resulting in venereal disease
cases being underreported and inaccurate estimates for disease incidence and prevalence
(Parran, 1937). To reduce ignorance, and thereby, decrease the risk of venereal infection,
the U.S. government just before and after World War II encouraged publicity on the
matter, for the taboo long associated with public discussion of these contagious diseases
had given rise to serious public-health problems. A nationwide campaign was initiated in
1937 by Thomas Parran, then serving as U.S. Surgeon General, to educate the public
about the incidence, cause, and cure of venereal diseases. As a result, the number of new
cases in the United States steadily declined each year until the 1950s, when a rise was
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noted, especially among teenagers and young adults (Jones, Shainberg, & Byer, 1974;
Rosebury, 1971).
Additional venereal diseases were discovered after the 1960s and due to the
coordinated effort by the Communicable Disease Center, now known as the Centers for
Disease Control and Prevention, and their expertise in disease surveillance, with the
assistance of local and state health departments (CDC, 1996), more reliable trend data are
available for reportable STIs. The 1980s brought additional challenges, as incurable,
viral STIs became prevalent, such as genital herpes and HIV. In addition, more
information about the complications on women’s reproductive health was being
discovered. In 1992, pelvic inflammatory disease (PID) was recognized, along with it
being a cause of infertility among women in the United States, and, in 1996, HPV was
recognized as the primary cause of cervical cancer (McCormack, 2000). In 1998,
concerned by high U.S. rates of such common STIs as HPV, genital herpes, and
chlamydia, as well as local outbreaks of syphilis and gonorrhea, the Centers for Disease
Control and Prevention began a new far-reaching campaign to combat STIs (Stolberg,
1998).
More than 25 pathogens are spread primarily through sexual activity, and
although there is a smaller group that is more prevalent than others (Table 1), they pose a
significant public health challenge. More is known about the frequency and trends of
some of these STIs than others, because many of the diseases are difficult to track (CDC,
2001).
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Table 1
Major STI Pathogens
Pathogen

Type of Infection

Neisseria gonorrhoeae

Disease Name or
Associated Condition
Gonorrhea

Treponema pallidum

Syphilis

Bacterial

Chlamydia trachomatis

Chlamydia

Bacterial

Haemophilus ducreyi

Chancroid

Bacterial

Klebsiella granulomatis

Granuloma inguinale or

Bacterial

Bacterial

donovanosis
Herpes simplex virus

Genital herpes

Viral

Human papilloma virus

Genital warts

Viral

Hepatitis B virus

Viral

Cytomegalovirus

Viral

Trichonomas vaginalis

Vaginitis

Parasitic

Candida albicans

Yeast infection in women
and inflammation of the
glans penis and foreskin in
men

Parasitic

Adapted from the Joint United Nations Programme on HIV/AIDS (UNAIDS). (May
1998). The public health approach to STD control: UNAIDS Technical Update.
The Centers for Disease Control and Prevention (2004) estimate that 19 million
new infections occur each year, with almost half of them being among young people,
ages 15 to 24 (Weinstock, Berman, & Cates, 2004). Only three out of numerous STIs
that affect adolescents and young people are reportable – chlamydia, gonorrhea, and
syphilis – and they have been useful for examining overall trends among these high-risk
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populations. However, the data on these populations represents only a small proportion
of the true burden of STIs in the U.S. Many cases of the notifiable STIs are not
diagnosed because of being asymptomatic or not treated, and some highly prevalent viral
infections that are not curable, such as genital herpes and HPV, are not reported at all
(CDC, 2004). Neither HPV infection nor genital warts are routinely reported to the state
health departments for the following reasons: 1) No justification exists for recommending
STI case reporting – even though numerous epidemiological studies have demonstrated
that HPV is the most prevalent of all the sexually transmitted infections; 2) most HPV
and genital herpes infections clear spontaneously, and 3) case reporting would create a
large burden for providers, health departments and laboratories due to the high
prevalence of HPV infection (CDC, 1999).
Epidemiology, Detection, and Natural History of HPV
Epidemiology of HPV. Data on HPV prevalence and incidence is limited
because it is not a reportable STI. Because of HPV being non-reportable, the scope and
magnitude of genital HPV infection is derived from extrapolations of epidemiological
studies. Those studies that detect HPV DNA measure current infection, and studies that
detect HPV antibodies using blood tests provide approximation of lifetime infection
(CDC, 2004). The HPV trend data that are available demonstrate that HPV prevalence
has increased at an alarming rate, as millions of people have been diagnosed with the
virus over the past two decades (Hager et. al, 2004). Based on the available data and
comparison with other STI infections, HPV is reported as the most prevalent of all viral
sexually transmitted infections, more common than herpes and HIV combined, and HPV
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has been referred to as the most common STI among young, sexually active people
(CDC, 2001).
Overall, in the U.S., an estimated 20 million people, or 15% of the population, are
currently infected with HPV, and 50% to 75% have the high-risk type of HPV, or the
type of HPV that can potentially cause cancer. The most recent incidence rate reported is
that approximately 6.2 million people are infected with HPV each year (Weinstock &
Cates, 2004). It is important to note, however, that the annual HPV infection rates are
likely to be higher than 6.2 million people, because this figure is from 2000. The data
from the CDC STD –Surveillance 2008 report indicates that the overall STI infection has
risen to 19 million in 2008 from 15 million in 2000. Because almost half of the 19
million new infections occur among sexually active youth, ages 15 to 24, and HPV is
reported as the most prevalent STI among this age group, the annual HPV infection rate
may currently be higher than 6.2 million people.
The DNA HPV virus causes infection among both sexually active men and
women, although it is most common among adolescent and young adult women (Hager et
al., 2004). It has been estimated that at least 50% of sexually active men and women
acquire genital HPV infection at some point in their lives, and 80% of women will have
acquired genital HPV by age 50 (Koutsky et al., 1988; Myers, McCrory, Nanda, Bastian,
& Matchar, 2000).
Prevalence studies in the U.S. have included primarily convenience samples of
women attending managed care, STI, or university clinics. These studies have found that
the prevalence of HPV infection is lowest in women who have never had sexual
intercourse (Fairly et al., 1992; Koutsky & Kiviat, 1999; Rylander, Ruusuvaara,
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Almstromer, Evander, & Wadell, 1994; Winer et al., 2003), and is especially common
among sexually active women, less than 25 years of age, with prevalence decreasing with
increased age (Baken et al., 1995; Bauer et al., 1993; Bauer et al., 1991; Burk et al., 1996;
Giuliano et al., 2002; Ho, Bierman, Beardsley, Chang, & Burk, 1998; Ley et al., 1991;
Peyton et al., 2001; Wheeler et al., 1993).
Detection of HPV. Human papillomaviruses are members of the
Papillomaviridae family of DNA viruses. Because HPV cannot be cultured easily in the
laboratory, HPV infection is most commonly diagnosed by detecting abnormal cells in
the cervix by a Pap test and detecting HPV DNA via a sampling of the cervical cells
(CDC, 2004). Blood tests that detect the antibodies to the outer protein of the DNA have
been useful in detecting previous HPV infection (Stone et al., 2002). However, an HPV
DNA test is now available that can analyze biopsies and cells from a liquid- based Pap by
nucleic acid hybridization to detect the presence of high-risk types of DNA (Digene
Corporation, 2004). There can be false negatives with the Pap test, as it has been shown
to be 50% to 80% accurate in identifying women with cancer and cervical disease. A
study by Leyden, et al. (2005) revealed that one-third of all cervical cancers occurred due
to Pap test failure. Therefore, the ability to detect women at high risk of cervical cancer
is greater when the HPV test is used in conjunction with the Pap test, than using the Pap
test alone.
Some researchers and clinicians have expressed concern that increased public
awareness of the link between HPV and cervical for screening cancer could lead to
stigmatization of cervical cancer, resulting in women’s reluctance to be screened because
the virus is sexually transmitted (Waller, Marlow, & Wardle, 2007). This idea is
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consistent with findings from studies on other STI screening, such as chlamydia,
gonorrhea and HIV (Duncan, Hart, Scoular, & Bigrigg, 2001; Fortenberry et al., 2002).
Some qualitative studies assessing reaction to HPV testing have had similar results, as
women testing positive for HPV in the context of cervical screening report feelings of
stigma and shame, but only when they are aware that the virus is sexually transmitted.
Studies have also demonstrated that higher anxiety is associated with a HPV diagnosis
compared to an abnormal Pap test result. However, a recent study demonstrated that
increasing awareness about the sexually transmitted nature of HPV among young women
may reduce stigma, shame and anxiety associated with HPV diagnosis, perhaps by
increasing the normalization and social acceptability about the infection (Waller et al.,
2007).
The prevalence of genital HPV infection in men is more difficult to assess
because it is not clear which are the optimal anatomic sites or specimens to test. Most
published studies have been conducted outside the U.S., in men attending STI or
university clinics, or among male partners of women with HPV infection, and have
demonstrated that HPV DNA in men can be detected in the penis, urethra, scrotum or
anus as well as in urine and semen (Baldwin et al., 2003; Aynaud, Poveda, Huynh,
Guillemotonia, & Barrasso, 2002; Svare et al., 2002).
Differences in DNA sequences are used to determine different types, and more
than 100 types of HPV DNA sequences have been identified. Over 30 HPV sequences
identified can infect the genital area. Although the majority of genital HPV infections
cause no symptoms and may go away on their own, some HPV types can cause cervical
cancer in women (CDC, 2004).
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Natural history and progression of HPV. Adolescent and young adult women
are biologically more susceptible to HPV disease because the cervix has not yet reached
its maturity, and the cells of the cervix are more susceptible to bacterial and viral
infection with STI pathogens, such as chlamydia, gonorrhea, and HPV. Sometimes the
cells on the immature cervix can form into pre-cancerous cells, also called cervical
dysplasia, and cervical dysplasia can evolve to cervical cancer (Joffe et al., 1992).
Most HPV infections are transient and asymptomatic, causing no clinical
problems. For most adolescents, HPV infection is cleared by the immune system (Hillard
& Kahn, 2005). Studies have shown that 70% of new HPV infections clear within one
year and as many as 91% clear within two years (Molano et al., 2003; Franco et al., 1999;
Ho et al., 1998). Some types of HPV may cause warts to appear on or around the genitals
and anus. Genital warts, technically known as condylomata acuminata, are most
commonly associated with two HPV types, HPV-6 and HPV-11 (NCI, 2004). Only about
10% of patients infected with HPV have genital warts, and the incubation period between
HPV infection and genital warts ranges from 30 days to 9 months and once a person is
infected, the virus persists for an average of 8 months, with a range of 3 to 15 months (Ho
et al., 1998).
Some types of HPVs are referred to as “low-risk” viruses because they rarely
develop into cancer, and those HPVs that are referred to as “high-risk” are more likely to
develop into cancer. Both high-risk and low-risk types of HPVs can cause abnormal cell
growth, but generally only the high-risk HPV types will lead to cervical cancer.
Approximately 18 high-risk types have been identified that potentially can cause cancer
but most of these disappear and do not evolve into cancer. However, there are two high52

risk types that are most likely to persist than others, HPV-16 and HPV-18. These highrisk types are responsible for more than 70% of all cervical dysplasia and cancer
(Clifford, Smith, Plummer, Munoz, & Franceschi, 2003; Handsfield, 1990; NCI, 2004).
HPV and Cervical Cancer
Since the late 1800s, researchers have suspected that cervical cancer was sexually
transmitted as medical records from this time noted that nuns and virgins were not likely
to have cervical cancer. Also, wives of men who traveled often, or who were previously
married to women who died of cervical cancer, were more likely to develop cervical
cancer (Cockerell, 1995). At the present time, certain types of HPV have been
established as causal agents in the development of cellular changes that can evolve into
cervical cancer (Janicek & Averette, 2001). Persistent infection with HPV is the leading
cause of cervical cancer, and progression from HPV into cervical cancer is estimated to
take 10 to 15 years (NCI, 2005). The mechanism through which HPV causes cancer is
related to specific parts of the virus’s genetic structure called oncogenes. The genetic
mechanisms of cervical cancer are still unknown as there are opposing scientific views as
to whether there is a gene associated with susceptibility to HPV-associated cervical
cancer (de Araujo Souza & Villa, 2003). Studies have demonstrated that HPV itself
causes a change in the cell’s genetic structure that can cause abnormal cell growth and
cancer (O’Brien et al., 2001; Goodwin & DiMaio, 2001). HPV has two oncogenes – E6
and E7 - that can interfere with normal cell function, cause abnormal cell growth, and can
prevent the repair of damaged cells. The action of these oncogenes can cause
precancerous changes in cervical cells, called dysplasia, or even more serious, squamous
cancer cells of the cervix, also referred to as cervical cancer. This same process also can
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damage and transform cells of the vulva and anus of females, and cells of the penis and
anus in males (Hager et al., 2004).
Based on numerous studies, the International Agency for Research on Cancer and
the U.S. National Institutes of Health (NIH) have concluded that high-risk genital HPV
infections act as carcinogens in the development of cervical cancer (NIH, 1996; WHO,
1995). Therefore, while infection with the high-risk types of HPV appears to be
necessary for the development of cervical cancer, it is not sufficient because the majority
of women infected with HPV do not develop cervical cancer (NIH, 1996; WHO, 1995).
Other co-factors appear to be necessary for HPV to evolve into cervical cancer, such as
smoking, long-term use of hormonal contraceptives, immune suppression, low vitamin
intake or absorption, and co-infection with other STIs such as chlamydia, HIV, syphilis,
cytomegalovirus, herpes simplex virus type-2, and, possibly, regular exposure to
secondhand smoke (Castellsague, Bosch, & Munoz, 2002; Castellsague & Munoz, 2003;
Castle et al., 2003; Gunnell et al., 2006; Harris et al., 2004; Hildesheim et al., 2001;
Munoz, 2000; Munoz & Bosch, 1989; Sedjo et al., 2003; Smith et al., 2002; Trimble et
al., 2005).
Several decades ago, cervical cancer was one of the most common and deadly
cancers in women in the U.S. (Eddy, 1990). Since the middle of the 20th century, cervical
cancer mortality has decreased by over 70% in the U.S. because of cervical cancer
screening through the use of the Pap test (Kahn & Hillard, 2005). However, cervical
cancer is the third most common cancer worldwide, as nearly 500,000 new cases are
identified each year, with 80% of cases being identified in developing countries (Ferlay,
Bray, Pisani, & Parkin, 2004). Cervical cancer remains a leading cause of death among
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women in some developing countries where there is a high incidence of cervical cancer,
such as Latin America, the Caribbean, Sub-Saharan Africa, South Asia, and where access
to cervical cancer screening is limited (Danaei et al., 2005; Katz & Wright, 2006; Pisani,
Parkin, Bray, & Ferlay, 1999). In the United States, high cervical cancer mortality has
been found among African-Americans in the South, Latinos along the Texas-Mexico
border and Caucasians in Appalachia, most likely due to poor access to health care and
Pap screening (Freeman & Wingrove, 2005).
The purpose of the Pap test is to detect abnormal changes in cervical cells, so that
the cells can be treated, preventing the progression of abnormal cells into cervical cancer.
In addition, the Pap test can be used to detect cervical cancer at a very early stage (Myers,
McCrory, Nanda, Bastian, & Matchar, 2000). Survival rates for cervical cancer are high
if the disease is detected early and managed promptly (American Cancer Society, 2003).
The Pap test is often included in the standard gynecological exam but the optimal age to
begin Pap screening is unknown. Data on the natural history of HPV infection and the
incidence of high grade lesions and cervical cancer suggest that screening can be safely
delayed until three years after a woman has become sexually active or by age 21,
whichever comes first (Smith et al., 2002). How often a woman should receive a Pap test
depends upon multiple factors, such as age, results of past Pap tests, medical history,
history of STIs, and whether or not she is a smoker (U.S. Food and Drug Administration,
2005). The American College of Obstetricians and Gynecologists recommend that
women under the age of 30 receive annual Pap tests (USDHHS, 2005). The U.S.
Preventive Services Task Force guidelines recommend that women have a Pap test at
least once every three years, beginning about three years after they begin to have sexual
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intercourse, but no later than age 21 (NCI, 2005). Experts recommend waiting
approximately three years following the first sexual encounter because most HPV
infections and cervical cell changes are transient and it takes a few years for any
significant cell abnormalities to develop. In addition, cervical cancer is rare in women
under the age of 25. Therefore, having a first Pap by the age of 21 should help detect
cervical cell changes at early stages (NCI, 2003).
Because of the Pap test, cervical cancer has become relatively uncommon among
women in the U.S. because the Pap test can detect precancerous cells in the cervix before
they develop into cancer. However, cervical cancer has a major global impact on
women’s health. Nearly 500,000 new cases of cervical cancer occur each year among
women, and 274,000 of women die of this disease annually. Over 80% of cervical cancer
cases occur in developing countries (Parkin, Bray, Ferlay, & Pisani, 2005). Cervical
cancer is the most common cause of cancer in developing countries and the leading cause
of cancer death among women in developing countries, especially in the poorest regions,
where cervical cancer screening is not available or limited (Danaei et al., 2005; WHO,
2004). Regions with the highest incidence of cervical cancer include Central and South
America, the Caribbean, sub-Saharan Africa, and Asia (Parkin, et al., 2005).
Although cervical cancer is not as common in the U.S. as it was 40 or more years
ago, the disease remains a serious health threat among women. All women are at risk for
cervical cancer, and it is most often diagnosed in women aged 30 and older (CDC, 2008).
Approximately 12,200 women develop cervical cancer each year in the U.S., and
approximately 4,100 women die from cervical cancer each year (American Cancer
Society, 2003). Approximately half of these cases will occur among women who have
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never been screened, and an additional 10% will occur in women who have not been
screened in the past five years (National Institutes of Heatlh, 1996). It is estimated that
approximately 1.7 billion dollars each year is spent annually on cervical cancer treatment
in the U.S. (Brown, Riley, Schussler, & Etzioni, 2002).
Recent trends show that the cervical cancer incidence rates for Hispanic women
are higher than for non-Hispanic women. Furthermore, the cervical cancer death rate
among African-Americans continues to be twice as high as that among Caucasian women
(NCI, 2005). In addition, both screening and treatment procedures are costly. A recent
National Health Interview Survey (2000) indicated that cervical cancer screening is not
adequate among some women in the U.S., as approximately 18% of women of
reproductive age have not had a Pap test in the last three years (Swan, Breen, Coates,
Rimer, & Lee, 2003). The higher cervical cancer rates among these ethnic populations
demonstrate that racial and ethnic health disparities remain a challenge in cervical cancer
screening. In addition to racial and ethnic issues, additional challenges exist in cervical
cancer prevention, such as the high cost of screening and treatment procedures, abnormal
results of a Pap test may lead to psychological distress, and treatment procedures may be
painful and associated with long-term health consequences. The availability of a vaccine
for primary prevention of the high-risk types of HPV associated with cervical cancer may
help to remove some of the limitations that are currently involved with cervical cancer
screening and treatment (Hillard & Kahn, 2005).
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Transmission and Prevention of HPV
Transmission of HPV. HPV is transmitted by skin-to-skin contact, as the virus
requires access to superficial skin cell layers or basal cells. HPV can infect basal cells
through micro-abrasions or small tears in the superficial or mucosal layers of the skin that
are often produced by sexual activity (Schiffman & Kjaer, 2003). In rare cases, HPV also
can be transmitted from a mother to her newborn baby during vaginal delivery, and this
process can result in recurrent respiratory papillomatosis (RRP) that can be fatal if the
papillomas or small growths block the airway (Moscicki, 2005; Recurrent Respiratory
Papillomatosis Foundation, 2005). In addition, unexplained and rare cases of HPV have
been reported in newborns delivered by cesarean section (Smith et al., 2004). Finally,
casual contact or sexual abuse may produce genital warts in children (Kahn, 2005).
Genital HPV infection occurs primarily as a consequence of genital contact,
mostly through sexual intercourse (Koutsky & Kiviat, 1999; Schiffman & Kjaer, 2003).
HPV infection has been reported among women who have had sex with women and who
have never had sexual intercourse with men, and among women who had genital contact
but not sexual intercourse with men (Marrazzo, Koutsky, Kiviat, Kuypers, & Stine, 2001;
Winer et al., 2003). Therefore, HPV can be transmitted through other types of genital
contact, such as skin-to-skin contact during finger and genital foreplay that does not
include intercourse, oral-genital contact and through the use of sex toys (Moscicki, 2005;
Winer et al., 2003). In rare cases, individuals who have oral-genital sex with other
persons infected with HPV may also be at risk of developing RRP (Kashima, Mounts, &
Shah, 1996; Clarke, Terry, & Lacey, 1991).
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Alternative routes of HPV transmission are less common than the route of sexual
intercourse (Coutlee et al., 1997; Marrazzo, Stine, & Koutsky, 2000). Adolescents or
young adults who abstain from sexual intercourse, but not other forms of sexual activity,
remain at risk, and those persons who use condoms to protect themselves from STIs and
pregnancy during sexual intercourse are still at risk of acquiring HPV at infected skin
sites not covered by a condom (Winer et al., 2003).
The most consistent predictor of HPV infection has been the total number of sex
partners (Ho, Bierman, Beardsley, Chang, & Burk, 1998; Karlsson et al., 1995; Koutsky,
1997; Moscicki et al., 2001). Among women, the risk of contracting HPV infections
increases with an increased number of lifetime sex partners. In addition, having sex with
a new partner may place a person at higher risk than having sex with a steady partner
(Castle et al., 2002; Karlsson et al., 1995; Ley et al., 1991; Peyton et al., 2001).
Furthermore, a woman’s risk of HPV infection is impacted by the sexual activity of her
partner. Studies have shown that female adolescents and young women with partners
who had previous multiple sex partners and with an unknown number of prior sex
partners had a significantly greater risk of contracting HPV compared to those females
who had male partners with no prior sex partners (Winer et al, 2003; Moscicki et al.,
2001). Infection with HPV among women may be controlled by factors other than
having sex with an infected partner. The likelihood that an uninfected person woman
will become infected with HPV may be influenced by age and immunity. The risk of
HPV infection decreases with increased age, and this may be due to older women
developing an acquired immunity to HPV from previous exposure (Burk et al., 1996;
Centers for Disease Control and Prevention, 2004; Moscicki, 2005). However, it is
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difficult to determine when a woman is more susceptible to being infected with HPV
based upon whether her immune system will be able to combat the virus or if she has had
past exposure to the virus. The detectability of HPV DNA in a given individual varies
over time. Therefore, determining if a person is infected or if an infection is new or preexisting is an arduous task (Moscicki et al., 1998; Schneider, Kirchhoff, Meinhardt, &
Gissmann, 1992). Due to the asymptomatic and transient nature of the virus and the fact
that it is difficult to confirm current or past infection with the virus at any given time,
sexually active adolescents and young adults must take preventive measures to ensure as
much protection as possible from becoming infected with HPV.
Prevention of HPV. The most effective method to prevent HPV transmission is
to abstain from sexual activity that can result in direct contact with the virus. However,
this practice is not a realistic one for many adolescents and young adults, as most are, and
continue to be, sexually active. Therefore, adolescents and young adults need to be
educated about HPV, the risks associated with HPV, and methods of protection.
The most common approach to preventing HPV and other STIs is the use of
physical barriers such as condoms. Although condom use is often perceived by health
care professionals as important in the control of HPV infections (Moscicki, 2005), recent
reviews of studies involving the male latex condom in the prevention of STIs concluded
there is no substantial evidence from epidemiological studies that demonstrates its
effectiveness in preventing HPV infection. However, some authorities view these studies
as inadequate for drawing conclusions due to their methodological shortcomings
(Manhart & Koutsky, 2002; NIAID, 2001).
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Use of latex condoms during sexual intercourse may provide some protection in
reducing HPV infection on some parts of the penis as studies have demonstrated that
latex condoms provide an adequate barrier to molecules that are the size of HPV (Lytle,
Duff, et al., 1997; Lytle, Routson, et al., 1997). Some studies also suggest that condoms
reduce the risk of outcomes of genital warts and cervical cancer. Possible explanations
for reducing these outcomes is that condoms reduce the quantity of HPV transmitted or
decrease the likelihood of re-exposure , thereby decreasing persistent infection and the
chance of the progression of the virus into genital warts or cervical cancer (CDC, 1999;
Hogewoning et al., 2003; Manhart & Koutsky, 2002). Another alternative explanation is
that condom use may reduce the risk of an individual developing a co-factor, such as
chlamydia or genital herpes, thereby reducing the risk of a high-risk type of HPV
progressing into cervical cancer (Manhart & Koutsky, 2002). However, correct and
consistent use of condoms would not be expected to offer complete protection against
HPV because infections also may occur at sites not covered by a condom, such as the
scrotum, groin area, base of the penis, and anus (Change, Perry, Kurland, & Ilstrup, 1984;
Hippelainen et al., 1993; Kennedy, Buntine, O’Connor, & Frazer, 1988; Krebs &
Schneider, 1987; Schultz et al., 1990; van den Hoek, Coutinho, & Quin, 1994; Van
Doornum et al., 1994; Weaver et al., 2004). For women, HPV infection can occur on the
outside of the vulva, an area that comes into contact with the genital skin of a man using
a condom during intercourse. In addition, HPV infection can be transmitted through
finger-to-genital contact during foreplay and oral-genital contact during oral sex, further
supporting the belief that condom use is not a completely effective method in preventing
HPV. Based on these studies, latex condoms would not be a good primary strategy for
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preventing HPV, but, perhaps, could be used in combination with other methods of
prevention.
Practicing other safer sex behaviors, in addition to condom use, also may be
effective in preventing HPV. Engaging in safer sex behaviors is what individuals can do
to lower their risk of developing HPV (Planned Parenthood Federation of America,
2004). Examples of safer sex behaviors include abstinence from sexual intercourse or
any type of sexual activity that increases the risk of getting an STI. Safer sex behaviors
also can include communication, such as asking a partner to get tested for HPV before
participating in sexual activity and communicating with partners about concerns about
STIs. Practicing intimate behaviors that are alternatives to sexual intercourse, such as
kissing and massaging, are considered safer sex practices. For individuals who are
sexually active, staying in a monogamous relationship with a partner who has been tested
and has not had any history of STIs can be considered practicing safer sex. If a vaccine
were available for a particular STI, being vaccinated against that STI also could be
considered a protective behavior.
Topical microbicides have been proposed as agents to prevent transmission of
certain STIs, including HPV. These agents are thought to prevent HPV by inactivating
the virus at the mucosal surface where infection can occur (Coutlee & Voyer, 1998;
Howett & Kuhl, 2005). Evaluation of the ability of microbicides to prevent genital HPV
infection has been limited by the difficulties in cultivating HPV in vitro (CDC, 1999).
Recent laboratory studies suggest that some compounds may inhibit HPV infection
(Coutlee & Voyer, 1998; Christensen et al., 2001; Howett et al., 1999; Sokal &
Hermonat, 1995). Currently, over 60 microbicides are in clinical trials and over 40 are in
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pre-clinical development, and some of these future microbicides may be effective in
preventing HPV as well as other STIs (CDC, 2004; Howett & Kuhl, 2005).
In addition to certain preventive measures, treatment for genital warts and
precursors to cervical cancer may reduce disease infectiousness. Current treatment
options for both genital warts and pre-cancerous cells include a variety of local
procedures that remove high-grade and low-grade cervical lesions, such as cryotherapy,
electrocautery, laser therapy, and surgical incision. Genital warts also are treated with
topical agents and immune stimulating drugs, such as Imiquimod (Beutner, Reitano,
Richwald, & Wiley, 1998). Although topical agents for genital warts and removal of
cervical lesions do not cure the virus, they may lower its infectivity by reducing the
amount of HPV DNA in the skin, although the impact that these agents have in reducing
the virus remains unclear (Beutner et al., 1998; Bodner et al., 2002; Bollen et al., 1999;
Costa et al., 2003; Elfgren, Jacobs, Walboomers, Meijer, & Dillner, 2002; Centers for
Disease Control and Prevention, 2004; Jain, Tseng, Horng, Soong, & Pao, 2001;
Kjellberg et al., 2000). There is often a 10% to 20% recurrence rate of HPV-associated
lesions following standard therapy (Mitchell et al., 1998; Wright, Cox, Massad, Twiggs,
& Wilkinson, 2002) and 20% to 50% recurrence rate after treatment of genital warts
(Beutner et al., 1998). The area between normal skin and the cervical mucosal layer near
HPV-associated lesion may create a reservoir that harbors HPV. Such a reservoir may be
the explanation for the recurrence of cervical lesions and genital warts (Colgan et al.,
1989; Ferenczy, Mitao, Nagai, Silverstein, & Crum, 1985). In addition, treatment of
partners of persons infected with HPV does not influence recurrence rates of genital
warts or cervical lesions. This lack of influence may be due to the persistence of HPV
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infection in the skin and mucosal layer (Krebs & Helmkamp, 1991). Therefore, current
available therapies may reduce, but not eliminate, HPV infection, in the cases where HPV
does not subside on its own.
Vaccination as an effective prevention strategy. Vaccination is an essential
component of modern public health programs and is among some of the most costeffective medical interventions. Vaccines have been the most effective public health
tools for preventing disease, disability and death and controlling health care costs (CDC,
1999; Hilleman, 2000; WHO, 1999). Prevention can save the health care industry
billions of dollars in health care costs by eliminating physician visits, hospitalizations and
treatments for diseases that are otherwise preventable, such as through vaccination.
Vaccination can be an effective preventive strategy for reducing the incidence and
prevalence of STIs. Vaccines that protect against the most common and progressive
HPV types are predicted to prevent thousands of cases of cervical cancer worldwide
(Harper, 2004). In addition, significant savings in health costs associated with treating
HPV can result (Goldie et al., 2004; Kulasingam & Myers, 2003; Taira, Neukermans, &
Sanders, 2004).
Vaccines in development fall into two categories – prophylactic and therapeutic.
Prophylactic vaccines are designed to prevent primary HPV infection by inducing a
virus-neutralizing antibody that provides protection against infection with the virus. The
HPV vaccines developed by Merck & Co., Inc. and GlaxoSmithKline are referred to as
prophylactic vaccines, as they are effective in preventing HPV infection and the
progression of HPV into pre-cancerous cells. Therapeutic vaccines are designed to
prevent progression of HPV infection to low-grade or high-grade squamous
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intraepithelial lesions that can lead to cervical cancer, to reduce cervical intraepithelial
neoplasia or the amount of abnormal cells in the cervical lining, and to prevent the
development of genital warts. In addition to preventive characteristics, the design of
therapeutic HPV vaccines enables them to treat cervical cancer, by eliminating residual
malignant cells (Kahn, 2005, Marshall, 2003).
The purpose of the HPV vaccine is to prevent infection with HPV-16 and HPV18, two high-risk types that cause over 70% of all cervical cancer cases, and to prevent
infection with HPV-6 and HPV-11, two low-risk types that are primarily responsible for
the development of genital warts. Currently, there are two competing vaccines:
GARDASIL® developed by Merck & Co., Inc., and Cervarix® developed by
GlaxoSmithkline. GARDASIL® is a quadrivalent vaccine that protects against HPV-16,
18, 6 and 11; therefore, it protects against HPV types implicated in genital warts and
cervical cancer. Cervarix® is a bivalent vaccine that protects against HPV-16 and HPV18, and therefore, protects only against cervical cancer.
Numerous clinical studies have demonstrated that the vaccines are effective in
three different doses, with a low dose administered over a six-month time period,
specifically at baseline, two months, and six months (Harper et al., 2004; Koutsky et al.,
2002; Mao et al., 2006; Villa et al., 2005; Reinis, 2004; Wheeler et al., 2005). These
clinical trials have demonstrated that the vaccine is nearly 100 percent effective in
preventing HPV in girls and women between the ages of 9 and 26. Due to high vaccine
efficacy, the FDA approved the use of the GARDASIL® vaccine in pre-adolescents,
adolescents and young women. GARDASIL® or Cervarix® may also benefit women over
the age of 26; however, it will depend on the duration of vaccine efficacy. According to
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Harper (2009), if the duration of vaccine efficacy is greater than 15 years, there may be
health benefits and cost savings associated with the prevention of new HPV infections
and cervical cancers in young women and women over 25 years of age.

A clinical trial

by Shwarz (2006) has demonstrated that GlaxoSmithKline’s vaccine is effective in
preventing HPV types 16 and 18 in adolescents and women ages 15 to 55, and Merck &
Co., Inc. is awaiting approval from the FDA to expand the use of GARDASIL® in
women, ages 27 to 45 (Merck & Co., Inc., 2008a)
Overall, there are many positive outcomes associated with the HPV vaccines.
Clinical trials suggest that the vaccines are capable of producing an immune response
against specific types of HPV, are safe, well tolerated with minimal side effects, and
prevent both HPV infection and cervical cancer. One clinical trial demonstrated that
GARDASIL® is also safe and effective when administered with the Hepatitis B vaccine –
the only other STI vaccine in the U.S. (Merck & Co., Inc., 2006). However, certain
clinical outcomes remain in question, such as how long the vaccine is effective,
expressed in duration of antibody response after vaccination, and impact of vaccination
on cervical cancer screening and other health-related behaviors, including safer sex
behaviors (Christensen, 2005; Schiller & Davies, 2004).
Potential priority populations identified by pharmaceutical companies and
immunization experts to receive the HPV vaccine have included children and
adolescents, ages 11 to 15, young adult women, ages 18 to 25, and women over the age
of 25 who have been diagnosed with an infection from HPV-16 or HPV-18 and need to
protect themselves against cervical cancer (Kahn, 2005; Koutsky, 2005; Monteyne,
2005). In June 2006, FDA approved the use of GARDASIL® in girls and young women,
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ages 9 to 26. Before vaccine approval, it was unclear as to whether the vaccine would be
promoted as an STI vaccine or a cervical cancer vaccine, and which approach would be
more acceptable, not only to those included as priority populations, but to society in
general. Acceptance of the HPV vaccine among those prioritized for receiving the
vaccine and those administering the vaccine, in addition to societal acceptance, are
critical components for development and success of future HPV vaccination programs.
Merck & Co., Inc. is marketing the vaccine as a cervical cancer rather than an STD/STI
vaccine, and is providing GARDASIL® to the poor and uninsured (Associated Press,
2006).
Vaccine Therapy and Acceptance
At the beginning of the 20th century, the most serious threat to human life and
well-being was infectious disease. Outbreaks of diseases such as diphtheria and pertussis
were common, and mortality was significant. For example, 160 of every 1,000 children
born at the beginning of the 20th century died of an infectious disease before the age of
five years (Waldman & Kluge, 1984). Today, parents in developed countries no longer
fear these diseases due to vaccine availability.
However, the development of vaccines has a history of provoking controversy. In
the late 1800s, Louis Pasteur’s administration of the first rabies vaccines to humans was
strongly protested by physicians and the public, and efforts to immunize British troops
against typhoid at the turn of the 20th century were bitterly opposed despite the
encouraging results of earlier immunization efforts and the serious risk of typhoid faced
by troops serving in the Boer War (Plotkin & Mortimer, 1994). In the mid-1950s,
vaccines were developed that were effective against diphtheria, pertussis, tetanus,
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typhoid, rabies, and polio, and as vaccines came into more widespread use, the incidence
of these diseases rapidly declined. In addition, advances in vaccine technology brought
substantial reductions in the incidence and severity of side effects associated with rabies
and typhoid vaccines. Especially after the availability of the Salk polio vaccine, the
benefit to any vaccinated child was clear, and eliminating the possibility of contracting
disease far outweighed the small risk of a serious adverse side effect. As a result, public
concerns about vaccines lessened and there was an increased acceptance of vaccination as
a valuable safeguard of individual and public health (Ellenberg & Chen, 1997). In the
late 1970s and early 1980s, there was concern over the safety of the whole-cell pertussis,
also referred to as “whooping cough”, vaccine (CDC, 1997). A few parents who believed
their children had been seriously injured as a result of vaccination brought their concerns
to the public about adverse events in Japan and the United Kingdom. Such notoriety led
to a decline in immunization rate, and pertussis, once again, became the cause of an
epidemic (Kimura & Kuno-Sakai, 1990; Miller, Madge, Diamond, Wadsworth, & Ross,
1993). A similar increase in pertussis occurred in Sweden after the country discontinued
the pertussis vaccination due to concerns over its efficacy and safety (Krantz, Taranger,
& Trollfors, 1989). Whereas public acceptance of the pertussis vaccine remained high in
the United States, numerous lawsuits were filed against vaccine manufacturers (Hinman,
1986). This flurry of litigation resulted in major increases in prices and decisions by
pharmaceutical companies to discontinue pertussis vaccines, thereby creating a temporary
vaccine shortage (CDC, 1984; Mariner & Clark, 1986).
In response to these events, significant steps were taken in the United States to
assess and increase the safety of vaccinations, such as the passage of the National
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Childhood Vaccine Injury Act (NCVIA) in 1986 that led to the development of the
Vaccine Adverse Event Reporting System (VAERS) (Chen et al., 1994). The VAERS,
Vaccine Safety Datalink and Clinical Immunization Safety Assessment are three systems
currently used to monitor the safety of vaccines after they are licensed and administered
in the United States. The safety of the HPV vaccine, GARDASIL®, has been closely
monitored by these systems since its licensure in 2006 (CDC, 2008).
In addition to the existence of vaccine safety surveillance programs, vaccines
must go through extensive clinical testing before they are marketed. However, unlike
many other initiatives of the medical and pharmaceutical communities, vaccination
programs primarily focus on children, and society is less willing to accept and impose
unnecessary risks on healthy infants and children. Therefore, vaccine developers must be
particularly sensitive to the risks of adverse effects (Ellenberg & Chen, 1997).
Although vaccines have proven to be effective in reducing the risk of diseases that
have caused millions of deaths among certain populations and disabled many people,
there is still controversy over their benefits (Ellenberg & Chen, 1997). There has been an
increasing concern, especially among parents, that the negative side effects of vaccines
and vaccines that have prevented so much morbidity and mortality now cause more harm
than is justified by the benefits they offer (Ellenberg & Chen, 1997). As a result,
increasing numbers of parents are refusing immunizations for their children. A variety of
factors are responsible for this concern: religious and philosophical beliefs; freedom and
individualism; mistrust of the government; misinformation and overperception about
health risks associated with vaccines. A major concern regarding negative vaccine side
effects has been related to the preservatives in certain childhood vaccines and autism.
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The internet exacerbates this fear regarding vaccine safety as numerous web sites publish
unfounded, alarming information about the risks of vaccines (Calandrillo, 2004).
However, studies haved found no definitive link between any of the childhood
vaccinations and autism or autistic spectrum disorders (Fombonne & Chakrabarti, 2001;
Halsey, Hyman, & Conference Writing Panel, 2000).
There have been over 10,000 VAERS report of adverse events following
GARDASIL®, and 94% of these reports are considered to be non-serious, and 6% of
these reports are considered to be serious. The most common non-serious side effects
associated with GARDASIL® vaccination have included fainting, pain and swelling at the
injection site, headache, nausea, and fever. Based on all the information about the
vaccine to-date, the CDC and FDA have determined that GARDASIL® is safe to use and
effective in preventing four types of HPV. However, as with all vaccines, the CDC and
FDA will continue to monitor the safety of the HPV vaccine (CDC, 2008).
Although the HPV vaccine has proven to be safe with limited side effects (CDC,
2008; Zahn, 2005), the vaccine poses another challenge for acceptance as it is a vaccine
that has been designed to prevent STI infection, and therefore, vaccinating children
before they become sexually active is a priority. This vaccine, therefore, requires
parental consent for children under the age of 18, and before the vaccine was approved,
there was concern as to whether parents would accept a vaccine to prevent an STI that is
administered to children. There were questions as to whether health care providers,
parents, and adolescents would be comfortable with administering an STI vaccine for an
STI that is poorly understood by many adolescents and young women (Rosenthal, 2005;
Zimet et al., 2000). There have been questions as to whether most parents would be
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willing to have their children vaccinated. The research to-date on parental attitudes about
HPV/STI vaccination has revealed that the majority of parents, across a variety of
countries, are interested in protecting their children against HPV and other STIs, and
would view an HPV vaccine beneficial for their adolescents. Parent acceptability has
been the best predictor of their adolescents’ attitudes about STI vaccines, a point
suggesting that parents’ beliefs influence adolescent beliefs about STI prevention and
vaccines. Vaccine efficacy was the most important issue regarding vaccination against
STIs, followed by severity of infection, availability of behavioral prevention, and sexual
transmissibility (Zimet et al., 2005). Concern about STI vaccination leading to unsafe
sex was associated with lower acceptability, but the majority of parents recognized that
the benefits of an HPV vaccine significantly outweigh the risks of becoming infected
with HPV (Davis, Dickman, Ferris, & Dias, 2004; Dempsey, Zimet, Davis, & Koutsky,
2006; Lazcano-Ponce et al., 2001; Olshen, Woods, Austin, Luskin, & Bauchner, 2005;
Zimet, Mays, et al., 2005; Zimet et al., 2005). Whereas studies have demonstrated that
most parents accept STI vaccines, some do not perceive their children at risk for STIs, or
express concerns that adolescents who are vaccinated may practice risky sexual behaviors
(Zimet et al., 2005; Olshen et al., 2005; Mays et al., 2004). Therefore, the high
acceptance among parents may not necessarily mean that they would have their children
vaccinated if it were offered by a pediatrician.
Health care providers should anticipate that parents will have different degrees of
comfort with vaccination, including those in complete opposition. Complete opposition
may come from those who are broadly anti-vaccine, as well as those who have specific
concerns about STI vaccines and the belief that permitting their child to get an STI
71

vaccination also gives their child permission to be sexually active. Themes emerging
from some of these studies on parental acceptance of an HPV vaccine are consistent with
past research reports that included the importance of pediatrician recommendations about
vaccination, and that physicians had the strongest influence on parents’ decisions about
vaccinating their children (Davis et al., 2004; Olshen et al., 2005). Parents and caregivers
will look to health care providers as an important source of information and for guidance
in making decisions on whether or not to vaccinate their child and adolescent against
HPV. Therefore, the success of the HPV vaccination programs will depend on physician
willingness and ability to recommend HPV vaccines to their patients (Zimet, 2005).
There are few studies that have evaluated health care provider attitudes about STI
vaccinations. In one study, nurse acceptance of a vaccine to prevent mononucleosis,
genital herpes, and HIV were highest for older adolescent patients and if the American
Academy of Pediatrics endorsed the vaccine (Mays & Zimet, 2004). The first national
study of mothers’ attitudes and intentions to vaccine their daughters and themselves
against HPV was conducted among mothers who were all nurses. Mothers’ intention to
vaccinate against HPV decreased with a daughter’s age, with the lowest intentions to
vaccinate for a daughter less than 13 years old. Forty-eight percent of these mothers also
intended to vaccinate themselves, if it was clinically recommended (Kahn, et al., 2009).
There have been two studies specifically assessing physician acceptance of an
HPV vaccine. Raley et al. (2004) found that obstetricians and gynecologists rated
vaccine efficacy and ACOG approval as the most important factors influencing their
decision to recommend vaccination, and physicians were reluctant to recommend
vaccination for younger patients, such as 13-year-old girls or to recommend a vaccine
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that only prevented warts. Another study found that family physicians were significantly
more willing to consider vaccination of older adolescent girls, such as ones ages 14
through 17, versus girls, ages 11 and younger. As in similar studies, endorsement by
professional organizations, such as the American Academy of Family Physicians was
viewed as important. A majority of these family physicians also viewed vaccine safety
and efficacy as important factors in their decision to recommend the vaccine. These
studies revealed that endorsement from professional associations and reluctance to
vaccinate younger children, 13 years of age or younger, are common influential factors
among pediatricians, OB/GYNs, and family physicians decision to recommend the
administration of an HPV vaccine. Although these studies demonstrate overall positive
attitudes among physicians regarding the HPV vaccine, research has shown inconsistent
utilization of another type of STI vaccine, the hepatitis B vaccine, by pediatricians (Rupp,
Stanberry, & Rosenthal, 2004) and studies also have demonstrated the reluctance of
health care providers to discuss sexuality with adolescent patients (Maheux, Haley,
Rivard, & Gervais, 1995; Millstein, Igra, & Gans, 1996; Schuster, Bell, Petersen, &
Kanouse, 1996; Siegel, Baker, Kotagal, & Balistreri, 1994; Torkko, Gershman, Crane,
Hamman, & Baron, 2000). These issues will need to be addressed in planning HPV
vaccine educational and promotional campaigns.
Primary care physicians also report challenges and barriers in educating their
patients, including young adults about STI prevention (Ashton et al., 2002), and suboptimal communication between the high-risk young adult population, such as
homosexual men and women, and their providers concerning protection from STIs, such
as HIV (Elford, Bolding, Maquire, & Sherr, 2000). Discussion of sexuality and
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prevention of STIs, especially HPV, among young adults is also an important issue that
needs to be addressed because HPV is highly prevalent among young adults, especially
college students since they do not consider themselves at high risk of STIs yet often do
not protect themselves from STIs during sexual activity. Furthermore, many college
students may have HPV and do not know it.
A review of HPV studies by Revzina and DiClemente (2005) demonstrated that
the highest prevalence of HPV was identified among women attending STD clinics and
college students, identifying them as priority populations for HPV prevention
interventions. The college population would benefit from the HPV vaccine because it
prevents both HPV and cervical cancer (Harper et al., 2004; Reinis, 2004). Therefore,
the vaccine may benefit older adolescents and young adults who are infected with HPVtype 16 or 18 that has not yet evolved into pre-cancer. Acceptance of the HPV vaccine is
important among college students and other young adults because they have been
identified as priority populations for the vaccine (Monteyne, 2005), and they do not need
parental consent to acquire the vaccine.
Although the majority of women have been poorly educated about HPV, research
indicates that there is a desire for information about HPV infection, such as how the virus
is transmitted and how they can prevent becoming infected (Anhang, Wright, Smock, &
Goldie, 2004; Holcomb, Bailey, Crawford, & Ruffin, 2004). Furthermore, despite the
fact that women and adolescents have a limited understanding of HPV, there is interest in
HPV vaccination among young women as well as adolescents (Boehner et al., 2003;
Hoover et al., 2000; Kahn et al., 2003; Zimet et al., 2000), and both of these groups view
vaccine efficacy and physician recommendation as important factors in their decision to
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get vaccinated against HPV (Zimet et al., 2000). Studies have found that most college
students have a positive attitude about HPV vaccination, and that parental and partner
acceptance are associated with positive attitudes (Boehner et al., 2003). In the majority
of vaccine acceptability studies among college students, individuals who consider
themselves at higher risk, such as by having a higher number of sex partners, have a
higher acceptance of the vaccine (Boehner et al., 2003; Kahn et al., 2003; Hoover et al.,
2000; Zimet et al., 2000). In addition, Boehner et al. found that acceptance rates do not
differ by sex or on the basis of whether the vaccine was described as a cervical cancer
vaccine or as an STI vaccine. One study also found that a vaccine that protected against
genital warts was more acceptable among female college students compared to a cervical
cancer vaccine (Hoover et al., 2000). The authors of this study did not explain the
rationale for why a genital warts vaccine would be more acceptable but one thought is
that women would prefer it to reduce the embarrassment of the visibility of genital warts
or any associated discomfort. Further research is needed on sex differences in acceptance
among young adults and college students and differences in acceptance for an STI versus
a cervical cancer vaccine. Furthermore, no studies have been conducted on college
students’ willingness to practice other safer sex behaviors in addition to being vaccinated
against HPV. Given that HPV is an STI, potential barriers to acceptance may include the
stigma associated with STIs and the possibility that acceptance of the vaccine may be
viewed as an invitation to participate in risky sexual behavior (Zimet et al., 2000).
Therefore, research is needed to determine if college students perceive being vaccinated
against HPV as protection against other STIs.
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Politics, Science, and HPV
The administration of a vaccine that protects against a sexually transmitted virus
among children and adolescents has resulted in opposition from certain groups expressing
concern over the possibility of making the vaccine mandatory, as the groups think it
could send the message to the public, especially parents, condoning sexual activity before
marriage (Stein, 2005).
The CDC added GARDASIL® to the Vaccines for Children Program (VFC)
contract (Merck & Co., Inc., 2006). The VFC program supplies vaccines to all U.S.
states, territories and the District of Columbia for use by participating providers. All
childhood vaccines recommended by the Advisory Committee on Immunization Practices
(ACIP) are available through VFC program. The ACIP is a panel of experts brought
together by the CDC. The ACIP sets the nation’s list of recommended immunizations,
setting vaccine standards for physicians and insurers and for public funding of
vaccinations. The ACIP’s rulings are not mandates, but most states look to its
recommendations to mandate which vaccines children must get before they enter the
public school system. The panel issues widely followed guidelines, including
recommendations for childhood vaccines that become the basis for vaccination
requirements set by public schools. The ACIP recommends routine vaccination of three
doses of the HPV vaccine for girls, ages 11 to 12, with vaccination starting as early as
nine years of age. The ACIP also recommends vaccination for girls and young women,
ages 13 to 26 who have not previously been vaccinated or who have not completed the
vaccination series (Markowitz et al., 2007). Following the approval of GARDASIL®,
there have been debates in numerous states about whether to mandate the vaccine for
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school entry. Nineteen states have enacted legislation to require, fund, or educate the
public about the HPV vaccine. In 24 states and Washington, D.C., legislation has been
introduced to mandate the vaccine for school entry. The Michigan Senate was the first to
introduce legislation in September 1996 to mandate the HPV vaccine for all girls entering
sixth grade, but the bill was not enacted. Whereas Texas was the first state to mandate
the vaccine in 1997 for girls entering the sixth grade, through the Governor’s executive
order, the Texas legislature subsequently voted to override the executive order. The
District of Columbia has enacted the legislation that mandates all girls receive the
vaccination before the age of 13, but parents can opt out of this requirement. Virginia
also has a state law that mandates HPV vaccination for girls entering the sixth grade
(National Conference of State Legislatures, 2010).
Professional provider organizations, such as the American College of
Pediatricians, and leading researchers that conducted clinical trials on the HPV vaccine
strongly oppose requiring students to obtain the HPV vaccine for public school
attendance. The reasons for opposing mandatory vaccination for public school entry is
because HPV is spread only by sexual activity, not in a classroom, and the duration of the
vaccine’s effectiveness, as well as the long-term side effects of the vaccine are unknown.
Dr. Diane Harper, a lead researcher and developer of the HPV vaccine, states that
administering GARDASIL® to 11-year-old girls is a “great big public health experiment”
as the clinical trial data are not representative of 11 and 12-year-old girls (Alliance for
Human Research Protection, March 14, 2007). Harper’s clinical trials were on girls and
women between the ages of 15 to 25. Because of the unknown side effects and duration
of effectiveness in young girls, Harper believes the ideal way of administering the
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vaccine is to offer it to women ages 18 and older (Alliance for Human Research
Protection, 2007; American College of Pediatricians, 2007).
The HPV vaccine, GARDASIL®, is being promoted as a cervical cancer vaccine.
However, marketing the vaccine as a cervical cancer vaccine leads to the concern of how
parents, caregivers and young adults will be educated about the vaccine, and whether
parents will be given all of the necessary and accurate information about the vaccine
needed to make an informed decision about whether to get their child or themselves
vaccinated. Regardless of whether or not the vaccine to prevent HPV is promoted on
terms related to cervical cancer, parents need to be informed that the vaccines’
therapeutic effects are targeted to an STI to which their child could be exposed. Studies
have shown that parents who initially have reservations about the HPV vaccine favored
vaccination when they learned that HPV was an STI and is the main cause of cervical
cancer (Mays, Sturm, et al., 2004; Olshen, et al., 2005). This finding demonstrates the
importance of educating parents about the link between HPV and cervical cancer.
Although HPV vaccines may be presented to adolescents and their parents as a
vaccine that prevents cervical cancer, thereby avoiding or minimizing the STI issue, any
vaccine that protects against the HPV types responsible for both genital warts and
cervical cancer must be categorized as an STI vaccine. In addition, all consumers of
health care have a right to receive complete, accurate information about HPV infection
and vaccination (Zimet, 2005). Merck & Co., Inc. has developed a free information kit
that includes a patient information sheet on GARDASIL®, in addition to other
educational brochures for consumers that are available at www.GARDASIL.com. This
information sheet does include a statement about the link between HPV and cervical
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cancer. However, there is not a clear explanation about how HPV is an STI and
transmitted solely through sexual activity. HPV is referred to as a “common virus,” on
the information sheet, and under the section of key information about the vaccine, there is
a statement that reads “This vaccine will not protect against other diseases not caused by
HPV” (Merck & Co., Inc., 2006). These types of statements do not clearly describe HPV
as an STI. Health care providers, such as physicians and nurses who administer the
vaccine, will need to provide additional information about HPV and STI prevention.
Vaccinating adolescents against HPV has become a controversial issue and has
received more focus in the media compared to other priority populations. Because the
vaccine is licensed for use in girls and women ages 9 to 26, young adults are a priority
population (Merck & Co., Inc., 2006). One of the benefits in vaccinating young adults, in
addition to the protecting them against specific types of HPV and cervical cancer, is that
persons in this population can make their own decision to become vaccinated. Thus far,
there has been no controversy in vaccinating this population, perhaps due to the fact that
sexual activity among young adults is deemed more socially acceptable in society
(Ambert, 2005).
Education about the HPV vaccine should be included as part of comprehensive
health education, including education about other STIs, Pap smears, DNA testing for
HPV, and other behavioral risk factors that can exacerbate cervical cancer risk.
Information about the HPV vaccine also can be provided to young adults and college
students at non-traditional settings, such as bars and concert venues, and through social
norms marketing and promotional media campaigns.
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Application of the Health Belief Model and Theory of Planned Behavior
The most common models, theories, and frameworks that have been used to
explain the likelihood of behavior change are the health belief model (Rosenstock, 1974),
the theory of reasoned action (Ajzen & Fishbein, 1980), the theory of planned behavior
(Ajzen, 1988), social cognitive theory (Bandura, 1986), and the stages of change theory, a
portion of the transtheoretical model (Prochaska & DiClemente, 1982). Contemporary
models of health behavior at the individual and interpersonal levels usually fall within the
broad category of cognitive-behavioral theories. There are two core concepts associated
with these theories: 1) Behavior is considered to be mediated through cognitions, for
instance, what we think and know affects how we act, and 2) Knowledge is necessary but
not sufficient to produce behavior change. Perceptions, motivations, skills, and factors in
the social environment also play important roles in behavior change (Glanz, Lewis, &
Rimer, 1990). A combination of the health belief model and the theory of planned
behavior will be applied in this study.
The health belief model (HBM), originally introduced by psychologists working
in the U.S. Public Health Service in the 1950s, was one of the first models that adapted
theory from the behavioral sciences to health problems (Rosenstock, 1974). The HBM is
one of the most researched models of the relationship between cognitive-attitudinal
factors and health behavior change (Patterson, 2001), and it is one of the most widely
recognized conceptual frameworks of health behavior (Hochbaum & Lorig, 1992). The
HBM is used in explaining and predicting preventive health behavior, as well as sick-role
and illness behavior. Although the HBM was originally developed to explain health
behavior, the HBM has also been successfully used to search for why high-risk health
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behaviors occur and to identify possible points for behavior change. The HBM has been
used to help in developing health education messages to persuade people to make healthy
decisions in areas such as hypertension, eating disorders, breast-self examination, and
contraceptive use (Garcia & Mann, 2003; Middleton, 2009; Roye & Hudson, 2003;
Tavafian, Hasani, Aghamolaei, Zare, & Gregory, 2009).
The HBM attempts to predict health-related behavior in terms of certain belief
patterns. The HBM includes four constructs representing perceived health threats and
perceived benefits: perceived susceptibility, perceived severity, perceived benefits and
perceived barriers. These concepts are proposed as accounting for people’s “readiness to
act” (Figure 1).
An added concept, cues to action, activates readiness and stimulates overt
behavior or action (Rosenstock, 1974). A recent addition to the HBM is the concept of
“self-efficacy,” or one’s confidence in the ability to perform an action successfully. This
concept was added by Rosenstock et al. (1988) so the HBM could fit better with the
interpersonal challenges of changing unhealthy behaviors.
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Figure 1. The Health Belief Model (Adapted from Rosenstock, 1974, p. 334).
The HBM states that the perception of a personal health behavior threat is itself
influenced by at least three factors: general health values, including interest and concern
about health; specific health beliefs about vulnerability to a particular health threat; and
beliefs about consequences of the health problem. Once an individual perceives a threat
to his/her health and is simultaneously cued to action, and his/her perceived benefits
outweighs his/her perceived barriers, then that individual is most likely to undertake the
recommended preventive health action. There may be some variables that can influence
an individual’s decision, such as demographics (e.g., age, sex, race or ethnicity), sociopsychological factors (e.g., personality, social class, peer pressure) and structural (e.g.,
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knowledge about the disease and prior experience with the disease). Rosenstock (1974)
explained that the role of demographic, socio-psychological and structural variables was
that they served to condition both individual perceptions and the perceived benefits of
preventive actions. The HBM has been successful in identifying differences in individual
perceptions and predicting preventive health behavior for a variety of diseases, including
STIs.
For example, the HBM has predicted adolescent behavior in the prevention of
STIs, specifically for condom use (Hiltabiddle, 1996; Orr & Langefeld, 2003). The HBM
also has been used to examine college students’ knowledge and beliefs about STIs and to
predict their behaviors associated with STIs, such as condom use (Lollis, Johnson, &
Antoni, 1997; Mahoney, Thombs, & Ford, 1995; Zak-Place & Stern, 2004). Gielen,
Faden, O’Campo, Kass, and Anderson (1994) applied the constructs of the HBM to
distinguish women who would practice protective measures to protect themselves from
HIV versus those who would fail to take protective measures. The importance of the
participants’ health beliefs to the adoption of protective sexual behaviors was also
measured. Gielen et al. (1994) found that beliefs about personal susceptibility and
barriers were highly associated with adopting multiple sexual protective behaviors, such
as having sex less often, deciding not to have sex, and carrying condoms.
The HBM has also been applied to examine health beliefs about cervical cancer
screening in college women (Burak & Meyer, 1997), and to assess attitudes about the
HPV vaccine among college women (Kahn et al., 2003). Kahn et al. (2003) also studied
the relationship between attitudes about HPV vaccination and intention to receive the
vaccine, applying a theory-based model with constructs from the HBM to study attitudes
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and constructs from other theories and to study how attitudes can predict behavioral
intention, such as the theory of reasoned action (TRA) (Ajzen & Fishbein, 1980). The
TRA will be discussed later in this chapter. Kahn et al. (2003) found that young women
who reported a positive attitude about receiving the HPV vaccine also had high intention
to receive the vaccine for themselves and their daughters. A more recent study by Kahn
et al. (2009) applied the TPB, HBM and social cognitive theory to determine variables
associated with mothers’ intention to vaccinate daughters’ against HPV. The researchers
found that positive beliefs about the HPV vaccine were significantly associated with
intention to vaccinate.
The HBM is used in the current study to measure college students’ perceptions
about HPV, including perceived susceptibility of getting HPV, perceived severity of
HPV, perceived benefits of protecting themselves against HPV, including getting
vaccinated against HPV, what motivates college students to take action in protecting
themselves against HPV, and their level of self-efficacy in practicing safer sex behaviors.
The constructs of the HBM are applied in the following way:
A) Perceived Susceptibility – College students’ beliefs of their risks of contracting
HPV, in addition to the risks of others. This perception is measured by a series of
Likert-type scales, from the low end, where individuals deny any possibility of
contracting HPV, to the high end where individuals feel they are at a real danger
of contracting HPV.
B) Perceived Severity – College students’ beliefs concerning the health effects of
contracting HPV. For instance, symptoms and long-term consequences, such as
susceptibility to developing cervical cancer.
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C) Perceived Benefits and Barriers of Taking Action – College students’ perceptions
about the importance of certain influential factors and barriers to becoming
vaccinated against HPV.
D) Cues to Action – College students’ beliefs about what would influence them to
become vaccinated against HPV. Differences in perceptions about what factors
are more influential over others also are determined among college students.
E) Self-Efficacy – College students’ perceived abilities in carrying out certain safer
sex behaviors. Safer sex behaviors include those defined by The Planned
Parenthood Federation of American (2004), and questions on perceived
behavioral control in carrying out certain safer sex behaviors are included.
However, self-efficacy is addressed through measuring perceived behavioral
control, by applying the theory of planned behavior. Differences in perceived
behavioral control over carrying out certain safer sexual behaviors also are
determined and may reveal which behaviors college students are more confident
in practicing to protect themselves against STIs.
There are some weaknesses associated with the HBM that are relevant to
examining if there are any relationships between individual’s beliefs about HPV, vaccine
acceptance and intentions to practice safer sex behaviors. One of the limitations of the
HBM is that it does not incorporate social norms as a modifying factor in an individual’s
health beliefs (Brown, 1999). Also, the health belief model focuses on the health
behavior beliefs of an individual, and individual behavioral beliefs can compete with
other beliefs and attitudes that can influence behaviors, such as social normative beliefs.
Furthermore, the HBM does not measure behavioral intentions (Weinstein, 1993). In
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addition to examining college students’ beliefs about HPV, perceived barriers and
benefits of becoming vaccinated against HPV, this study also assesses college students’
intentions to practice safer sex behaviors. Additional beliefs that can affect an
individual’s intentions are normative beliefs – or beliefs about the normative expectations
of others and motivation of the individual to comply with others’ expectations and
control beliefs – beliefs about the presence of factors that may facilitate or impede
performance of the behavior and perceived power of these factors. Therefore, a theory
that incorporates normative beliefs and control beliefs to predict behavioral intention is
used to supplement the HBM in this study.
The theory of reasoned action (TRA) and the theory of planned behavior (TPB)
also provide frameworks to study attitudes towards behaviors. These models have been
used extensively to explain knowledge, attitudes, and predict behaviors in different
populations for reducing risk of contracting STIs, in addition to designing STI prevention
and STI intervention programs (Baker, Morrison, Carter, & Verdon, 1996; Blecher,
Steinberg, Pick, Hennink, Durcan, 1995; Boehner, Howe, Bernstein, & Rosenthal, 2003;
Jemmott, 2000; Manhart, Dialmy, Ryan, Mahjour, 2000; O'Donnell, San Doval, Vornfett,
& DeJong, 1994; Strader, Beaman, & McSweeney, 1992; Strader & Beaman, 1991,
1992).
According to the TRA, the most important determinant of an individual’s
behavior is behavioral intention, and an individual’s intention to perform a behavior is a
combination of attitude and subjective norms related to that behavior. Ajzen and
Fishbein (1980) theorized that intentions are a function of two major determinants: 1)
attitudes toward the behavior and 2) the subjective norms related to the behavior.
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Attitude is the first antecedent of behavioral intention and it is an individual’s positive or
negative belief about performing a specific behavior. Attitudes are determined by the
individual’s beliefs about the consequences of performing a behavior (behavioral beliefs),
weighted by his or her evaluation of those consequences (outcome evaluations). These
attitudes are believed to have a direct effect on behavioral intention and are linked with
subjective norms. Subjective norms also are assumed to be a function of beliefs that
specific individuals approve or disapprove of performing the behavior, and these beliefs
are termed normative beliefs. According to the TRA, an individual will intend to perform
a certain behavior when he/she perceives that prominent persons or figures in their life
think they should. Prominent persons may be partners, spouses, parents, close friends,
physicians, or other key individuals. The TRA was developed to predict behaviors that
are under a person’s volitional or actual control, and the TRA works most successfully
with behaviors that are perceived to be under a person’s control (Ajzen & Fishbein,
1980). Boehner et al. (2003) applied the TRA in a study assessing the genital herpes and
HPV vaccine among college students, and found that persons who believed their parents,
partners, or physicians would encourage vaccination were more likely to accept the HPV
vaccine. Whereas this study found that beliefs about the HPV vaccine were influential in
an individual’s acceptance about the vaccine, it was not clear whether the beliefs of
others had any effect on an individual’s intentions to become vaccinated. Furthermore,
the researchers did not measure individual’s attitudes, beliefs or abilities related to
practicing other safer sex behaviors, including their perceptions of control over practicing
safer sex behaviors in current or future relationships, and how these perceptions were
associated with their acceptance of the HPV vaccine. Assessing attitudes, beliefs –
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individual and normative, and abilities in practicing safer sexual behaviors can predict
college students’ intentions in practicing these behaviors. Assessing the relationship
between college students intentions to practice safer sex behaviors and likelihood of
becoming vaccinated against HPV, may help to reveal whether college students that
intend to become vaccinated, would also continue to protect themselves, by practicing
other safer sex behaviors against other types of HPV and STIs.
This study applies the TPB as a theoretical framework to complement the HBM to
determine college students’ perceived behavioral control and intentions to practice other
safer sexual behaviors. The TPB differs from the TRA through the addition of the
construct of “perceived behavioral control.” Researchers have realized that one of the
greatest limitations of the TRA occurs when people feel they have little power over their
behaviors and attitudes (Godin & Kok, 1996; Madden, Ellen, & Ajzen, 1992). Ajzen
(1988) described the aspects of behavior and attitudes as being on a continuum, from one
of little control to one of great control, and to predict behaviors that are or that are not
perceived to be under a person’s control. Ajzen (1988) added the third determinant of
“perceived behavioral control” to the TRA to address behaviors that are or may not be
perceived as being under a person’s control, and this addition resulted in the newer, TPB.
The TPB proposes that attitudes about performing a behavior, perceived benefits
of others regarding its performance, and perceived behavioral control over one’s ability
to perform the behavior all affect the intention to perform that behavior and, in turn,
predicts actual behavior (Figure 2). Perceived behavioral control is determined by two
factors - control beliefs and perceived power. Perceived behavioral control indicates that
a person's motivation is influenced by how difficult the behaviors are perceived to be, as
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well as the perception of how successfully the individual can, or cannot, perform the
activity. If a person holds strong control beliefs about the existence of factors that
facilitate a behavior, then the individual will have highly perceived behavioral control
over that behavior. Conversely, the person has a low perception of control if she or he
holds strong control beliefs that impede the behavior. This perception can reflect past
experiences, anticipation of upcoming circumstances, and the attitudes of the influential
norms that surround the individual. As a general rule, the more favorable the attitude and
subjective norm, and greater the perceived behavioral control, the stronger is the person’s
intention to perform the behavior in question. Given a sufficient degree of actual control
over the behavior, people are expected to carry out their intentions once they have the
opportunity to do so. However, some behaviors are too difficult to carry out, and
therefore, may not be perceived as being under an individual’s control. Therefore,
perceived behavioral control, in addition to intention, needs to be considered to help
predict the behavior in question (Ajzen, 2002).
Whereas there have been no studies that have applied the TPB to the study of
sexual behavior, specifically in regards to the prevention of HPV, there have been
numerous studies that have applied the TPB to predict sexual behaviors and condom use
in the prevention of STIs, with the majority of studies focusing on HIV/AIDS prevention
and risk reduction (Bensley et al., 2004; Boily, Godin, Hogben, Sherr, & Bastos, 2005;
Bowen, 1996; Koniak-Griffin, Lesser, Uman, & Nyamathi, 2003).
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Figure 2. Theory of Planned Behavior (Ajzen, 2002).
Bryan, Fisher, and Fisher (2002) applied the TPB to determine whether
preparatory safer sex behaviors, such as discussing safer sex with partners and obtaining
condoms, can have a mediational role between attitudes and perceived social norms about
safer sex and condom use among high school and college students. The authors found
that safer sex behaviors can have a highly significant mediation role and bridge the gap
between attitudes about safer sex and carrying out the intended action of using condoms.
The normative beliefs, control beliefs, and behavioral intent aspects of the TPB
will be applied in this study, as a complimentary theoretical framework to the HBM, to
measure college students’ perceived behavioral control over practicing certain safer sex
behaviors, by measuring difficulty in carrying out those behaviors (See Figure 3).
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______________________________________________________________________
Figure 3. A theoretical framework of the HBM with the addition of the TPB constructs
of “normative beliefs,” “control beliefs,” and “behavioral intention.”

The TPB has been chosen over the TRA for a theoretical framework in this study
because this study includes measuring perceived difficulty of behaviors that may or may
not be perceived as being under a person’s control. For example, staying in a
monogamous relationship with a person that does not have an STI, or only having sex
with partners that have been tested and have no history of STIs, may not be perceived as
behaviors that are under an individual’s control, but rather, more under a partner’s
control. Measuring the difficulty in carrying out different sexual behaviors also may help
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to determine which behaviors are most often or less often perceived to be under an
individual’s control.
The TPB is used in this study to examine college students’ perceived beliefs of
others regarding the HPV vaccine and beliefs in practicing other safer sex behaviors, and
college students’ perceived behavioral control beliefs over practicing in safer sex
behaviors. Measuring social normative beliefs and perceived behavioral control in
getting vaccinated against HPV and practicing in safer sex behaviors, may help to
determine the level of college students’ intentions for getting vaccinated against HPV and
practicing in safer sex behaviors.
Online Surveys and College Students
The variables in this study will be measured through an online survey. Increasing
number of studies are utilizing online surveys to collect data among college students on
high risk behaviors and health beliefs, including assessing STI behaviors and acceptance
of preventive measures to reduce risk of STIs (Collins, Logan, & Neighbors, 2010;
Gullette & Lyons, 2006; Lindley, Nicholson, & Kerby, 2003; Opt, Loffredo, Knowles, &
Fletcher, 2007). The majority of college students use the Internet for social and
educational purposes, and, therefore, are experienced in navigating through web sites and
online programs. Furthermore, an equal percent of female and male students use
computers regularly (Hargittai, 2002). Online surveys are also beneficial as data can be
downloaded directly into analysis software programs compared to manual data entry or
scanning paper-and-pencil surveys. Further detail on the rationale for choosing an online
survey as the data collection instrument in this study is provided in Chapter 3.
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Chapter Three
Methods

Introduction
Sexually transmitted infections continue to be a challenging public health issue on
college campuses, as the majority of college students are sexually active and engage in
unsafe sex behaviors that put them at risk of contracting STIs (Eisenberg, 2001; Gately,
2003). Human papillomavirus (HPV) is estimated to be the most common STI in the
United States and has been shown to infect more than 40% of sexually active college
students (Eisenberg, 2001; Winer, Lee, Hughes, Adam, & Koutsky, 2004). HPV among
college women poses a serious public health concern as high-risk types of HPV are
associated with nearly 100% of cervical cancer cases (Munoz et al., 2003). Despite the
high prevalence of HPV among college students, there continues to be a low level of
awareness about the risk factors, symptoms and methods of prevention of STIs, including
HPV (Eisenberg, 2001; Gately, 2003; Yacobi, Tennant, Ferrante, & Roetzheim, 1999).
There are numerous methods of HPV prevention that involves behavioral intervention,
and the HPV vaccine is the most recent innovation in HPV prevention. The vaccine is
available for women at most university and college campuses, and there is a high
acceptance of the vaccine among female college students. Although the HPV vaccine
protects against multiple types of HPV, including those that are primarily responsible for
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cervical cancer and genital warts, it does not protect against all types of HPV or other
STIs. Therefore, it will be imperative for female college students who receive the HPV
vaccine to receive accurate information about transmission and prevention of HPV, in
addition to all other types of STIs and diseases associated with STIs. This education also
should include information and reinforcing messages concerning how college students
can practice safer sex behaviors to prevent contracting other types of HPV and other
STIs.
Purpose of the Study
The purpose of this study is to expand previous research on female college
student perceptions and acceptance of the HPV vaccine through assessing knowledge
about HPV and the HPV vaccine, assessing the relationship between health beliefs about
HPV and vaccine acceptance, and the relationship between vaccine acceptance and
intentions to practice in safer sexual behaviors, including their willingness to become
vaccinated against HPV. This information is expected to be helpful in understanding
whether female college students intend to practice safer sex behaviors if they are
vaccinated against HPV, or if they expect to feel less susceptible to acquiring STI
infections, and consequently, engage in risky sexual behaviors. Determining whether
there is a relationship between knowledge about HPV and intentions to practice safer sex
behaviors may help to reinforce the need for increased education about HPV and other
STIs by health care providers for college-aged women, and also encourage providers to
use the time for vaccination as a teachable moment to educate students about HPV and
safer sex behaviors. University student health centers that are administering the vaccine
are interested in targeting female college students with vaccine education and promotion
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campaigns. Understanding the factors that play a role in vaccine acceptance, and the
relationship between vaccine acceptance and intentions to practice safer sex behaviors
may help university student health centers in developing these campaigns.
Research Questions
The questions to be investigated are:
•

What is the relationship between knowledge about HPV and intentions to practice
safer sex behaviors among women attending college?
o What is the relationship between knowledge about HPV and attitudes
towards practicing safer sex behaviors?
o What is the relationship between knowledge about HPV and normative
beliefs about practicing safer sex behaviors?
o What is the relationship between knowledge about HPV and perceived
control about practicing safer sex behaviors?

•

What is the relationship between knowledge of the HPV vaccine and acceptance
of the HPV vaccine among women attending college?

•

What is the relationship between health beliefs about HPV and acceptance of the
HPV vaccine among women attending college?
o What is the relationship between perceived susceptibility to HPV and
acceptance of the HPV vaccine?
o What is the relationship between perceived severity of HPV and
acceptance of the HPV vaccine?

•

What is the relationship between acceptance of the HPV vaccine and intentions to
practice safer sex behaviors among women attending college?
o What is the relationship between acceptance of the HPV vaccine and
attitudes towards practicing safer sex behaviors?
o What is the relationship between acceptance of the HPV vaccine and
normative beliefs about practicing safer sex behaviors?
o What is the relationship between acceptance of the HPV vaccine and
perceived control towards practicing safer sex behaviors?
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Study Design
This study was a descriptive, cross-sectional study that used primarily quantitative
methods to explore undergraduate female college students’ knowledge and awareness of
HPV, examine the relationships between college students’ perceived susceptibility in
contracting HPV, their perceived ability to engage in safer sexual behaviors, cues to
action, and their willingness to become vaccinated against HPV. The study included the
implementation of an online questionnaire adapted from an instrument developed by
researchers at the University of South Florida (USF) in 2001 to assess the impact of
receiving an HPV diagnosis among women (CDC, 2005). This questionnaire included
several items assessing knowledge and awareness of HPV, the HPV vaccine, and vaccine
acceptance, including perceived barriers and benefits of getting vaccinated against HPV.
It also included items that assessed attitudes about practicing safer sex behaviors and
perceptions of partners’ and friends’ attitudes about practicing safer sex behaviors. Items
that assessed perceived ability and control over practicing safer sexual behaviors were
adapted from a sexual behavior scale developed by Morrison, Ho, Beardsley, Bierman,
and Burke (1998). The survey also assessed demographic information about the
participants, such as age, ethnicity, income, sexual preference, relationship status,
whether they have children, educational status, and whether they have health insurance.
Sample, Recruitment, and Size
A convenience sample of female undergraduate students, 18 to 24 years of age,
were recruited to complete the online survey on the University of South Florida (USF),
Office of Academic Computing online survey tool site, Survey.acomp, at
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http://survey.acomp.usf.edu. Students enrolled at three public universities, USF, Central
Michigan University (CMU), and Western Michigan University (WMU) were recruited
to complete the survey in the spring and summer 2009 semesters. Students were
recruited to participate in the study via student health services at each university and via
e-mail. Letters of commitment for participation in the study were submitted by student
health center staff for each participating university.
Student health centers were an appropriate venue for recruiting students to
complete an online survey about the HPV vaccine, as there is a large number of women
who seek care for medical and preventive health services (Boehm, Selves, Raleigh,
Ronis, Butler, & Jacobs, 1993; Sawyer & Moss, 1993; Foote, Harris, Gilles, Ahner,
Roice, Becksted, Messinger, Bunch, & Bilant, 1996). Students also were recruited
through snowball sampling where, at the end of the survey, a statement encouraged
survey takers to ask other eligible female students or friends attending the university
about the survey and to provide them with the survey web site address. Students who
completed the online survey were entered into a one-time cash drawing for $500, and one
student was randomly selected to receive the incentive.
The three participating universities employed different methods to recruit female
undergraduate students to maximize outreach to students and sample size. Fliers that
included the direct URL address to the survey were posted on bulletin boards throughout
the student health centers and were distributed to female students when they checked in
for clinic visits, or attended student health services seminars and on-campus events at all
three universities. Though it was proposed that all three universities include a direct link
to the survey on the student health center web site, only Western Michigan University did
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so (http://www.wmich.edu/shc/), as the student health center web sites at the other two
participating universities were being updated and the information technology staff could
not add the survey link.
An additional recruitment strategy was employed as response rates were low from
recruiting participants through student health services. The other option for recruitment
was to e-mail the students directly. The USF Registrar’s Office dispatched the survey to
13,120 undergraduate female students, ages 18 to 24 (E. Rosenthal, personal
communication, May, 12, 2009). Western Michigan University Sindecuse Health Center
dispatched the survey to 2,493 female undergraduate students, ages 18 to 24 (C.
Cumming, personal communication, June 4, 2009). However, access to student e-mail
was not granted by CMU as the university’s policy does not permit surveys to be sent to
students via e-mail.
The principal investigator’s contact information was provided at the end of the
online informed consent, as well as at the end of the survey, if participants had any
questions regarding their participation in the survey. Contact information for each
participating university student health center also was included at the end of the online
informed consent if students had any questions about HPV and the HPV vaccine. A
statement was also included, at the end of the informed consent, reminding students that
they would be contacted via e-mail by the principal investigator for the purpose of
receiving an incentive for participation.
All students had the chance to receive free educational materials about HPV and
the HPV vaccine from the university student health centers. A monetary incentive was
offered to students by entering them into a one-time cash drawing of $500. Students also
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were given contact information for questions regarding their participation in the study as
well as for HPV-related resources after they complete the survey. Students were eligible
to participate in the study regardless of whether they have ever been diagnosed with
HPV.
Only women attending college were recruited to participate because the vaccine
was available to them at the time the data was collected for this study, and vaccine
acceptance was assessed. Assessing acceptance among men may have threatened the
validity of the study because they would have answered questions related to a
hypothetical situation of becoming vaccinated against HPV. Male responses may have
been biased by the fact that the vaccine was not yet available to them, and therefore,
males were excluded from participating in this study.
Undergraduate female students, between the ages of 18 and 24, from the main
campuses of three public universities, were eligible to participate in this study. A total of
15,356 female undergraduate students, ages 18 to 24, were enrolled at the USF main
campus in Tampa, Florida (D. Hayward, personal communication, September 10, 2008)
compared to 9,486 female undergraduate students at the Central Michigan University
(CMU) main campus in Mt. Pleasant, Michigan (M. Meier, personal communication,
September 11, 2008), and 8,528 female undergraduate students at the Western Michigan
University (WMU) main campus in Kalamazoo, Michigan (J. Jach, personal
communication, September 12, 2008). Although there are limitations in non-probability
sampling, such as increased risk of participant bias and the sample being nonrepresentative of the priority population, there are methods that can be employed to
increase the study’s statistical power. A strategy to increase the study’s power is to set a
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clear sampling frame with specific exclusion and inclusion criteria and to increase the
sample size.
An adequate sample size is jointly determined by the power, the alpha or
significance level, such as .05, effect size, and variability expected to be present in the
data collected. Power is the ability of a statistical test to detect a statistically significant
difference when one exists between two study variables or study groups. A power level
of .80 is an acceptable standard among researchers in the social and behavioral sciences
(Cohen, 1988). Effect size is the minimum size of the expected difference or, in the case
of this study, the relationship you would expect to see between two variables. The
significance test of multiple linear regression was applied in this study to determine
sample size because degree of relationships and predictor variables for intentions to
practice safer sex behaviors were addressed through the research questions. According to
Cohen (1988), .02 is indicative of a small effect, 0.15 a medium effect, and 0.35 a large
effect size for multiple correlation and regression tests. As the effect size is made
smaller, a larger sample size is needed to detect statistically significant differences (Eng,
2003). There is limited research on factors predicting female college student intentions to
practice safer sex behaviors, including becoming vaccinated against HPV. Crosby et al.
(2007) found three correlates from multiple linear regression were significantly linked to
HPV vaccine acceptance among college-aged women. These correlates were having sex,
having an STI, and having an abnormal Pap smear but they were not linked to intentions.
The following three predictor variables for intentions to practice safer sex
behaviors were measured in this study: attitudes, normative beliefs and control beliefs.
The level of relationships between these predictor variables and intentions were
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calculated via multiple linear regression, from participant data (N = 125) from the second
pilot test of the survey instrument in SPSS 13. The results of this analysis were used to
determine the sample size of female undergraduate students needed to participate in the
study based upon a power of .80, a medium effect size of .15 and an alpha of .05.
Multiple linear regression assessing the strength of the relationship between attitudes,
normative beliefs and perceived control beliefs and intentions was calculated via SPSS
13. The R-squared value was calculated for the three predictor model (attitudes vs.
normative beliefs vs. control beliefs) on intentions, and for each of three 2-predictor
models (attitudes vs. normative beliefs, normative beliefs vs. control beliefs, attitudes vs.
control beliefs) on intentions. The differences between each of the 2-predictor models
and the three-predictor model were then calculated to determine the strength of each
factor in predicting intentions, and these differences were entered as estimated values into
a sample size estimation calculation in a SAS software program. Results of the analyses
demonstrated that attitudes had the strongest relationship with intentions (effect size or f2
= .90) followed by normative beliefs (f2 = .049), and control beliefs (f2 = .0046). Based
upon the results of the analysis, a total of 1700 female college students were needed to
participate in this study to have a power of .80 for all three predictor variables (Appendix
A).
Instrument
There are conflicting results from studies assessing college student response to
online surveys. Some studies have found that paper-and-pencil survey have higher
response rates among college students (Hanwerk, Carson & Blackwell, 2000; Matz,
1999; Tomsic, Hendel, & Matross, 2000), some have found that online surveys elicit
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higher response rates among college students (Antons, Dilla, & Fultz, 1997), whereas
other studies have found no difference between the two types of surveys with respect to
response rates (Carini, Hayek, Kuh, Kennedy, & Ouimet, 2003; Underwood, Kim, and
Matier, 2000). Some studies of online survey methods have found that response rates in
e-mail surveys are equal to or greater than those for traditional mailed surveys (Mehta &
Suvadas, 1995; Stanton, 1998; Thompson, Surface, Martin, & Sanders, 2003) and others
have found that online surveys have a lower response than mail surveys. One of the
issues for lower response rates is invalid e-mail addresses or the participant not
completing the survey in a timely manner (Solomon, 2001; Couper, 2000). Invalid email addresses and participants not completing online surveys in a timely manner were
not issues for lower response rates in the two pilot tests conducted for this study.
Participant e-mail addresses were legitimate, as the principal investigator did not receive
any of the e-mail addresses back in error. Furthermore, participants were reminded by
e-mail to complete the survey re-test, and 45% of the participants who took the initial
survey, responded and completed the survey re-test.
An online survey was chosen as the instrument for this study based upon the
positive outcomes from the three pilot tests, as there were no major barriers or challenges
in participants completing the online survey. The majority of college students use the
Internet and online surveys can be more convenient for more “computer savvy”
participants (Carini et al., 2003). Research on gender gaps in new educational
technologies has demonstrated that nearly an equal percent of female and male students
use computers regularly. Research has demonstrated no significant gender difference in
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ability to navigate the Web or in the time it takes to learn how to browse the Web
(Hargittai, 2002).
A Pew Internet and American Life Project found that 86% of college students
have gone online, and the majority of college students own their own computers, have
access to computers at school, or use the Internet as part of their daily routine (Jones,
2002). The majority of college students use the Internet for social networking, as a way
to communicate with friends about social issues, such as via Friendster, Facebook,
Twitter and MySpace, for entertainment, and for online courses (Jones, Johnson-Yale,
Millermaier, & Perez, 2009). College students often participate in online polls and
surveys including ones related to health, job preferences, entertainment and politics.
Therefore, college students comprise a population that is accustomed to participating in
online surveys. In addition, there are additional benefits to completing online surveys
compared to paper-and-pencil surveys that are relevant to this study, such as elimination
of paper, copying, and postage costs. Also, processing data is easier with the ability to
download survey data directly into spreadsheets, databases, and data analysis programs.
An online informed consent was provided to students upon going to the survey
link (Appendix B). Upon going to the survey site, students were provided with a
summary of the purpose of the survey, their participation, why they were being asked to
participate and how they can participate, information about anonymity and
confidentiality, and a statement about how they are giving their consent to participate by
logging onto the site and completing the survey. Students were informed that they would
be required to include their e-mail address at the end of the survey for the purposes of
receiving an incentive and the last four digits of their student identification number to
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prevent any participant from taking the survey more than once. Because the survey
assesses their personal attitudes, beliefs, and behaviors, students were asked to answer the
questions as honestly as possible. Students were informed that the survey contains
questions about sexual activity and that they do not have to answer any questions that
make them uncomfortable and they can stop taking the survey at any time. A statement
was included that choosing not to participate would not affect their status or the services
they receive from the university. In addition, in the informed consent, participants were
reminded that because they were completing a survey over the Internet that there was a
slight chance, albeit a small one, that an unauthorized person, such as a hacker, could
gain access to their survey, and pose a risk to confidentiality of their responses. To
minimize this risk, the principal investigator downloaded all survey responses into
another secure electronic database for data analysis once the surveys were completed.
Students were informed that once they completed their survey, their responses would be
downloaded into an off-line, secured electronic database, and their responses would be
coded and not contain any of their identification information. The principal
investigator’s contact information was provided at the end of the informed consent
section, as well as at the end of the survey, if participants had any questions regarding the
survey. Contact information for each participating university student health center was
also included if students had any questions or needed information about HPV and the
HPV vaccine. A statement was included, at the end of the informed consent section,
reminding students that they would be contacted via e-mail by the principal investigator
for the purpose of receiving an incentive for participation.
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An online survey was developed and pilot tested with three samples of
participants representative of the target population for this study (Appendix C).
Undergraduate, female college students, between the ages of 18 to 24, completed the
survey at http://survey.acomp.usf.edu - the USF, Office of Academic Computing online
survey tool site. This survey tool is free, offers a more secured data collection site for
students compared to online commercial survey tools, does not feature pop-up
advertisements that can distract respondents, and includes university staff support that is
easily accessible for questions and technical difficulties. The URL for the survey was
http://survey.acomp.usf.edu/survey/entry.jsp?id=1172716175300.
The survey contained 57 items and took approximately 10 minutes to complete.
The survey was designed to answer the research questions and assess the relationships
among study variables. Items were developed to measure the following study variables:
knowledge about HPV; knowledge about the HPV vaccine; health beliefs through
perceived severity of and susceptibility to HPV; vaccine acceptance through perceptions
about the influential factors and barriers to becoming vaccinated against HPV; and
attitudes, normative beliefs, and perceived control in practicing safer sex behaviors.
Demographic and other personal information about participants, such as age,
gender, ethnicity, educational status, sexual orientation, number of sexual partners during
the past 12 months, current sexual activity, marital status, and whether they have children
was also collected. An item assessing whether the participant had health insurance was
included on the survey as insurance status may influence vaccine acceptance (Appendix
C, Section Nine, question eleven).
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The survey consists of a variety of closed-ended questions, such as true/false,
yes/no/not sure, and Likert-type scales. Survey items assessing HPV knowledge were
adapted from a questionnaire developed by researchers at the USF College of Public
Health in a study conducted from 2001 to 2004 to assess the impact of an HPV-related
diagnosis among women (CDC, 2005). Items in this subscale addressed the research
question concerning the relationship between knowledge about HPV and intentions to
practice safer sex behaviors (Appendix C, Section One, question one). The subscale
assessing knowledge about the HPV vaccine also has been adapted from the
questionnaire described above. This item addressed the research question concerning the
relationship between knowledge about the HPV vaccine and HPV vaccine acceptance
(Appendix C, Section Three, question one).
Vaccine acceptance was assessed through the constructs of general vaccine
acceptance, influential factors to becoming vaccinated against HPV and barriers to
becoming vaccinated against HPV. These subscales are comprised of items also adapted
from the questionnaire developed by USF researchers described above (CDC, 2005).
Items in this section were also developed based upon responses from individual
interviews with undergraduate female college students, ages 18 to 24. Items in this
subscale assessed participant perception of the importance of vaccination, whether
participants received at least one dose of the HPV vaccine, whether they are likely to
become vaccinated if they have not yet received the vaccine, what would influence them
to become vaccinated against HPV, and what are the barriers to becoming vaccinated
against HPV (Appendix C, Section Five, questions one through five). These items are
related to the research questions on the following relationships: knowledge about the
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HPV vaccine and HPV vaccine acceptance, health beliefs about HPV and HPV vaccine
acceptance, and HPV vaccine acceptance and intentions to practice safer sex behaviors.
Health beliefs about HPV were assessed through the constructs of perceived
susceptibility and severity questions about HPV and were adapted from items developed
by Kahn, Goodman, Slap, Huang, and Emans (2001) to assess health beliefs about the
perceived susceptibility and severity of having an abnormal Pap smear among adolescent
girls and young women. The construct of perceived susceptibility was measured by a
subscale that included items related to the research question about relationships among
health beliefs, specifically, perceived susceptibility, and HPV vaccine acceptance. This
subscale included items that assessed perceived risk of contracting HPV (Appendix C,
Section Seven, questions one through five). The construct of perceived severity was
measured by a subscale that included items related to the research question concerning
the relationship among health beliefs, specifically, perceived severity, and HPV vaccine
acceptance. This subscale included items that assessed perceptions about how serious a
health problem HPV is and the consequences of HPV (Appendix C, Section Eight,
questions one through four).
Although the most reliable way to prevent transmission of STIs is to abstain from
sexual intercourse, defined as vaginal, oral, or anal sex (CDC, 2002), there are some
STIs, such as HPV that can be transmitted through any sexual activity that involves
“skin-to-skin” contact (Moscicki, 2005; Winer et al., 2003). Because the survey assessed
attitudes and behaviors related to preventing and transmitting HPV, the terms sexually
active and sexual activity were used to describe sexual behavior instead of sexual
intercourse.
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The safer sex behaviors measured in this study were several of those described
previously in Chapter One. The behaviors were defined by Planned Parenthood (2004)
and were selected because they can be effective methods of reducing the risk of acquiring
HPV infection and other STIs. Furthermore, some of these same behaviors, specifically
those related to condom use, talking with partners about STIs, and refusing to have sex
with someone that has not been tested for an STI, were included as protective sexual
behaviors in the Gielen et al. (1994) study that applied the HBM to assess the extent to
which women in an urban area protected themselves against HIV. The safer sex
behaviors measured in this study were also based upon the results of an expert panel
review and pilot testing the survey instrument to be a valid and reliable measure.
The following safer sex behaviors were measured in this study:
1) Abstinence
2) Communicating with a new partner about STIs
a. Telling a new partner that you will not be sexually active with them
until they have been tested for an STI
3) Refusing to have sex with a new partner if they will not use a condom
4) Avoiding using drugs or alcohol before engaging in sexual activity
5) Asking a health care provider about how to reduce the risk of getting STIs
An attitude toward a behavior is defined as a person’s overall evaluation of
performing the behavior in question (Ajzen, 1991). Therefore, attitudes towards a
behavior play a significant role in an individual’s perceived ability, and according to the
TPB, attitude, along with normative beliefs and behavioral control beliefs can directly
affect intention to carry out a certain behavior. Likert-type scales assessing attitudes
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practicing in safer sex behaviors, and perceptions of others’ beliefs towards practicing in
safer sex behaviors was adapted from the guide “Constructing a TPB Questionnaire:
Conceptual and Methodological Considerations” developed by TPB author, Icek Ajzen
(2006). To be sure the subscales of the instrument were compatible with each other, the
constructs of attitudes, subjective norms, and perceived control were defined in terms of
the same elements (Ajzen, 2002). Although the Likert-type scales used to measure some
of the constructs differed, the behavior of interest was defined in the same manner.
According to Ajzen (2006), in the final questionnaire the different items assessing each
construct are separated and listed in a non-systematic order, interspersed with items
measuring other constructs. Therefore, the subscales of the instrument measuring
attitudes, perceived normative beliefs, perceived control, and intentions to practicing
safer sex behaviors were interspersed with each other. Furthermore, items measuring the
subscales of attitudes, normative beliefs, perceived control and intentions regarding
practicing safer sex behaviors were divided throughout the survey to minimize reader
fatigue (Appendix C, Sections Two, Four and Six). Items assessing attitudes, normative
beliefs, perceived control, and intentions addressed the research questions concerning the
relationship between knowledge and intentions to practice safer sex behaviors and the
relationship between HPV vaccine acceptance and intentions to practice safer sex
behaviors.
Some of the items assessing the construct of attitudes have been adapted from
Morrison et al. (1998) to measure low-risk and high-risk sexual behaviors among collegeaged women. The subscale assessing attitudes includes items assessing the extent to
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which a participant agrees that practicing certain safer sex behaviors are easy with Likerttype scale “Strongly agree” and “Strongly disagree” endpoints.
The construct of normative beliefs, or perceived beliefs of others, about practicing
safer sex behaviors was assessed by asking participants if they agreed that college
students could practice certain safer sex behaviors. In addition to measuring subjective
norms through beliefs of others, it is important to include questions that measure
descriptive norms, such as whether persons considered important to the participant also
would practice safer sex behaviors themselves (Ajzen, 2006). Items assessing normative
beliefs were adapted from Ajzen’s (2006) questionnaire development guide. This
subscale included items assessing normative beliefs about practicing certain safer sex
behaviors with a Likert-type scale with “Strongly agree” and “Strongly disagree”
endpoints.
Perceived control to carry out safer sex behaviors were determined by assessing
the individual’s confidence in performing the behavior and perceived control in
performing it. Perceived self-efficacy, a behavioral belief that is influential on outcomes
in the HBM and TPB, also determines people’s confidence with respect to what they are
capable of achieving. Self-efficacy is defined as “beliefs in one's capability to organize
and execute the courses of action required to manage prospective situations" (Bandura,
1997, p. 2). According to Bandura (1997), self-efficacy beliefs are key elements in a
person’s perceived behavioral control and the exercise of control over a certain action.
To the extent that individuals are realistic in their judgment and confident in
carrying out a behavior, perceived behavioral control can substitute for actual control and
contribute to the prediction of the individual’s intention to take action. According to the
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TPB, the combination of attitudes, beliefs, subjective norms, and perceived behavioral
control lead to the formation of a behavioral intention (Ajzen, 1988). A perceived
behavioral control scale should contain items assessing a person’s perceived capability or
self-efficacy and control over performing a certain behavior (Ajzen, 2002). An
individual’s perceived capability and self-efficacy is strengthened by experience
(Bandura, 1997). The construct of perceived behavioral control includes items assessing
how much control participants have in performing certain safer sex behaviors with a
Likert-type containing “Complete control” and “No control” endpoints.
Items assessing behavioral intention are included in the survey to compare with
participant responses to the constructs that, according to the TPB can predict intentions,
such as attitudes, normative beliefs and perceived behavioral control. According to
Ajzen (2006), including only direct measures of the TPB constructs, such as intentions,
can yield low reliabilities and lead to an underestimate of the relations among the theories
constructs and its predicative validities. The construct of intentions included items that
assessed intentions to practice safer sex behaviors. These items were related to the
research questions concerning the relationship between knowledge of HPV and intentions
to practice safer sex behaviors and the relationship between HPV vaccine acceptance and
intentions to practice safer sex behaviors.
For data analysis, each Likert-type scale with a neutral response and forced choice
format, included in the online survey instrument, were scored in a unipolar fashion from
5, 4, 3, 2, 1 without any negative numbers. The responses were coded consistently with
the meaning of the response. Thus, scores were higher for favorable beliefs, with the
strongest favorable attitude or belief having the highest value (e.g., 5). The score was
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lower for the strongest unfavorable attitudes or beliefs. Dichotomous scales were scored
as “2” for “Yes” and “1” for “No, and certain scales included a score of “1.5” for “Not
sure” and “True/False” items were scored “1” for the correct answer and “0” for the
incorrect answer. Data were analyzed using multiple methods described in the analysis
section of this chapter.
Protection of Human Subjects
The survey instrument was revised based upon a review by a panel of experts and
pilot testing. The study, including each of the pilot tests, and a copy of the instrument
was approved by the USF Institutional Review Board (IRB), CMU, and the WMU IRB.
Pilot Testing
Individual telephone interviews were conducted in a sample of 15 undergraduate
female college students, between the ages of 18 to 24, from the three participating
universities. Five undergraduate female students from each university participated in the
interview and the average duration of the interview was 15 minutes. The interview
questions assessed participant beliefs about becoming vaccinated against HPV
(Appendix D). The purpose of these interviews was to refine the survey instrument,
specifically for items assessing barriers to, benefits, and influential factors to becoming
vaccinated. Student health services staff recruited participants by posting fliers in health
clinics and other campus locations, and distributing fliers to students at clinic visits and at
health education workshops. Participants were undergraduate female students, between
the ages of 18 to 24, including those who were and who were not vaccinated against
HPV. Students provided verbal informed consent over the phone before participating in
the interview (Appendix D), and each respondent received $25 for their participation.
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Interview responses were categorized into themes (Appendix E). The instrument was
revised based upon the themes, as additional barriers, benefits, influential factors to
becoming vaccinated against HPV were identified and added to the survey. A question
concerning whether the participants had health insurance was added to the demographic
section of the survey, as health insurance status was reported to be a factor in influencing
and being a barrier participants from becoming vaccinated against HPV.
The instrument was revised based upon the interview data, content analyses by a
panel of experts and pilot test results. The instrument was pilot tested for construct
validity, internal consistency reliability, and test-retest reliability.
Reliability and Validity of Instruments
It is important to assess the reliability and validity of data collection instruments
so that the instruments measure what they are supposed to measure and that the data are
free from measurement error (Sarvela & McDermott, 1993). Validity is the most
important consideration in designing and developing an instrument, as it refers to the
quality of the data derived from the instrument and whether the instrument measures
what it is supposed to measure.
After development, the instrument underwent a preliminary review by a panel of
experts (Appendix F). There were specific criteria for membership on the expert panel.
Membership required that individuals have longevity in the fields of HPV-related
research and content areas, STI prevention and education, application of health education
and behavioral change theories in STI prevention and treatment , and research methods
and design. Longevity was defined by having published scholarly papers, being
instructors and serving as consultants in the above fields. The HPV-related content areas
113

relative to this study include: HPV knowledge and awareness among young adults and
college students, vaccine acceptance, and HPV vaccine development. Panel members
with experience in research design, methods, measurement, and behavioral change
theories are the following advisors and members of the dissertation committee: Dr.
Robert McDermott, Dr. Karen Perrin, and Dr. Ellen Daley from the USF College of
Public Health. In addition to providing direction and guidance in the logistics of the
dissertation process, these panel members were asked to provide assistance with the
research methodology of the study. These members were asked to provide feedback on
sample recruitment and selection, and instrument validation to ensure that the survey
items are representative of the study constructs the instrument is intended to measure.
These individuals also provided feedback on the instrument’s readability, format and
directions. Dr. Jeffrey Kromrey from the USF College of Education, Department of
Educational Measurement and Research, is also a member of the dissertation committee
and provided assistance in statistical methods and data analysis. Dr. Kromrey assisted
with sample size determination for the study and the factor and reliability analyses of the
pilot test data. Dr. Kromrey also provided assistance with analysis of the survey data.
Additional individuals were asked to assist in the process of instrument
development and validation, specifically for instrument content and construct validity.
For content validity, this expert panel of reviewers helped to reduce the number of items
by assigning scale items to factor labels and selecting the most salient items for factor
analysis for construct validity. The methods for content and construct validity is further
described in a later section of this chapter.
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Dr. Richard Roetzheim from the USF Department of Family Medicine
participated in the panel review for content validation of the instrument. Dr. Roetzheim
has conducted research and published in the areas of HPV knowledge and awareness
among college students.
Dr. Gregory Zimet from the Department of Pediatrics at the Indiana University
School of Medicine also participated in the panel review of the survey instrument for
content validation. In addition to publishing in the areas of HPV vaccine acceptance and
prevention, Dr. Zimet applied the HBM in studying STI vaccine acceptance.
Additional expertise for validation of the survey was sought from Dr. Anna
Guiliano from H. Lee Moffitt Comprehensive Cancer Center, Dr. Jessica Kahn from the
Cincinnati Children’s Hospital Medical Center, and Dr. Laura Koutsky from the
University of Washington School of Public Health. However, these individuals were not
able to review the survey due to time constraints.
Content and Construct Validity
Content validity demonstrates the degree to which a sample of items or questions
on a test or survey are representative of a defined content domain. This type of validity
should be used when developing all data collection instruments (Sarvela & McDermott,
1993). Content validity is especially important in developing achievement and aptitude
tests, and for instruments measuring social behavior (Isaac & Michael, 1995). The
content domains developed and tested in this study were as follows: knowledge about
HPV, knowledge about the HPV vaccine, perceived susceptibility to HPV, perceived
severity of HPV, HPV vaccine acceptance, attitudes about practicing other safer sex
behaviors, normative beliefs about practicing safer sex behaviors, perceived control in
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practicing safer sex behaviors, and intentions to practice safer sex behaviors. The initial
instrument included a total of 96 survey items assessing nine constructs from the HBM
and TPB for the panel review. To ensure content validity, the panel of experts
(Appendix F) was asked to assess the degree to which the instrument items matched the
objectives of the instrument through Instructional Quality Inventory (IQI) methods
(Wulfeck, Ellis, Richards, Wood, & Merrill, 1978). Experts were e-mailed a synopsis of
the study, including the study research questions and the IQI method that included each
item and an assessment matrix for each question. Reviewers were asked to assess the
following elements for each item: appropriateness of the question based upon the
construct being measured; if the question was clearly stated, and if the response options
were adequate or inadequate. A comments box was also included for each item for
reviewers to include suggestions for revisions, additions or deletions. Three members of
the expert panel completed the instrument review. The number of survey items, from this
review, was reduced from 96 to 76 for pilot testing among female, undergraduate
students, ages 18 to 24
Construct validity demonstrates whether the instrument adequately measures the
construct under study. Factor analysis can be used to determine how well items in a
specific subscale measure a particular construct, and which items in each subscale can be
retained or discarded. One of the purposes of factor analysis is to validate a scale or
index by demonstrating that scale items or variables load on the same factor, and to
eliminate scale items that load on more than one factor. Factor analysis produces factor
scores that can be used as weights in creating an index of constructs with their related
items. Factor analysis results can reveal whether more than one survey item is associated
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with one or more construct being studied. A factor loading of .30 was used as the cut-off
or criterion score in this study, as this score is one of the most popular criteria for the
interpretation of factor analysis results (Nunnally, 1978; Tabachnick & Fidell, 1983).
Exploratory factor analysis, specifically principal axis factoring, was used for
factor analysis and data reduction in this study. Principal axis factoring is recommended
when the primary concern is determining the minimum number of factors that account for
maximum variance in the data for use in subsequent data analysis (Bryant & Yarnold,
1995). Principal axis factoring was used to detect whether the subscale items in the
survey instrument adequately measure the constructs in the combined model of the HBM
and the TPB. The constructs measured were those included in the HBM and TPB, as
follows: knowledge of HPV and the HPV vaccine, perceived susceptibility of HPV,
perceived severity of HPV, HPV vaccine acceptance, attitudes, normative beliefs,
perceived behavioral control, and intentions in practicing safer sex behaviors, including
being vaccinated against HPV. The Kaiser rule is to drop all components with
eigenvalues under 1.0, as it may overestimate or underestimate the true number of
factors.
Interval or ratio level measurement is preferred for factor analysis, and extra
caution is needed for interpretation of ordinal scales (Neuman, 1997). Factor
interpretations and labels must be rooted in theory, with scale items that are focused on
theorized dimensions or constructs (Froman, 2001). The subscale items in the survey for
this study were developed to measure the constructs in the HBM and TPB.
Certain precautions can be taken to ensure meaningful results and address
challenges related to factor analysis, such as the non-normal distribution of data,
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multivariate outliers, linear bivariate relationships between variables, and sufficient
multicollinearity of the variables. If distributions are non-normal, data may require
transformations or other special procedures to adjust data from dichotomous response
scales before conducting a factor analysis. Factor analysis was conducted in the first and
second pilot tests. Each data set was analyzed for kurtosis and skewness in SPSS 13, and
the distribution of data was normal in each pilot test. Therefore, additional procedures to
normalize the pilot test data were not necessary.
Outliers can impact correlations between scale items, and therefore, distort factor
analysis (Bryant & Yarnold, 1995). Mahalanobi’s distance was applied in the pilot test to
identify the cases that were multivariate outliers, using the same number of predictors for
intentions that were used to calculate the study sample size. A rule of thumb is l chisquare value with degrees of freedom distance should not exceed the critical chi-square
value at α = .001 or outliers could be equal to the number of predictors and that the
maximum value for Mahalanobi’s a problem in the data (Tabachnick & Fidell, 2001). A
chi-square distribution table was referred to (Kuzma, 1992), and the maximum value for
Mahalanobi’s distance for the predictors of attitudes, normative beliefs and control
beliefs did not exceed the critical chi-square value at df = 3 and α = .001. Therefore, the
results demonstrated there were no multivariate outliers in the pilot test data. These same
procedures were used to test the study data for normal distributions, skewness, and
multivariate outliers.
At the stage of factor analysis, it is easier to remove items in a survey rather than
add them, as adding items would require selection of another sample size for a second
round of pilot testing. An excess of items may demand a large sample to allow a
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reasonable subject to item ratio, and may be difficult to assess for exploratory factor
analysis. For exploratory factor analysis, Thurstone recommends at least three items per
factor (Kim & Mueller, 1978), whereas other researchers have recommended at least five
items but fewer than ten items for each dimension defining the construct (Tabachnick &
Fidell, 2001). There were at least three items for each factor in the survey instrument.
Reliability
In addition to testing for practicality and construct validity, the pilot test data were
used to measure the internal consistency and test-retest reliability of the survey
instrument. A reliable instrument is one that is reliable, consistent, and stable (Kerlinger,
1973), and reliability is measured by the degree to which measurement instruments are
free from measurement error (Sarvela & McDermott, 1993). The survey questionnaire
was tested for internal-consistency reliability to determine how well the survey items
used to measure particular study variables relate to each other or “hang together”
(Nunally, 1978). Because internal consistency is important in determining how items on
test or scale relate to each other, researchers recommend calculating internal-consistency
reliability for knowledge and attitude scales (Sarvela & McDermott, 1993). Cronbach’s
alpha is a measure of the degree to which scale items co-vary and indicates the proportion
of variance of the scale that is due to the variance in underlying variables or to
measurement error or random variation. The sexual behavior scale developed by
Morrison et al. (1998) was tested for its reliability. A Cronbach’s alpha score of .79
demonstrated adequate reliability (DeVellis, 1991). Because the survey includes a
section of the sexual behavior scale with items that specifically measure college students’
perceived ability to engage in safer sex behaviors, along with items from other attitude
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and knowledge scales, the survey developed in this study was tested for internal
consistency reliability using Cronbach’s alpha. The Kudar-Richardson-20 is a test that is
analogous to Cronbach’s alpha, and was used to assess internal consistency reliability for
dichotomous scale items, such as yes/no and true/false. There is no set interpretation as
to what is an acceptable alpha value; however, a rule of thumb applied in most research
situations is that an alpha score of .70 is considered acceptable (George & Mallery, 2006;
Nunnally, 1978).
The instrument was also tested for stability or test-retest reliability. Test-retest
reliability is estimated by correlating the results of a test that have been administered to
the same group of participants two or more times (Ferguson, 1981). The mean factor
scores of participant responses from the pre-test and retest were calculated for items
measuring each construct. The pre-test and retest data for each construct were correlated
to determine the scale’s test-retest reliability.
Pilot test #1. The online survey was pilot tested in Fall 2007, with a convenience
sample of undergraduate students (N = 140) ages 18 to 24 enrolled in undergraduate
courses at USF College of Public Health, Central Michigan University, and Western
Michigan University. The participants completed the survey on the University of South
Florida’s online survey tool, Survey.acomp. Five instructors from the three participating
universities assisted with the recruitment of female, undergraduate students from the
following health-related courses: “Assessment, Planning and Evaluation,” “Community
Health,” “Critical Issues in Public Health,” “Health and Wellness,” “Healthy Lifestyles,”
“Survey of Human Disease,” and “School Health Methods”. Two of these courses,
specifically, “Critical Issues in Public Health” and “Survey of Human Disease” were
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online courses. Female, undergraduate students enrolled in an athletic training program
at Central Michigan University also were recruited to participate in the pilot test.
Participants who completed the survey and provided their e-mail address and last four
digits of their student ID were entered into a one-time $500 cash drawing. Students were
recruited by instructors posting the online survey link to their course web sites via the
university Blackboard system and e-mailing the link directly to students via Blackboard
sites. Some instructors also made announcements about the pilot test to students in class.
Although the survey was pilot tested with a total of 140 undergraduate students,
ten participants were omitted for the data analysis. These participants were omitted for
one or more of the following reasons: 1) Five percent or more of survey items had
missing responses, 2) Age or gender was not reported, or 3) Age reported did not match
the criteria for participation in the study. Therefore, pilot test data were analyzed for 130
undergraduate female students, between the ages of 18 to 24. A random selection of
survey code numbers was generated via SPSS 13, and one participant was randomly
selected and received a cashier’s check for $500. The instrument was initially pilot-tested
with students for practicality, and to obtain reactions to the survey, specifically to
determine readability, clarity, scope, and sequence of the survey items, completion time,
and ease of use in completing the survey online. The purpose of the pilot test also was to
reduce the number of survey items.
The average time it took participants to complete the survey was 14.8 minutes.
Forty-seven percent (N = 61) of participants reported that the survey was too long, and
20% (N = 26) of the participants reported that the questions were repetitive. The data
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were normally distributed as skewness and kurtosis values for the majority of survey
items were between ±2.
The survey was revised based upon participant feedback, specifically re-wording
questions and response options and revising skip patterns in the survey. In addition, the
number of survey items, was reduced from 76 to 59 items through factor analysis. A
second pilot test was necessary to determine the duration of the revised survey, to
reconduct a factor analysis of revised survey items to ensure construct validity of the
revised instrument, to further reduce the number of survey items, if warranted, and to
conduct a test-re-test to determine the reliability of the revised survey.
Pilot test #2. The second pilot test of the revised instrument was conducted in
Spring 2008 with a convenience sample of female, undergraduate students (N = 127),
ages 18 to 24, at the three participating universities. The same instructors from the three
participating universities who assisted with recruitment for the first pilot test also assisted
with recruitment for the second pilot test. Participants were recruited in the same manner
as the first pilot test and were recruited from the following courses: “Community
Health,” “Critical Issues in Public Health,” “Diversity,” “Foundations of Maternal and
Child Health,” “Health and Wellness,” “Healthy Lifestyles,” and “Teaching Methods”.
Participants were asked to complete the online survey and then re-take the same
instrument two-weeks later for test-re-test reliability. Participants who completed the
initial survey were sent e-mail reminders by the principal investigator one week and one
day before their scheduled date to re-take the survey.
Although 127 participants completed the initial survey, two participants were
omitted from the data analysis. These participants were omitted for one or more of the
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following reasons: 1) Five percent or more of survey items had missing responses and 2)
Age or gender was not reported. Therefore, pilot test data were analyzed for 125
undergraduate female students, between the ages of 18 to 24.
Because the number of items in the survey was reduced from 76 to 59 items from
the first pilot test, the duration required by participants to complete the revised survey
was reduced by approximately five minutes. The average time it took participants to
complete the revised survey was 9.6 minutes, compared to 14.8 minutes in the first pilot
test. Furthermore, approximately 5% of participants (N = 7) reported that the length of
the revised survey was too long, compared to 47% of participants (N = 61) in the first
pilot test, and 2% of participants (N = 2) reported that the questions were repetitive
compared to 20% of participants (N = 26) in the first pilot test. The data were normally
distributed as skewness and kurtosis values for the majority of survey items were
between ±2.
Approximately 45% of the participants (N = 57) who completed the initial survey
also completed the survey re-test, and the majority (76%) of these participants completed
the re-test in exactly two weeks from the initial survey. Twenty-four percent of the
participants (N = 13) completed the retest before or after the two week interval, ranging
from 10 to 23 days. Three participants were omitted from the reliability analysis as one
participant had missing data for over 5% of the items on the re-test and two participants
did not include an e-mail address, and therefore, their re-test data could not be matched to
data from the initial survey.
A factor analysis was conducted on the pilot test data to ensure construct validity
and the data was analyzed for internal consistency reliability, described in a later section.
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The results from the factor analysis demonstrated that each study construct was
represented by one factor, except HPV vaccine acceptance (Appendix G). The additional
section on benefits was removed, as the results of factor analysis revealed none of the
items intended to measure benefits had a factor loading of .30 or higher on any of the
factors representing vaccine acceptance (i.e., influential factors, benefits, barriers). The
construct of vaccine acceptance was represented by the follow three factors: general
vaccine acceptance, issues that would influence one to become vaccinated against HPV
and barriers to becoming vaccinated against HPV. The number of questions was reduced
from 59 to 56 items. One item was removed from the scale on knowledge about HPV
and two items were removed from two of the following scales measuring HPV vaccine
acceptance – issues that would influence one to become vaccinated and barriers to
becoming vaccinated. In addition, five response options were removed from the item
measuring knowledge about the HPV vaccine.
The analysis of data from the second pilot test also helped to determine a sample
size needed for the study. Multiple regression analysis of mean factor scores from the
pre-test data revealed that 1700 participants were needed to participate in the study, based
upon a medium effect size (f2 = .15) and a power of .80. Participants who completed the
survey re-test were entered into a one-time $500 cash drawing, and one participant was
randomly selected to receive the incentive.
The survey was tested for internal consistency reliability. Cronbach’s alpha was
calculated for each scale measuring the different study constructs. Although some of the
scale values were below .70, the values were considered to be in an acceptable range by
the statistics advisor on the committee (Appendix H). However, the test-retest reliability
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analysis demonstrated that there was not a significant correlation between mean factor
scores for the scale measuring the severity of HPV. There were significant correlations
between the mean factor scores for each of the scales measuring the other study
constructs (Appendix I). A fourth item was added to increase the reliability of the scale
on the severity of HPV, and a third pilot test was conducted only for this scale. This item
was included in the scale on the severity of HPV in the initial survey instrument, but was
removed because it did not meet a criterion score of .45 for factor loading that was
initially selected. This factor loading was determined by a calculation that incorporated
the sample size of the pilot test. However, because the sample size for the study was
unknown, and anticipated to be larger, it was determined that .45 was too stringent and a
criterion score of .30 was used in the factor analysis of survey data from the second pilot
test. The fourth item loaded well on the one factor for severity of HPV from the factor
analysis of the first pilot test with a cut-off score of .352 for factor loading. Therefore,
this item was added back to the existing scale to pilot test for test-retest reliability, instead
of developing a new survey item.
Pilot test #3. A sample size of 15 to 20 participants was necessary for this pilot
test as only one section of the survey (entitled “How HPV can affect you”) was tested.
The online pilot test survey included four items intended to measure the severity of HPV,
in addition to items assessing age, gender, year in college, and university, to ensure that
only eligible participants completed the test-retest. An online informed consent was
included before the survey, and participants were asked to review the informed consent
before proceeding with the pilot test. Participants were also asked to include the last four
digits of their student ID and e-mail address to be eligible to receive an incentive.
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Participants were recruited in the same manner as the first and second pilot tests and were
recruited from the following courses: “Contemporary Health Sciences,” Health and
Wellness,” “Healthy Lifestyles,” and “School Health Methods”. Instructors from the
three participating universities assisted with the recruitment for the pre-test. However,
the sample size that was necessary consisted of students only from Central Michigan
University and the University of South Florida. A convenience sample of undergraduate
female college students (N = 27), between the ages of 18 to 24, completed the test-retest.
There was no missing data among the participants, and the data was normally distributed
as skewness and kurtosis values for each of the survey items were between ±2.
Participants who completed the test-retest were entered into a one-time $25 cash drawing,
and one participant was selected to receive the incentive. The test-re-test reliability
analysis demonstrated that there was a significant correlation between mean factor scores
for the revised scale measuring HPV severity (Appendix J). Because the item increased
the reliability of this scale, the item was added back to the survey, and there were a total
of 57 items on the final survey instrument.
Analysis of Data
The data was analyzed using multiple methods in SPSS 13. Frequency
percentages and measures of central tendency, such as the mean and standard deviation,
were calculated for univariate data. The univariate data include demographics and sexual
history, knowledge about HPV and the HPV vaccine, in addition to attitudes and beliefs
about practicing safer sex behaviors. Linear correlation can be calculated to confirm
relationships and strength of relationships between quantitative variables, for example,
age and number of sexual partners, and number of sexual partners and level of HPV
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vaccine acceptance. The Pearson product-moment correlation coefficient (r) was
calculated to measure relationships between variables in this study. The Pearson r
coefficient may take on values from –1 to +1. Coefficient values that are close to +1
indicate a high positive correlation, values close to -1 indicate a high inverse correlation,
and values close to zero indicate no correlation. To determine if the correlations are
significant and to test the null hypothesis that there are no linear correlations between the
variables – a test of significance will be performed and confidence intervals will be
estimated.
Multiple linear regression was used to measure the degree of relationships
between the same variables by calculating the regression coefficient or the amount of
change in the dependent variable for a given change in the independent variable (Kuzma,
1992). Multiple regression shares the same assumptions as correlation and the
assumptions are as follows: the relationships are linear so there is a constant rate of
change between 2 variables, there is the same level of relationship throughout the ranges
of the independent variable or “homoscedasticity,” absence of outliers, normal
distribution of data and independence of data or observations (Kleinbaum, Kupper, &
Muller, 1988).
Specifically, the degree of relationships was assessed among variables such as the
relationship between HPV vaccine acceptance and attitudes, normative beliefs, control
beliefs, and intentions to practice safer sex behaviors. Multiple linear regression was
used determine the strongest predictors of the relationships between study variables, for
instance, the variables that are the strongest predictors for intentions. To determine how
reliable the regression equation is in predicting the degree of relationships between
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variables, a test of significance using the standard error of estimate was calculated, and
confidence intervals were estimated.
Below are lists of the research questions, followed by an explanation of the data
analysis procedures that addressed each question.
•

What is the relationship between knowledge about HPV and intentions to practice
safer sex behaviors among women attending college?
o What is the relationship between knowledge about HPV and attitudes
towards practicing safer sex behaviors?
o What is the relationship between knowledge about HPV and normative
beliefs about practicing safer sex behaviors?
o What is the relationship between knowledge about HPV and perceived
control towards practicing safer sex behaviors?
The Pearson product-moment correlation coefficient (r) was calculated between

the mean values of knowledge about HPV to determine if there were significant
relationships between knowledge about HPV and the predictors of intentions, including
attitudes, normative beliefs, and control beliefs, as well as a signficant relationship
between knowledge and the variable of intentions as measured via survey items.
•

What is the relationship between knowledge of the HPV vaccine and acceptance
of the HPV vaccine among women attending college?
The Pearson product-moment correlation coefficient (r) was calculated between

the variables of general vaccine acceptance and knowledge of the HPV vaccine. For
those variables of acceptance that had a significant correlation with knowledge of HPV,
multiple linear regression was calculated to determine the strength of the relationship
between each influential factor to acquiring the HPV vaccine and knowledge of the
vaccine and each barrier to acquiring the HPV vaccine and knowledge of the vaccine.
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•

What is the relationship between health beliefs about HPV and acceptance of the
HPV vaccine among women attending college?
o What is the relationship between perceived susceptibility to HPV and
vaccine acceptance?
o What is the relationship between perceived severity of the HPV vaccine
and vaccine acceptance?
The Pearson product-moment correlation coefficient (r) was calculated between

the perceived susceptibility of HPV and each variable of vaccine acceptance (i.e., general
vaccine acceptance, influential factors, and barriers) and perceived severity of HPV and
each variable of vaccine acceptance. For those correlations that were significant,
multiple linear regression was calculated to determine the strength of the relationship
between each influential factor to acquiring the HPV vaccine and perceived susceptibility
and perceived severity and the strength of the relationship between each barrier to
acquiring the HPV vaccine and perceived susceptibility and perceived severity.
•

What is the relationship between acceptance of the HPV vaccine and intentions to
practice other safer sex behaviors among women attending college?
o What is the relationship between acceptance of the HPV vaccine and
attitudes towards practicing safer sex behaviors?
o What is the relationship between acceptance of the HPV vaccine and
normative beliefs about practicing safer sex behaviors?
o What is the relationship between acceptance of the HPV vaccine and
perceived control towards practicing safer sex behaviors?

The Pearson product-moment correlation coefficient (r) was calculated between
each variable of vaccine acceptance (i.e., general vaccine acceptance, influential factors,
and barriers) and attitudes, normative beliefs, perceived control, and intentions towards
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practicing safer sex behaviors. For those correlations were significant, multiple linear
regression was calculated to determine the strength of the relationship between each
influential factor to acquiring the HPV vaccine and attitudes, normative beliefs, perceived
control, and intentions and each barrier to acquiring the HPV vaccine and attitudes,
normative beliefs, perceived control, and intentions.
Missing Data
Because the survey content was about STIs and protective sexual behaviors, some
students may have chosen not to answer certain questions. Students were provided an
informed consent option before they were asked to participate in the pilot tests and study
survey, and this informed consent included the nature of the survey and informed them
that the survey contained items about their sexuality and sexual behaviors that may make
them feel uncomfortable. Consequently, they did not have to complete the survey if they
thought it would make them feel uncomfortable; also, they did not have to answer any
questions that made them feel uncomfortable. In addition, students were informed of
their right to stop taking the survey at any time through the informed consent (Appendix
B).
One of the purposes of pilot testing is to rephrase and omit questions that make
the majority of participants feel uncomfortable. By rephrasing questions so they are less
intimidating or intrusive, removing controversial questions after the pilot test, and
informing students about the nature of the survey, missing data were anticipated to be
minimal. However, missing data continue to be problematic in behavioral research
(Azar, 2002), so it was expected that there would be some missing data in this study.
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According to Little and Rubin (1997), the rule of thumb for analyzing missing
data and not deleting missing cases, is when a particular subject or variable has more than
5% missing values, but many researchers are more stringent. Participants with less than
5% of missing data were not omitted from the pilot tests or study, i.e., they were included
in the data analysis. Omitting participants could have potentially skewed data and
resulted in biased study conclusions. Although the pilot test and study samples were not
randomly selected, omitting data from participants could have resulted in the loss of
valuable data, as individuals who refused to respond to certain questions may be
systematically different than those who agree to take part, and those differences could be
related to variables of interest in the study. Also, if most participants have missing data
for the same questions, it may indicate that the questions were not well understood by
participants.
Missing data, for the pilot tests and study, were assigned a missing value code of
“99” so they could be analyzed separately from other survey responses. Analyzing
missing data separately reduced the chanced of skewed results, minimizing the risk that
study conclusions could become biased. Missing values for the pilot test and survey data
were analyzed to determine if they were missing completely at random (MCAR) when
the missing values are randomly distributed across all observations, or are missing at
random (MAR), when missing values are not randomly distributed across all observations
but are randomly distributed within one or more stratified samples, such as certain ethnic
groups.
Little’s MCAR test, a chi-square test, was calculated for each pilot test to
determine if missing data values were completely at random. Mean differences were
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calculated on demographic variables using t-tests and other key variables to establish that
the two groups did not differ significantly from each other. Because the data were
MCAR, missing values did not need to be imputed.
Missing data for “Pilot Test #1” and “Pilot Test #2” were MCAR; therefore,
pairwise deletion was conducted to remove cases with missing data for specific
calculations. Participants or cases that had more than 5% missing data were removed
from the data analysis, and t-tests for mean differences and analysis of variance
(ANOVA) were calculated to determine if there were significant differences for
demographic variables between the group of participants with missing data and the group
of participants without missing data. There were no significant differences between
groups in the first pilot test. However, there were significant differences between groups
in the second pilot test. Participants who were in their senior year of college and who
were 21 years of age had significantly more missing data compared to participants of
other class rankings and ages. Cross-tabulation results revealed that the majority of
students who were seniors were also age 21. There were no missing data among
participants in the third pilot test.
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Chapter Four
Results
This chapter describes the study participants, their responses to the survey,
including lack of survey responses or missing data, and results related to the research
questions.
Description of Respondents
A convenience sample of 2,872 undergraduate students enrolled at CMU, USF
and WMU completed the online “HPV Vaccine Survey” between January 12 to July 3,
2009. A formula was developed in Microsoft Excel to identify survey takers who
participated in one of the three pilot tests, and to identify ones who completed the survey
twice. For persons who completed the survey twice, the second survey was deleted (N =
73). In addition, 12 participants were omitted due to their dual participation in the survey
and one of the three survey pilot tests.
For the main survey, three participants who completed it were male, and 19
participants did not respond to the gender question. An additional 12 participants did not
respond to the question on age. Because of these participants being male, or of unknown
gender or age, these 34 participants also were omitted from the study.
Missing data analysis was conducted for 2,753 participants. An additional 47
participants were omitted from the study due to having five percent or more of survey
items with missing responses.
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A sample size of 2,706 female undergraduate students, between the ages of 18
and 24 were included in the data analysis. There were of 8.3% of participants that had
missing responses for < 5 percent of the survey items. Little MCAR’s test was conducted
with missing data for these participants. Because the chi square test statistic was not
significant (χ 2 = 3324.496, df = 3424, p = .886), missing data were assumed to be
MCAR. Independent-sample t-tests, for two groups, and one-way analysis of variance
(ANOVA), for three or more groups, were conducted to determine if there were any
significant differences for demographic variables between groups with and without
missing data. Tukey’s honestly significant difference (HSD) post hoc test was conducted
to determine which specific groups significantly differed from each other for missing data
(Appendix K). The difference in means for missing data between certain ethnic groups
was statistically significant F(8, 2690) = 2.951, p = .003. Specifically, African-American
participants were significantly more likely to have missing data than White participants,
MD = .079, p = .001. In addition, the difference in means for missing data between
participant groups with different sexual orientations was statistically significant F(3,
2695) = 2.930, p = .032. Participants who had sex with women were more likely to have
missing data compared to participants who had sex with men; however, the difference in
means was not significant at the .05 level (MD = .094, p = .061). There were no
significant differences between participants with and without missing data for any of the
other demographic variables: age, marital status, number of sexual partners, whether they
were currently sexually active, whether they had children, year in college, university
enrollment, and whether they had health insurance that covered the HPV vaccine.

134

Pairwise deletion was conducted to remove cases with missing data for specific
calculations.
There was a normal distribution of participants, based on measures of skewness
and kurtosis, for nearly all of the demographic variables, except for number of sexual
partners. See description of frequencies below under “Sexual orientation, number of
sexual partners, and current sexual activity” for further detail. Appendix L contains
statistics tables that include measures of central tendency (i.e., mean, median, mode),
standard error of the mean, standard deviation, variance, and skewness and kurtosis
values.
Age and ethnicity. The mean age of the participants was 20.7 years (SD = 1.580)
with a range of 18 to 24 years. The majority of participants (70.1%) were White,
followed by Multi-racial (8.6%), African-American (8.3%), Hispanic or Latino (8.1%),
Asian (3.0%), Other (1.0%), Arab-American (0.4%), Native Hawaiian or other Pacific
Islander (0.3%), American-Indian or Alaska Native (0.1%). Age distribution by ethnicity
is reported in Table 2. Age and ethnic distributions are illustrated in Figure 4 and Figure
5.
University and year in college. The majority of participants (73.8%) were
enrolled at USF, 24.7% were enrolled at WMU and 1.5% were enrolled at CMU. The
highest percentage (46.4%) of students were seniors, and the majority of seniors (87%)
were 21 years of age and older. University enrollment by year in college is reported in
Table 3 and illustrated in Figure 6.
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Table 2
Age of Respondents by Ethnicity
________________________________________________________________________
Age
________________________________________________________________________
18
19
20
21
22
23
24
________________________________________________________________________
Ethnicity
Percent
________________________________________________________________________
White
6.2%
17.3%
22.4% 24.9%
15.2%
9.0%
5.0%

AfricanAmerican

9.3%

20.4%

18.7%

12.9%

17.8%

12.4%

8.4%

Multi-racial

9.0%

23.2%

20.6%

17.6%

15.9%

8.6%

5.2%

Hispanic or
Latino

7.3%

21.5%

22.8%

19.6%

16.4%

5.9%

6.4%

11.1%

11.1%

21.0%

23.5%

17.3%

13.6%

2.5%

8.3%

8.3%

33.3%

16.7%

16.7%

16.7%

0.0%

14.3%

14.3%

28.6%

14.3%

14.3%

14.3%

0.0%

.0%

25.0%

50.0%

25.0%

0.0%

0.0%

0.0%

-

15.4%

19.2%

15.4%

23.1%

11.5%

15.4%_____

Asian

ArabAmerican
Native
Hawaiian
or Pacific
Islander
AmericanIndian or
Alaska
Native
Other
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Figure 4. Age distribution
Sexual orientation, marital status, number of sexual partners, and current
sexual activity. Only women between the ages of 18 and 24 participated in this study.
Most participants (80.1%) reported that they were heterosexual, by responding that they
had sex with men, whereas the remainder of participants reported that they did not have
sex (15.2%), had sex with men and women (2.7%), or had sex exclusively with women
(2%). The highest percentage of participants (49%) reported that they were single and in
a monogamous relationship. Over half of participants (51%) reported having one sexual
partner in the past 12 months, 14.4% reported having two partners, 17.8% had three or
more partners, and 16.6% reported having no sexual partners. Because the majority of
participants reported having only one sexual partner, and the range for this response was
between one and 20, the skewness (3.057) and kurtosis (15.608) values were larger than
what is considered acceptable for a normal distribution.
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Figure 5. Ethnic distribution
Most participants (70.4%) reported that they were currently sexually active.
Based on a chi-square test of independence, it appears that participants who reported
having a greater number of sex partners in the past year were also significantly more
likely to be currently sexually active, χ2(4, N = 2663) = 1289.54, p < .001. There was a
significant difference in current sexual activity among groups of participants in different
types of relationships, χ2(4, N = 2685) = 1461.55, p < .001. Participants who reported
that they were married were more likely to be currently sexually active compared to
participants who were in any other type of relationship. There was also a significant
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difference in current sexual activity among groups of participants based on age, χ2(6, N =
2692) = 64.205, p < .001. Current sexual activity increased with age, except for
participants older than 23 years of age (Figure 7).

Table 3
University Enrollment by Year in College
________________________________________________________________________
University
_______________________________________________________________________
CMU
USF
WMU
Totals
_______________________________________________________
Year in College
N
Percent
N
Percent
N
Percent
N
Percent
_______________________________________________________________________
Freshman
5
3.2%
125
80.1%
26
16.7%
156 100%
7

1.6%

375

84.4%

62

14.0%

444

100%

Junior

8

.9%

664

78.5%

174

20.6%

846

100%

Senior

20

1.6%

827

66.1%

405

32.3%

Percent

Sophomore

90
80
70
60
50
40
30
20
10
0

1252 100%

Freshman
Sophomore
Junior
Senior

CMU

USF

WMU

University

Figure 6. University enrollment by year in college
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Figure 7. Current sexual activity by age

Children, marital status, and age. The majority of participants (97.5%)
reported that they did not have children. The skewness (6.062) and kurtosis values
(34.769) were out of the normal range for this item. There were 68 (2.5%) participants
who reported they had children. A chi-square test of independence revealed that there
was a significant difference in marital status with children, χ2(4, N = 2692) = 118.97, p <
.001. The majority of participants with children were separated or divorced (50.0%),
compared to participants who were married (16.0%) and participants who were single
and sexually active (2.7%).
A chi-square test of independence revealed that there was a significant difference
in age of participants with children, χ2(6, N = 2698) = 56.05, p < .001, and the highest
percentage of participants with children were 24 years of age (10.3%). Number of
children by age is reported in Table 4.
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Table 4
Children by Age of Participants
________________________________________________________________________
Children
________________________________________________________________________
Yes
No
Totals
_________________________________________________________
Age
N Percent
N Percent
N Percent
________________________________________________________________________
18
3
1.6%
183
98.4%
186 100%
19

5

1.0%

481

99.0%

486

100%

20

9

1.5%

585

98.5%

594

100%

21

8

1.3%

604

98.7%

612

100%

22

20

4.7%

404

95.3%

424

100%

23

8

3.2%

243

96.8%

251

100%

24

15

10.3%

130

89.7%

145

100%__

Health insurance status. Forty-one percent (N = 1119) of participants reported
that they had health insurance that covered the HPV vaccine, whereas 24.2% (N = 654) of
participants reported that they did not have health insurance that covered the HPV
vaccine and 34.3% (N = 925) reported that they were “not sure.” The relationships
between each of the demographic variables and health insurance status were assessed. A
chi-square test of independence revealed that participants who were freshman, χ2(6, N =
2693) = 30.983, p < .001 were more likely to report that they had health insurance that
covered the HPV vaccine, compared to those who were in any other year in college. In
addition, those who reported that they did have health insurance that covered the HPV
vaccine were more likely to be sexually active compared to those who had health
insurance that covered the vaccine or who were not sure about their health insurance
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status, χ2(2, N = 2684) = 8.785, p =.012. The relationship between having health
insurance that covered the vaccine and cost of the vaccine being a barrier was assessed.
Participants who did not have health insurance that covered the HPV vaccine were
significantly more likely to perceive cost as an important barrier to becoming vaccinated
compared to those who were not sure if they had insurance or who had insurance, χ2(4, N
= 1693) = 293.168, p < .001. Most participants who had health insurance that covered
the vaccine reported that they were “Very Likely” to become vaccinated, 36% (N = 72).
However, it is interesting to note that those who were unsure about their health insurance
covering the vaccine were more likely to become vaccinated compared to those who were
or who were not covered, χ2(8, N = 1692) = 62.337, p < .001. Health insurance status by
year in college is reported in Table 5 and illustrated in Figure 8. Health insurance status
by sexual activity is reported in Table 6 and illustrated in Figure 9. Cost of the vaccine
being a barrier by health insurance status is reported in Table 7 and reported in Figure 10.
Likelihood of getting the vaccine by health insurance status is reported in Table 8 and
Figure 11.
Knowledge about HPV and the HPV Vaccine
Most participants 70.4% (N = 1904) responded accurately to all three
True/False statements about HPV. In addition, most (44.8% , N = 1211) checked all of
the four correct statements about the HPV vaccine and 28.9% (N = 781) checked three
out of the four correct statements about the vaccine. The statement that was checked the
most frequently by participants (81%) was, “The vaccine prevents women from getting
high-risk HPV,” followed by “The vaccine will protect against cervical cancer” (78.4%).
Cross-tabulation, as shown in Table 10, demonstrated that most participants (67%)
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checked off both of these statements. Three percent of participants (N = 81) had not
heard about the HPV vaccine.

Table 5
Health Insurance by Year in College
________________________________________________________________________
Health Insurance
___________________________________________________________
Yes
No
Not sure
Totals
___________________________________________________________
Year in College N
Percent
N Percent
N Percent
N Percent
________________________________________________________________________
Freshman
77
49.0%
26
16.6%
54 34.4%
157
100%
Sophomore

214

48.3%

105

23.7%

124

28.0%

443

100%

Junior

369

43.8%

189

22.4%

285

33.8%

843

100%

Senior

457

36.6%

333

26.6%

460

36.8%

1250

100%_

60
50

Percent

40

Freshman
Sophomore

30

Junior
Senior

20
10
0
Yes

No

Not sure

Health Insurance that Covers the HPV Vaccine

Figure 8. Health insurance by year in college
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Table 6
Health Insurance by Current Sexual Activity
_______________________________________________________________________
Sexually activity in the past 60 days
__________________________________________________________
No
Yes
Totals
__________________________________________________________
Health insurance
N
Percent
N
Percent
N
Percent
that covers the
HPV vaccine
_______________________________________________________________________
No
166
25.5%
485
74.5%
651
100%
Not sure

298

32.4%

621

67.6%

919

Yes

332

29.8%

782

70.2%

1114

100%
100%___

Percent

80
70
60
50

Sexually active

40
30
20

Not sexually active

10
0
Yes

No

Not sure

Health Insurance Status

Figure 9. Health insurance by current sexual activity
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Table 7
Cost of the Vaccine as a Barrier by Health Insurance Status
________________________________________________________________________
Cost of the Vaccine Would Prevent Me From Becoming Vaccinated
___________________________________________________________
Not important
Somewhat
Very
Totals
at all
important
important
___________________________________________________________
Health
N
Percent
N Percent
N Percent
N Percent
insurance that
covers the
HPV vaccine
________________________________________________________________________
Yes
160
42.2%
129
34.0%
90 23.7%
379
100%
Not sure

115

14.0%

326

39.8%

379

46.2%

820

100%

26

1.7%

123

24.9%

345

69.8%

494

100%

No

80

Percent

70
60

Very important

50

Somewhat important

40

Not important at all

30
20
10
0
Yes

No

Not sure

Figure 10. Importance of cost of the vaccine as a barrier by health insurance status
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Table 8
Health Insurance Status and Likelihood of Becoming Vaccinated
____________________________________________________________________________
Health Insurance Status
_______________________________________________________________
No
Not sure
Yes
Totals
_______________________________________________________________
N Percent
N Percent
N Percent
N Percent
Likelihood of
becoming vaccinated
_____________________________________
Very unlikely
101 25.8%
171 43.6%
120 30.6%
392 100%
A little likely

123

31.8%

206

53.2%

58

15.0%

387

100%

Somewhat likely

134

32.0%

221

52.7%

64

15.3%

419

100%

Likely

92

31.3%

139

47.3%

63

21.4%

294

100%

Very likely

44

22.0%

84

42.0%

72

36.0%

200

100%___

60
50

Very unlikely

Percent

40

A little likely

30

Somewhat likely
Likely

20

Very likely
10
0

No

Not sure

Yes

Figure 11. Likelihood of becoming vaccinated against HPV based upon insurance status
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Table 10
Knowledge about the HPV Vaccine
________________________________________________________________________
The vaccine will protect against cervical cancer
___________________________________________________________
Not Checked
Checked
Totals
___________________________________________________________
The vaccine
N
Percent
N
Percent
N
Percent
protects women
from getting
high risk HPV
________________________________________________________________________
Not checked
207
40.2%
308
59.8%
515
100.0%

Checked
377
17.2%
1814
82.8%
2191
100.0%
________________________________________________________________________

There were 16.1% (N = 436) of participants who were told they had HPV by a
health care provider, compared to 82% (N = 2215) who had not been told and 1.9% (N =
51) who were “Not sure.” Appendix M contains tables of participant responses to items
assessing knowledge of HPV and the HPV vaccine.
HPV Vaccine Acceptance
The majority (68.9%) of participants thought that vaccinations, in general, were
“Very important”, and 37.3% (N = 1006) received at least one dose of the HPV vaccine.
There were 1,693 participants who reported that they had not received at least one dose of
the vaccine, and there were seven participants who had missing data on whether they
received the vaccine. It is important to note that some of the seven participants who did
not respond to whether they were vaccinated against HPV did respond to subsequent
questions assessing HPV vaccine acceptance, including likelihood on becoming
vaccinated. Because these participants had missing data, and therefore, may not have
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been vaccinated, or mistakenly skipped the question, their responses were included in the
assessment of the specific factors measuring HPV vaccine acceptance, in addition to the
assessment of overall acceptance to address the study research questions. Over onefourth of the participants (N = 494) who reported that they had not yet received the HPV
vaccine responded that they were either “Very likely” or “Likely” to get vaccinated.
A skip pattern was included in the survey and participants who reported they
received the vaccine were directed to skip the questions on HPV vaccine acceptance.
The majority of participants who received the vaccine followed the skip pattern.
Responses to items on vaccine acceptance from participants who had received the
vaccine were coded as “skipped” items.
The influential factor in becoming vaccinated against HPV, that most participants
rated as “Very Important” was “If I had an abnormal pap smear” (77.2%, N = 1307) and
the influential factor that most participants rated as “Not important at all” was “If my
friends think I should get it,” (50.4%, N = 856). The importance of influential factors to
becoming vaccinated against HPV, rated from highest to lowest for “Very important” is
reported in Table 11. The factor that most participants reported as “Very important” to
being a barrier in becoming vaccinated against HPV was the “The cost of the vaccine”
(48.0%, N = 814), and the factor that was rated by most participants as “Not important at
all” to being a barrier in becoming vaccinated against HPV was “Fear of vaccines”
(72.6%, N = 1232). The importance of barriers in becoming vaccinated against HPV,
rated from highest to lowest for “Very important” is reported in Table 12. Appendix M
contains tables, including frequency percentages, item means and standard deviations, of
participant responses to factors associated with HPV vaccine acceptance.
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Table 11
HPV Vaccine Acceptance – Influential Factors for Vaccination
________________________________________________________________________
Issues that would influence you to become vaccinated against HPV
___________________________________________________________
Very
Somewhat
Not at all
Totalsa
important
important
important
___________________________________________________________
Issues
N
Percent
N
Percent
N
Percent
N
Percent
_______________________________________________________________________
If I had an
1307
77.2
322
19.0
63
3.7
1692
100.0
abnormal Pap
smear
If my health 1140
insurance covers
it

67.2

381

22.4

176

10.4

1697

100.0

If someone 1093
in my family
has cancer

64.4

474

27.9

130

7.7

1697

100.0

If my health 1078
care provider
thinks I should
get it

63.6

506

29.8

112

6.6

1696

100.0

Whether
I practice
safe sex

1077

63.6

447

26.4

170

10.0

1694

100.0

791

46.7

716

42.3

186

11.0

1693

100.0

If my sex
721
partner thinks
I should get it

42.6

751

44.4

220

13.0

1692

100.0

If my family
thinks I
should get
it

If my friends 172
10.1
670
39.5
856
50.4
1698
100.0
think I should
get it___________________________________________________________________
Note. a The total N includes only those participants that did not receive at least one dose of the
HPV vaccine.

149

Table 12
HPV Vaccine Acceptance – Barriers to Vaccination
________________________________________________________________________
Issues that would be barriers to becoming vaccinated HPV
___________________________________________________________
Very
Somewhat
Not important
Totalsa
important
important
at all
___________________________________________________________
Issues
N
Percent
N
Percent
N
Percent
N
Percent
_______________________________________________________________________
The cost of
814
48.0
580
34.2
302
17.8
1696
100.0
the vaccine
Possible
512
side effects
of the vaccine

30.2

793

46.7

391

23.1

1696

100.0

Not knowing
where to get
the vaccine

293

17.3

537

31.7

864

51.0

1694

100.0

Having to
258
get additional
boosters after
getting three
shots

15.3

691

40.9

741

43.8

1690

100.0

Fear of
vaccines

166

9.8

299

17.6

1232

72.6

1697

100.0

Getting three
shots over a
six-month
period

146

8.6

410

24.2

67.2

1697

100.0

1141

Having to
135
8.0
502
29.7
1053
62.3
1690
100.0
wait at my
doctor’s office
for approval
to get the vaccine_________________________________________________________
Note. a The total N includes only those participants that did not receive at least one dose of the
HPV vaccine.
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Attitudes, Beliefs, and Intentions Regarding Practicing Safer Sex Behaviors
Attitudes. The majority of participants had a favorable attitude towards
practicing safer sex behaviors. The mean response (M = 3.95) for items measuring
attitudes was approximately “Agree” on the Likert-type scale. The safer sex behavior
that most participants reported would be very easy for them was refusing to have sex with
a partner that will not use a condom by reporting “Strongly agree” (N = 1399, 51.8%)
and“Agree” (n = 702, 26.0%), followed by avoiding the use of drugs or alcohol before
engaging in sexual activity [“Strongly Agree” (N = 1380, 51.1%) and “Agree” (N = 602;
22.3%]. Over 50% (N = 1403) of participants responded that they “Agree” and “Strongly
agree” that telling a partner that they would not be sexually active with them until they
have been tested for STIs would be very easy for them. However, telling a partner that
they will not be sexually active with them until they have been tested for STIs was also
the safer sex behavior that had the highest percentage of participants “Disagree” (N =
512, 19.0%) and “Strongly disagree” (N = 67, 2.5%) that it would be easy for them.
Appendix M contains tables, including frequency percentages, item means and standard
deviations, of participant responses to attitudes regarding practicing safer sex behaviors.
The number and type of responses to survey items measuring attitudes about practicing
safer sex behaviors are also illustrated in Figures 12 through 14.
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Number of participants

1600
1400
1200
1000
800
600
400
200
0
Strongly
disagree

Disagree

Somewhat
agree

Agree

Strongly agree

Figure 12. Refusing to have sex with a partner if they will not use a condom would be
very easy for me.

Number of participants

800
700
600
500
400
300
200
100
0
Strongly
disagree

Disagree

Somewhat
agree

Agree

Strongly agree

Figure 13. Telling a partner that I will not be sexually active with them until they have
been tested for sexually transmitted infections would be very easy for me.
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Number of participants

1600
1400
1200
1000
800
600
400
200
0
Strongly
disagree

Disagree

Somewhat
agree

Agree

Strongly agree

Figure 14. Avoiding the use of drugs or alcohol before engaging in sexual activity
would be very easy for me.

Normative beliefs. The majority of participants had negative normative beliefs
in terms of their peers practicing safer sex behaviors compared to their own attitudes
about practicing safer sex behaviors. The mean (M = 2.30) response for items measuring
normative beliefs was between “Somewhat agree” and “Disagree” on the Likert-type
scale. The safer sex behavior that most participants did not think would be easy for their
peers was telling a partner to get tested for sexually transmitted infections before
becoming sexually active with them by responding “Disagree (N = 1473, 54.5%) and
“Strongly disagree” (N = 503; 18.6%). In addition, the majority of participants did not
think that most of their peers would avoid the use of drugs or alcohol before engaging in
sexual activity, by responding “Disagree” (N = 1398, 51.7%) or “Strongly disagree” (N =
531; 19.6%). The safer sex behavior that the highest percentage of participants thought
their peers would do, by responding “Agree” (N = 369, 13.7%) and “Strongly agree” (N =
76, 2.8%), was ask their health care provider about how to reduce their risk for sexually
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transmitted infections. Compared to the results for attitudes, a larger percentage of
participants thought that practicing certain safer sex behaviors, such as avoiding the use
of drugs or alcohol before engaging in sexual activity and telling a partner to get tested
before becoming sexually active with them would be very easy to do themselves, but
would not be done by their peers. Appendix M contains tables, including frequency
percentages, item means and standard deviations, of participant responses to normative
beliefs regarding practicing safer sex behaviors. The number and type of responses to
survey items measuring normative beliefs regarding practicing safer sex behaviors are
also illustrated in Figures 15 through 17.

Number of participants

1600
1400
1200
1000
800
600
400
200
0
Strongly
disagree

Disagree

Somewhat
agree

Agree

Strongly agree

Figure 15. Most college students would avoid using drugs or alcohol before engaging
in sexual activity.
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Number of participants

1200
1000
800
600
400
200
0
Strongly
disagree

Disagree

Somewhat
agree

Agree

Strongly agree

Figure 16. Most college students would ask their health care provider about how to
reduce their risk for STIs.

Number of participants

1600
1400
1200
1000
800
600
400
200
0
Strongly
disagree

Disagree

Somewhat
agree

Agree

Strongly agree

Figure 17. Most college students would tell a partner to get tested for STIs before
becoming sexually active with them.

Control beliefs. Overall, participants reported they had a high level of perceived
control over practicing safer sex behaviors. The mean response (M = 4.26) for items
measuring control beliefs was between “A lot of control” and “Complete control” on the
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Likert-type scale. The safer sex behavior that had the highest percentage of participants
report they had complete control was asking a health care provider about how to reduce
their risk of sexually transmitted infections, as 67.8% (N = 1827) of participants reported
they had “Complete control” and 21.6% (N = 582) of participants reported they had “A
lot of control.” The safer sex behavior that had the highest percentage of participants
report lack of control was being abstinent from sexual activity until they were married, as
11.7% (N = 315) reported “No Control” and 8.4% (N = 227) of participants reported
“Little control.” According to results of crosstabulations, the highest percentage of
participants who reported little control or no control for this item were women who were
either “single and in monogamous relationship” or “single and sexually active.” The
majority of participants (N = 2057) in this study were from both of these groups;
therefore, it may be that these participants reported that they did not have control in being
abstinent from sexual activity until they were married because they already had sex. The
majority of participants (N = 343, 64.4%) that were “single and abstinent” reported the
highest level of control in being abstinent from sexual activity. Appendix N contains the
cross-tabulation between marital status and level of control in being abstinent from sexual
activity until marriage. Appendix M contains tables, including frequency percentages,
item means and standard deviations, of participant responses to control beliefs regarding
practicing safer sex behaviors. The number and type of responses to survey items
measuring control beliefs regarding practicing safer sex behaviors are also illustrated in
Figures 18 through 22.
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Number of participants

1200
1000
800
600
400
200
0
No control

Little control

Some control A lot of control

Complete
control

Number of participants

Figure 18. Control in being abstinent from sexual activity until marriage

1600
1400
1200
1000
800
600
400
200
0
No control

Little control

Some control A lot of control

Complete
control

Figure 19. Control in refusing to have sex with a partner who will not use a condom
Intentions. Overall, participants had a high level of intention to practicing safer
sex behaviors, as the mean response (M = 3.86) for items measuring intentions was
between “Somewhat agree” to “Agree” on the Likert-type scale.
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Number of participants

1800
1600
1400
1200
1000
800
600
400
200
0
No control

Little control

Some control A lot of control

Complete
control

Figure 20. Control in avoiding the use of drugs or alcohol before engaging in sexual
activity

Number of participants

1400
1200
1000
800
600
400
200
0
No control

Little control

Some control A lot of control

Complete
control

Figure 21. Control in telling a partner to get tested for STIs before becoming sexually
active with them
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Number of participants

2000
1800
1600
1400
1200
1000
800
600
400
200
0
No control

Little control

Some control A lot of control

Complete
control

Figure 22. Control in asking a health care provider about how to reduce my risk of STIs

Forty-eight percent (N = 1295) of participants reported that they “Strongly agree”
and 23.4% (N = 632) “Agree” to intending to refuse to have sex with a partner that will
not use a condom, and this was the safer sex behavior with the greatest reported
intentions. Telling a partner to get tested for STIs before becoming sexually active with
them was the safer sex behavior with the lowest reported intentions, as the highest
percentage of participants disagreed with this item, by choosing either “Disagree”
(14.6%, N = 393) or “Strongly disagree” (1.3%, N = 36). The fact that participants had
the lowest intentions for telling a partner to get tested for an STI before becoming
sexually active is in parallel with participants also reporting the most negative attitudes
and normative beliefs regarding this particular safer sex behavior. Multiple linear
regression was used to determine the strongest predictors for intentions in carrying out
safer sex behaviors and is further described in a subsequent section of this chapter.
Appendix M contains tables, including frequency percentages, item means and standard
deviations, of participant responses to intentions regarding practicing safer sex behaviors.
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The number and type of responses to survey items measuring intentions to practice safer
sex behaviors are also illustrated in Figures 23 through 25.
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Figure 23. Intentions to tell a partner to get tested for STIs before becoming sexually
active with them
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Figure 24. Intentions to refuse to have sex with a partner if they will not use a condom
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Figure 25. Intentions to avoid drugs or alcohol before engaging in sexual activity

Perceived Susceptibility and Severity
Overall, participants perceived themselves as having a low susceptibility to
contracting HPV. Approximately 68% (N = 1845) of participants thought they were
“Very Unlikely” to currently have HPV, and approximately 54% (N = 1480) of
participants did not think they were likely to contract HPV. Although only 8.2% (N =
221) of participants reported that they were either “Very likely” or “Likely” to contract
HPV within the next year, a higher percentage (22.5%, N = 609) of participants reported
that they were more likely to get HPV sometime in their life. Participants reported that
they thought their peers were likely to contract HPV (50.2%, N = 1352) compared to
themselves (18.6%, N = 502).
Most participants thought HPV would be a serious problem for them by reporting
“Serious” (N = 1450, 53.6%) or “The most serious” (N = 286, 10.6%). However, based
on cross-tabulations, many of these participants also thought that HPV was not a big
problem because it is very easy to treat by reporting “Somewhat agree” (N = 797, 29.5%)
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and “Strongly agree” (N = 638, 23.6%) and 33.9% (N = 915) of participants were “Not
sure.” The majority of participants were “Not sure” (N = 1416, 52.5%) if it was likely
that they would get genital warts from HPV, but most reported “Somewhat likely” (N =
1319, 48.9%) and “Not sure” (N = 907, 33.6%) that they would get cancer.
Appendix M contains tables, including frequency percentages, item means and
standard deviations, of participant responses to perceived susceptibility and severity to
HPV. The number and types of responses to survey items measuring perceived
susceptibility and severity are also illustrated in Figures 26 through 34.
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Figure 26. Whether participants think they are likely to contract HPV
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Figure 27. Likelihood of currently having HPV
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Figure 28. Whether participants think their friends or peers are likely to contract HPV
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Figure 29. Likelihood of getting HPV within the next year
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Figure 30. Likelihood of getting HPV some time in life
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Figure 31. How serious a health problem HPV would be
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Figure 32. If you get HPV, it is not a big problem because it is very easy to treat
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Figure 33. Likelihood of getting genital warts if you get HPV
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Figure 34. Likelihood of getting cancer if you get HPV

Predictors of Intentions
Multiple linear regression was calculated to determine the strongest predictors of
intentions, such as attitudes, normative beliefs or control beliefs. Mean values for each
predictor and intentions were used in the regression calculation.
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The variables of attitudes, normative beliefs, and control beliefs combined to
strongly predict intentions, R = .730, p < .001. The predictor that had the greatest
influence on intentions was attitudes (β = .666), 95% CI [.649, .711], followed by control
beliefs (β = .082), 95% CI [.062, .132], and then normative beliefs (β = .076), 95% CI
[.062, .129]. Linear regression analysis for outliers using Mahalanobi’s distance
revealed 141 outliers among participants for residuals or discrepancies for “Mean
Intentions” (χ2 > 25.113, p = .001) at two standard deviations from the mean. Linear
regression analysis was performed both with and without the outliers but the influence of
predictors did not change. Attitudes remained the most influential predictor of intentions
(β = .768), followed by control beliefs (β = .074) and then normative beliefs (β = .063).
Because the results for the predictors for intentions did not change, the results are
reported with the outliers in the sample. Appendix O contains tables displaying the
multiple linear regression results for the predictors of intentions.
Research Questions
Research question #1. What is the relationship between knowledge about HPV
and intentions to practice safer sex behaviors among women attending college?
Subquestions.
o What is the relationship between knowledge about HPV and attitudes
towards practicing safer sex behaviors?
o What is the relationship between knowledge about HPV and normative
beliefs about practicing safer sex behaviors?
o What is the relationship between knowledge about HPV and perceived
control towards practicing safer sex behaviors?
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The Pearson product-moment correlation coefficient (r) was calculated between
the mean values of knowledge about HPV to determine if there were significant
relationships between knowledge about HPV and the predictors of intentions, including
attitudes, normative beliefs, and control beliefs, as well as a significant relationship
between knowledge and the variable of intentions as measured by survey items.
Significant negative correlations were found between knowledge of HPV and
attitudes (r = -.097, p < .01) and knowledge of HPV and intentions (r = -.099, p < .01)
towards practicing safer sex behaviors. There was also a negative correlation between
knowledge and normative beliefs, and a negative correlation between knowledge and
control beliefs; however, these correlations were not significant. Appendix O contains
tables displaying the correlation results.
Research question #2. What is the relationship between knowledge of the HPV
vaccine and acceptance of the HPV vaccine among women attending college?
Vaccine acceptance was measured in this study by general vaccine acceptance,
factors that would influence vaccination against HPV, and barriers to HPV vaccination.
The Pearson product-moment correlation coefficient (r) was calculated between the
variables of general vaccine acceptance and knowledge of the HPV vaccine, and there
was a significant positive correlation between these two variables, r =.215, p < .001.
There was not a significant correlation between knowledge about the HPV vaccine and
importance of factors that would influence HPV vaccination, r = .034, p = .166, or the
importance of barriers to vaccination, r = -.010, p = .680. Multiple linear regression was
employed to determine if any of the eight influential factors were significantly correlated
with knowledge about the HPV vaccine. Multiple linear regression demonstrated that
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there was a significant linear relationship between knowledge of the vaccine and certain
influential factors to becoming vaccinated, R = .130, p < .001, RMSE = .21593. Of the
eight influential factors, there was a significant positive relationship between “If someone
in my family has cancer” (β = .130, B = .045), 95% CI [.028, .062] and knowledge of the
HPV vaccine, and there was a significant negative relationship between “If my friends
think I should get it” (β = -.065, B = -.021), 95% CI [-.037, -.005] and knowledge of the
HPV vaccine. Multiple linear regression demonstrated that there was a significant linear
relationship between knowledge of the vaccine and certain barriers to vaccination, R =
.132, p < .001, RMSE = .21588. Of the seven barriers, there was a significant negative
relationship between “Possible side effects of the vaccine” (β = -.113, B = -.034), 95% CI
[-.048, -.020] and “Not knowing where to get the vaccine” (β = -.059, B = -.017), 95% CI
[-.031, -.003] and knowledge of the HPV vaccine. Appendix O contains tables
displaying the correlation and multiple linear regression results.
Research question #3.
•

What is the relationship between health beliefs about HPV and acceptance of the
HPV vaccine among women attending college?
Subquestions.
o What is the relationship between perceived susceptibility to HPV and
vaccine acceptance?
o What is the relationship between perceived severity of the HPV vaccine
and vaccine acceptance?
Vaccine acceptance was measured by general vaccine acceptance, factors that

would influence vaccination, and barriers to vaccination: health beliefs were measured by
perceived susceptibility to and severity of HPV based on the HBM. The Pearson
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product-moment correlation coefficient (r) was calculated for the variables of general
vaccine acceptance and perceived susceptibility. There was a significant positive
correlation between general vaccine acceptance and perceived susceptibility to HPV, r =
.067, p = .001. Multiple linear regression could not be calculated for the three specific
items measuring general vaccine acceptance because one of the items had a dichotomous
response scale compared to the other two items that had a ranked scale. Further
correlation analysis, via the Pearson r, revealed a low correlation between whether
participants thought if universal vaccination was important and perceived HPV
susceptibility, r = .008, p = .696. A chi-square statistic was calculated to assess the
differences in perceived susceptibility in participants who had received the HPV vaccine
and those who had not, because one of the items had a dichotomous response scale and
the other item had an ordinal response scale. The results were significant revealing that
participants who received the HPV vaccine had a lower perceived susceptibility to HPV,
compared to those who had not received the vaccine, χ2(31, N = 2699) = 63.945, p < .01.
There was a significant positive correlation between perceived susceptibility and
likelihood of becoming vaccinated against HPV, r = .145, p < .01.
There was not a significant correlation between perceived susceptibility and
influential factors or barriers to becoming vaccinated against HPV per the Pearson r
calculation. However, multiple linear regression demonstrated that there was a
significant linear relationship between perceived susceptibility to HPV and certain
influential factors to becoming vaccinated, R = .172, p < .001, RMSE = .72662. Of the
eight influential factors, there was a significant positive relationship between perceived
susceptibility and “if my health insurance covers it” (β = .143, B = .157), 95% CI [.098,
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.216] and “if my health care provider thinks I should get it”, (β = .086, B = .103), 95% CI
[.038, .168], whereas there was a significant negative relationship between perceived
susceptibility and “if I had an abnormal pap smear” (β = -.068, B = -.096), 95% CI [-.173,
-.019]. Multiple linear regression demonstrated that there was a significant linear
relationship between perceived susceptibility to HPV and certain barriers to becoming
vaccinated against HPV, R = .107, p < .001, RMSE = .73315. Of the seven barriers, there
was a significant positive relationship between perceived susceptibility and the cost of the
vaccine (β = .063, B = .061), 95% CI [.015, .108] and a significant negative relationship
between perceived susceptibility and possible side effects of the vaccine (β = -.087, B = .088), 95% CI [-.137, -.040].
There was a significant positive correlation between general vaccine acceptance
and perceived severity of HPV, r = .088, p < .001. Further correlation analysis, via the
Pearson r, revealed a significant positive correlation between whether participants
thought if universal vaccination was important and perceived HPV severity, r = .077, p <
.001. As with perceived susceptibility described above, a chi-square statistic was
calculated to determine the differences in perceived severity among participants who had
received the HPV vaccine versus those who had not, because one of the items had a
dichotomous response scale and the other item had an ordinal response scale. There was
not a significant relationship between perceived severity and vaccine status. Based on
previous results of perceived severity, most participants agreed that HPV was not a
serious problem because it was very easy to treat. The Pearson product-moment
correlation coefficient (r) was calculated to determine if there was a relationship between
likelihood of becoming vaccinated and the perception that HPV was not a serious
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problem because it is very easy to treat. The Pearson r revealed that there was a small,
non-signficant negative relationship between these this type of perceived severity and
likelihood of becoming vaccinated, r = -.009, p = .717. There was a significant, positive
correlation between perceived severity and likelihood of becoming vaccinated against
HPV, r = .110, p < .01.
The Pearson product-moment correlation revealed that there was a significant
positive correlation between perceived severity and influential factors to becoming
vaccinated against HPV, r = .072, p = .003. Multiple linear regression was then used to
determine the influential factors that had the strongest relationship with perceived
severity. There was a significant linear relationship between influential factors to getting
vaccinated and perceived severity, R = .152, p < .001, RMSE = .43833. Of the eight
influential factors, “if someone in my family has cancer” (β = .118, B = .083), 95% CI
[.048, .118], followed by “if my family thinks I should get it” (β = .062, B = .041), 95%
CI [.008, .074] had significant positive relationships with perceived severity. The
Pearson product-moment correlation revealed that there was not a significant correlation
between perceived severity and barriers to becoming vaccinated against HPV, r = .072, p
= .003. However, multiple linear regression demonstrated was calculated to determine if
there was a significant linear relationship between perceived severity to HPV and certain
barriers to becoming vaccinated. Of the seven barriers, “cost of the vaccine” (β = .059, B
= .035), 95% CI [.007, .063] was the only factor that had a significant, positive
relationship with perceived severity, R = .059, p = .016, RMSE = .44256. Appendix O
contains tables displaying the correlation and multiple linear regression results.
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Research question #4.
•

What is the relationship between acceptance of the HPV vaccine and intentions to
practice other safer sex behaviors among women attending college?
Subquestions.
o What is the relationship between acceptance of the HPV vaccine and
attitudes towards practicing safer sex behaviors?
o What is the relationship between acceptance of the HPV vaccine and
normative beliefs about practicing safer sex behaviors?
o What is the relationship between acceptance of the HPV vaccine and
perceived control towards practicing safer sex behaviors?
The Pearson product-moment correlation coefficient (r) was calculated and there

was not a significant correlation between the variables of general vaccine acceptance and
mean attitudes towards practicing safer sex behaviors and, r = .029, p = .128. Further
correlational analysis revealed a significant, positive relationship between the importance
of vaccinations in general among participants and attitudes towards practicing safer sex
behaviors, r = .059, p = .002; however, there was a low, non-significant, positive
correlation between attitudes towards practicing safer sex behaviors and likelihood of
becoming vaccinated against HPV, r = .024, p = .326. A chi-square statistic was
calculated to determine the differences in attitudes among participants who had received
the HPV vaccine and those who had not, and there were no significant differences, χ2(12,
N = 2699) = 15.543, p = .213. Multiple linear regression was used to determine
differences in strengths in relationships among influential factors for becoming
vaccinated against HPV and attitudes towards practicing safer sex behaviors. There was
a significant linear relationship between influential factors for becoming vaccinated
against HPV and attitudes toward practicing safer sex behaviors, R = .195, p < .001,
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RMSE = .77713. Of the eight influential factors, “if my health insurance covers it” (β = .165, B = -.194), 95% CI [-.251, -.137] had a significant negative relationship with
attitudes towards practicing safer sex behaviors, and there was a significant positive
relationship between “whether I practice safe sex” and attitudes towards practicing safer
sex behaviors (β = .152, B = .180), 95% CI [.122, .237]. There was also a significant
linear relationship between barriers to vaccination against HPV and attitudes towards
practicing safer sex behaviors, R = .167, p < .001, RMSE = .78119. Of the seven
barriers, there was a significant negative relationship between the cost of the vaccine (β =
-.122, B = -.128), 95% CI [-.180, -.077] and not knowing where to get the vaccine (β = .086, B = -.090), 95% CI [-.142, -.039] and attitudes towards practicing safer sex
behaviors.
There was a significant positive correlation between general vaccine acceptance
and normative beliefs regarding practicing safer sex behaviors, r = .113, p < .001.
Further correlational analysis revealed a significant, positive relationship between the
likelihood of getting the HPV vaccine and normative beliefs, r = .111, p < .001.
A chi-square statistic was calculated to determine the differences in normative beliefs
among participants who had received the HPV vaccine and those who had not, and there
were no significant differences, χ2(13, N = 2699) = 20.169, p = .091. Multiple linear
regression was employed to determine differences in the strength of the relationships
among influential factors for becoming vaccinated against HPV and normative beliefs
towards practicing safer sex behaviors. There was a significant linear relationship
between influential factors for becoming vaccinated against HPV and normative beliefs
regarding practicing safer sex behaviors, R = .159, p < .001, RMSE = .63422. Of the
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eight influential factors, there was a significant, positive relationship between “whether I
practice safe sex” (β = .098, B = .094), 95% CI [.046, .141], “if my friends think I should
get it” (β = .062, B = .059), 95% CI [.009, .110] and “if my family thinks I should get it”
(β = .058, B = .056), 95% CI [.005, .106] and normative beliefs regarding safer sex
behaviors. There were no significant relationships between any of the barriers to
vaccination against HPV and normative beliefs regarding practicing safer sex behaviors.
There was not a significant relationship between general vaccine acceptance and
perceived control beliefs in practicing safer sex behaviors, r = .005, p = .778. Further
correlational analysis revealed a significant, positive relationship between the importance
of vaccinations in general among participants and perceived control towards practicing
safer sex behaviors and, r = .054, p = .005. However, there was a low, non-significant,
negative correlation between likelihood of becoming vaccinated against HPV and
perceived control beliefs in practicing safer sex behaviors and, r = -.029, p = .226.
A chi-square statistic was calculated to determine the differences in control beliefs among
participants who had received the HPV vaccine and those who had not, and there were no
significant differences, χ2(19, N = 2699) = 21.011, p = .336. Multiple linear regression
was used to determine the difference in the strength of the relationships of influential
factors for becoming vaccinated against HPV and perceived control beliefs in practicing
safer sex behaviors. There was a statistically significant linear relationship between
influential factors to becoming vaccinated against HPV and perceived control beliefs in
practicing safer sex behaviors, R = .163, p < .001, RMSE = .67421. Of the eight
influential factors, there was a statistically significant, negative relationship between “if
my health insurance covers it” (β = -.151, B = -.154), 95% CI [-.203, -.104] and perceived
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control beliefs and there was a significant positive relationship between “whether I
practice safe sex” (β = .108, B = .110), 95% CI [.060, .160] and perceived control beliefs.
There was also a statistically significant linear relationship between barriers to becoming
vaccinated against HPV and perceived control beliefs in practicing safer sex behaviors, R
= .166, p < .001, RMSE = .67402. Of the seven barriers, there was a statistically
significant negative relationship between “the cost of the vaccine” (β = -.123, B = -.111),
95% CI [-.155, -.067] and “having to wait at my doctor’s office for approval to get the
vaccine” (β = -.083, B = -.089), 95% CI [-.141, -.036] and perceived control beliefs. In
addition, there was a statistically significant positive relationship between “possible side
effects of the vaccine would prevent me from becoming vaccinated” and perceived
control beliefs (β = .053, B = .050), 95% CI [.004, .095].
The Pearson product-moment correlation coefficient (r) was calculated and there
was a statistically significant positive correlation between the variables of general
vaccine acceptance and mean intentions towards practicing safer sex behaviors, r = .087,
p < .001. Further correlational analysis revealed that there was also a statistically
significant positive correlation between the importance of vaccinations in general, and
intentions to practice safer sex behaviors, r = .081, p < .001. Additional correlational
analysis revealed that there was also a statistically significant positive correlation
between the likelihood of becoming vaccinated against HPV and intentions to practice
safer sex behaviors, r = .098, p < .001. The application of multiple linear regression
revealed a statistically significant linear relationship between influential factors to
becoming vaccinated against HPV and intentions to practice safer sex behaviors, R =
.244, p < .001, RMSE = .78479. Of the eight influential factors, there was a statistically
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significant positive relationship between “whether I practice safe sex” (β = .191, B =
.230), 95% CI [.169, .290], “if someone in my family has cancer” (β = .062, B = .079),
95% CI [.013, .145], and “if my friends think I should get it” (β = .056,
B = .068), 95% CI [.008, .129] and intentions. There was a statistically significant
negative relationship between “if my health insurance covers it” (β = -.183, B = -.219),
95% CI [-.281, -.158] and intentions. Based upon the results of multiple linear
regression, there was also a statistically significant linear relationship between certain
barriers to vaccination and intentions to practicing safer sex behaviors, R = .128,
p < .001, RMSE = .80225. There was a statistically significant, negative relationship
between “the cost of the vaccine” (β = -.101, B = -.109), 95% CI [-.162, -.056] and “not
knowing where to get the vaccine” (β = -.055, B = -.059), 95% CI [-.112, -.006] and
intentions to practicing safer sex behaviors. Appendix O contains tables displaying the
correlation and multiple linear regression results.
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Chapter Five
Discussion

This study produced a large sample size (N = 2,872) of undergraduate students,
across three universities, participating in the online survey in less than six months. At
one university, 1,195 students completed the survey within 48 hours of it becoming
available. This level of participation suggests the topics of HPV and the corresponding
vaccine were of great salience to this audience. It is further indicative of the importance
and timeliness of educating female undergraduates about their risks of getting HPV, the
availability of the HPV vaccine, and the need for practicing safer sex behaviors.
Studies have examined whether the vaccine will lead to riskier sexual behaviors
among adolescents (Forster, Wardle, Stephenson, & Waller, 2010; Marlow, Forster,
Wardle, & Waller, 2009; Waller, Marlow, & Wardle, 2006). However, no published
studies to-date have yet examined whether the vaccine will lead to riskier sexual
behaviors among college-aged females who are also a target population for the vaccine
and are of legal age to make the decision to become vaccinated. This is the first study to
assess the relationship between HPV vaccine acceptance and intentions to practice safer
sex behaviors among female college students. Studying attitudes, beliefs, and intentions
to practicing safer sex behaviors in relation to HPV vaccine acceptance may provide a
better understanding of whether the vaccine will lead to riskier sexual behaviors among
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the female college student population. This information is vital to the reproductive health
of female college students because the HPV vaccine does not protect against all high-risk
types of HPV and other STIs. The relationship between knowledge about HPV and
intentions to practice safer sex behaviors was also assessed to determine if those students
who knew more about HPV were also more likely to protect themselves against not only
getting HPV, but other STIs. Globally, there have been many studies on the relationship
between knowledge about HPV, perceived risk and severity of HPV, and intentions for
vaccination among female college students (Kang and Moneyham, 2010; Licht, et al.,
2010; Mehu-Parant, Rouzier, & Soulat, 2010; Wong and Sam, 2010). However, this was
the first comprehensive study to assess the relationship between knowledge about HPV,
health beliefs regarding HPV, HPV vaccine acceptance, and intentions to practice safer
sex behaviors through the application of a combined framework of the HBM and TPB.
Relationship Between Knowledge about HPV and Intentions to Practice Safer Sex
Behaviors
Though past studies have assessed knowledge about HPV among college
students, this study was the first to assess the relationship between knowledge about HPV
and intentions to practice safer sex behaviors. The majority of participants in this study
had a high level of knowledge about HPV, also found in similar studies among collegeaged women, since FDA approval of the GARDASIL® in 2006 (Licht et al., 2010;
Sandfort and Pleasant, 2009). The high level of knowledge about HPV among this
population may be due to consumer media campaigns, university-based education
programming or education by health care providers. There were significant negative
relationships between HPV knowledge and attitudes and HPV knowledge and intentions
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towards practicing safer sex behaviors among participants in this study, and a nonsignificant negative relationship between HPV knowledge and normative beliefs and
HPV knowledge and control beliefs to practice safer sex behaviors. These findings may
indicate that although female college students have a high level of knowledge about
HPV, they may not think that practicing safer sex behaviors would be easy, they have
control over practicing these behaviors, or have intentions to practice these behaviors.
Furthermore, the majority of participants in this study reported that they were currently
sexually active in monogamous relationships, and these findings may also indicate that
they do not practice safer sex behaviors in those relationships. These findings
demonstrate the need for university student health centers to develop marketing
campaigns that include the combination of promoting the HPV vaccine, in addition to the
promotion of safer sex behaviors that are targeted not only to females, but also to couples
who are in monogamous relationships. Targeting heterosexual couples for the vaccine
would be relevant since the vaccine is now available to college-aged men (Merck & Co.,
Inc., 2009), and studies have demonstrated a high level of vaccine acceptance among
male college students (Daley et al., 2010; Liddon, et al., 2010). University student health
centers can also incorporate education on STIs into their peer education classes for first
year students, with an emphasis on how sexually active students who are single or in
monogamous relationships can protect themselves from STIs by continuing to practice
safer sex behaviors, including acquiring the HPV vaccine. This education can be offered
through seminars, such as those offered at residence halls. College campuses can also
utilize different types of social media (i.e., Facebook, Twitter, YouTube, and Myspace) to
reach female college students through these media campaigns.
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Regarding perceived control beliefs, it is important to note that the survey item
that assessed the level of control in being abstinent from sexual activity until marriage
was answered by participants who had already engaged in sexual activity, such as
participants who were “single and sexually active”, “single and in a monogamous
relationship”, “married”, and “separated/divorced.” Although this item was intended to
measure perceived control in a hypothetical situation, having all participants answer this
item may have reduced the validity of assessing perceived control beliefs about
abstinence since most participants were sexually active. Future studies assessing
attitudes or beliefs regarding safers sex behaviors, including abstinence, may want to
incorporate additional skip patterns into surveys so that participants who had not
previously engaged in sexual activity respond to questions about abstinence.
Relationship Between Knowledge of the HPV Vaccine and Acceptance of the HPV
Vaccine Among Women Attending College
Most participants in this study knew about the HPV vaccine and had a high level
of acceptance of the HPV vaccine and vaccinations in general, and over a third of the
participants received at least one dose of the vaccine. Studies have not shown whether
there are more benefits to receiving three doses of the HPV vaccine compared to one or
two doses (CDC, 2009). A subset of participants, females ages 16 to 23 years, from the
phase II clinical trial of the quadrivalent GARDASIL® vaccine, are being followed for
vaccine efficacy after 60 months after receiving one dose, but the results are not yet
known (Villa, et al., 2006). The average duration of protection against the HPV vaccine
types ranges, on average, from five to six years, depending upon the type of vaccine –
GARDASIL® or Cervarix®. Additional studies are needed to determine if one dose is just
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as effective or if additional boosters beyond the three doses of the vaccine are necessary.
Regardless of knowledge level of HPV, the major influences to becoming vaccinated
against HPV were having an abnormal Pap smear, whether they had health insurance that
covered the HPV vaccine, and whether someone in their family had cancer. Though it
was not the most influential factor, Crosby et al. (2007) also found that having an
abnormal Pap smear was significantly linked to HPV vaccine acceptance among collegeaged women, in addition to having vaginal sex in the past 12 months and having an STI.
An abnormal Pap smear being the most significant influential factor to becoming
vaccinated for college women who have a high level of knowledge of HPV is interesting
because the HPV vaccines, Cervarix® and GARDASIL®, do not protect against HPV
types 16 and 18 after a person has contracted these viruses, and there is no guarantee the
vaccine will prevent cervical cancer in a person who already has either of these virus
types. Furthermore, getting the vaccine after being diagnosed with an abnormal Pap
smear will not prevent further abnormal Pap tests results, as the vaccines do not protect
against existing HPV infections and the vaccines do not protect against all types of HPV.
However, both HPV vaccines, Cervarix® and GARDASIL®, can protect against persistent
infection against the high-risk vaccine HPV types that cause cervical cancer (Gilsdorf &
Markowitz, 2006; GlaxoSmithKline, 2009). Because items assessing HPV vaccine
knowledge in this study did not measure students’ understanding of how the vaccine
worked, it cannot be determined whether students that were most influenced to become
vaccinated based upon an abnormal Pap smear, knew about the role of HPV vaccine in
preventing persistent infection or thought the vaccine can cure an existing HPV infection.
Items that assess students’ knowledge of the mechanics of the HPV vaccine in preventing
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infection and cervical cancer should be included on surveys in future studies that assess
the relationship between knowledge and acceptance of the vaccine.
The influence of whether their health care provider or their family members
thought they should get the vaccine were nearly equal in importance, possibly indicating
that family members and health care providers may have a similar level of influence for
female college students in their decision to get vaccinated against HPV. Interestingly, the
factor that had the most influence in becoming vaccinated for participants with a high
level knowledge about the HPV vaccine, was whether someone in the family had cancer,
and the factor that had the least importance was whether their friends thought they should
get the vaccine. These results may indicate that students who know more about the
vaccine, are more likely to be influenced by family history of cancer and less likely
influenced by peer pressure. This is an interesting finding, as research has demonstrated
that hereditary factors are not linked to cervical cancer, but rather that it is a virally
induced cancer caused only by behavioral factors (Vink, et al., 2010). However, a
hereditary component, such as a mutation in the p53 gene and certain gene complexes,
has been found that may increase an individual’s susceptibility of HPV developing into
cancer. Additional research is needed to determine if there is a familial genetic link
between HPV and its progression into cervical cancer (de Araujo Souza & Villa, 2003;
Maciag & Villa, 1999; Magnusson & Gyllensten, 2000). Furthermore, future studies
need to determine if certain high risk health behaviors, such as smoking or unsafe sexual
behaviors that can cause persistent infection with HPV, can impact those who have a
genetic susceptibility of HPV developing into cervical cancer.
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Social marketing campaigns that promote the fact that a high percentage of
students have already received the vaccine may not have an impact on students who have
a high level of knowledge about the vaccine, but rather campaigns focused on the health
consequences of not becoming vaccinated, such as risk of cervical cancer, may be more
influential on targeting a more educated college female population. However, these
findings also reinforce the need for university student health centers to convey messages
about the importance of practicing safer sex behaviors targeted to all students through oncampus educational campaigns and to combine these messages with information about
the etiology of cervical cancer, specifically how it is caused only by environmental
factors, specifically sexual behaviors.
Major barriers to becoming vaccinated were cost of the vaccine, possible side
effects of the vaccine, and not knowing where to get the vaccine. However, for
participants with a high level of knowledge about the vaccine, possible side effects and
not knowing where to get the vaccine were barriers of least importance. These results
indicate that barriers associated with knowledge of the vaccine, such as possible side
effects and places where the vaccine is available, are not issues for those female college
students who are more educated about the vaccine.
Overall, the study findings on HPV vaccine acceptance associated with
knowledge about the vaccine among female college students demonstrate the need for
university student health center staff to educate students about their options in paying for
the vaccine, and to help students determine if the cost of the vaccine is covered under
their health insurance or if uninsured, whether they are eligible and how to apply for
coverage through Merck & Co., Inc. or GlaxoSmithKline. Having university student
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health center staff conduct a community assessment of the local availability of the
vaccine may be useful for students in knowing where they can obtain the vaccine.
A university or college media campaign that includes multiple components, such as
promoting the availability of the vaccine on campus and throughout the community, how
both insured and uninsured students can determine if they are eligible to receive the
vaccine at no cost; and, educating students on the limited, though possible side effects of
the vaccine may help students make an informed decision on whether to become
vaccinated.
Relationship Between Health Beliefs About HPV and Acceptance of the HPV
Vaccine Among Women Attending College
The majority of participants in this study believed that HPV would be a serious
problem for them; however, many participants also agreed that HPV would not be a big
problem because it was very easy to treat. In addition, there was a high percentage of
participants who were unsure, and it may be because of how the survey question was
worded. Participants might have had conflicting responses to each part of the question,
for instance, they may have thought that HPV was not a big problem but they may not
have known how to respond whether it was very easy to treat, because it depended upon
what stage HPV was diagnosed. Therefore, future studies assessing health beliefs about
HPV among young women, may want to include more specific survey items that measure
perceived severity, for instance, when HPV is diagnosed early compared to a later
diagnosis.
There was a small, non-significant negative relationship between likelihood of
getting the vaccine and agreeing that HPV was not a serious problem because it is very
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easy to treat. These findings indicate that female college students who think that HPV is
easy to treat may not be likely to get the vaccine to protect themselves from the types of
HPV viruses that pose the highest risk of getting cervical cancer and genital warts. In
addition, these results may indicate that those students who think HPV is easy to treat are
more likely to get recommended Pap and HPV DNA tests for early detection, rather than
become vaccinated. Future studies may help to determine if female college students who
have been vaccinated against HPV, and have a low perceived susceptibility of HPV, are
more likely to get tested for early diagnosis and treatment rather than acquire the HPV
vaccine.
Participants in this study were also more likely to think that they would get cancer
as most were not sure if they would be likely to get genital warts. This perception may
be due to the education they are receiving from the consumer marketing campaigns for
the HPV vaccine that are focused more on HPV being linked to cervical cancer, with less
emphasis on genital warts. This finding may indicate a need for university health centers
to include a greater, but equal focus on the association between HPV and genital warts, in
addition to cervical cancer, in on-campus HPV education and vaccine marketing
campaigns targeting female college students.
There was a significant positive relationship between general vaccine acceptance
and perceived susceptibility to and perceived susceptibility of HPV. This finding may
indicate that those students who think vaccines are important in general, perceive
themselves to be more susceptible to getting those vaccine-preventable diseases,
including HPV, and perceive vaccine-preventable diseases to be more serious. In
addition, those students who were more likely to report that they would get the HPV
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vaccine also perceived themselves to be more susceptible to contracting HPV and
perceived HPV to be more serious compared to those who were less likely to get the
vaccine. This finding is consistent with the framework of the HBM, where those
individuals who perceive themselves at high risk of getting a disease and associate a
disease with greater severity, are more likely to take action to prevent the disease
compared to those individuals who perceive themselves at lesser risk or think there is less
severity associated with a disease (Rosenstock, 1988).
Participants who perceived themselves to be more susceptible to HPV were more
likely to be influenced by certain factors in becoming vaccinated against HPV. Those
participants who perceived themselves to be more susceptible to HPV were more likely
to be influenced by whether their health insurance covered the vaccine and whether their
health care provider recommended that they become vaccinated against HPV.
Interestingly, participants who perceived themselves to be more susceptible were
significantly less likely to be influenced to becoming vaccinated based upon whether they
had an abnormal pap smear. Therefore, these findings may indicate that there may be
other non-health related factors that play a role in female college students’ decision to
become vaccinated against HPV, even those who perceive themselves to be susceptible to
getting the STI or that female college students who think they are more susceptible do not
know the purpose of a Pap test. This finding may indicate that university student health
centers may need to increase their education on the role that Pap tests have in diagnosing
HPV and its importance as a primary prevention measure for cervical cancer, regardless
of their health beliefs. As with the majority of participants, regardless of their health
beliefs participants that perceived HPV to be more severe were most influenced by
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whether or not someone in the participant’s family had cancer, followed by if their family
thought they should get the vaccine. This finding may be different than the previous one,
described earlier in the discussion, on the relationship between influential factors to
vaccination and knowledge, where students who were more educated about the vaccine
were more influenced by whether someone in their family had cancer on their decision to
become vaccinated against HPV. The issue here may not just be that college students are
not knowledgeable about the etiology of cervical cancer, but that those students who have
a family history of any type of cancer, may be more likely to perceive HPV to be severe
because is associated with cervical cancer, regardless of whether the cancer is caused by
environmental or hereditary factors. Future studies are needed to confirm the relationship
between students’ knowledge of the etiology of cervical cancer, perceived severity of
HPV and influential factors to becoming vaccinated.
This study found that the greatest barrier to vaccination, for female college
students who perceived themselves as the most susceptible and perceived HPV to be the
most severe, was the cost of the vaccine, and this was a similar finding for the majority of
participants, regardless of health beliefs. These results further reinforce the need for
university student health center staff to provide education on all of the different options
available to pay for the HPV vaccine, as well as consultation on what options may work
best for students, depending upon their income and insurance status. Primary care
providers in the general community could also play a role in providing education and
consultation on the cost of the HPV vaccine to all young adult female clients who are
eligible to receive the vaccine, and this is relevant to college students as not all of
members of this population obtain health care on campus.
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Relationship Between Acceptance of the HPV Vaccine and Intentions to Practice
Other Safer Sex Behaviors Among Women Attending College
The safer sex behavior that seemed to be the easiest for female college students in
this study, based upon attitudes, was refusing to have sex with a partner that would not
wear a condom, followed by avoiding drugs or alcohol before engaging in sexual activity.
The purpose of measuring students’ attitudes, normative beliefs and perceived control in
avoidance of drugs or alcohol before engaging in sexual activity was primarily to assess
practicing this specific safer sex behavior compared to others, not to assess the frequency
of this behavior among students to control for having safe sex. However, this study
finding is interesting since research has demonstrated that most college students use
alcohol and that its use is often involved in sexual activity. The Youth Risk Behavior
Survey (1995) conducted among college students at four-year institutions, showed that
nearly 20% of students had drunk alcohol or used drugs at last sexual intercourse (CDC,
1997). Furthermore, results from the Core Institute Survey (2006), completed mostly by
female undergraduate students from 134 universities in the U.S., revealed that over 70%
of students used alcohol over the past 30 days, and over 80% used alcohol at least once
during the past year, with freshman to seniors, averaging approximately from 5 to 6
drinks per week. Although this survey did not measure the relationship between alcohol
use and sexual activity, results revealed that over 10% of college students were taken
advantage of sexually and over 3% took advantage of others sexually as a consequence of
alcohol use a year before taking the survey. Studies have demonstrated that female
college students with higher self-regulation and use drinking protective behavioral
strategies, such as not drinking or limited alcohol consumption before or during sexual
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activity, have lower risk sexual behavior and fewer sex-related alcohol negative
consequences (Lewis, Rees, Logan, Kaysen, & Kilmer, 2010; Quinn & Fromme, 2010).
The prevalence of alcohol and drug use was not measured in this study; therefore, it
cannot be determined whether students who had a positive attitude about avoiding using
drugs or alcohol before engaging in sexual activity did not use alcohol or drugs or
whether these students have high self-regulation or use drinking protective behavioral
strategies before engaging in sexual activity. Future studies assessing safer sex behaviors
related to the use of alcohol or drugs among college students should also assess the
prevalence of drugs or alcohol to determine if there is a relationship between the use of
drugs or alcohol and avoiding this behavior before engaging in sexual activity and
whether alcohol and drug use is avoided by students to reduce high risk sexual behaviors
and sex-related alcohol negative consequences.
Overall, participants reported having a high level of control over practicing all of
the safer sex behaviors, especially refusing to have sex with a partner that would not wear
a condom and asking a health care provider about how to reduce their risk of STIs.
Sandfort and Pleasant (2009) found that male and female undergraduate students
preferred to receive information about sexual health from their primary health care
providers. Therefore, female college students may prefer to receive health care
information from health care providers because they may feel like they have more control
in doing so. Although students in this study had a positive attitude and seemed in control
over having partners use condoms, it is still concerning because condom usage does not
fully protect an individual from getting certain STIs, including HPV. This finding
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reinforces the need for university-based STI prevention campaigns to include an
emphasis on practicing other safer sex behaviors in conjunction with correct condom use.
The safer sex behavior that seemed to be the most difficult and that participants
perceived they had less control over and less intention to carry out, was telling a partner
they would not be sexually active with them until they were tested for STIs. Therefore,
university student health centers may want to run ad campaigns that focus on men and
women talking with partners about getting tested for STIs before becoming sexually
active with them, as well as provide tips, in new or existing educational pamphlets on STI
prevention, on how couples can talk to each other about getting tested. In addition,
information on types of STIs, tests for STIs, and where individuals can get tested can be
included in these pamphlets.
Most participants did not believe that their peers would carry out certain safer sex
behaviors, compared to their own positive attitudes and perceived control about carrying
out those same behaviors. Participants also perceived their peers being more susceptible
to contracting HPV compared to themselves. These findings are similar to results of
other studies on students’ perceived norms about high risk behaviors, including alcohol
use and sexual behaviors. College students often overestimate peers engaging in certain
high risk behaviors more than they actually do and more than themselves (Martens, Page,
Mowry, Damann, Taylor, & Cimini, 2006; Pedersen & LaBrie, 2008; Scholly, Katz,
Gascoigne, & Holck, 2005). However, findings from this study are critical because
normative beliefs can be influential in peer behavior, and university student health
centers can address these beliefs by implementing social norm campaigns for the
prevention of STIs by promoting the message that most female college students have
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positive attitudes about practicing safer sex behaviors, despite commonly held beliefs that
peers practice risky sexual behaviors.
A combination of the HBM and the TPB was applied in this study to determine
the greatest predictor of intentions regarding practicing safer sex behaviors. The
strongest predictor of intentions to practice safer sex behaviors in this study was attitudes,
followed by control beliefs and then normative beliefs. The positive relationship
between attitudes and intentions to practicing preventive health risk behaviors among
young adult women has been well documented in the literature (Auslander et al., 2005;
Hiltabiddle, 1996; Kahn et al., 2003; Lollis, Johnson & Antoni, 1997; McKinley &
Billingham, 1998; Orr & Langefeld, 2003; Zak-Place & Stern, 2004). In addition, the
TPB has been applied in studies assessing college students’ intentions to practice safer
sex behaviors (Bensley et al., 2004; Boily, Godin, Hogben, Sherr, & Bastos, 2005; Bryan,
Fisher, & Brian, 2002; Koniak-Griffin, Lesser, Uman, & Nyamathi, 2003). However,
this was the first study to apply both the HBM and TPB to assess attitudes, normative
beliefs, and control beliefs to predict intentions to practice safer sex behaviors and to
assess the relationship between those intentions with HPV vaccine acceptance.
Findings from this study revealed that there was a significant positive relationship
between vaccine acceptance, specifically likelihood of becoming vaccinated, and
normative beliefs to practicing safer sex behaviors; however, there was a non-significant
relationship between likelihood of getting vaccinated and attitudes and a non-signficant
negative relationship between likelihood of getting vaccinated and perceived control in
practicing safer sex behaviors. These findings may indicate that those female college
students who are more likely to become vaccinated have a greater perception of their
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peers practicing safer sex behaviors, compared to those who do not perceive their peers to
be practicing safer sex behaviors. Although the finding was not significant, there was a
weak, positive relationship between likelihood of becoming vaccinated and attitudes
regarding practicing safer sex behaviors, and a weak, non-signficant negative relationship
between likelihood of becoming vaccinated and perceived control beliefs in practicing
safer sex behaviors. This finding is concerning because attitudes was the strongest
predictor of intentions to practicing safer sex behaviors in this study, based upon the
combined application of the HBM and the TPB. These findings may indicate that female
college students who become vaccinated may not have strong positive attitudes or
perceived control in practicing safer sex behaviors. In measuring intentions directly, via
survey items on intentions, participants who were more likely to become vaccinated
against HPV had higher intentions to practicing safer sex behaviors. The factor most
likely to influence vaccination for those who had greater intentions to practice safer sex
was whether or not they practiced safe sex. Those with greater intentions on practicing
safer sex behaviors were least likely influenced by health insurance coverage for
vaccination. For participants with greater intentions, cost was the least likely barrier for
vaccination against HPV, followed by not knowing where to get the vaccine. This was
the only group of students that reported they would not be affected by the cost of the
vaccine, indicating that certain factors that may prevent others from getting the vaccine,
such as those who perceive themselves to be highly susceptible to HPV and those who
perceive HPV to be more severe, would not prevent those who have greater intentions to
practicing safer sex behaviors. This is an interesting finding because getting vaccinated
against HPV can also be considered a safer sex behavior, and it may be that those
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students who have greater intentions to practice safer sex behaviors, as defined in this
study, are also more likely to carry out other actions to protect themselves against STIs.
To confirm these findings, longitudinal studies are needed to determine whether female
college students and young women who become vaccinated against HPV are also more
likely to practice safer sex behaviors. Additional studies are needed to determine whether
female college students who have been vaccinated against HPV have lower rates of STIs
overall, compared to those female college students who have not been vaccinated.
Conclusions and Recommendations
Findings from this study confirm the need for university health centers to include
HPV vaccination as part of a broader STI educational campaign targeting female college
students who are single, as well as those in monogamous relationships, on how to
practice other safer sex behaviors, emphasizing how to ask partners to get tested for STIs
before becoming sexually active with them. Campaigns can also include localized
information on where to get the vaccine in the community and how to determine
eligibility for low-cost or free vaccination.
To further prevent and reduce the rate of HPV among female college students,
follow-up studies are needed to determine acceptance of the HPV vaccine among male
college students as it relates to HPV knowledge, knowledge of the vaccine, and intentions
to practice safer sex behaviors. Findings from these studies would also be valuable in
preventing HPV among young women because males are often carriers of HPV and they
can actively assist their female partners in carrying out safer sex behaviors that includes
becoming vaccinated against HPV. Furthermore, a national survey conducted among a
randomly selected sample of undergraduate male and female students from a randomly
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selected group of universities across the U.S. may be valuable to researchers as well as
health educators and health care providers in understanding the level of awareness and
acceptance of the HPV vaccine among college students, including the percentage who
have been vaccinated and intentions to practice other safer sex behaviors.
Study Delimitations
The study was delimited to college students enrolled at three public universities –
two in Michigan and one in Florida. Thus, results may not be generalizable to the
national population of college students. Participants were delimited to those who
volunteered to respond to the survey items constructed for this study and who were
accessible at the time of administration. The study was also delimited to the specific
universe of questions and items contained in the survey instrument to measure health
beliefs and behavioral intentions.
Study Limitations
•

Not all invited subjects participated in this study, limiting the generalizability of
the results primarily to the respondent groups at the University of South Florida,
Central Michigan University, and Western Michigan University. Students who
chose to participate in this study may have differed in health beliefs about HPV
and the HPV vaccine, HPV vaccine acceptance and intentions to be vaccinated
against HPV and practice safer sex behaviors from those who chose not to
participate.

•

A small number of participants did not respond to the question concerning their
HPV vaccine status, but did provide responses to the questions measuring HPV
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vaccine acceptance, certain measures of HPV vaccine acceptance may have
included responses from participants that had already been vaccinated.
•

Participants in the study were from a convenience sample rather than a random
sample, so there may have been self-selection bias - a threat to internal validity
through inherent differences in students who complete the survey compared to
those who choose not to complete the survey. Offering the online survey to all
female students who visit university student health services, attend wellness
seminars in residence halls, as well as offering the survey to all female,
undergraduate students, ages 18 to 24, via campus e-mail listservs may have
helped to reduce self-selection bias.

•

There may have been a social desirability response bias whereby respondents
provided answers to survey items that illustrated their carrying out a socially
desirable practice, or assuming positions on issues that do not represent their true
feelings or likely behaviors. Through the informed consent, informing students
that the survey contains personal questions about their past and current sexual
behaviors and asking students to respond as honestly as possible to survey items
may have helped to reduce social desirability response bias. Re-wording
questions to increase the likelihood of participants responding more honestly to
questions may have also helped to reduce this type of bias.

•

Participation was not controlled for those few students who participated in Pilot
Test #1 and Pilot Test #2 and did not provide their e-mail address and last four
digits of their student ID number, but who also may have participated in the final
survey. Recruiting students via the same ten courses that participated in the pilot
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tests would have possibly prevented pilot test participants from participating in
the survey; however, this recruitment method would not have offered the
opportunity to gather a sample size of at least 1,700 female undergraduate
students from the three participating universities. Furthermore, the total number
of students registered in all ten courses, for each pilot test, did not exceed 600
students and not at all of the students were females. Furthermore, any participants
that had matching student IDs and e-mail addresses for any of the pilot tests and
the final survey were omitted from the study.
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Appendix A: Sample Size Estimates for Regression

Power Estimate for Test of Partial Regression Weight for Control Beliefs
Obs
rsq_big rsq_sml n k_big k_sml
alpha
f2
nc
power
1
0.572 0.57 1700 3
2
0.05 .004672897 7.93458 0.80380

Power Estimate for Test of Partial Regression Weight for Normative Beliefs
Obs
rsq_big rsq_sml
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Appendix B: Online Informed Consent

The purpose of this survey is to find out about your knowledge and beliefs about
human papillomavirus (HPV), the HPV vaccine, and practicing other safer sex behaviors.
Your responses will be very helpful in understanding what college students know about
human papillomavirus (HPV), thoughts about being vaccinated against HPV, and
intentions in carrying out safer sex behaviors. Ultimately, your responses will be helpful
in developing programs and materials for the prevention and treatment of sexually
transmitted infections among college students and young adults.
Because the purpose of this survey is to assess your attitudes, thoughts, and
beliefs, please answer the questions as honestly as possible. There are some personal
questions on the survey that will ask you about your past and current sexual practices and
your attitudes and beliefs about practicing safer sexual behaviors. Because you are
completing the survey on the Internet, there is a slight chance that an authorized person,
such as a hacker, can gain access to your survey responses. Although access by an
authorized person is highly unlikely, this poses a potential risk to the confidentiality of
your survey responses. Therefore, you do not have to answer any questions that make
you feel uncomfortable, and you can stop completing the survey at any time. You will
not be penalized in any way for choosing not to complete the survey, and your decision to
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participate or not participate in this survey will not affect your student status in any way
nor the student services available to you.
You have the option to not include identification information on the survey if you
want to participate but do not want to receive an incentive. You can participate in the
survey without including identifiers. At the end of the survey, there is an option to
include your e-mail address and the last four digits of your student identification (ID)
number. You have the option of not including this information if you do not want your
survey responses linked to your identification information. The principal investigator
will not follow up with you regarding an incentive because they will not have your
contact information.
If you want to participate and be eligible to receive an incentive, you will be
asked to provide your university e-mail address so the principal investigator of the study
can contact you regarding your incentive for participation. You will be entered into a
random, one-time $500 cash drawing. A code number will be assigned to your survey. If
your survey code number is selected, the principal investigator will e-mail you and ask
for a name and address where the incentive will be mailed. The name and address will be
printed directly on to the envelope where the check will be mailed and will not be written
down on any other place, nor shared with anyone. The name and address you provide
will not be linked to your survey responses. The principal investigator will ask for you to
confirm, by e-mail, that you have received the incentive because the name and address
where the check is to be mailed will not be kept. You will also be asked to provide the
last four digits of your student ID number as an identifier, and this is to ensure that
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participants take the survey only once since an incentive is being offered. Therefore,
your e-mail address and the last four digits of your student ID will be linked to your
survey responses. However, your identification information will not be shared with
anyone nor used for any other purpose and will be kept in a secured file.
Participant e-mail addresses and student ID numbers will be tracked so that each
participant receives only one incentive. Once you have received your incentive, your email address and the last four digits of your student ID will be discarded in a secure
manner and no one will have access to it. A code consisting of numbers will be assigned
to your survey, instead of the last four digits of your student ID or e-mail
address, and the survey responses will be analyzed directly from the secured electronic
database, to further protect your identity and confidentiality of your responses.
If you continue to take this survey after reading this web greeting, you are giving
your consent to participate, and you can start taking the survey at any time. If you
include your e-mail address and last four digits of you student ID number, and your
survey code number is selected, you will be notified about the cash incentive within one
week after student participation in this survey has ended. As a reminder, you are not
required to include your e-mail address and your student ID number if you do not want to
be eligible to receive an incentive.
If you have any questions about this study or your participation in this survey,
please contact Teri Wilson at (248) 231-2007. If you have any questions or need
information about HPV and other STI prevention and treatment, the HPV vaccine, or
would like a copy of the study results, please contact your student health center.
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Contact information for all participating student health centers is included below. Thank
you for your participation in this online survey.
Participating university health centers:
University of South Florida, Student Health Services – 813-974-2331
Central Michigan University Health Services – 989-774-6599
Western Michigan University, Sindecuse Health Center – 269-387-3284
Please start the survey below.
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Section One. What you know about HPV
1. Please mark the following items as "True" or "False".
HPV is more common than HIV.
□ True
□ False
Only women get HPV.
□ True
□ False
You can always tell when someone else has HPV.
□ True
□ False
2. Has a health care provider ever told you that you have HPV? (A health care
provider would be a doctor, nurse practitioner or physician assistant.)
□ Yes
□ No
□ Not sure
Section Two. Your attitudes and intentions regarding practicing safer sex
behaviors*
*Please note: This section includes questions on your thoughts about sex and sexual
activity. Sex is defined in this survey as sexual intercourse. Sexual activity is defined in
this survey as having oral, anal or vaginal sex.
1. Refusing to have sex with a partner if they will not use a condom would be very
easy for me.
□ Strongly agree
□ Agree
□ Somewhat agree
□ Disagree
□ Strongly disagree
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2. I intend to tell a partner to get tested for sexually transmitted infections before I
become sexually active with them.
□ Strongly agree
□ Agree
□ Somewhat agree
□ Disagree
□ Strongly disagree
3. Telling a partner that I will not be sexually active with them until they have been
tested for sexually transmitted infections would be very easy for me.
□ Strongly agree
□ Agree
□ Somewhat agree
□ Disagree
□ Strongly disagree
4. I intend to refuse to have sex with a partner if they will not use a condom.
□ Strongly agree
□ Agree
□ Somewhat agree
□ Disagree
□ Strongly disagree
5. Avoiding the use of drugs or alcohol before engaging in sexual activity would be
very easy for me.
□ Strongly agree
□ Agree
□ Somewhat agree
□ Disagree
□ Strongly disagree
6. I intend to avoid drugs or alcohol before engaging in sexual activity.
□ Strongly agree
□ Agree
□ Somewhat agree
□ Disagree
□ Strongly disagree
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Section Three. What you know about the HPV vaccine
1. What have you heard about the HPV vaccine from the media, friends, family or
your health care provider? (Check all the following you have heard.)
□ The vaccine is safe.
□ The vaccine prevents women from getting high risk HPV.
□ The vaccine will protect against cervical cancer.
□ The vaccine consists of three shots over a six-month period.
□ I have not heard about the HPV vaccine.
Section Four. Your beliefs regarding practicing safer sex behaviors*
*Please note: This section includes questions on your thoughts about the beliefs of others
regarding sexual activity. Sexual activity is defined in this survey as having oral, anal or
vaginal sex.
1. Most college students would avoid using drugs or alcohol before engaging in
sexual activity.
□ Strongly agree
□ Agree
□ Somewhat agree
□ Disagree
□ Strongly disagree
2. Most college students would ask their health care provider about how to reduce
their risk for sexually transmitted infections.
□ Strongly agree
□ Agree
□ Somewhat agree
□ Disagree
□ Strongly disagree
3. Most college students would tell a partner to get tested for sexually transmitted
infections before becoming sexually active with them.
□ Strongly agree
□ Agree
□ Somewhat agree
□ Disagree
□ Strongly disagree
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Section Five. Your acceptance of the HPV vaccine
1. How important do you think vaccinations are, in general?
□ Very important
□ Somewhat important
□ Not important at all
2. Have you received at least one dose of the HPV vaccine? (IF "Yes", PLEASE
SKIP TO SECTION SIX OF THE SURVEY, IF "NO", PLEASE GO TO
QUESTION #3.)
□ Yes
□ No
3. The vaccine is currently available for young girls and women between the ages of
9 through 26. How likely is it that you will get vaccinated against HPV?
□ Very likely
□ Likely
□ Somewhat likely
□ A little likely
□ Very unlikely
4. How important are the following issues in influencing your decision to become
vaccinated against HPV? Please check the following statements below as "Very
important", "Somewhat important", or "Not important at all".
If my friends think I should get it
□ Very important
□ Somewhat important
□ Not important at all
If my health insurance covers it
□ Very important
□ Somewhat important
□ Not important at all
If I had an abnormal Pap smear
□ Very important
□ Somewhat important
□ Not important at all
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If my family thinks I should get it
□ Very important
□ Somewhat important
□ Not important at all
If my sex partner thinks I should get it
□ Very important
□ Somewhat important
□ Not important at all
If my health care provider thinks I should get it
□ Very important
□ Somewhat important
□ Not important at all
If someone in my family has cancer
□ Very important
□ Somewhat important
□ Not important at all
Whether I practice safe sex
□ Very important
□ Somewhat important
□ Not important at all
5. How important are the following issues in preventing you from becoming
vaccinated against HPV? Please check the following statements below as "Very
important", "Somewhat important", or "Not important at all".
The cost of the vaccine would prevent me from becoming vaccinated.
□ Very important
□ Somewhat important
□ Not important at all
Getting three shots over a six-month period would prevent me from becoming
vaccinated.
□ Very important
□ Somewhat important
□ Not important at all
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Fear of vaccines would prevent me from becoming vaccinated.
□ Very important
□ Somewhat important
□ Not important at all
Possible side effects of the vaccine would prevent me from becoming vaccinated.
□ Very important
□ Somewhat important
□ Not important at all
Having to get additional boosters after getting three shots would prevent me from
becoming vaccinated.
□ Very important
□ Somewhat important
□ Not important at all
Having to wait at my doctor's office for approval to get the vaccine would prevent
me from becoming vaccinated.
□ Very important
□ Somewhat important
□ Not important at all
Not knowing where to get the vaccine would prevent me from becoming vaccinated.
□ Very important
□ Somewhat important
□ Not important at all

Section Six. Your beliefs about practicing safer sex behaviors*
*Please note: This section includes questions on your thoughts about abstinence, sex and
sexual activity. Abstinence is defined in this survey as not participating in sexual activity,
such as oral, anal or vaginal sex, with anyone until you are married. Sex is defined in this
survey as sexual intercourse. Sexual activity is defined in this survey as having oral, anal
or vaginal sex.
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1. How much control do you have in being abstinent from sexual activity until you
are married?
□ Complete control
□ A lot of control
□ Some control
□ Little control
□ No control
2. How much control do you have in refusing to have sex with a partner that will not
use a condom?
□ Complete control
□ A lot of control
□ Some control
□ Little control
□ No control
3. How much control do you have in avoiding the use of drugs or alcohol before
engaging in sexual activity?
□ Complete control
□ A lot of control
□ Some control
□ Little control
□ No control
4. How much control do you have in telling a partner to get tested for sexually
transmitted infections before becoming sexually active with them?
□ Complete control
□ A lot of control
□ Some control
□ Little control
□ No control
5. How much control do you have in asking a health care provider about how to
reduce your risk for sexually transmitted infections?
□ Complete control
□ A lot of control
□ Some control
□ Little control
□ No control
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Section Seven. Your thoughts about HPV risk
1. Do you think you are likely to contract HPV?
□ Yes
□ No
□ Not sure
2. How likely is it that you currently have HPV?
□ Very likely
□ Likely
□ Somewhat likely
□ A little likely
□ Very unlikely
3. Do you think your friends or peers are likely to contract HPV?
□ Yes
□ No
□ Not sure
4. What is the likelihood that you could get HPV within the next year?
□ Very likely
□ Likely
□ Somewhat likely
□ A little likely
□ Very unlikely
5. What is the likelihood that you could get HPV some time in your life?
□ Very likely
□ Likely
□ Somewhat likely
□ A little likely
□ Very unlikely
Section Eight. How HPV can affect you
1. How serious a health problem would HPV be for you?
□ The most serious
□ Serious
□ Not sure
□ A little serious
□ Not at all serious

270

Appendix C (Continued) HPV Vaccine Survey Online Questionnaire
2. If you get HPV, it is not a big problem because it is very easy to treat.
□ Strongly agree
□ Somewhat agree
□ Not sure
□ Somewhat disagree
□ Strongly disagree
3. If you get HPV, how likely is it that you will get genital warts?
□ Very likely
□ Somewhat likely
□ Not sure
□ Somewhat unlikely
□ Very unlikely
4. If you get HPV, how likely is it that you will get cancer?
□ Very likely
□ Somewhat likely
□ Not sure
□ Somewhat unlikely
□ Very unlikely

Section Nine. Information about you
1. How old are you? _________
2. What is your gender?
□ Male
□ Female
3. How do you describe yourself? (Check all that apply.)
□ African-American
□ Hispanic or Latino
□ Asian
□ American Indian or Alaska Native
□ Native Hawaiian or other Pacific Islander
□ Arab-American
□ White
□ Multi-racial
□ Other, please specify here: __________________________
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4. What is your sexual orientation?
□ I have sex with men.
□ I have sex with women.
□ I have sex with men and women.
□ I don't have sex.
5. Within the past 12 months, with how many partners, if any, have you had oral,
anal or vaginal sex? ______________
6. Have you had oral, anal or vaginal sex with a partner in the past 60 days?
□ Yes
□ No
7. What is your marital status?
□ Single and abstinent
□ Single and sexually active
□ Single and in a monogamous relationship
□ Married
□ Separated/Divorced
□ Widowed
8. Do you have children?
□ Yes
□ No
9. What is your current year in college?
□ Freshman
□ Sophomore
□ Junior
□ Senior
10. What university are you attending?
□ Central Michigan University
□ University of South Florida
□ Western Michigan University
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11. Do you currently have health insurance that covers the cost of the HPV vaccine?
□ Yes
□ No
□ Not sure
If you want to be eligible to receive an incentive for your participation, please
include the last four digits of your student ID and your e-mail address before you
click "Submit" to complete your survey.What is the last four digits of your student
ID?_______________
What is your e-mail address? ________________________________________
Please click on the "Submit" button below to submit your survey.
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Hi, my name is Teri Wilson, and I will be conducting this interview with you.
The purpose of this interview is to ask you some questions regarding what you think are
some benefits and barriers to becoming vaccinated against HPV. The information you
provide will help with the development of questions for an online survey that will be
conducted among undergraduate female college students for a study on vaccine
acceptance and intentions to practice safer sex behaviors. I am the principal investigator
for this study. Your participation in this interview is completely voluntary, you can stop
taking the survey at any time, and you do not have to answer any questions that make you
feel uncomfortable. Your responses will remain anonymous and your name nor your
telephone number will not be linked to your responses. There will be no identification
information linking you with your responses. The information you provide will be kept
confidential and will only be shared with me during our phone conversation. I will be
writing your responses down and after the interview, I will enter and save them in an
electronic document. I will keep your unidentifiable responses in a secure electronic file
and I will not share them with anyone, but will only use them to help me develop
questions for the online survey. You will receive a cash stipend of $25 for participating
in this interview and once we complete the survey, I will ask need to ask you for a name
and address where you would like the stipend sent. I will only write the name and
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address you provide me on the envelope where the check is being sent and will not write
that information anywhere else. I will provide you with my phone number and e-mail
after the interview and will ask you to contact me, only to let me know that you have
received the stipend. After hearing this information, do you still want to participate in the
interview? If “no”, thank the individual for their time. If “yes”, then proceed with the
interview – see questions below.
1) Have you heard about the human papillomavirus (HPV) vaccine, GARDASIL®?
Interviewer Script (if participant has not heard about the HPV vaccine): GARDASIL® is
a vaccine that prevents infection with four types of HPV – two that are the major causes
of genital warts and two that are major causes of cervical cancer. The vaccine requires
three doses given over a six-month period, and each dose costs $120 for a total cost of
$360.
2) What are some benefits of becoming vaccinated against HPV?
3) What are some barriers that would prevent you from becoming vaccinated against
HPV?
Probing question (if participant does not report cost): Would the cost of the vaccine
prevent you from becoming vaccinated?
4) How would the cost prevent you from becoming vaccinated?
5) Would lack of health insurance coverage prevent you from getting the vaccine?
Probing question: Do you know whether you currently have health insurance that helps
you to pay for your doctor visits or medications?
Interviewer Script: Women between the ages of 19 to 26, but have no health insurance or
who cannot afford the vaccine because they make less than $19,600 per year, can obtain
the vaccine through Merck’s patient assistance program. The woman has to wait a period
of time, from approximately 15 to 20 minutes, to obtain a approval from Merck to
receive the vaccine from her health care provider.
6) Would this process of waiting a certain period of time to obtain approval to receive
the vaccine prevent you from getting vaccinated? Why or why not?
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Thank you for time in participating in this interview!
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Question 1 - Knowledge of the HPV vaccine, GARDASIL®
Fourteen out of the 15 participants (93%) heard about the vaccine, and one
participant (7%) had not heard about the vaccine.

Question 2 - Benefits of becoming vaccinated against HPV
Theme: Promotes health
and prevents disease
One of the 15 participants (7%) reported that a benefit of becoming vaccinated
against HPV is for health and because it prevents diseases.
Matching Quote:
“Health.” “To prevent diseases.”

Theme: Increases HPV
awareness
One of the 15 participants (7%) reported that a benefit of becoming vaccinated
against HPV is that it can help to raise awareness about HPV among college
students, because HPV is not common to talk about separate from other STIs.
Matching Quote:
“Help raise awareness about HPV, and that it is a risk, good to raise awareness. Don’t
think college students know about it, it is not very common to talk about it because it is
usually packed with other types of STDs”.
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Theme: Protects against
HPV
Seven out of the 15 participants (47%) reported that a benefit of the vaccine was that it
protects against HPV, so they were aware that it directly prevents the STI.
Matching Quotes:

“It guards against different strands of HPV, and you feel safer, in general, about that.”
“From what I’ve heard, anybody can get HPV, so any vaccine you can get for it, you can
benefit from.”
“Do what you can to protect yourself. Heard only protects against six strands, you are
protecting that much and doing your part, taking measures.”
“Protection against HPV.”
“There are social problems that go with it, it is taboo to talk about it, but you have to
protect yourself and you have the responsibility to protect others.” – This participant was
vaccinated with the first two shots in the three-shot series.
“Well, for one thing, I mean, it will prevent among college students and high school
students, it will protect against STDs that were once incurable, so it will make students
and people safer because they are going to do it (have sex) anyway. At least the risk of
getting these four types of HPV are significantly lowered.”
“It can help prevent ovarian cancer…” this participant also responded…”and some
forms of HPV and genital herpes.”

Theme: Prevents cancer
Eight out of the 15 participants (53%) reported that a benefit of the HPV vaccine
was that it prevents cancer and half of these participants (27% of all participants)
specifically referred to the vaccine preventing cervical cancer.
Matching Quotes:
“Less chance of getting cervical cancer”
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“I saw the commercials about cervical cancer on T.V. and it scared me.” “It can give
you cancer…” – this same participant responded…”and it can make you infertile”. –
This participant had been vaccinated with the first shot in the three-shot series.
“For students that are younger to prevent them from getting it (HPV), so prevent cancers
that HPV will bring at an earlier age.”
“That it prevents cervical cancer, as far as I know that’s it (the only benefit).”
“All that information that I know, it can protect you against a couple of different types of
HPV that can cause cervical cancer, and that is why I was vaccinated.” This participant
had been vaccinated – it is not known how many shots she received.
“If there is a way to protect yourself for cancer which is very hard to do, then by all
means do it.” - This participant was vaccinated with the first two shots in the three-shot
series.
“Obviously preventing cancer and that is a good benefit, it gives good security for
women knowing that there is something out there for them. Primary benefit is that it can
prevent cancer.”
“It can help prevent ovarian cancer…” this participant also responded…”and some
forms of HPV and genital herpes.”

Theme: Personal experience
with abnormal Pap/HPV
One participant (7%) reported that she was previously treated for an abnormal Pap test,
and because of her experience, thinks every woman would benefit from getting
vaccinated against HPV.
Matching Quote:
“I was treated for an abnormal Pap when I was 18, and I’m 22. When I found out you
can get vaccinated against HPV, in my opinion, I want every woman to get it.” - This
participant was vaccinated with the first two shots in the three-shot series.
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Theme: Personal experience
with HPV and cancer
Matching Quotes:
Two participants (13%) reported that getting vaccinated against HPV is beneficial
because of their personal experience in knowing someone who had HPV or who had
developed cancer, and one of these participants got vaccinated because of a family
member being diagnosed with ovarian cancer.
“Personally, I know two girls that have developed symptoms of the virus, so that is scary,
and I would want to get vaccinated to prevent anything from happening to me.”
“My mom was just diagnosed with ovarian cancer.” – This participant had been
vaccinated with the first shot in the three-shot series.

Theme: HPV has no
symptoms
Two out of 15 participants (13%) reported that a reason to become vaccinated
against HPV is related to the fact that HPV has no symptoms.
Matching Quotes:
“A guy can have it and pass it on and not even know that he has it, for that a reason.
Because it is an unsure thing, and if a girl is sexually active, she may get it and may not
know it.”
“Sexual partners may have it but they may not tell.”- This participant was vaccinated
with the first two shots in the three-shot series.
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Question 3: Barriers to becoming vaccinated against HPV
Theme:
- Cost
Fourteen out of 15 participants (93%) identified cost as a barrier that would
prevent them from becoming vaccinated against HPV.
Matching Quotes:
“Cost, $360 is a lot of money.”
“Cost. I am not sure if it is covered.”
“The only thing I can think of is I’m a poor college student so I don’t know what the cost
is…”
“Maybe a little, but in the end it would be better to spend the money instead of getting cervical
cancer.”

“Cost.”
“Money.”
“Price of the vaccine. Because I don’t have health insurance. I saw the price and it is
very expensive for me, and that is why I didn’t get the vaccine.”
“The cost.”
“The cost of the vaccine, mainly. That would be it (the only barrier), nothing else.
“Cost of it is pretty high, good if it was discounted.”
“Cost, money. Being able to afford the shots. A social worker at the student health
center at Western helped me to get the financial assistance based upon a limited college
student income”. Getting treatment is way more expensive than getting the 3-dose shot.”
This participant was vaccinated with the first two shots in the three-shot series.
“It is expensive, actually my mom called around to find out who offered it at the cheapest
price and Western was the cheapest place we found.” This participant had been
vaccinated – it is not known how many shots she received.
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“It is very expensive I think, but my insurance covers it. If it did not cover it, then I
would not be able to pay for it.”
“The cost if insurance does not cover it. If the cost is $350 or whatever you said, $360, if
insurance does not cover it, then high school students and college students are not going
to be able to pull it out of their pocket.” – This was the one participant who had not heard
about the HPV vaccine, GARDASIL®.
“No. My parents thought I should get it, my parents are taking care of the cost. My
parents were more concerned and got me informed on that. My mom was just diagnosed
with ovarian cancer.” This participant had been vaccinated with the first shot in the
three-shot series.
If “cost” was a response, the participants were asked the following question:
Question 4: How would the cost prevent you from becoming vaccinated?
Participants reported that cost would prevent them from becoming vaccinated for
the following reasons: the high cost of the vaccine at $360 (73%); because of being a
college student and not having enough money to pay for the vaccine (60%); having
other items to pay for that are of higher priority than becoming vaccinated, such as
rent, books, tuition, student loans, and one participant also reported paying for
birth control (13%) .
Two out of the 15 participants (13%) that reported that cost would prevent them
from becoming vaccinated also reported there can be other ways to prevent HPV,
instead of the vaccine, and one out of the two participants reported having safe sex.
Matching Quotes:
“For college students, $360 is more than a month’s rent. Could prevent it (HPV) in
other ways, instead of the vaccine.”
“If it is not covered by your insurance, if it cost too much, too. In general, college
students don’t have a lot of money lying around.”
“Well, as of right now, I have pretty crappy health insurance, and I’m not working and
thousands of dollars in debt, so $50 is a lot of money (referring to a dollar amount, not
the cost of the vaccine).
“Three-hundred and sixty dollars is a lot of money for a college kid.”
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“It cost too much being a college student. That is why I haven’t done it.”
“Cost too much money to get vaccinated.”
“I am already paying for birth control out of my pocket. I pay for everything on my own.
I don’t ask my parents for money. If I had the money, I would do it.”
“It is too expensive. It is 300 and some dollars. I am a college student, and I don’t have
the means to come up with the extra $300 for the vaccine.”
“It is expensive, and since I’m a student, I can’t afford to pay for it.”
“Spending that much money on something you may or may not get. If you have
the same boyfriend for a while, you are not really going to get it. However, you don’t
know what it is going to be like in a year, what you will be doing and you may not know
who your boyfriend has been with.”
“Without the fact that they have a social worker and you have to go to the clinic
on campus, it (financial assistance) is not well publicized. Financial assistance is not
very well known.” This participant was vaccinated with the first two shots in the threeshot series.
“Big chunk of change for a college student, have to worry about student loans, books,
and everything.”
“I guess, personally, cost doesn’t matter to me and I wanted to get it no matter what, and
honestly, I wanted to find a place where it was the cheapest. But I can imagine where it
can be expensive for a college student because each shot cost so much.” This participant
had been vaccinated – it is not known how many shots she received.
“Being the age I am and in college, there are a lot of other costs that are higher in
priority than the vaccination, like rent, books, and tuition. There are other things that
are more important than the vaccination.”
“Well, at the current cost of $360, with that type of cost, I would just say I would just
rather practice safe sex than get the vaccine.”
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Question 5: Would lack of health insurance coverage prevent you from getting the
vaccine?

Theme: Lack of health
insurance
Eight participants (53%) reported that lack of health insurance would prevent them
from getting vaccinated and five out of the eight participants (62%) had health
insurance but they did not know or did not think that their insurance would cover
the vaccine. The remaining three participants (37%) reported that they did not
have health insurance.
Seven participants (47%) reported that lack of health insurance would not prevent
them from getting vaccinated, and six out of seven of these participants (86%) had
health insurance. Only one of these participants did not have health insurance, but
reported that they would do get vaccinated if they had the money.
(Four out of the 15 participants (27%) did not have health insurance.)

Matching Quotes:
“Yes. It depends on your health insurance, because could still have health insurance but
it may not cover it. I have health insurance but I do not think it would cover it.”
Response to probing question on whether they currently have health insurance that helps
them to pay for doctor’s visits or medications - “I have health insurance that helps me to
pay for doctor visits but not medications.”
“Yes.” Response to probing question on whether they currently have health insurance that helps
them to pay for doctor’s visits or medications – “I have insurance. I don’t know if it would cover
the vaccine or not.”
“Probably, I don’t know what the health insurance covers, it covers basic services.”

Response to probing question on whether they currently have health insurance that helps
them to pay for doctor’s visits or medications – “Helps pay, don’t know what the
percentage is because I’m paying more now for doctor visits and medications than I did
for my previous insurance. I used to pay $10 for a doctor visit, now I pay more, $75 per
visit.”
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“No.” Response to probing question on whether they currently have health insurance
that helps them to pay for doctor’s visits or medications – “Yes, yes it does. I am pretty
sure it does. Not prescriptions, most doctor visits.” – This same participant had been
vaccinated with the first shot in the three-shot series, and she also reported that her
parents are taking care of the cost.
“I don’t know if it would fully prevent me, but it would definitely have an impact. I am not sure if
my health insurance would cover the vaccine. I would probably still go ahead and get it because
you never know the long-term effects.” Response to probing question on whether they
currently have health insurance that helps them to pay for doctor’s visits or medications –
“Yes, it does. It pays for emergency visits, but I do not get doctor visits.”
“Yes. I don’t have health insurance.”

“Yes. I do not have health insurance”.
“No. I would do it if I had the money.” This participant also reported that they did not
have health insurance.
“No.” Response to probing question on whether they currently have health insurance that
helps them to pay for doctor’s visits or medications – “Yes, it pays for doctor visits and
medications.” – This participant reported that she already had HPV.
“Yes, that, too.” Response to probing question on whether they currently have health
insurance that helps them to pay for doctor’s visits or medications – “No, I don’t have
health insurance.”
“No. I have health insurance but I am not sure if it covers the vaccine.” This participant
did not answer the probing question on whether they currently have health insurance that
helps them to pay for doctor’s visits or medications.
“No, there is financial assistance. I had a hard time getting it. I do have health
insurance but it doesn’t cover it for each shot.” Response to probing question on whether
they currently have health insurance that helps them to pay for doctor’s visits or
medications – “Yes, for doctor visits and medications.” This participant was vaccinated
with the first two shots in the three-shot series.
“Personally, no, because well, I do have health insurance but mine didn’t cover it, but I
still obviously got it.” Response to probing question on whether they currently have
health insurance that helps them to pay for doctor’s visits or medications – “It covers
doctors’ visits but I don’t have coverage for prescriptions.” This participant had been
vaccinated – it is not known how many shots she received.
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“Don’t think it really would, so eventually, even if I did not have health insurance,
because the cost of the vaccine is nothing compared to paying for cancer bills.”
Response to probing question on whether they currently have health insurance that helps
them to pay for doctor’s visits or medications – “Yes, pays for both, I’m still on my mom’s
insurance.”

“Yes. The next question is how many partners am I gonna have sex with and how safe of
sex will I be practicing. Those are the two things that would dictate whether I would get
the vaccine.” Response to probing question on whether they currently have health
insurance that helps them to pay for doctor’s visits or medications – “My health
insurance covers everything. I have a $15 co-pay. Some things are not covered.”
Theme: Access &
Availability
Four of the 15 participants (27%) reported that barriers were access and
availability, such as having a hard time finding a place where they had access to the
vaccine, or where or when the vaccine was available.
Matching Quotes:

“Also, availability, if the vaccine were not available to you.”

“Availability. I don’t know when it is offered and where it is offered.”
“…and I’m going home (for the summer) and I don’t know where to get it. So, this
summer, I’m checking into my regular doctors with my mom.”
“One of the hard things that I had problems with was finding a place that I had access to
it. Being a college student, it is harder around here to find a place to get it done.” This
participant had been vaccinated – it is not known how many shots she received.
Theme: Having to get
multiple shots
Two out of the 15 participants (13%) reported a barrier that would prevent them
from becoming vaccinated would be getting multiple shots.
Matching Quotes:
“Inconvenience. I heard you have to get several shots”.
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“Vaccination is over a long period, it takes a long time to get three shots, so people may forget.”

Theme: Lack of available
information about the vaccine
Three out of the 15 participants (20%) reported that lack of information about the
vaccine would be a barrier that would prevent them from becoming vaccinated
against HPV.
Matching Quotes:
“Lack of information in general. I tried to look it up online and could not find anything that was
useful.”

“Lack of knowledge and resources”.
“I didn’t hear anything about it, they were not promoting it on T.V. I think I heard one
commercial.”
Theme: Side
effects
Five out of the 15 participants (33%) reported that potential side effects of the
vaccine would be a barrier that would prevent them from becoming vaccinated
against HPV.

Matching Quotes:
“If there are side effects to it, otherwise, no barriers.”
This participant was asked the probing question of would the cost prevent her from
getting the vaccine, and she responded, “No. My parents thought I should get it, my
parents are taking care of the cost.” “My parents were more concerned and got me
informed about that.” - This participant had been vaccinated with the first shot in the
three-shot series and her mother was diagnosed with ovarian cancer.
“No barriers for me, unless there are serious side effects, but probably not.”
“Possible side effects.”
“Because it so new, I don’t know what the side effects I would get in the long-term.”
This participant was vaccinated with the first two shots in the three-shot series.
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“Well, there are always potential side effects because it is a vaccine it could hurt
someone. I don’t know what the side effects are, I am not familiar with the studies that
were done on the vaccine. I don’t know if the potential side effects outweigh the good of
the vaccine.”
Theme: Personal experience
with HPV
One out of the 15 participants (7%) reported a barrier that would prevent her from
becoming vaccinated against HPV was that she already had HPV.
Matching Quote:
“I already have HPV.” This participant reported that cost also was a barrier.
Theme: Fear
One out of the 15 participants (7%) reported that fear of getting the vaccine would
be a barrier.
Matching Quote:
“Scary to do, like getting an AIDS test, because it is something that you may get, it is
something real.”

Theme: Social stigma of
getting a vaccine to prevent
HPV
One out of the 15 participants (7%) reported that the social stigma of getting the
vaccine could be barrier that would prevent someone from getting the vaccine – not
for her, as she has already been vaccinated with two out of the three shots.
Matching Quote:
“Also, taboo, they don’t want to talk about it, there is a social stigma. Because when people ask
you why you are going to the health clinic, you do not want to really say “Oh, because I am
getting an HPV vaccine.”
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Theme: Skepticism about
how well the vaccine works
One out of the 15 participants (7%) reported that skepticism about whether the
vaccine really does what it is supposed to may be a barrier that would prevent her
from becoming vaccinated against HPV.
Matching Quote:

“The vaccine is to prevent cancer, so people may think that cannot be and people may be
skeptical to what the long term effects are and if it really is to do what they say.”

Theme: Additional booster shots
One out of the 15 participants (7%) reported that having to get the vaccine again
after several years of getting the vaccine, because the initial vaccine was no longer
effective, would be a barrier that would prevent her from becoming vaccinated
against HPV.
Matching Quote:

“Also, how long is the vaccine effective for? If I have to shell out money to get it and
then need it again in four years, and it will cost $180, then I would not get it. What is
going to be the return on the investment? Information about how it is not known whether
women will need a booster should be shared with them before they are vaccinated.”
Theme: Waiting a certain period of
time for approval to receive the
vaccine for free
Twelve out of the 15 participants (80%) reported that waiting a certain period of
time to receive the vaccine for free would not be a barrier. The participants
reported that time would not be a factor for the following reasons: waiting 15 to 20
minutes is not that much time; waiting is worth it if you want the vaccine; it is worth
waiting to get the vaccine for free; it is important to get vaccinated; waiting to get
the vaccine and getting the vaccine is better than getting cervical cancer; you
already have to wait during doctors’ appointments; you have to wait to get the
vaccine over a six month period.
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Matching Quotes:

“I don’t think waiting 15 to 20 minutes is that much time. If you are working or really
busy, it may not be worth it. I would do it, waiting 15 to 20 minutes would not prevent
me from getting vaccinated.”
“Perhaps. I suppose if I was dead set on getting it, nothing would stop me from getting
it. But, otherwise, it would be an inconvenience to wait.”
“No, I would wait.”
“No, not at all. I would want the vaccination, so waiting 15 to 20 minutes is not anything
at all.” This participant had been vaccinated with the first shot in the three-shot series
and her mother was diagnosed with ovarian cancer.
“No. I don’t think 15 minutes or a couple of days is a problem getting it. Because in the
end, I’d rather wait a couple of days to get the vaccine and get the vaccine, than getting
cervical cancer.”
“Yes, just having to wait, you would get tired, even though it is free. If it was immediate,
that would be different.”
“No. It is important and the wait time would not be a factor.”
“No. It could help me. Waiting 15 to 20 minutes wouldn’t kill me. Fifteen to 20 minutes
is nothing.”
“No. Because if waiting 15 to 20 minutes or waiting a day is what you have to do to get
protection, then it is worth it.”
“Not at all. I’d rather have the vaccine. I don’t care if I have to wait, if they can pay for
it.”
“No. Because waiting 15 to 20 minutes for a vaccine that you know will be free of
charge is worth it, you can read a magazine during that time, and you have to wait for
your appointment anyway. But it would not be worth it if you had to wait for a longer
period of time, like three to five days, or had to fill out the form, go home and then go
back to the health center.”
“It is a long process in getting the vaccine, day after day to get paperwork faxed and
approved, that is why I have not yet gotten the 3rd one (shot) yet, because I’ve been out of
town. Right now, it is preventing me from getting the 3rd shot, because I am having to
wait a long period of time. I am months behind on my last shot. A month ago, I had to
leave and I could just get it because I had approval. Because it has been over a month
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since approval, they had to re-approve it. It takes a lot of persistence and I would really
like to get it done at this point.” This participant was vaccinated with the first two shots
in the three-shot series.
“No. Because I think that, obviously, the outcome of me waiting would be a great
advantage to myself and being able to get the vaccine would be obviously worth the
wait.” This participant had been vaccinated – it is not known how many shots she
received.
“I don’t think so, no. I think that’s actually a good plan, it is a hunk of time but not bad
at all. You wait that long in a doctor’s office. I think it’s worth it.”
“No. I can say I understand business and red tape. If I want the vaccine, and knowing
that I can get it for free, waiting and filling out paperwork is not going to be a big deal, if
it is going to take six months to get it anyway.”

Telling your parents
One out of 15 participants (7%) reported that having to tell your parents about having an
abnormal Pap test could be a barrier; and this was based on the participant’s personal
experience. However, this was not a barrier for this participant as she had been
vaccinated with two out of the three shots.
Matching Quote:

“Also, you have to tell your parents when you get an abnormal Pap test, why you have
this.”
Additional comments from the interview, not related to the questions:

“I would have called you regardless of the incentive. I think everyone should get this.
I’ve been really trying to advocate.”
One out of the 15 participants (7%) reported that a consequence – more so than a barrierof the vaccine would be that younger girls would think they could go out and start having
sex and be safe.
Matching Quote:
“The only thing would be for younger girls because they would think they could go out
and start having sex and be safe.” – This same participant responded, ““No barriers for
me, unless there are serious side effects, but probably not.”
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The following panel of experts participated in a review to refine the survey instrument
which measures HPV and HPV vaccine knowledge, acceptance of the HPV vaccine, and
attitudes, beliefs and intentions regarding practicing safer sex behaviors. This group of
specialists included members with substantive experience in the areas noted that were
identified as necessary to the revision process.

Gregory Zimet, Ph.D.

Author of numerous articles on HPV
prevention and STI/HPV vaccine
acceptance, among adolescents, parents and
pediatricians.

Richard Roetzheim, M.D.

Expertise in family medicine. Involved in
research on HPV knowledge and awareness
among college students.

Jeffrey Kromrey, Ph.D.

Expertise in educational research and
measurement

Karen Perrin, Ph.D.

Expertise in research design and
methodology and behavioral change
theories. Involved in research on womens’
diagnosis and acceptance of the HPV
vaccine.

Ellen Daley, Ph.D.

Expertise in research design and
methodology. Involved in research on
womens’ perceptions about HPV, reactions
to HPV diagnosis and acceptance of the
HPV vaccine. Principal investigator of a
longitudinal study assessing the emotional
and cognitive responses to HPV diagnosis
among men
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Robert McDermott, Ph.D.

Author of numerous articles on health
behavior and health education, including
those on risk behaviors associated with
STIs. Expertise in research design and
methodology. Involved in research on
womens’ perceptions about HPV, reactions
to HPV diagnosis and acceptance of the
HPV vaccine.
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Appendix G: Factor Analysis of Survey Constructs
Construct: Knowledge
Factor Matrix
Factor
1
HPVis more common
than HIV
You can always tell
when someone else has
HPV
Only women get HPV

.846
.510
.418

Extraction Method: Principal Axis Factoring.

Construct: Knowledge about the HPV vaccine
Factor Matrix
Factor
1
Women will not need to
get Pap smears any more
if they get this

.033

Men will not be able to
-.400
get this vaccine
The vaccine is safe
.543
The vaccine prevents
women from getting
.633
high risk HPV
The vaccine will cost a
.220
lot of money
The vaccine will prevent
women from getting
.255
genital warts
Only people with
insurance will be able to
.006
get this vaccine
The vaccine will protect
.497
against cervical cancer
The vaccine consists of
three shots over a six
.491
month period
I have not heard about
-.510
the HPV vaccine
Extraction Method: Principal Axis Factoring.
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Construct: HPV vaccine acceptance – Universal acceptance
Factor Matrix
Factor
1
How important do you
think vaccinations are in
.727
general
Have you received at
least one dose of the
.503
HPV vaccine
The vaccine is currently
available for young girls
.603
and women
Extraction Method: Principal Axis Factoring.
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Construct: HPV vaccine acceptance – Issues that would influence and barriers to
becoming vaccinated
Rotated Factor Matrix
Factor
1
If my friends think I
should get it
If my health insurance
covers it
If I had an abnormal Pap
smear
If my family thinks I
should get it
If my sex partner thinks
I should get it
If my health care
provider thinks I should
get it
If someone in my family
has cancer
Whether I practice safe
sex
Number of sex partners
Ive had
The cost of the vaccine
would prevent me from
becoming vaccinated.
Getting three shots over
a six month period
would prevent me from
becoming vaccinated.
Fear of vaccines would
prevent me from
becoming vaccinated.
Possible side effects of
the vaccine would
prevent me from
becoming vaccinated.
Lack of health insurance
would prevent me from
becoming vaccinated.

2
.480

.183

.475

.287

.773
.543
.506
.647
.652
.449
.225
.225

.373

.639

.733

-.361

.556

.199

.268
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Rotated Factor Matrix (Continued)
Having to get
additional boosters
.569
after getting three shots
-.284
would prevent me from
becoming vaccinated.
Having to wait at my
.556
.135
doctors office for
approval to get the
vaccine would prevent
me from becoming
vaccinated.
Not knowing where to
.503
.205
get the vaccine would
prevent me from
becoming vaccinated.
Extraction Method: Principal Axis Factoring.
Rotation Method: Varimax with Kaiser Normalization.
Construct: Attitudes towards practicing safer sex behaviors
Factor Matrix
Factor
1
Telling a partner that I
will not be sexually
active with them until
they have been tested for
.995
sexually transmitted
infections would be very
easy for me.
Avoiding the use of
drugs or alcohol before
engaging in sexual
.428
activity would be very
easy for me.
Refusing to have sex
with a partner if they
will not use a condom
.380
would be very easy for
me.
Extraction Method: Principal Axis Factoring.
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Construct: Normative beliefs about practicing safer sex behaviors
Factor Matrix
Factor
1
Most college
students would tell
a partner to get
tested for sexually
transmitted
infections before
becoming sexually
active with them.
Most college
students would
avoid using drugs
or alcohol before
engaging in sexual
activity.
Most college
students would ask
their health care
provider about how
to reduce their risk
for sexually
transmitted
infections.

.691

.516

.483

Extraction Method: Principal Axis Factoring.
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Construct: Intentions to practice safer sex behaviors
Factor Matrix
Factor
1
I intend to tell a partner
to get tested for
sexually transmitted
.935
infections before I
become sexually active
with them.
I intend to refuse to
have sex with a partner
.395
if they will not use a
condom.
I intend to avoid drugs
or alcohol before
.366
engaging in sexual
activity.
Extraction Method: Principal Axis Factoring.
Construct: Susceptibility to HPV
Factor Matrix
Factor
1
What is the likelihood
that you could get
.846
HPV sometime in your
life?
How likely is it that
you currently have
.808
HPV?
What is the likelihood
that you could get
.749
HPV within the next
year?
Doyouthinkyouarelikel
.746
ytocontractHPV
Doyouthinkyourfriend
sorpeersarelikelytocont
.344
ractHPV
Extraction Method: Principal Axis Factoring.
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Construct: Severity of HPV
Factor Matrix
Factor
1
Do you think there
are immediate,
negative health
.201
effects of getting
HPV?
How serious a health
problem would HPV
.591
be for you?
If you get HPV, it is
not a big problem
.352
because it is very
easy to treat.
If you get HPV, how
likely is it to be
.249
painful?
If you get HPV, how
likely is it that you
.485
will get genital warts?
If you get HPV, how
likely is it that you
.459
will get cancer?
Extraction Method: Principal Axis Factoring.
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Appendix H: HPV Survey Instrument – Internal Consistency Reliability
Scale: Knowledge
Reliability Statistics
Cronbach's
Alpha Based
on
Cronbach's
Standardized
Alpha
Items
.531
.620

N of
Items
3

Item Statistics
Mean
HPV is more common
than HIV.
Only women get HPV.
You can always tell when
someone else has HPV.

Std.
Deviation

N

.91

.293

54

.74

.442

54

.98

.136

54

Scale: Knowledge about the HPV Vaccine
Reliability Statistics

Cronbach's
Alpha
.602

N of
Items
4

Item Statistics

The vaccine is safe.
The vaccine prevents
women from getting
high risk HPV.
The vaccine will
protect against
cervical cancer.
The vaccine consists
of three shots over a
six month period.

Mean
.65

Std.
Deviation
.482

.81

.392

54

.70

.461

54

.78

.420

54

301

N
54

Appendix H (Continued) HPV Survey Instrument – Internal Consistency Reliability
Scale: HPV Vaccine Acceptance – General Vaccine Acceptance
Reliability Statistics
Cronbach's
Alpha Based
on
Cronbach's
Standardized
Alpha
Items
.501
.618

N of
Items
3

Item Statistics
Mean
How important do you
think vaccinations are, in
general?
Have you received at
least one dose of the
HPVvaccine?
The vaccine is currently
available for young girls
and women between the
ages of 9 through 26.
How likely is it that you
will get vaccinated
against HPV?

Std.
Deviation

N

2.65

.533

40

1.08

.267

40

3.50

1.281

40
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Scale: HPV Vaccine Acceptance – Issues That Would Influence One to Become
Vaccinated Against HPV
Reliability Statistics
Cronbach's
N of
Alpha
Items
.781
8
Item Statistics
Mean
If my friends think I
should get it
If my health insurance
covers it
If I had an abnormal Pap
smear
If my family thinks I
should get it
If my sex partner thinks
I should get it
If my health care
provider thinks I should
get it
If someone in my family
has cancer
Whether I practice safe
sex

Std.
Deviation

N

1.79

.656

39

2.72

.560

39

2.85

.489

39

2.41

.715

39

2.41

.677

39

2.82

.506

39

2.74

.442

39

2.69

.521

39

Scale: HPV Vaccine Acceptance – Issues That Would Prevent One from Becoming
Vaccinated Against HPV
Reliability Statistics
Cronbach's
N of
Alpha
Items
.825
7

303

Appendix H (Continued) HPV Survey Instrument – Internal Consistency Reliability
Item Statistics
Mean
The cost of the
vaccine would
prevent me from
becoming
vaccinated.
Getting three shots
over a six month
period would
prevent me from
becoming
vaccinated.
Fear of vaccines
would prevent me
from becoming
vaccinated.
Possible side effects
of the vaccine
would prevent me
from becoming
vaccinated.
Having to get
additional boosters
after getting three
shots would prevent
me from becoming
vaccinated.
Having to wait at
my doctors office
for approval to get
the vaccine would
prevent me from
becoming
vaccinated.
Not knowing where
to get the vaccine
would prevent me
from becoming
vaccinated.

Std.
Deviation

N

2.21

.801

39

1.49

.756

39

1.44

.754

39

1.97

.628

39

1.67

.701

39

1.41

.595

39

1.54

.555

39
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Subscale: Attitudes
Reliability Statistics
Cronbach's
Alpha Based
on
Cronbach's
Standardized
Alpha
Items
.674
.701

N of
Items
3

Item Statistics
Mean
Refusing to have sex
with a partner if they
will not use a condom
would be very easy for
me.
Telling a partner that I
will not be sexually
active with them until
they have been tested for
sexually transmitted
infections would be very
easy for me.
Avoiding the use of
drugs or alcohol before
engaging in sexual
activity would be very
easy for me.

Std.
Deviation

4.22

.861

54

3.91

.917

54

3.98

1.157

54

Scale: Normative Beliefs
Reliability Statistics
Cronbach's
Alpha Based
on
Cronbach's
Standardized
Alpha
Items
.763
.765

N

N of
Items
3
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Item Statistics
Mean
Most college
students would
avoid using drugs
or alcohol before
engaging in sexual
activity.
Most college
students would ask
their health care
provider about
how to reduce
their risk for
sexually
transmitted
infections.
Most college
students would tell
a partner to get
tested for sexually
transmitted
infections before
becoming sexually
active with them.

Std.
Deviation

N

2.41

.942

54

2.98

.858

54

2.78

1.022

54

Scale: Control Beliefs
Reliability Statistics
Cronbach's
Alpha Based
on
Cronbach's
Standardized
Alpha
Items
.860
.866

N of
Items
5
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Item Statistics
Mean
How much control
do you have in
being abstinent
from sexual
activity until you
are married?
How much control
do you have in
refusing to have
sex with a partner
that will not use a
condom?
How much control
do you have in
avoiding the use of
drugs or alcohol
before engaging in
sexual activity?
How much control
do you have in
telling a partner to
get tested for
sexually
transmitted
infections before
becoming sexually
active with them?
How much control
do you have in
asking a health
care provider
about how to
reduce your risk
for sexually
transmitted
infections?

Std.
Deviation

N

4.31

.961

52

4.62

.661

52

4.50

.804

52

4.44

.669

52

4.71

.572

52
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Scale: Intentions
Reliability Statistics
Cronbach's
N of
Alpha
Items
.659
3
Item Statistics
Mean
I intend to tell a partner
to get tested for
sexually transmitted
infections before
becoming sexually
active with them.
I intend to refuse to
have sex with a partner
if they will not use a
condom.
I intend to avoid drugs
or alcohol before
engaging in sexual
activity.

Std.
Deviation

3.96

.889

54

4.13

.953

54

4.02

1.073

54

Scale: Severity of HPV
Reliability Statistics
Cronbach's
Alpha Based
on
Cronbach's
Standardized
Alpha
Items
.512
.527

N

N of
Items
3
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Item Statistics
Std.
Deviation

Mean
How serious a health
problem would HPV be
for you?
If you get HPV how
likely is it that you will
get genital warts?
If you get HPV how
likely is it
that you will get
cancer?

N

3.76

.612

54

3.28

.960

54

3.52

.885

54

Scale: Susceptibility to HPV
Reliability Statistics
Cronbach's
Alpha Based
on
Cronbach's
Standardized
Alpha
Items
.822
.850

N of
Items
5

Item Statistics
Mean
Do you think you
are likely to
contract HPV?
How likely is it
that you currently
have HPV?
Do you think your
friends or peers
are likely to
contract HPV?
What is the
likelihood that you
could get HPV
within the next
year?
What is the
likelihood that you
could get HPV
sometime in your
life?

SD

N

1.274

.3612

53

1.585

1.0640

53

1.698

.3445

53

1.698

1.1533

53

2.396

1.2761

53
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Appendix I: HPV Survey Instrument – Test-Retest Reliability
Correlations – “Knowledge about HPV”
Mean
Knowledge
Score 1
Mean Knowledge
Score 1

Mean Knowledge
Score 2

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation

Sig. (2-tailed)
N
**Correlation is significant at the 0.01 level (2-tailed).

Mean
Knowledge
Score 2
1

.809(**)

54

.000
54

.809(**)

1

.000
54

54

Correlations – “Knowledge about the HPV Vaccine”
Mean HPV
Vaccine
Knowledge
Score1
Mean HPV Vaccine
Pearson Correlation
1
Knowledge Score 1
Sig. (2-tailed)
N
54
Mean HPV Vaccine
Pearson Correlation
.444(**)
Knowledge Score 2
Sig. (2-tailed)
.001
N
54
**Correlation is significant at the 0.01 level (2-tailed).
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Mean HPV
Vaccine
Knowledge
Score 2
.444(**)
.001
54
1
54

Appendix I (Continued) HPV Survey Instrument – Test-Retest Reliability
Correlations – HPV Vaccine Acceptance – “General Acceptance”
Mean Score
Mean Score
General
General
Vaccine
Vaccine
Acceptance 1 Acceptance 2
Mean Score
Pearson Correlation
General Vaccine
1
.649(**)
Acceptance 1
Sig. (2-tailed)
.000
N
54
54
Mean Score
Pearson Correlation
General Vaccine
.649(**)
1
Acceptance 2
Sig. (2-tailed)
.000
N
54
54
**Correlation is significant at the 0.01 level (2-tailed).
Correlations – HPV Vaccine Acceptance – “Influences to Being Vaccinated”
Mean Score
Mean Score
HPV Vaccine HPV Vaccine
Acceptance
Acceptance
Influence 1
Influence 2
Mean Score HPV
Pearson Correlation
Vaccine Acceptance
1
.582(**)
Influence 1
Sig. (2-tailed)
.000
N
40
38
Mean Score HPV
Pearson Correlation
Vaccine Acceptance
.582(**)
1
Influence 2
Sig. (2-tailed)
.000
N
38
42
**Correlation is significant at the 0.01 level (2-tailed).
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Appendix I (Continued) HPV Survey Instrument – Test-Retest Reliability
Correlations – HPV Vaccine Acceptance – “Issues That Would Prevent Being Vaccinated”
Mean Score
Mean Score
HPV Vaccine HPV Vaccine
Acceptance
Acceptance
Prevent 1
Prevent 2
Mean Score HPV
Pearson Correlation
Vaccine Acceptance
1
.678(**)
Prevent 1
Sig. (2-tailed)
.000
N
40
38
Mean Score HPV
Pearson Correlation
Vaccine Acceptance
.678(**)
1
Prevent 2
Sig. (2-tailed)
.000
N
38
42
**Correlation is significant at the 0.01 level (2-tailed).
Correlations – Attitudes towards practicing safer sex behaviors
MeanAttitude MeanAttitude
Score 1
Score 2
Mean Attitude
Pearson Correlation
1
.769(**)
Score 1
Sig. (2-tailed)
.000
N
54
54
Mean Attitude
Pearson Correlation
.769(**)
1
Score 2
Sig. (2-tailed)
.000
N
54
54
**Correlation is significant at the 0.01 level (2-tailed).
Correlations – Normative beliefs about practicing safer sex behaviors
Mean
Mean
Normative
Normative
Beliefs Score Beliefs Score
1
2
Mean Normative
Pearson Correlation
1
.476(**)
Beliefs Score 1
Sig. (2-tailed)
.000
N
54
54
Mean Normative
Pearson Correlation
.476(**)
1
Beliefs Score 2
Sig. (2-tailed)
.000
N
54
54
**Correlation is significant at the 0.01 level (2-tailed).
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Appendix I (Continued) HPV Survey Instrument – Test-Retest Reliability
Correlations – Control beliefs about practicing safer sex behaviors
Mean Score
Mean Score
Control
Control
Beliefs 1
Beliefs 2
Mean Score
Pearson Correlation
Control Beliefs
1
.722(**)
1
Sig. (2-tailed)
.000
N
54
54
Mean Score
Pearson Correlation
Control Beliefs
.722(**)
1
2
Sig. (2-tailed)
.000
N
54
54
**Correlation is significant at the 0.01 level (2-tailed)
Correlations – Intentions to practice safer sex behaviors
Mean
Intentions
Score1
Mean Intentions
Pearson
1
Score 1
Correlation
Sig. (2-tailed)
N
54
Mean Intentions
Pearson
.780(**)
Score 2
Correlation
Sig. (2-tailed)
.000
N
54

Mean
Intentions
Score2
.780(**)
.000
54
1
54

**Correlation is significant at the 0.01 level (2-tailed).
Correlations – HPV Susceptibility
Mean Score
HPV
Susceptibility
1
Mean Score HPV
Susceptibility 1

Mean Score HPV
Susceptibility 2

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation

1

.884(**)

54

.000
54

.884(**)

1

Sig. (2-tailed)
N
**Correlation is significant at the 0.01 level (2-tailed).
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Mean Score
HPV
Susceptibility
2

.000
54

54

Appendix I (Continued) HPV Survey Instrument – Test-Retest Reliability
Correlations – HPV Severity
Mean Score
HPV
Severity 1
Mean Score HPV
Severity 1

Mean Score HPV
Severity 2

Pearson
Correlation
Sig. (2-tailed)
N
Pearson
Correlation
Sig. (2-tailed)
N
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Mean Score
HPV
Severity 2
1

.202

54

.142
54

.202

1

.142
54

54

Appendix J: HPV Severity Scale – Test-Retest Reliability

Correlations – HPV Severity

Mean HPV
Severity
Score 1

Mean HPV
Severity
Score 2

Mean HPV
Severity
Score 1

Mean HPV
Severity
Score 2

1

.609(**)

27

.001
27

.609(**)

1

Pearson Correlation

Sig. (2-tailed)
N
Pearson Correlation

Sig. (2-tailed)
.001
N
27
**Correlation is significant at the 0.01 level (2-tailed).
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Appendix K: Missing Data Analysis
Table 1. ANOVA - Missing Data for Ethnicity
Sum of
Squares
df
Mean Square
Between
1.743
8
.218
Groups
Within Groups
198.649
2690
.074
Total
200.392
2698

F

Sig.

2.951

Table 2. Tukey HSD for Mean Differences in Missing Data for Ethnicity
Dependent Variable: Missing Data
How do you describe (J) How do you
Mean
yourself?
describe yourself?
Difference
Check all that apply.
Check all that apply.
(I-J)
Std. Error
African-American
Hispanic or Latino
.073
.026
Asian
.040
.035
American Indian or
-.099
.137
Alaska Native
Native Hawaiian or
.151
.104
other Pacific Islander
Arab-American
-.016
.081
White
Multi-racial
Other
*The mean difference is significant at the .05 level.

.079*
.074
.151

Table 3. ANOVA – Missing Data for Age
How old are
Sum of
you?
Squares
df
Mean Square
Between
.128
6
.021
Groups
Within Groups
206.163
2699
.076
Total
206.292
2705
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.019
.025
.056

F
.280

.003

Sig.
.102
.969
.999
.879
1.000
.001
.087
.154

Sig.
.946

Appendix K (Continued) - Missing Data Analysis
Table 4. ANOVA – Missing Data for Sexual Orientation
Sum of
Squares
df
Mean Square
Between
.652
3
.217
Groups
Within Groups
199.740
2695
.074
Total
200.392
2698

F
2.930

Sig.
.032

Table 5. Tukey HSD for Mean Differences in Missing Data for Sexual Orientation
Dependent Variable: Missing Data
Mean
What is your sexual
(J) What is your
Difference
orientation?
sexual orientation?
(I-J)
Std. Error
Sig.
I have sex with men. I have sex with
-.094
.038
.061
women.
I have sex with men
.008
.032
.995
and women.
I don't have sex.
-.025
.015
.326
I have sex with
women.

I have sex with men
and women.

I have sex with men.

.094

.038

.061

I have sex with men
and women.
I don't have sex.
I have sex with men.

.102

.049

.158

.070
-.008

.040
.032

.298
.995

-.102

.049

.158

-.033
.025
-.070

.034
.015
.040

.778
.326
.298

.033

.034

.778

I have sex with
women.
I don't have sex.
I don't have sex.
I have sex with men.
I have sex with
women.
I have sex with men
and women.
*The mean difference is significant at the .05 level.

Table 6. ANOVA - Missing Data for Marital Status
What is your
Sum of
marital status?
Squares
df
Mean Square
Between
.173
4
.043
Groups
Within Groups
200.219
2694
.074
Total
200.392
2698
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F
.581

Sig.
.676

Appendix K (Continued) - Missing Data Analysis
Table 7. ANOVA – Missing Data for Number of Sexual Partners
Within the past
12 months, with
how many
partners, if any,
have you had
oral, anal or
Sum of
vaginal sex?
Squares
df
Mean Square
F
Between
.676
16
.042
.640
Groups
Within Groups
174.946
2653
.066
Total
175.621
2669

Sig.
.853

Table 8. Independent Samples T-Test – Missing Data for Those Participants That Are
or Are Not Currently Sexually Active
Levene's Test
for Equality
of Variances
t-test for Equality of Means
Have you
had oral,
anal or
vaginal
sex with a
partner in
Sig.
Std.
the past
2Mean Error
60 days?
F
Sig.
t
df
tailed
Diff.
Diff.
95% C.I.
Missing
Data
Equal
variances
assumed

Lower

.058
Equal
variances
not
assumed

.810

Upper

-.120

2690

.905

-.001

.011

-.024

.021

-.120

1505.568

.904

-.001

.011

-.024

.021
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Appendix K (Continued) - Missing Data Analysis
Table 9. Independent Samples T-Test – Missing Data for Those Participants With or
Without Children
Levene's Test
for Equality
of Variances
t-test for Equality of Means
Do you
Sig.
Std.
have
2Mean Error
children?
F
Sig.
t
df
tailed
Diff.
Diff.
95% C.I.
Missing
Data
Equal
variances
assumed

Lower

1.813
Equal
variances
not
assumed

.178

Upper

-.691

2696

.490

-.023

.033

-.089

.042

-.616

69.744

.540

-.023

.037

-.098

.052

Table 10. ANOVA - Missing Data for Year in College
What is your
current year in
Sum of
college?
Squares
df
Mean Square
Between
.235
3
.078
Groups
Within Groups
201.846
2697
.075
Total
202.081
2700

F
1.046

Sig.
.371

Table 11. ANOVA – Missing Data for University Enrollment
What university
are you
Sum of
attending?
Squares
df
Mean Square
Between
.164
2
.082
Groups
Within Groups
203.603
2700
.075
Total
203.767
2702

F
1.085

Sig.
.338
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Appendix K (Continued) - Missing Data Analysis
Table 12. Independent Samples T-Test – Missing Data for Health Insurance Coverage of
HPV Vaccine
Levene's Test
for Equality
of Variances
t-test for Equality of Means
Do you
currently
have
health
insurance
that
covers
the cost
of the
Sig.
Std.
HPV
2Mean Error
vaccine?
F
Sig.
t
df
tailed Diff. Diff.
95% C.I.
Missing
Data
Equal
variances
assumed

Lower

9.522
Equal
variances
not
assumed

.002

Upper

-1.529

1771

.126

-.021

.014

-.048

.006

-1.577

1497.918

.115

-.021

.013

-.047

.005
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Appendix L: Statistics Tables for Demographic Variables
Subjects were asked questions regarding their age, ethnicity, sexual orientation,
number of sexual partners, current sexual activity, marital status, whether they had
children, current year in college, what university they were attending, and whether they
had health insurance that covered the cost of the HPV vaccine. These tables are to
demonstrate that there were normal distributions of the population for the majority of the
demographic variables, except for the number of sexual partners. Skewness and kurtosis
values between + 2 are considered to be in an acceptable range.
Table 1. Age
N

Valid
Missing

2706
0
20.72
.030
21.00
21
1.580
2.497
.249
.047
-.656
.094
6
18
24

Mean
Std. Error of Mean
Median
Mode
Std. Deviation
Variance
Skewness
Std. Error of Skewness
Kurtosis
Std. Error of Kurtosis
Range
Minimum
Maximum
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Appendix L (Continued) Statistics Tables for Demographic Variables
Table 2. Ethnicity
N

Valid
Missing

2699
7
a
Mean
6.07
Std. Error of Mean
.042
Median
7.00
Mode
7
Std. Deviation
2.189
Variance
4.791
Skewness
-1.501
Std. Error of Skewness
.047
Kurtosis
.586
Std. Error of Kurtosis
.094
Range
8
Minimum
1
Maximum
9
a
Note. Mean frequency rating where 1 = African-American, 2 = Hispanic
or Latino, 3 = Asian, 4 = American Indian or Alaska Native,
5 = Native Hawaiian or other Pacific Islander, 6 = Arab-American,
7 = White, 8 = Multi-racial, and 9 = Other

Table 3. University
N

Valid
Missing

2703
3
a
Mean
2.23
Std. Error of Mean
.009
Median
2.00
Mode
2
Std. Deviation
.456
Variance
.208
Skewness
.790
Std. Error of Skewness
.047
Kurtosis
-.174
Std. Error of Kurtosis
.094
Range
2
Minimum
1
Maximum
3
Note. a Mean frequency rating where 1 = Central Michigan University,
2 = University of South Florida and 3 = Western Michigan University
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Appendix L (Continued) Statistics Tables for Demographic Variables
Table 4. Year in college
N
Valid
2701
Missing
5
a
Mean
3.18
Std. Error of Mean
.018
Median
3.00
Mode
4
Std. Deviation
.910
Variance
.828
Skewness
-.832
Std. Error of Skewness
.047
Kurtosis
-.299
Std. Error of Kurtosis
.094
Range
3
Minimum
1
Maximum
4
a
Note. Mean frequency rating where 1 = Freshman, 2 = Sophomore,
3 = Junior, and 4 = Senior
Table 5. Sexual orientation
N
Valid
2699
Missing
7
a
Mean
1.53
Std. Error of Mean
.021
Median
1.00
Mode
1
Std. Deviation
1.102
Variance
1.214
Skewness
1.690
Std. Error of Skewness
.047
Kurtosis
.972
Std. Error of Kurtosis
.094
Range
3
Minimum
1
Maximum
4
a
Note. Mean frequency rating where 1 = I have sex with men,
2 = I have sex with women, 3 = I have sex with men
and women, and 4 = I don’t have sex

323

Appendix L (Continued) Statistics Tables for Demographic Variables
Table 6. Marital Status
N
Valid
2699
Missing
7
a
Mean
4.63
Std. Error of Mean
.016
Median
4.00
Mode
4
Std. Deviation
.844
Variance
.713
Skewness
.357
Std. Error of Skewness
.047
Kurtosis
-.807
Std. Error of Kurtosis
.094
Range
4
Minimum
2
Maximum
6
a
Note. Mean frequency rating where 1 = Widowed, 2 = Separated/Divorced
3 = Married, 4 = Single and in a monogamous relationship,
5 = Single and sexually active, and 6 = Single and abstinent
Table 7. Number of sexual partners in the past 12 months
N
Valid
2670
Missing
36
Mean
1.61
Std. Error of Mean
.034
Median
1.00
Mode
1
Std. Deviation
1.748
Variance
3.056
Skewness
3.057
Std. Error of Skewness
.047
Kurtosis
15.608
Std. Error of Kurtosis
.095
Range
20
Minimum
0
Maximum
20
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Appendix L (Continued) Statistics Tables for Demographic Variables
Table 8. Current sexual activity
N
Valid
2692
Missing
14
a
Mean
1.70
Std. Error of Mean
.009
Median
2.00
Mode
2
Std. Deviation
.457
Variance
.208
Skewness
-.894
Std. Error of Skewness
.047
Kurtosis
-1.202
Std. Error of Kurtosis
.094
Range
1
Minimum
1
Maximum
2
Note. a Mean frequency rating where 1 = No and 2 = Yes
Table 9. Children
N

Valid
Missing

2698
8
a
Mean
1.03
Std. Error of Mean
.003
Median
1.00
Mode
1
Std. Deviation
.157
Variance
.025
Skewness
6.062
Std. Error of Skewness
.047
Kurtosis
34.769
Std. Error of Kurtosis
.094
Range
1
Minimum
1
Maximum
2
Note. a Mean frequency rating where 1 = No and 2 = Yes
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Appendix L (Continued) Statistics Tables for Demographic Variables
Table 10. Health insurance
N
Valid
2698
Missing
8
a
Mean
1.586
Std. Error of Mean
.0076
Median
1.500
Mode
2.0
Std. Deviation
.3961
Variance
.157
Skewness
-.316
Std. Error of Skewness
.047
Kurtosis
-1.342
Std. Error of Kurtosis
.094
Range
1.0
Minimum
1.0
Maximum
2.0
a
Note. Mean frequency rating where 1 = No and 2 = Yes
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Appendix M: HPV Vaccine Survey - Item Frequencies, Means, and Standard Deviations
Section One. Knowledge about HPV
1. HPV is more common than HIV.

N
2702

Missing
4

Mean
.89

SD
.310

True
%
89.2

False
%
10.8

Total
%
100.0

Mean
.77

SD
.422

True
%
23.2

False
%
76.8

Total
%
100.0

True
%
.5

False
%
99.5

Total
%
100.0

Not sure
%
1.9

Total
%
100.0

2. Only women get HPV.

N
2702

Missing
4

3. You can always tell when someone else has HPV.

N
2703

Missing
3

Mean
.99

SD
.072

4. Has a health care provider ever told you that you have HPV?

N
2702

Missing
4

Mean
1.171

SD
.3701

Yes
%
16.1

No
%
82.0

Section Two. Attitudes and intentions regarding practicing safer sex behaviors
1. Refusing to have sex with a partner if they will not use a condom would be very easy
for me.

%
26.0
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%
14.9

%
5.8

Strongly
disagree

%
51.8

Disagree

SD
1.001

Somewhat
agree

Mean
4.20

Agree

Missing
3

Strongly
agree

N
2703

Total

%
1.6

%
100.0

Appendix M (Continued) HPV Vaccine Survey – Item Frequencies and Means
2. I intend to tell a partner to get tested for sexually transmitted infections before I
become sexually active with them.

%
28.7

%
28.2

%
14.6

Strongly
disagree

%
27.2

Disagree

SD
1.068

Somewhat
agree

Mean
3.66

Agree

Missing
5

Strongly
agree

N
2701

Total

%
1.3

%
100.0

3. Telling a partner that I will not be sexually active with them until they have been
tested for sexually transmitted infections would be very easy for me.

%
26.3

%
26.6

%
19.0

Strongly
disagree

%
25.7

Disagree

SD
1.136

Somewhat
agree

Mean
3.54

Agree

Missing
6

Strongly
agree

N
2700

Total

%
2.5

%
100.0

4. I intend to refuse to have sex with a partner if they will not use a condom.

%
23.4

328

%
16.1

%
10.6

Strongly
disagree

%
48.0

Disagree

SD
1.110

Somewhat
agree

Mean
4.05

Agree

Missing
8

Strongly
agree

N
2698

Total

%
1.9

%
100.0

Appendix M (Continued) HPV Vaccine Survey – Item Frequencies and Means
5. Avoiding the use of drugs or alcohol before engaging in sexual activity would be very
easy for me.

%
16.1

%
8.9

%
1.5

%
100.0

Strongly
disagree

%
22.3

Strongly
disagree

%
51.1

Disagree

SD
1.071

Somewhat
agree

Mean
4.13

Agree

Missing
8

Strongly
agree

N
2698

Total

Total

%
2.2

%
100.0

6. I intend to avoid drugs or alcohol before engaging in sexual activity.

%
41.5

%
23.5

%
21.3

Section Three. Knowledge about the HPV Vaccine
1. The vaccine is safe.
Checked Not
checked

N
2706

Missing
0

Mean
.68

SD
.466

%
68.1

%
31.9
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Total

%
100.0

Disagree

SD
1.131

Somewhat
agree

Mean
3.90

Agree

Missing
7

Strongly
agree

N
2699

%
11.5

Appendix M (Continued) HPV Vaccine Survey – Item Frequencies and Means
2. The vaccine prevents women from getting high risk HPV.
Checked Not
checked

N
2706

Missing
0

Mean
.81

SD
.393

%
81.0

%
19.0

Total

%
100.0

3. The vaccine will protect against cervical cancer.
Checked Not
checked

N
2706

Missing
0

Mean
.78

SD
.411

%
78.4

%
21.6

Total

%
100.0

4. The vaccine consists of three shots over a six month period.
Checked Not
checked

N
2706

Missing
0

Mean
.77

SD
.421

%
77.1

%
22.9

Total

%
100.0

5. I have not heard about the HPV vaccine.
Checked Not
checked

N
2706

Missing
0

Mean
.03

SD
.158

%
2.5

%
97.5
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Total

%
100.0

Appendix M (Continued) HPV Vaccine Survey – Item Frequencies and Means
Section Four. Normative Beliefs Regarding Practicing Safer Sex Behaviors
1. Most college students would avoid using drugs or alcohol before engaging in sexual
activity.

%
1.3

%
4.3

%
23.2

%
51.7

Strongly
disagree

SD
.829

Disagree

Mean
2.16

Somewhat
agree

Missing
2

Agree

Strongly
agree

N
2704

Total

%
19.6

%
100.0

2. Most college students would ask their health care provider about how to reduce their
risk for sexually transmitted infections.

%
2.8

%
13.7

%
35.3

%
38.7

Strongly
disagree

SD
.933

Disagree

Mean
2.62

Somewhat
agree

Missing
9

Agree

Strongly
agree

N
2697

Total

%
9.5

%
100.0

3. Most college students would tell a partner to get tested for sexually transmitted
infections before becoming sexually active with them.
Strongly
disagree

SD
.782

Disagree

Mean
2.14

Somewhat
agree

Missing
2

Agree

Strongly
agree

N
2704

%

%

%

%

%

0.4

4.8

21.7

54.5

18.6
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Total

%
100.0

Appendix M (Continued) HPV Vaccine Survey – Item Frequencies and Means
Section Five. Acceptance of the HPV vaccine
1. How important do you think vaccinations are, in general?

SD
.506

Not at all
important

Mean
2.67

Somewhat
important

Missing
6

Very
important

N
2700

%

%

%

68.9

29.4

1.7

Total

%
100.0

2. Have you received at least one dose of the HPV vaccine?

N
2699

Missing
7

Mean
1.37

SD
.484

Yes

No

Total

%

%

37.3

62.7

%
100.0

3. The vaccine is currently available for young girls and women between the ages of 9
through
26. How likely is it that you will get vaccinated against HPV?
A little likely

Very
unlikely

Somewhat
likely

%
23.2%
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Likely

Very likely

N
Skippeda Missing
Mean
SD
%
%
%
%
1695
1006
5
2.72
1.313 11.8%
17.4% 24.7% 22.8%
Note. aThese participants skipped the question because they received the HPV vaccine.

Appendix M (Continued) HPV Vaccine Survey – Item Frequencies and Means
4. How important are the following issues in influencing your decision to become
vaccinated against HPV?
If my friends think I should get it
Not
important at
all

Somewhat
important

Very
important

N
Skippeda Missing Mean
SD
%
%
%
1698
1006
2
1.60
.666
10.1
39.5
50.4
Note. aThese participants skipped the question because they received the HPV vaccine.

Total

%
100.0

If my health insurance covers it
Not
important at
all

Somewhat
important

Very
important

N
Skippeda Missing Mean
SD
%
%
%
1697
1006
3
2.57
.673
67.2
22.4
10.4
Note. aThese participants skipped the question because they received the HPV vaccine.

Total

%
100.0

If I had an abnormal pap smear
Not
important at
all

Somewhat
important

Very
important

N
Skippeda Missing Mean
SD
%
%
%
1692
1006
8
2.74
.519
77.2
19.0
3.7
Note. aThese participants skipped the question because they received the HPV vaccine.

Total

%
100.0

If my family thinks I should get it
Not
important at
all

Somewhat
important

Very
important

N
Skippeda Missing Mean
SD
%
%
%
1693
1006
7
2.36
.671
46.7
42.3
11.0
Note. aThese participants skipped the question because they received the HPV vaccine.
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Total

%
100.0

Appendix M (Continued) HPV Vaccine Survey – Item Frequencies and Means
If my sex partner thinks I should get it
Not
important at
all

Somewhat
important

Very
important

N
Skippeda Missing Mean
SD
%
%
%
1692
1006
8
2.30
.685
42.6
44.4
13.0
Note. aThese participants skipped the question because they received the HPV vaccine.

Total

%
100.0

If my health care provider thinks I should get it
Not
important at
all

Somewhat
important

Very
important

N
Skippeda Missing Mean
SD
%
%
%
1696
1006
4
2.57
.614
63.6
29.8
6.6
Note. aThese participants skipped the question because they received the HPV vaccine.

Total

%
100.0

If someone in my family has cancer
Not
important at
all

Somewhat
important

Very
important

N
Skippeda Missing Mean
SD
%
%
%
1697
1006
3
2.57
.632
64.4
27.9
7.7
Note. aThese participants skipped the question because they received the HPV vaccine.

Total

%
100.0

Whether I practice safe sex
Not
important at
all

Somewhat
important

Very
important

N
Skippeda Missing
Mean
SD
%
%
%
1694
1006
6
2.54
.671
63.6
26.4
10.0
Note. aThese participants skipped the question because they received the HPV vaccine.
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Total

%
100.0

Appendix M (Continued) HPV Vaccine Survey – Item Frequencies and Means
5. How important are the following issues in preventing you from becoming vaccinated
against HPV?
The cost of the vaccine
Not
important at
all

Somewhat
important

Very
important

N
Skippeda Missing
Mean
SD
%
%
%
1696
1006
4
2.30
.753
48.0
34.2
17.8
Note. aThese participants skipped the question because they received the HPV vaccine.

Total

%
100.0

Getting three shots over a six month period
Not
important at
all

Somewhat
important

Very
important

N
Skippeda Missing
Mean
SD
%
%
%
1697
1006
3
1.41
.644
8.6
24.2
67.2
Note. aThese participants skipped the question because they received the HPV vaccine.

Total

%
100.0

Fear of vaccines
Not
important at
all

Somewhat
important

Very
important

N
Skippeda Missing
Mean
SD
%
%
%
1697
1006
3
1.37
.655
9.8
17.6
72.6
Note. aThese participants skipped the question because they received the HPV vaccine.

Total

%
100.0

Possible side effects of the vaccine
Not
important at
all

Somewhat
important

Very
important

N
Skippeda Missing
Mean
SD
%
%
%
1696
1006
4
2.07
.726
30.2
46.8
23.1
a
Note. These participants skipped the question because they received the HPV vaccine.
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%
100.0
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Having to get additional boosters after getting three shots
Not
important at
all

Somewhat
important

Very
important

N
Skippeda Missing
Mean
SD
%
%
%
1690
1006
10
1.71
.714
15.3
40.9
43.8
Note. aThese participants skipped the question because they received the HPV vaccine.

Total

%
100.0

Having to wait at my doctor’s office for approval to get the vaccine
Not
important at
all

Somewhat
important

Very
important

N
Skippeda Missing
Mean
SD
%
%
%
1690
1006
10
1.46
.639
8.0
29.7
62.3
Note. aThese participants skipped the question because they received the HPV vaccine.

Total

%
100.0

Not knowing where to get the vaccine
Not
important at
all

Somewhat
important

Very
important

N
Skippeda Missing
Mean
SD
%
%
%
1694
1006
6
1.66
.755
17.3
31.7
51.0
a
Note. These participants skipped the question because they received the HPV vaccine.

336

Total

%
100.0
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Section Six. Control beliefs about practicing safer sex behaviors
1. How much control do you have in being abstinent from sexual activity until you are
married?
No control

Little
control

A lot of
control

Some
control

Complete
control

N

Missing

Mean

SD

%

%

%

%

%

%

2701

5

3.74

1.379

42.1

22.0

15.8

8.4

11.7

100.0

Total

2. How much control do you have in refusing to have sex with a partner who will not use
a condom?
No control

Little
control

A lot of
control

Some
control

Complete
control

N

Missing

Mean

SD

%

%

%

%

%

%

2694

12

4.49

.767

62.5

26.4

8.9

1.7

.5

100.0

Total

3. How much control do you have in avoiding the use of drugs or alcohol before
engaging in sexual activity?
No control

Little
control

A lot of
control

Missing

Mean

SD

%

%

%

%

%

%

2699

7

4.49

.804

65.5

21.4

10.4

2.4

.4

100.0
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Some
control

Complete
control

N

Total
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4. How much control do you have in telling a partner to get tested for sexually
transmitted infections before becoming sexually active with them?
No control

Little
control

A lot of
control

Some
control

Complete
control

N

Missing

Mean

SD

%

%

%

%

%

%

2696

10

4.10

.980

45.2

27.0

21.4

5.5

.9

100.0

Total

5. How much control do you have in asking a health care provider about how to reduce
your risk of sexually transmitted infections?
No control

Little
control

A lot of
control

Some
control

Complete
control

N

Missing

Mean

SD

%

%

%

%

%

%

2696

10

4.55

.748

67.8

21.6

8.7

1.6

.4

100.0

Total

Section Seven. Perceived susceptibilty to HPV
1. Do you think you are likely to contract HPV?

N

Missing

Mean

SD

Yes
%

2701

5

1.32

.388

18.6

No
%

Not sure
%

Total
%

54.8

26.6

100.0

2. How likely is it that you currently have HPV?
A little
likely

Very
unlikely

N

Missing

Mean

SD

%

%

%

%

%

%

2702

4

1.69

1.23

8.3

2.8

6.9

13.8

68.3

100.0
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Somewhat
likley

Likely

Very likely

Total
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3. Do you think your friends or peers are likely to contract HPV?

N

Missing

Mean

SD

Yes
%

2692

14

1.70

.330

50.2

No
%

Not sure
%

Total
%

40.1

9.7

100.0

4. What is the likelihood that you could get HPV within the next year?
A little
likely

Very
unlikely

Somewhat
likley

Likely

Very likely

Total

N

Missing

Mean

SD

%

%

%

%

%

%

2694

12

1.63

1.094

5.1

3.1

8.2

16.8

66.8

100.0

5. What is the likelihood that you could get HPV some time in your life?
A little
likely

Very
unlikely

Somewhat
likley

Likely

Very likely

Total

N

Missing

Mean

SD

%

%

%

%

%

%

2697

9

2.49

1.348

13.3

9.2

19.5

28.8

29.1

100.0

Section Eight. Perceived severity of HPV
1. How serious a health problem would HPV be for you?
A little
serious

Not at all
serious

Missing

Mean

SD

%

%

%

%

%

%

2701

5

3.66

.805

10.6

53.7

27.5

7.0

1.1

100.0
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Not sure

Serious

The most
serious

N

Total
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2. If you get HPV, it is not a big problem because it is very easy to treat.
Somewhat
agree

Somewhat
disagree

Strongly
disagree

Not sure

Strongly
agree

Total

N

Missing

Mean

SD

%

%

%

%

%

%

2701

5

2.37

.998

23.6

29.5

33.9

12.3

.7

100.0

3. If you get HPV, how likely is it that you will get genital warts?
Somewhat
unlikely

Very
unlikely

Not sure

Somewhat
likely

Very likely

Total

N

Missing

Mean

SD

%

%

%

%

%

%

2698

8

3.31

.904

9.5

27.4

52.5

5.7

5.0

100.0

4. If you get HPV, how likely is it that you will get cancer?
Somewhat
unlikely

Very
unlikely

N

Missing

Mean

SD

%

%

%

%

%

%

2699

7

3.59

.803

9.7

48.9

33.6

6.5

1.3

100.0
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Not sure

Somewhat
likely

Very likely

Total

Appendix N: Perceived Control in Being Abstinent from
Sexual Activity by Marital Status
Table 1. Perceived Control in Being Abstinent from Sexual Activity by Marital Status
No control

Little
control

Some
control

A lot of
control

Complete
control

Marital status

Totals

(N) %

(N) %

(N) %

(N) %

(N) %

(N) %

Separated/
Divorced

(4) 100.0

(0) .0

(0) .0

(0) .0

(0) .0

(4) 100

Married

(41) 41.0

(22) 22.0

(22) 22.0

(6) 6.0

(9) 9.0

(100) 100

Single and in a
monogamous
relationship

(517) 39.2

(266) 20.2

(217) 16.4

(126) 9.5

(194) 14.7

(1320) 100

Single and
sexually active

(231) 31.3

(161) 21.8

(150) 20.4

(88) 11.9

(107) 14.5

(737) 100

Single and
abstinent

(343) 64.4

(143) 26.8

(36) 6.8

(6) 1.1

(5) .9

(533) 100
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Tables 1-3. Multiple Linear Regression Results for Predictors of Intentions to Practice Safer
Sex Behaviors
1. Model Summary
Adjusted Std. Error of
Model
R
R Square R Square the Estimate
1
.730(a)
.533
.532
.55279
a Predictors: (Constant), Mean Control Beliefs, Mean Normative Beliefs, Mean Attitude

2. ANOVA(b)
Sum of
Squares
df
Mean Square
F
Regression
942.040
3
314.013 1027.602
Residual
825.674 2702
.306
Total
1767.715 2705
a. Predictors: (Constant), Mean Control Beliefs, Mean Normative Beliefs,
Mean Attitude
b. Dependent Variable: Mean Intentions
Model
1

Sig.
.000(a)

3. Coefficientsa

Model

Unstandardized
Coefficients

B

Standardized
Coefficients

Std.
Error

1
(Constant)
.547
.076
Mean
Attitude
.680
.016
Mean
Normative
Beliefs
.096
.017
Mean
Control
Beliefs
.097
.018
a. Dependent Variable: Mean Intentions

95% Confidence
Interval for B

t

Sig.

Lower
Bound

Upper
Bound

7.194

.000

.398

.697

.666

43.258

.000

.649

.711

.076

5.631

.000

.062

.129

.082

5.424

.000

.062

.132

Beta
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Table 4. Correlation Between Knowledge about HPV and Attitudes Towards Practicing
Safer Sex Behaviors

Mean Knowledge

Mean Attitude

Mean Knowledge

Pearson
1
Correlation
Sig. (2-tailed)
N
2706
Mean Attitude
Pearson
-.097(**)
Correlation
Sig. (2-tailed)
.000
N
2706
**Correlation is significant at the 0.01 level (2-tailed).

-.097(**)
.000
2706
1
2706

Table 5. Correlation Between Knowledge about HPV and Normative Beliefs Towards
Practicing Safer Sex Behaviors

Mean Normative
Beliefs

Mean Knowledge
Mean Knowledge

Mean Normative Beliefs

Pearson
Correlation
Sig. (2-tailed)
N
Pearson
Correlation
Sig. (2-tailed)
N

1

-.033

2706

.084
2706

-.033

1

.084
2706

2706

Table 6. Correlation Between Knowledge about HPV and Control Beliefs Towards
Practicing Safer Sex Behaviors
Mean
Knowledge
Mean Knowledge

Mean Control Beliefs

Pearson
Correlation
Sig. (2-tailed)
N
Pearson
Correlation
Sig. (2-tailed)
N

343

Mean Control
Beliefs
1

-.034

2706

.078
2706

-.034

1

.078
2706

2706

Appendix O (Continued) Summary Tables of Correlation
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Table 7. Correlation Between Knowledge about HPV and Intentions To Practice Safer Sex
Behaviors

Mean Knowledge
Mean Knowledge

Pearson
1
Correlation
Sig. (2-tailed)
N
2706
Mean Intentions
Pearson
-.099(**)
Correlation
Sig. (2-tailed)
.000
N
2706
**Correlation is significant at the 0.01 level (2-tailed).

Mean
Intentions
-.099(**)
.000
2706
1
2706

Table 8. Correlation Between Knowledge of HPV Vaccine and General Vaccine Acceptance
Mean
Knowledge of
Vaccine
Mean Knowledge of
Vaccine

Pearson
1
Correlation
Sig. (2tailed)
N
2706
Mean General Vaccine Pearson
.215(**)
Acceptance
Correlation
Sig. (2.000
tailed)
N
2705
**Correlation is significant at the 0.01 level (2-tailed).
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Mean General
Vaccine
Acceptance
.215(**)
.000
2705
1

2705

Appendix O (Continued) Summary Tables of Correlation
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Table 9. Correlation Between Knowledge of the HPV Vaccine and Influential Factors to
Becoming Vaccinated Against HPV

Mean Knowledge
of Vaccine
Mean Knowledge of
Vaccine

Pearson
Correlation
Sig. (2tailed)
N
Mean VaccineAcceptance Pearson
Influential Factors
Correlation
Sig. (2tailed)
N

1

Mean Vaccine
Acceptance Influential
Factors
.034
.166

2706

1701

.034

1

.166
1701

1701

Table 10. Correlation Between Knowledge of the HPV Vaccine and Barriers to Becoming
Vaccinated Against HPV

Mean
Knowledge
of Vaccine
Mean Knowledge of
Vaccine

Mean Vaccine
Acceptance Factors That
Would Prevent

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation

1

-.010

2706

.680
1702

-.010

1

Sig. (2-tailed)

.680

N

1702
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Mean Vaccine
Acceptance Barriers

1702
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Tables 11-14. Multiple Linear Regression Results for the Relationship Between Knowledge of
the HPV Vaccine and the Importance of Influential Factors to Becoming
Vaccinated Against HPV
11. Model Summary
Adjusted Std. Error of
Model
R
R Square R Square the Estimate
1
.113(a)
.013
.012
.21631
2
.130(b)
.017
.016
.21593
a. Predictors: (Constant), If someone in my family has cancer
b. Predictors: (Constant), If someone in my family has cancer, If my friends think I should get it
12. ANOVA(c)
Sum of
Mean
Squares
df
Square
F
Sig.
Regression
1.027
1
1.027
21.940
.000(a)
Residual
78.697
1682
.047
Total
79.724
1683
2
Regression
1.346
2
.673
14.433
.000(b)
Residual
78.378
1681
.047
Total
79.724
1683
a. Predictors: (Constant), If someone in my family has cancer
b. Predictors: (Constant), If someone in my family has cancer, If my friends think I should get it
c. Dependent Variable: Mean Knowledge of Vaccine
Model
1
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13. Coefficientsa

Model

Unstandardized
Coefficients

B
1
(Constant)
If someone
in my
family has
cancer
2
(Constant)

.509

.022

.039

.008

.528
If someone
in my
family has
cancer

Std.
Error

.045

Standardized
Coefficients

Beta

t

.113

.023

.009

95% Confidence
Interval for B

.130

If my
friends
think I
-.021
.008
-.065
should get
it
Dependent Variable: Mean Knowledge of Vaccine
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Sig.

23.046

.000

4.684

.000

Lower
Bound

Upper
Bound

.465

.552

.023

.055

22.720

.000

5.206

.000

.028

.062

-2.617

.009

-.037

-.005

.482

.574

Appendix O (Continued) Summary Tables of Correlation
and Multiple Linear Regression Results
14. Excluded Variables(c)

Beta In

t

Model

Sig.

Partial
Correlation

Collinearity
Statistics
Tolerance

1

If my friends thinkI
-.065(a)
-2.617
.009
-.064
.934
should get it
If my health insurance
.020(a)
.774
.439
.019
.882
covers it
If I had an abnormal
-.009(a)
-.346
.729
-.008
.789
Pap smear
If my family thinks I
-.050(a)
-1.944
.052
-.047
.876
should get it
If my sex partner
-.050(a)
-1.935
.053
-.047
.882
thinks I should get it
If my health care
provider thinks I
-.031(a)
-1.155
.248
-.028
.840
should get it
Whether I practice
.011(a)
.446
.655
.011
.888
safe sex
2
If my health insurance
.038(b)
1.451
.147
.035
.830
covers it
If I had an abnormal
.000(b)
.002
.998
.000
.775
Pap smear
If my family thinks I
-.029(b)
-1.061
.289
-.026
.758
should get it
If my sex partner
-.030(b)
-1.071
.284
-.026
.769
thinks I should get it
If my health care
provider thinks I
-.016(b)
-.605
.545
-.015
.801
should get it
Whether I practice
.022(b)
.844
.399
.021
.868
safe sex
a Predictors in the Model: (Constant), If someone in my family has cancer
b Predictors in the Model: (Constant), If someone in my family has cancer, If my friends think I
should get it
c Dependent Variable: Mean Knowledge of Vaccine
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Table 15-18. Multiple Linear Regression Results for the Relationship Between Knowledge of the
HPV Vaccine and the Importance of Barriers to Becoming Vaccinated
Against HPV
15. Model Summary
Adjusted Std. Error of
Model
R
R Square R Square the Estimate
1
.118(a)
.014
.013
.21620
2
.132(b)
.017
.016
.21588
a. Predictors: (Constant), Possible side effects of the vaccine would prevent me from becoming
vaccinated
b. Predictors: (Constant), Possible side effects of the vaccine would prevent me from becoming
vaccinated, Not knowing where to get the vaccine would prevent me
from becoming vaccinated
16. ANOVA(c)
Mean
Model
Sum of Squares
df
Square
F
Sig.
1
Regression
1.101
1
1.101
23.550
.000(a)
Residual
78.481 1679
.047
Total
79.582 1680
2
Regression
1.379
2
.689
14.793
.000(b)
Residual
78.203 1678
.047
Total
79.582 1680
a Predictors: (Constant), Possible side effects of the vaccine would prevent me from becoming
vaccinated
b Predictors: (Constant), Possible side effects of the vaccine would prevent me from becoming
vaccinated, Not knowing where to get the vaccine would prevent me
from becoming vaccinated
c Dependent Variable: Mean Knowledge of Vaccine
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17. Coefficientsa

Model

Unstandardized
Coefficients

B
1
(Constant)
Possible
side effects
of the
vaccine
2
(Constant)

Std.
Error

.682

.016

-.035

.007

.708

.019

Standardized
Coefficients

Beta

-.118

95% Confidence
Interval for B

t

Sig.

42.794

.000

Lower
Bound

Upper
Bound

.651

.713

-4.853

.000

-.049

-.021

37.145

.000

.670

.745

-4.656

.000

-.048

-.020

-2.442

.000

-.031

-.003

Possible
side effects
of the
vaccine
-.034
.007
-.113
Not
knowing
where to
get the
vaccine
-.017
.007
-.059
Dependent Variable: Mean Knowledge of Vaccine
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18. Excluded Variables(c)
t
Model
1

Beta In
The cost of the vaccine

Collinearity
Statistics
Tolerance

.019(a)

.803

.422

.020

1.000

-.054(a)

-2.205

.028

-.054

.963

-.032(a)

-1.239

.215

-.030

.878

-.049(a)

-1.882

.060

-.046

.848

-.036(a)

-1.458

.145

-.036

.970

-.059(a)

-2.442

.015

-.060

.994

.038(b)

1.522

.128

.037

.927

Getting three shots over a
six month period

-.046(b)

-1.843

.065

-.045

.938

Fear of vaccines

-.031(b)

-1.198

.231

-.029

.878

-.040(b)

-1.481

.139

-.036

.822

-.016(b)

-.598

.550

-.015

.837

Getting three shots over a
six month period
Fear of vaccines
Having to get additional
boosters after getting
three shots
Having to wait at my
doctors office for
approval to get the
vaccine
Not knowing where to get
the vaccine
2

Sig.

Partial
Correlation

The cost of the vaccine

Having to get additional
boosters after getting
three shots
Not knowing where to get
the vaccine

a. Predictors in the Model: (Constant), Possible side effects of the vaccine
b. Predictors in the Model: (Constant), Possible side effects of the vaccine, Not knowing where
to get the vaccine
c. Dependent Variable: Mean Knowledge of Vaccine
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Table 19. Correlation Between General Vaccine Acceptance and Perceived Susceptibility
of HPV
Mean General
Vaccine
Mean
Acceptance Susceptibility
Mean General
Vaccine
Acceptance

Pearson Correlation
1

.067(**)

2705

.001
2705

.067(**)

1

Sig. (2-tailed)
.001
N
2705
**Correlation is significant at the 0.01 level (2-tailed).

2706

Mean
Susceptibility

Sig. (2-tailed)
N
Pearson Correlation

Table 20. Correlation Between Universal Vaccine Acceptance and Perceived Susceptibility
of HPV

Mean
Susceptibility
How important do you
think vaccinations are in
general?

Mean Susceptibility

How important
do you think
vaccinations are
in general?

Pearson Correlation
.008
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
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2700
1
.696
2706

1
.696
2700
.008
2700

Appendix O (Continued) Summary Tables of Correlation
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Tables 21-22. Chi-Square for Relationship Between Whether Participants Received At Least One
Dose of the Vaccine and Perceived Susceptiblity
20. Cross-Tabulation

Received At Least One Dose of
the HPV Vaccine
No
Yes

Low
.60-1.60
N
%
952
56.2%
672

Mean Susceptibility
Medium
1.70-2.60
N
%
497
29.4%

66.8%

224

High
2.70-3.80
N
%
244
14.4%

22.3%

110

22. Chi-Square Tests

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value
63.945(a)
66.885
23.860

Asymp. Sig.
df
(2-sided)
31
.000
31
.000
1

.000

2699

a. 13 cells (20.3%) have expected count less than 5. The minimum expected count is .37.
Table 23. Correlation Between Perceived Susceptibility of HPV and Likelihood of
Getting Vaccinated Against HPV
Likelihood of
getting
vaccinated
against HPV
Likelihood of
Pearson Correlation
getting vaccinated
1
against HPV
Sig. (2-tailed)
N
1695
Mean
Pearson Correlation
.145(**)
Susceptibility
Sig. (2-tailed)
.000
N
1695
**Correlation is significant at the 0.01 level (2-tailed).
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Mean Susceptibility
.145(**)
.000
1695
1
2706

10.9%
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Table 24. Correlation Between Perceived Susceptibility of HPV and Influential Factors to
Becoming Vaccinated Against HPV

Mean Vaccine
Acceptance - Influential
Factors

Mean Susceptibility

Mean
Vaccine
Acceptance Influential
Factors

Mean
Susceptibility

1

.009

Pearson Correlation

Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N

1701
.009
.724
1701

.724
1701
1
2706

Table 25. Correlation Between Perceived Susceptibility of HPV and Barriers to
Becoming Vaccinated Against HPV
Mean
Vaccine
Acceptance
Factors Barriers
Mean Vaccine
Acceptance - Barriers

Mean Susceptibility

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
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Mean
Susceptibility
1

1702
.020
.400
1702

.020
.400
1702
1
2706
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Tables 26-29. Multiple Linear Regression Results for the Relationship Between Susceptibilty to
HPV and the Importance of Influential Factors to Becoming Vaccinated Against
HPV
26. Model Summary
Adjusted Std. Error of
Model
R
R Square R Square the Estimate
1
.150(a)
.023
.022
.72881
2
.162(b)
.026
.025
.72769
3
.172(c)
.030
.028
.72662
a. Predictors: (Constant), If my health insurance covers it
b. Predictors: (Constant), If my health insurance covers it, If my health care provider thinks I
should get it
c. Predictors: (Constant), If my health insurance covers it, If my health care provider thinks I
should get it, If I had an abnormal Papsmear
27. ANOVA(d)
Sum of
Model
Squares
df
Mean Square
F
Sig.
1
Regression
20.613
1
20.613 38.806
.000(a)
Residual
893.422
1682
.531
Total
914.035
1683
2
Regression
23.900
2
11.950 22.567
.000(b)
Residual
890.135
1681
.530
Total
914.035
1683
3
Regression
27.040
3
9.013 17.071
.000(c)
Residual
886.995
1680
.528
Total
914.035
1683
a. Predictors: (Constant), If my health insurance covers it
b. Predictors: (Constant), If my health insurance covers it, If my health care provider thinks I
should get it
c. Predictors: (Constant), If my health insurance covers it, If my health care provider thinks I
should get it, If I had an abnormal Pap smear
d. Dependent Variable: Mean Susceptibility
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28. Coefficientsa

Model

Unstandardized
Coefficients

B

Std.
Error

Standardized
Coefficients

Beta

95% Confidence
Interval for B

t

Sig.

Lower
Bound

Upper
Bound

1 (Constant)
1.338

.070

.164

.026

1.211

.087

.135

.029

.079

.032

1.355

.105

19.096

.000

1.201

1.475

6.229

.000

.113

.216

13.973

.000

1.041

1.381

.124

4.690

.000

.079

.192

.066

2.491

.013

.017

.141

12.935

.000

1.149

1.560

.143

5.208

.000

.098

.216

.086

3.119

.002

.038

.168

-.068

-2.439

.015

-.173

-.019

If my health
insurance
covers it
.150

2 (Constant)

If my health
insurance
covers it

If my health
care provider
thinks I
should get it
3(Constant)
If my health
insurance
.157
.030
covers it
If my health
care provider
thinks I
.103
.033
should get it
If I had an
abnormal Pap
-.096
.039
smear
a. Dependent Variable: Mean Susceptibility
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29. Excluded Variables(d)
Collinearity
Statistics
Model

Beta In
t

1

Sig.

Partial
Correlation

If my friends think I
.011(a)
.416
.678
should get it
If I had an abnormal
-.041(a)
-1.559
.119
Pap smear
If my family thinks I
-.025(a)
-1.003
.316
should get it
If my sex partner
.029(a)
1.114
.265
thinks I should get it
If my health care
provider thinks I
.066(a)
2.491
.013
should get it
If someone in my
.045(a)
1.761
.078
family has cancer
Whether I practice
-.025(a)
-1.005
.315
safe sex
2
If my friends think I
-.002(b)
-.069
.945
should get it
If I had an abnormal
-.068(b)
-2.439
.015
Pap smear
If my family thinks I
-.055(b)
-2.020
.044
should get it
If my sex partner
.006(b)
.221
.825
thinks I should get it
If someone in my
.028(b)
1.058
.290
family has cancer
Whether I practice
-.041(b)
-1.613
.107
safe sex
3
If my friends think I
.002(c)
.091
.928
should get it
If my family thinks I
-.044(c)
-1.584
.113
should get it
If my sex partner
.020(c)
.718
.473
thinks I should get it
If someone in my
.054(c)
1.900
.058
family has cancer
Whether I practice
-.030(c)
-1.167
.244
safe sex
a. Predictors in the Model: (Constant), If my health insurance covers it
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Tolerance

.010

.906

-.038

.827

-.024

.906

.027

.882

.061

.835

.043

.882

-.025

.939

-.002

.871

-.059

.750

-.049

.792

.005

.765

.026

.801

-.039

.891

.002

.868

-.039

.763

.018

.735

.046

.726

-.028

.858

Appendix O (Continued) Summary Tables of Correlation
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b. Predictors in the Model: (Constant), If my health insurance covers it, If my health care
provider thinks I should get it
c. Predictors in the Model: (Constant), If my health insurance covers it, If my health care
provider thinks I should get it, If I had an abnormal Pap
smear
d. Dependent Variable: Mean Susceptibility
Tables 30-33. Multiple Linear Regression Results for the Relationship Between Susceptibilty to
HPV and the Importance of Barriers to Becoming Vaccinated Against
HPV
30. Model Summary
Adjusted Std. Error of
Model
R
R Square R Square the Estimate
1
.087(a)
.008
.007
.73439
2
.107(b)
.011
.010
.73315
a. Predictors: (Constant), Possible side effects of the vaccine
b. Predictors: (Constant), Possible side effects of the vaccine, The cost of the vaccine
31. ANOVA(c)
Sum of
Model
Squares
df
Mean Square
F
Sig.
1
Regression
6.867
1
6.867 12.732
.000(a)
Residual
905.539
1679
.539
Total
912.405
1680
2
Regression
10.463
2
5.231
9.733
.000(b)
Residual
901.943
1678
.538
Total
912.405
1680
a. Predictors: (Constant), Possible side effects of the vaccine
b. Predictors: (Constant), Possible side effects of the vaccine, The cost of the vaccine
c. Dependent Variable: Mean Susceptibility
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32. Coefficientsa

Model

Unstandardized
Coefficients

B

Std.
Error

Standardized
Coefficients

Beta

95% Confidence
Interval for B

t

Sig.

Lower
Bound

Upper
Bound

1 (Constant)
1.934

.054

-.088

.025

1.802

.077

-.088

.025

35.879

.000

1.836

2.049

-3.568

.000

-.136

-.040

23.505

.000

1.652

1.952

-.087

-3.590

.000

-.137

-.040

.063

2.587

.010

.015

.108

Possible side
effects of the
vaccine
-.087

2 (Constant)

Possible side
effects of the
vaccine

The cost of
the vaccine

.061
.024
a. Dependent Variable: Mean Susceptibility
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33. Excluded Variables(c)
Model
Beta In
1

t

Sig.

Partial
Correlation

Collinearity
Statistics
Tolerance

The cost of the vaccine

Getting three shots over a
six month period

.063(a)

2.587

.010

.063

1.000

-.004(a)

-.168

.866

-.004

.963

.002(a)

.063

.950

.002

.878

-.009(a)

-.329

.742

-.008

.848

.051(a)

2.077

.038

.051

.970

.051(a)

2.097

.036

.051

.994

-.013(b)

-.523

.601

-.013

.945

.003(b)

.134

.894

.003

.877

-.019(b)

-.728

.467

-.018

.829

.039(b)

1.538

.124

.038

.921

.037(b)

1.453

.146

.035

.921

Fear of vaccines

Having to get additional
boosters after getting
three shots
Having to wait at my
doctors office for
approval to get the
vaccine
Not knowing where to get
the vaccine
2

Getting three shots over a
six month period
Fear of vaccines

Having to get additional
boosters after getting
three shots
Having to wait at my
doctors office for
approval to get the
vaccine
Not knowing where to get
the vaccine

a. Predictors in the Model: (Constant), Possible side effects of the vaccine
b. Predictors in the Model: (Constant), Possible side effects of the vaccine, The cost of the
vaccine
c. Dependent Variable: MeanSusceptibility
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Table 34. Correlation Between General Vaccine Acceptance and Perceived Severity
of HPV
Mean
General
Vaccine
Acceptance
Mean General
Vaccine
Acceptance

Mean Severity

Pearson Correlation
1

.088(**)

Sig. (2-tailed)
N
2705
Mean Severity
Pearson Correlation
.088(**)
Sig. (2-tailed)
.000
N
2705
**Correlation is significant at the 0.01 level (2-tailed).

.000
2705
1
2706

Table 35. Correlation Between Universal Vaccine Acceptance and Perceived Severity
of HPV
How
important do
you think
vaccinations
are in
general?
Mean Severity
How important do you
think vaccinations are in
general?

Pearson Correlation
1

.077(**)

Sig. (2-tailed)
N
2700
MeanSeverity
Pearson Correlation
.077(**)
Sig. (2-tailed)
.000
N
2700
** Correlation is significant at the 0.01 level (2-tailed).

.000
2700
1
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Tables 36-37. Chi-Square for Relationship Between Whether Participants Received At Least One
Dose of the Vaccine and Perceived Severity
36. Cross-Tabulation

Received At Least One Dose of
the HPV Vaccine
No
Yes

Low
1.00-2.00
N
%
28
1.6%

Mean Severity
Medium
2.25-3.25
N
%
1048
61.9%

High
3.50-4.50
N
%
617
36.4%

19

626

361

1.9%

62.2%

37. Chi-Square Tests

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value
8.964(a)
9.228
.393

Asymp. Sig.
df
(2-sided)
13
.776
13
.756
1

.531

2699

a 7 cells (25.0%) have expected count less than 5. The minimum expected count is .37.
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Table 38. Correlation Between Perception of HPV Not Being a Problem Because It is
Very Easy to Treat and Likelihood of Getting Vaccinated Against HPV
If you get
HPV it is not
a big problem
because it is
very easy to
treat

Likelihood of
getting vaccinated
against HPV

1

-.009

2701

.717
1692

-.009

1

If you get HPV it is Pearson Correlation
not a big problem
because it is very
easy to treat
Sig. (2-tailed)
N
Likelihood of
Pearson Correlation
getting vaccinated
against HPV
Sig. (2-tailed)

.717

N

1692

1695

Table 39. Correlation Between Perceived Severity of HPV and Likelihood of Getting
Vaccinated Against HPV
Likelihood of
getting
vaccinated
against HPV
Likelihood of
Pearson Correlation
getting vaccinated
1
against HPV
Sig. (2-tailed)
N
1695
Mean Severity
Pearson Correlation
.110(**)
Sig. (2-tailed)
.000
N
1695
**Correlation is significant at the 0.01 level (2-tailed).
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Mean Severity
.110(**)
.000
1695
1
2706

Appendix O (Continued) Summary Tables of Correlation
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Table 40. Correlation Between Perceived Severity of HPV and Influential Factors to
Becoming Vaccinated Against HPV
Mean
Vaccine
Acceptance –
Influential
Factors
Mean Vaccine
Acceptance - Influential
Factors

Mean
Severity

Pearson Correlation
1

.072(**)

Sig. (2-tailed)
N
1701
Mean Severity
Pearson Correlation
.072(**)
Sig. (2-tailed)
.003
N
1701
**Correlation is significant at the 0.01 level (2-tailed).

.003
1701
1
2706

Table 41. Correlation Between Perceived Severity of HPV and Barriers to
Becoming Vaccinated Against HPV
Mean
Vaccine
Acceptance Barriers
Mean Vaccine
Acceptance - Barriers

Mean Severity

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
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1
1702
.025
.308
1702

Mean
Severity
.025
.308
1702
1
2706

Appendix O (Continued) Summary Tables of Correlation
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Tables 42-45. Multiple Linear Regression Results for the Relationship Between Perceived
Severity and the Importance of Influential Factors to Becoming Vaccinated
Against HPV
42. Model Summary
Adjusted Std. Error of
Model
R
R Square R Square the Estimate
1
.140(a)
.020
.019
.43895
2
.152(b)
.023
.022
.43833
a Predictors: (Constant), If someone in my family has cancer
b Predictors: (Constant), If someone in my family has cancer, If my family thinks I should get it
43. ANOVA(c)
Model
Sum of Squares
df
Mean Square
F
Sig.
1
Regression
6.498
1
6.498
33.724
.000(a)
Residual
324.085
1682
.193
Total
330.583
1683
2
Regression
7.614
2
3.807
19.816
.000(b)
Residual
322.969
1681
.192
Total
330.583
1683
a. Predictors: (Constant), If someone in my family has cancer
b. Predictors: (Constant), If someone in my family has cancer, If my family thinks I should get it
c. Dependent Variable: MeanSeverity
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44. Coefficientsa

Model

Unstandardized
Coefficients

B

Standardized
Coefficients

Std.
Error

Beta

95% Confidence
Interval for B

t

Sig.

Lower
Bound

Upper
Bound

1 (Constant)
2.970

.045

.098

.017

2.913

.051

.083

.018

66.314

.000

2.882

3.058

5.807

.000

.065

.132

57.500

.000

2.814

3.012

.118

4.594

.000

.048

.118

.062

2.411

.016

.008

.074

If someone in
my family
has cancer
.140

2 (Constant)

If someone in
my family
has cancer

If my family
thinks I
should get it
.041
.017
a. Dependent Variable: Mean Severity
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45. Excluded Variables(c)
Model
Beta In

t

1

Sig.

Partial
Correlation

Collinearity
Statistics
Tolerance

If my friends think I
.028(a)
1.125
.261
.027
.934
should get it
If my health insurance
.061(a)
2.387
.017
.058
.882
covers it
If I had an abnormal
.060(a)
2.223
.026
.054
.789
Pap smear
If my family thinks I
.062(a)
2.411
.016
.059
.876
should get it
If my sex partner thinks
.046(a)
1.779
.075
.043
.882
I should get it
If my health care
provider thinks I should
.050(a)
1.900
.058
.046
.840
get it
Whether I practice safe
.033(a)
1.285
.199
.031
.888
sex
2
If my friends think I
.007(b)
.262
.794
.006
.809
should get it
If my health insurance
.050(b)
1.922
.055
.047
.842
covers it
If I had an abnormal
.047(b)
1.676
.094
.041
.740
Pap smear
If my sex partner thinks
.024(b)
.834
.405
.020
.722
I should get it
If my sex partner thinks
.032(b)
1.149
.251
.028
.743
I should get it
Whether I practice safe
.024(b)
.932
.351
.023
.867
sex
a Predictors in the Model: (Constant), If someone in my family has cancer
b Predictors in the Model: (Constant), If someone in my family has cancer, If my family thinks I
should get it
c Dependent Variable: Mean Severity
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Tables 46-49. Multiple Linear Regression Results for the Relationship Between Perceived
Severity and the Importance of Barriers to Becoming Vaccinated Against HPV
46. Model Summary
Adjusted Std. Error of
Model
R
R Square R Square the Estimate
1
.059(a)
.003
.003
.44256
a Predictors: (Constant), The cost of the vaccine
47. ANOVA(b)
Sum of
Model
Squares
df
Mean Square
1
Regression
1.145
1
1.145
Residual
328.849
1679
.196
Total
329.994
1680
a. Predictors: (Constant), The cost of the vaccine
b. Dependent Variable: Mean Severity

F
5.848

Sig.
.016(a)

48. Coefficientsa

Model

Unstandardized
Coefficients

B

Standardized
Coefficients

Std.
Error

Beta

95% Confidence
Interval for B

t

Sig.

Lower
Bound

Upper
Bound

1 (Constant)
3.143

.035

90.524

.000

3.075

3.211

2.418

.016

.007

.063

The cost of
the vaccine
.035
.014
a. Dependent Variable: Mean Severity

.059
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49. Excluded Variables(b)
Model
Beta In
1

Getting three shots
over a six month
period
Fear of vaccines

Possible side effects
of the vaccine
Having to get
additional boosters
after getting three
shots
Having to wait at
my doctors office
for approval to get
the vaccine
Not knowing where
to get the vaccine

t

Sig.

Partial
Correlation

Collinearity
Statistics
Tolerance

-.016(a)

-.633

.527

-.015

.982

-.023(a)

-.931

.352

-.023

.999

-.016(a)

-.638

.523

-.016

1.000

.003(a)

.108

.914

.003

.980

-.009(a)

-.340

.734

-.008

.951

.043(a)

1.691

.091

.041

.927

a. Predictors in the Model: (Constant), The cost of the vaccine
b. Dependent Variable: MeanSeverity

Table 50. Correlation Between Attitudes About Practicing Safer Sex Behaviors and General
Vaccine Acceptance

2706

Mean
General
Vaccine
Acceptance
.029
.128
2705

.029

1

.128
2705

2705

Mean
Attitude
Mean Attitude

Mean General
Vaccine
Acceptance

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation

1

Sig. (2-tailed)
N
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Table 51. Correlation Between Attitudes About Practicing Safer Sex Behaviors and Universal
Vaccine Acceptance
How important
do you think
vaccinations
are in general?

Mean
Attitude
Mean Attitude

How important do you
think vaccinations are in
general?

Pearson
Correlation
Sig. (2-tailed)
N
Pearson
Correlation

1

.059(**)

2706

.002
2700

.059(**)

1

Sig. (2-tailed)
N
** Correlation is significant at the 0.01 level (2-tailed).

.002
2700

2700

Table 52. Correlation Between Attitudes About Practicing Safer Sex Behaviors and Likelihood
of Getting Vaccinated Against HPV

MeanAttitude
MeanAttitude
Pearson Correlation
1
Sig. (2-tailed)
N
2706
Likelihood of
Pearson Correlation
getting vaccinated
.024
against HPV
Sig. (2-tailed)
.326
N
1695
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Likelihood of
getting vaccinated
against HPV
.024
.326
1695
1

1695

Appendix O (Continued) Summary Tables of Correlation
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Tables 53-54. Chi-Square for Relationship Between Whether Participants Received at Least One
Dose of the HPV Vaccine and Attitudes Towards Practicing Safer Sex Behaviors
53. Cross-Tabulation

Received At Least One Dose of
the HPV Vaccine
No
Yes

Low
1.00-2.00
N
%
39
2.3%

Mean Attitude
Medium
2.33-3.67
N
%
625
36.9%

High
4.00-5.00
N
%
1029
60.8%

26

415

565

2.6%

41.3%

56.1%

54. Chi-Square Tests

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value
15.543(a)
16.704
2.249

df

Asymp. Sig.
(2-sided)
12
.213
12
.161
1

.134

2699

a. 5 cells (19.2%) have expected count less than 5. The minimum expected count is .37.

Tables 55-58. Multiple Linear Regression Results for the Relationship Between Influential
Factors to Becoming Vaccinated Against HPV
Table 55. Model Summary
Adjusted Std. Error of
Model
R
R Square R Square the Estimate
1
.128(a)
.016
.016
.78562
2
.195(b)
.038
.037
.77713
a. Predictors: (Constant), If my health insurance covers it
b. Predictors: (Constant), If my health insurance covers it, Whether I practice safe sex
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Table 56. ANOVA(c)
Sum of
Mean
Model
Squares
df
Square
F
Sig.
1
Regression
17.188
1
17.188
27.849
.000(a)
Residual
1038.123
1682
.617
Total
1055.311
1683
2
Regression
40.107
2
20.053
33.205
.000(b)
Residual
1015.204
1681
.604
Total
1055.311
1683
a. Predictors: (Constant), If my health insurance covers it
b. Predictors: (Constant), If my health insurance covers it, Whether I practice safe sex
c. Dependent Variable: Mean Attitude
57. Coefficientsa

Model

Unstandardized
Coefficients

B

Standardized
Coefficients

Std.
Error

Beta

95% Confidence
Interval for B

t

Sig.

Lower
Bound

Upper
Bound

1 (Constant)
4.334

.076

-.150

.028

3.992

.093

-.194

.029

57.378

.000

4.186

4.482

-5.277

.000

-.206

-.094

42.896

.000

3.809

4.174

-.165

-6.692

.000

-.251

-.137

.152

6.160

.000

.122

.237

If my health
insurance
covers it
-.128

2 (Constant)

If my health
insurance
covers it

Whether I
practice safe
sex
.180
.029
a. Dependent Variable: Mean Attitude
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58. Excluded Variables(c)
Model
Beta In

t

1

Sig.

Partial
Correlation

Collinearity
Statistics
Tolerance

If my friends think I
.060(a)
2.357
.019
.057
.906
should get it
If I had an abnormal
.070(a)
2.642
.008
.064
.827
Pap smear
If my family thinks I
.043(a)
1.707
.088
.042
.906
should get it
If my sex partner
.023(a)
.877
.381
.021
.882
thinks I should get it
If my health care
provider thinks I
.051(a)
1.936
.053
.047
.835
should get it
If someone in my
.060(a)
2.319
.021
.056
.882
family has cancer
Whether I practice
.152(a)
6.160
.000
.149
.939
safe sex
2
If my friends think I
.036(b)
1.432
.152
.035
.883
should get it
If I had an abnormal
.032(b)
1.176
.240
.029
.776
Pap smear
If my family thinks I
.014(b)
.561
.575
.014
.873
should get it
If my sex partner
-.015(b)
-.573
.566
-.014
.834
thinks I should get it
If my sex partner
.016(b)
.577
.564
.014
.792
thinks I should get it
If someone in my
.018(b)
.673
.501
.016
.815
family has cancer
a. Predictors in the Model: (Constant), If my health insurance covers it
b. Predictors in the Model: (Constant), If my health insurance covers it, Whether I practice safe
sex
c. Dependent Variable: Mean Attitude
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Tables 59-62. Multiple Linear Regression Results for the Relationship Between Attitude and
Barriers to Becoming Vaccinated Against HPV
59. Model Summary
Adjusted Std. Error of
Model
R
R Square R Square the Estimate
1
.145(a)
.021
.020
.78370
2
.167(b)
.028
.027
.78119
a. Predictors: (Constant), The cost of the vaccine
b. Predictors: (Constant), The cost of the vaccine, Not knowing where to get the vaccine

60. ANOVA(c)
Sum of
Model
Squares
df
Mean Square
F
Sig.
1
Regression
22.208
1
22.208
36.159
.000(a)
Residual
1031.221
1679
.614
Total
1053.430
1680
2
Regression
29.414
2
14.707
24.100
.000(b)
Residual
1024.015
1678
.610
Total
1053.430
1680
a. Predictors: (Constant), The cost of the vaccine
b. Predictors: (Constant), The cost of the vaccine, Not knowing where to get the vaccine
c. Dependent Variable: Mean Attitude
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61. Coefficientsa

Model

Unstandardized
Coefficients

B

Standardized
Coefficients

Std.
Error

Beta

95% Confidence
Interval for B

t

Sig.

Lower
Bound

Upper
Bound

1 (Constant)
4.300

.061

-.153

.025

4.393

.067

-.128

.026

69.928

.000

4.179

4.420

-6.013

.000

-.202

-.103

65.493

.000

4.262

4.525

-.122

-4.880

.000

-.180

-.077

-.086

-3.436

.001

-.142

-.039

The cost of
the vaccine
-.145

2 (Constant)

The cost of
the vaccine

Not knowing
where to get
the vaccine
-.090
.026
a. Dependent Variable: Mean Attitude
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62. Excluded Variables(c)

Model
1

2

Beta In
Getting three
shots over a six
month period
Fear of vaccines

Possible side
effects of the
vaccine
Having to get
additional
boosters after
getting three shots
Having to wait at
my doctors office
for approval to
get the vaccine
Not knowing
where to get the
vaccine
Getting three
shots over a six
month period
Fear of vaccines

t

Sig.

Partial
Correlation

Collinearity
Statistics
Tolerance

-.035(a)

-1.418

.156

-.035

.982

-.013(a)

-.544

.586

-.013

.999

.035(a)

1.445

.149

.035

1.000

-.001(a)

-.046

.964

-.001

.980

-.069(a)

-2.795

.005

-.068

.951

-.086(a)

-3.436

.001

-.084

.927

-.023(b)

-.950

.342

-.023

.963

-.009(b)

-.367

.714

-.009

.997

.042

.994

.012

.955

-.042

.842

Possible side
effects of the
.042(b)
1.726
.084
vaccine
Having to get
additional
.013(b)
.509
.611
boosters after
getting three shots
Having to wait at
my doctors office
-.046(b)
-1.740
.082
for approval to
get the vaccine
a. Predictors in the Model: (Constant), The cost of the vaccine
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b. Predictors in the Model: (Constant), The cost of the vaccine, Not knowing where to get the
vaccine
c. Dependent Variable: Mean Attitude
Table 63. Correlation Between Normative Beliefs About Practicing Safer Sex Behaviors and
Universal Vaccine Acceptance
Mean
Normative
Beliefs
Mean Normative
Beliefs

Pearson Correlation

Mean General
Vaccine
Acceptance
1

.113(**)

2706

.000
2705

.113(**)

1

Sig. (2-tailed)
.000
N
2705
**Correlation is significant at the 0.01 level (2-tailed).

2705

Mean General
Vaccine Acceptance

Sig. (2-tailed)
N
Pearson Correlation

Table 63. Correlation Between Normative Beliefs About Practicing Safer Sex Behaviors and
Likelihood of Getting Vaccinated Against HPV
Likelihood of
getting
vaccinated
against HPV

Mean
Normative
Beliefs
Mean Normative
Beliefs

Likelihood of getting
vaccinated against
HPV

Pearson Correlation

1

.111(**)

2706

.000
1695

.111(**)

1

Sig. (2-tailed)
N
Pearson Correlation

Sig. (2-tailed)

.000

N

1695

**Correlation is significant at the 0.01 level (2-tailed).
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Tables 64-65. Chi-Square for Relationship Between Whether Participants Received at Least One
Dose of the HPV Vaccine and Normative Beliefs Towards Practicing Safer Sex
Behaviors
64. Cross-Tabulation

Received At Least One Dose of
the HPV Vaccine
No
Yes

Mean Normative Beliefs
Low
Medium
High
.33- 1.67
2.00-3.67
4.00-5.00
N
%
N
%
N
%
33
2.0%
358
21.1%
1302
76.9%
203

20.2%

782

77.7%

21

2.1%

65. Chi-Square Tests

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value
20.169(a)
20.175
5.502

df

Asymp. Sig.
(2-sided)
13
.091
13
.091
1

.019

2699

a. 7 cells (25.0%) have expected count less than 5. The minimum expected count is .37.
Tables 66-69. Multiple Linear Regression Results for the Relationship Between Attitude and
Barriers to Becoming Vaccinated Against HPV
66. Model Summary
Adjusted Std. Error of
Model
R
R Square R Square the Estimate
1
.126(a)
.016
.015
.63688
2
.150(b)
.023
.021
.63490
3
.159(c)
.025
.024
.63422
a. Predictors: (Constant), Whether I practice safe sex
b. Predictors: (Constant), Whether I practice safe sex, If my friends think I should get it
c. Predictors: (Constant), Whether I practice safe sex, If my friends think I should get it,
If my family thinks I should get it
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67. ANOVA(d)
Sum of
Mean
Model
Squares
df
Square
F
Sig.
1
Regression
10.998
1
10.998
27.114
.000(a)
Residual
682.252
1682
.406
Total
693.250
1683
2
Regression
15.648
2
7.824
19.410
.000(b)
Residual
677.602
1681
.403
Total
693.250
1683
3
Regression
17.506
3
5.835
14.507
.000(c)
Residual
675.744
1680
.402
Total
693.250
1683
a Predictors: (Constant), WhetherI practice safe sex
b Predictors: (Constant), Whether I practice safe sex, If my friends think I should get it
c Predictors: (Constant), Whether I practice safe sex, If my friends think Ishould get it, If my
family thinks I should get it
d Dependent Variable: Mean Normative Beliefs
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68. Coefficientsa

Model

Unstandardized
Coefficients

B

Std.
Error

Standardized
Coefficients

Beta

95% Confidence
Interval for B

t

Sig.

Lower
Bound

Upper
Bound

1 (Constant)
1.994

.061

.121

.023

1.910

.065

.103

.024

.081

.024

1.837

.074

32.850

.000

1.875

2.113

5.207

.000

.075

.166

29.199

.000

1.782

2.038

.107

4.346

.000

.056

.149

.084

3.396

.001

.034

.128

24.938

.000

1.693

1.981

3.894

.000

.046

.141

2.300

.022

.009

.110

2.149

.032

.005

.106

Whether I
practice safe
sex
.126

2 (Constant)

Whether I
practice safe
sex

If my friends
think I should
get it

3(Constant)
Whether I
practice safe
.094
.024
.098
sex
If my friends
think I should
get it
.059
.026
.062
If my family
thinks I
.056
.026
.058
should get it
a. Dependent Variable: Mean Normative Beliefs
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69. Excluded Variables(d)
Model
Beta In

t

1

Sig.

If my friends think I
.084(a)
3.396
.001
should get it
If my health insurance
.015(a)
.613
.540
covers it
If I had an abnormal
.014(a)
.549
.583
Pap smear
If my family thinks I
.082(a)
3.296
.001
should get it
If my sex partner thinks
.041(a)
1.600
.110
I should get it
If my health care
provider thinks I should .060(a)
2.388
.017
get it
If someone in my
.029(a)
1.119
.263
family has cancer
2
If my health insurance
-.304
.761
covers it
.008(b)
If I had an abnormal
-.043
.966
Pap smear
.001(b)
If my family thinks I
.058(b)
2.149
.032
should get it
If my sex partner thinks
.010(b)
.366
.715
I should get it
If my health care
provider thinks I should .042(b)
1.610
.107
get it
If someone in my
.012(b)
.458
.647
family has cancer
3
If my health insurance
-.018(c)
-.696
.486
covers it
If I had an abnormal
-.017(c)
-.651
.515
Pap smear
If my sex partner thinks
-.013(c)
-.444
.657
I should get it
If my health care
provider thinks I should .027(c)
.961
.336
get it
If someone in my
-.002(c)
-.059
.953
family has cancer
a. Predictors in the Model: (Constant), Whether I practice safe sex
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Partial
Correlation

Collinearity
Statistics
Tolerance

.083

.951

.015

.939

.013

.897

.080

.937

.039

.911

.058

.910

.027

.888

-.007

.872

-.001

.869

.052

.796

.009

.785

.039

.855

.011

.853

-.017

.844

-.016

.805

-.011

.681

.023

.764

-.001

.804
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b. Predictors in the Model: (Constant), Whether I practice safe sex, If my friends
think I should get it
c. Predictors in the Model: (Constant), Whether I practice safe sex, If my friends think I should
get it, If my family thinks I should get it
d. Dependent Variable: Mean Normative Beliefs

Table 70. Correlation Between Control Beliefs About Practicing Safer Sex Behaviors
and General Vaccine Acceptance

Mean Control
Beliefs
Mean Control
Beliefs

Mean General
Vaccine
Acceptance

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation

Sig. (2-tailed)
N

Mean General
Vaccine
Acceptance

1

.005

2706

.778
2705

.005

1

.778
2705

2705

Table 71. Correlation Between Control Beliefs About Practicing Safer Sex Behaviors
and Universal Vaccine Acceptance

Mean Control Beliefs

How important do you
think vaccinations are in
general?

Mean Control
Beliefs
Pearson Correlation
1
Sig. (2-tailed)
N
2706
Pearson Correlation
.054(**)

Sig. (2-tailed)
N
**Correlation is significant at the 0.01 level (2-tailed).
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.005
2700

How
important do
you think
vaccinations
are in
general?
.054(**)
.005
2700
1

2700
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Table 72. Correlation Between Control Beliefs About Practicing Safer Sex Behaviors
and Likelihood of Getting Vaccinated Against HPV

Mean Control
Beliefs

Likelihood of
getting vaccinated
against HPV

Mean Control
Beliefs

Likelihood of
getting vaccinated
against HPV

1

-.029

2706

.226
1695

-.029

1

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation

Sig. (2-tailed)

.226

N

1695

1695

Tables 73-74. Chi-Square for Relationship Between Whether Participants Received at Least One
Dose of the HPV Vaccine and Control Beliefs Towards Practicing Safer Sex
Behaviors
73. Cross-Tabulation

Received At Least One Dose of
the HPV Vaccine
No
Yes

Mean Control Beliefs
Low
Medium
High
1.00-2.60
2.80-3.80
4.00-5.00
N
%
N
%
N
%
1214
71.7%
43
2.5%
436
25.8%
16

1.6%

275

27.3%

715

74. Chi-Square Tests

Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases

Value
21.011(a)
23.305
.059

df

Asymp. Sig.
(2-sided)
19
.336
19
.224
1

.808

2699

a 11 cells (27.5%) have expected count less than 5. The minimum expected count is .37.
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Tables 75-78. Multiple Linear Regression Results for the Relationship Between Control Beliefs
About Practicing Safer Sex Behaviors and Influential Factors to Becoming
Vaccinated Against HPV
75. Model Summary
Adjusted Std. Error of
Model
R
R Square R Square the Estimate
1
.125(a)
.016
.015
.67779
2
.163(b)
.027
.025
.67421
a Predictors: (Constant), If my health insurance covers it
b Predictors: (Constant), If my health insurance covers it, Whether I practice safe sex
76. ANOVA(c)
Sum of
Model
Squares
df
Mean Square
F
Sig.
1
Regression
12.214
1
12.214 26.587
.000(a)
Residual
772.717
1682
.459
Total
784.931
1683
2
Regression
20.815
2
10.408 22.896
.000(b)
Residual
764.116
1681
.455
Total
784.931
1683
a Predictors: (Constant), If my health insurance covers it
b Predictors: (Constant), If my health insurance covers it, Whether I practice safe sex
c Dependent Variable: Mean Control Beliefs
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77. Coefficientsa

Model

Unstandardized
Coefficients

B

Std.
Error

Standardized
Coefficients

Beta

95% Confidence
Interval for B

t

Sig.

Lower
Bound

Upper
Bound

1 (Constant)
4.585

.065

-.127

.025

4.376

.081

-.154

.025

70.366

.000

4.457

4.713

-5.156

.000

-.175

-.078

54.200

.000

4.218

4.534

-.151

-6.098

.000

-.203

-.104

.108

4.350

.001

.060

.160

If my health
insurance
covers it
-.125

2 (Constant)

If my health
insurance
covers it

Whether I
practice safe
sex
.110
.025
a. Dependent Variable: Mean Control Beliefs
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78. Excluded Variables(c)
Model
Beta In

t

1

Sig.

Partial
Correlation

Collinearity
Statistics
Tolerance

If my friends think I
-.001(a)
-.055
.956
-.001
.906
should get it
If I had an abnormal
.021(a)
.776
.438
.019
.827
Pap smear
If my family thinks I
.016(a)
.627
.531
.015
.906
should get it
If my sex partner
-.012(a)
-.452
.651
-.011
.882
thinks I should get it
If my health care
provider thinks I
.037(a)
1.390
.165
.034
.835
should get it
If someone in my
.030(a)
1.163
.245
.028
.882
family has cancer
Whether I practice
.108(a)
4.350
.000
.106
.939
safe sex
2
If my friends think I
-.019(b)
-.747
.455
-.018
.883
should get it
If I had an abnormal
-.008(b)
-.306
.759
-.007
.776
Pap smear
If my family thinks I
-.005(b)
-.202
.840
-.005
.873
should get it
If my sex partner
-.040(b)
-1.517
.130
-.037
.834
thinks I should get it
If my health care
provider thinks I
.011(b)
.423
.672
.010
.792
should get it
If someone in my
-.001(b)
-.028
.978
-.001
.815
family has cancer
a. Predictors in the Model: (Constant), If my health insurance covers it
b. Predictors in the Model: (Constant), If my health insurance covers it, Whether I practice safe
sex
c. Dependent Variable: Mean Control Beliefs
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Tables 79-82. Multiple Linear Regression Results for the Relationship Between Control Beliefs
About Practicing Safer Sex Behaviors and Barriers to Becoming
Vaccinated Against HPV
79. Model Summary
Adjusted Std. Error of
Model
R
R Square R Square the Estimate
1
.141(a)
.020
.019
.67633
2
.158(b)
.025
.024
.67476
3
.166(c)
.028
.026
.67402
a. Predictors: (Constant), The cost of the vaccine
b. Predictors: (Constant), The cost of the vaccine, Having to wait at my doctors office for
approval to get the vaccine
c. Predictors: (Constant), The cost of the vaccine, Having to wait at my doctors office for
approval to get the vaccine, Possible side effects of the vaccine
80. ANOVA(d)
Sum of
Mean
Model
Squares
df
Square
F
Sig.
1
Regression
15.520
1
15.520 33.930
.000(a)
Residual
768.011
1679
.457
Total
783.532
1680
2
Regression
19.548
2
9.774 21.467
.000(b)
Residual
763.984
1678
.455
Total
783.532
1680
3
Regression
21.656
3
7.219 15.890
.000(c)
Residual
761.875
1677
.454
Total
783.532
1680
a. Predictors: (Constant), The cost of the vaccine
b. Predictors: (Constant), The cost of the vaccine, Having to wait at my doctors office for
approval to get the vaccine
c. Predictors: (Constant), The cost of the vaccine, Having to wait at my doctors office for
approval to get the vaccine, Possible side effects of the vaccine
d. Dependent Variable: Mean Control Beliefs
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81. Coefficientsa

Model

Unstandardized
Coefficients

B

Std.
Error

Standardized
Coefficients

Beta

95% Confidence
Interval for B

t

Sig.

Lower
Bound

Upper
Bound

1 (Constant)
4.554

.053

-.128

.022

4.634

.059

-.113

.022

-.079

.026

85.825

.000

4.450

4.658

6.229

.000

-.171

-.085

77.957

.000

4.518

4.751

-.124

-5.033

.000

-.157

-.069

-.074

-2.974

.003

-.130

-.027

62.210

.000

4.400

4.686

-.123

-4.963

.000

-.155

-.067

-.083

-3.310

.001

-.141

-.036

.053

2.154

.031

.004

.095

The cost of
the vaccine
-.141

2 (Constant)

The cost of
the vaccine

Having to
wait at my
doctor’s
office to get
the vaccine
3(Constant)

4.543
.073
The cost of
the vaccine
-.111
.022
Having to
wait at my
doctor’s
office to get
-.089
.027
the vaccine
Possible side
effects of the
.050
.023
vaccine
a. Dependent Variable: Mean Control Beliefs
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82. Excluded Variables(d)

Model
1

2

3

Beta In
Getting three shots
over a six month
period
Fear of vaccines
Possible side effects
of the vaccine
Having to get
additional boosters
after getting three
shots
Having to wait at
my doctors office
for approval to get
the vaccine
Not knowing where
to get the vaccine
Getting three shots
over a six month
period
Fear of vaccines
Possible side effects
of the vaccine
Having to get
additional boosters
after getting three
shots
Not knowing where
to get the vaccine
Getting three shots
over a six month
period
Fear of vaccines
Having to get
additional boosters
after getting three
shots
Not knowing where
to get the vaccine

t

Sig.

Partial
Correlation

Collinearity
Statistics
Tolerance

-.030(a)

-1.242

.215

-.030

.982

-.016(a)

-.651

.515

-.016

.999

.038(a)

1.592

.112

.039

1.000

-.008(a)

-.344

.731

-.008

.980

-.074(a)

-2.974

.003

-.072

.951

-.059(a)

-2.347

.019

-.057

.927

-.003(b)

-.120

.904

-.003

.840

-.003(b)

-.118

.906

-.003

.967

.053(b)

2.154

.031

.053

.969

.022(b)

.835

.404

.020

.842

-.038(b)

-1.430

.153

-.035

.821

-.011(c)

-.426

.670

-.010

.823

-.023(c)

-.873

.383

-.021

.863

.002(c)

.069

.945

.002

.734

-.039(c)

-1.477

.140

-.036

.821
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a Predictors in the Model: (Constant), The cost of the vaccine
b Predictors in the Model: (Constant), The cost of the vaccine, Having to wait at my doctors
office for approval to get the vaccine
c Predictors in the Model: (Constant), The cost of the vaccine, Having to wait at my doctors
office for approval to get the vaccine, Possible side effects
of the vaccine
d. Dependent Variable: Mean Control Beliefs

Table 83. Correlation Between Intentions to Practice Safer Sex Behaviors and General
Vaccine Acceptance

2706

Mean General
Vaccine
Acceptance
.087(**)
.000
2705

.087(**)

1

Sig. (2-tailed)
.000
N
2705
**Correlation is significant at the 0.01 level (2-tailed).

2705

Mean
Intentions
Mean Intentions

Mean General
Vaccine
Acceptance

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation

1

390

Appendix O (Continued) Summary Tables of Correlation
and Multiple Linear Regression Results
Table 84. Correlation Between Intentions to Practice Safer Sex Behaviors and Importance of
Vaccinations in General.

Mean Intentions

How important do you
think vaccinations are in
general?

How
important do
you think
vaccinations
Mean
are in
Intentions
general?
1
.081(**)
.000
2706
2700

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation

.081(**)

1

.000
2700

2700

Sig. (2-tailed)
N
** Correlation is significant at the 0.01 level (2-tailed).

Table 85. Correlation Between Intentions to Practice Safer Sex Behaviors and Likelihood of
Getting Vaccinated Against HPV

2706

Likelihood of
getting vaccinated
against HPV
.098(**)
.000
1695

.098(**)

1

Mean
Intentions
Mean Intentions

Likelihood of
getting vaccinated
against HPV

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation

1

Sig. (2-tailed)

.000

N

1695

** Correlation is significant at the 0.01 level (2-tailed).
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Tables 86-89. Multiple Linear Regression Results for the Relationship Between Intentions
to Practice Safer Sex Behaviors and Barriers to Becoming
Vaccinated Against HPV
86. Model Summary
Adjusted Std. Error of
Model
R
R Square R Square the Estimate
1
.179(a)
.032
.031
.79563
2
.230(b)
.053
.052
.78710
3
.239(c)
.057
.055
.78570
4
.244(d)
.060
.058
.78479
a Predictors: (Constant), Whether I practice safe sex
b Predictors: (Constant), Whether I practice safe sex, If my health insurance covers it
c Predictors: (Constant), Whether I practice safe sex, If my health insurance covers it, If someone
in my family has cancer
d Predictors: (Constant), Whether I practice safe sex, If my health insurance covers it, If
someone in my family has cancer, If my friends think Ishould get it
87. ANOVA(e)
Sum of
Mean
Model
Squares
df
Square
F
Sig.
1
Regression
35.080
1
35.080
55.416
.000(a)
Residual
1064.759
1682
.633
Total
1099.839
1683
2
Regression
58.420
2
29.210
47.149
.000(b)
Residual
1041.419
1681
.620
Total
1099.839
1683
3
Regression
62.744
3
20.915
33.880
.000(c)
Residual
1037.095
1680
.617
Total
1099.839
1683
4
Regression
65.742
4
16.436
26.685
.000(d)
Residual
1034.096
1679
.616
Total
1099.839
1683
a Predictors: (Constant), Whether I practice safe sex
b Predictors: (Constant), Whether I practice safe sex, If my health insurance covers it
c Predictors: (Constant), Whether I practice safe sex, If my health insurance covers it, If someone
in my family has cancer
d Predictors: (Constant), Whether I practice safe sex, If my health insurance covers it, If
someone in my family has cancer, If my friends think I should get it
e Dependent Variable: Mean Intentions
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88. Coefficientsa

Model

Unstandardized
Coefficients

B

Std.
Error

Standardized
Coefficients

Beta

95% Confidence
Interval for B

t

Sig.

Lower
Bound

Upper
Bound

1 (Constant)
3.318

.076

.215

.029

3.668

.094

.260

.030

-.181

.029

3.556

.103

.238

.031

-.204

43.751

.000

3.170

3.467

7.444

.000

.159

.272

38.921

.000

3.484

3.853

.216

8.808

.000

.202

.318

-.150

-6.138

-.238

-.123

Whether I
practice safe
sex
.179

2 (Constant)

Whether I
practice safe
sex
If my health
insurance
covers it
3 (Constant)
Whether I
practice safe
sex
If my health
insurance
covers it
If someone in
my family
has cancer
4 (Constant)
Whether I
practice safe
sex
If my health
insurance
covers it

34.466

.000

3.354

3.759

.197

7.756

.000

.178

.298

.031

-.170

-6.649

.000

-.264

-.144

.089

.034

.069

2.647

.008

.023

.155

3.533

.104

34.101

.000

3.330

3.736

.230

.031

.191

7.455

.000

.169

.290

-.219

.031

-.183

-6.982

.000

-.281

-.158
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88. Coefficientsa (Continued)

Model

Unstandardized
Coefficients

B

Std.
Error

If someone in
my family
has cancer
.079
.034
If my friends
think I should
get it
.068
.031
a. Dependent Variable: Intentions

Standardized
Coefficients

Beta

95% Confidence
Interval for B

t

Sig.

Lower
Bound

Upper
Bound

.062

2.335

.020

.013

.145

.056

2.206

.027

.008

.129
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89. Excluded Variables(e)

Model

Beta In

t

Sig.

Partial
Correlatio Collinearity
n
Statistics
Tolerance

1

2

3

If my friends think I
should get it
If my health insurance
covers it
If I had an abnormal
Pap smear
If my family thinks I
should get it
If my sex partner
thinks I should get it
If my health care
provider thinks I
should get it
If someone in my
family has cancer
If my friends think I
should get it
If I had an abnormal
Pap smear
If my family thinks I
should get it
If my sex partner
thinks I should get it
If my health care
provider thinks I
should get it
If someone in my
family has cancer
If my friends think I
should get it
If I had an abnormal
Pap smear
If I had an abnormal
Pap smear
If my sex partner
thinks I should get it
If my health care
provider thinks I
should get it

.019(a)

.787

.431

.019

.951

-.150(a)

-6.138

.000

-.148

.939

-.035(a)

-1.382

.167

-.034

.897

.017(a)

.699

.484

.017

.937

-.026(a)

-1.020

.308

-.025

.911

-.001(a)

-.046

.963

-.001

.910

.020(a)

.768

.443

.019

.888

.064(b)

2.533

.011

.062

.883

.025(b)

.921

.357

.022

.776

.061(b)

2.397

.017

.058

.873

.021(b)

.791

.429

.019

.834

.062(b)

2.313

.021

.056

.792

.069(b)

2.647

.008

.064

.815

.056(c)

2.206

.027

.054

.868

.002(c)

.067

.947

.002

.694

.048(c)

1.824

.068

.044

.824

.007(c)

.258

.796

.006

.799

.047(c)

1.692

.091

.041

.740
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Appendix O (Continued) Summary Tables of Correlation
and Multiple Linear Regression Results
89. Excluded Variables(e) (Continued)

Model

Beta In

t

4

Sig.

Partial
Correlatio Collinearity
n
Statistics
Tolerance

If I had an abnormal
-.001(d)
-.033
.973
-.001
.693
Pap smear
If my family thinks I
.032(d)
1.176
.240
.029
.738
should get it
If my sex partner
-.012(d)
-.427
.670
-.010
.726
thinks I should get it
If my health care
provider thinks I
.039(d)
1.404
.160
.034
.726
should get it
a Predictors in the Model: (Constant), Whether I practice safe sex
b. Predictors in the Model: (Constant), Whether I practice safe sex, If my health insurance covers
it
c. Predictors in the Model: (Constant), Whether I practice safe sex, If my health insurance covers
it, If someone in my family has cancer
d. Predictors in the Model: (Constant), Whether I practice safe sex, If my health insurance covers
it, If someone in my family has cancer, If my friends think
I should get it
e. Dependent Variable: Mean Intentions

Tables 90-93. Multiple Linear Regression Results for the Relationship Between Intentions
to Practice Safer Sex Behaviors and Barriers to Becoming
Vaccinated Against HPV
90. Model Summary
Adjusted Std. Error of
Model
R
R Square R Square the Estimate
1
.116(a)
.014
.013
.80315
2
.128(b)
.016
.015
.80225
a. Predictors: (Constant), The cost of the vaccine
b. Predictors: (Constant), The cost of the vaccine, Not knowing where to get the vaccine
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Appendix O (Continued) Summary Tables of Correlation
and Multiple Linear Regression Results
91. ANOVA(c)
Model
Sum of Squares
df
Mean Square
F
Sig.
1
Regression
14.837
1
14.837
23.001
.000(a)
Residual
1083.041
1679
.645
Total
1097.878
1680
2
Regression
17.912
2
8.956
13.916
.000(b)
Residual
1079.966
1678
.644
Total
1097.878
1680
a. Predictors: (Constant), The cost of the vaccine
b. Predictors: (Constant), The cost of the vaccine, Not knowing where to get the vaccine
c. Dependent Variable: Mean Intentions
92. Coefficientsa

Model

Unstandardized
Coefficients

B

Standardized
Coefficients

Std.
Error

Beta

95% Confidence
Interval for B

t

Sig.

Lower
Bound

Upper
Bound

1 (Constant)
4.151

.063

-.125

.026

4.213

.069

-.109

.027

65.882

.000

4.028

4.275

-4.796

.000

-.176

-.074

61.151

.000

4.077

4.348

-.101

-4.032

.000

-.162

-.056

-.055

-2.186

.029

-.112

-.006

The cost of
the vaccine
-.116

2 (Constant)

If my health
insurance
covers it

Whether I
practice safe
sex
-.059
.027
a. Dependent Variable: Mean Intentions
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Appendix O (Continued) Summary Tables of Correlation
and Multiple Linear Regression Results
93. Excluded Variables(c)

Model
1

2

Beta In
Getting three
shots over a six
month period
Fear of vaccines

Possible side
effects of the
vaccine
Having to get
additional
boosters after
getting three shots
Having to wait at
my doctors office
for approval to
get the vaccine
Not knowing
where to get the
vaccine
Getting three
shots over a six
month period
Fear of vaccines

t

Sig.

Partial
Correlation

Collinearity
Statistics
Tolerance

.015(a)

.607

.544

.015

.982

.000(a)

-.020

.984

.000

.999

.033(a)

1.375

.169

.034

1.000

.028(a)

1.163

.245

.028

.980

-.043(a)

-1.738

.082

-.042

.951

-.055(a)

-2.186

.029

-.053

.927

.023(b)

.924

.356

.023

.963

.002(b)

.094

.925

.002

.997

Possible side
effects of the
.038(b)
1.554
.120
.038
.994
vaccine
Having to get
additional
.038(b)
1.533
.125
.037
.955
boosters after
getting three shots
Having to wait at
my doctors office
-.028(b)
-1.063
.288
-.026
.842
for approval to
get the vaccine
a Predictors in the Model: (Constant), The cost of the vaccine
b Predictors in the Model: (Constant), The cost of the vaccine, Not knowing where to get the
vaccine
c Dependent Variable: Mean Intentions
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